{"f84e6c8b866ea0185973297cf2b97eb49a62e12d": [["T he renin-angiotensin system (RAS) regulates blood pressure, fluid and electrolyte balance, and vascular resistance.", [["blood", "ANATOMY", 46, 51], ["fluid", "ANATOMY", 62, 67], ["vascular", "ANATOMY", 97, 105], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 5, 29], ["RAS", "GENE_OR_GENE_PRODUCT", 31, 34], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["fluid", "ORGANISM_SUBSTANCE", 62, 67], ["vascular", "MULTI-TISSUE_STRUCTURE", 97, 105], ["renin", "PROTEIN", 5, 10], ["blood pressure", "TEST", 46, 60], ["fluid and electrolyte balance", "TEST", 62, 91], ["electrolyte balance", "OBSERVATION", 72, 91], ["vascular", "ANATOMY", 97, 105], ["resistance", "OBSERVATION", 106, 116]]], ["1 Sustained pulmonary vasoconstriction, concentric pulmonary vascular remodeling, and in situ thrombosis are major causes for the elevated pulmonary vascular resistance and pulmonary arterial pressure in patients with pulmonary arterial hypertension (PAH).", [["pulmonary", "ANATOMY", 12, 21], ["pulmonary vascular", "ANATOMY", 51, 69], ["pulmonary vascular", "ANATOMY", 139, 157], ["pulmonary arterial", "ANATOMY", 173, 191], ["pulmonary arterial", "ANATOMY", 218, 236], ["thrombosis", "DISEASE", 94, 104], ["pulmonary arterial hypertension", "DISEASE", 218, 249], ["PAH", "DISEASE", 251, 254], ["pulmonary", "ORGAN", 12, 21], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 51, 69], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 139, 157], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 173, 191], ["patients", "ORGANISM", 204, 212], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 218, 236], ["patients", "SPECIES", 204, 212], ["Sustained pulmonary vasoconstriction", "PROBLEM", 2, 38], ["concentric pulmonary vascular remodeling", "PROBLEM", 40, 80], ["situ thrombosis", "PROBLEM", 89, 104], ["the elevated pulmonary vascular resistance", "PROBLEM", 126, 168], ["pulmonary arterial pressure", "TEST", 173, 200], ["pulmonary arterial hypertension", "PROBLEM", 218, 249], ["pulmonary", "ANATOMY", 12, 21], ["vasoconstriction", "OBSERVATION", 22, 38], ["concentric", "OBSERVATION_MODIFIER", 40, 50], ["pulmonary vascular", "ANATOMY", 51, 69], ["remodeling", "OBSERVATION", 70, 80], ["situ", "OBSERVATION_MODIFIER", 89, 93], ["thrombosis", "OBSERVATION", 94, 104], ["elevated", "OBSERVATION", 130, 138], ["pulmonary vascular", "ANATOMY", 139, 157], ["resistance", "OBSERVATION", 158, 168], ["pulmonary arterial", "ANATOMY", 173, 191], ["pressure", "OBSERVATION_MODIFIER", 192, 200], ["pulmonary arterial", "ANATOMY", 218, 236], ["hypertension", "OBSERVATION", 237, 249]]], ["2,3 Within the RAS system, the angiotensinconverting enzyme 2 (ACE2)/angiotensin (Ang)-(1-7)/ Mas receptor axis counterposes the ACE1/Ang II/AT1 receptor axis.", [["angiotensin", "CHEMICAL", 69, 80], ["Ang", "CHEMICAL", 82, 85], ["Ang", "CHEMICAL", 134, 137], ["RAS", "GENE_OR_GENE_PRODUCT", 15, 18], ["angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 31, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 63, 67], ["angiotensin (Ang)-(1-7", "GENE_OR_GENE_PRODUCT", 69, 91], ["Mas receptor", "GENE_OR_GENE_PRODUCT", 94, 106], ["ACE1", "GENE_OR_GENE_PRODUCT", 129, 133], ["Ang II", "GENE_OR_GENE_PRODUCT", 134, 140], ["AT1 receptor", "GENE_OR_GENE_PRODUCT", 141, 153], ["ACE2", "PROTEIN", 63, 67], ["ACE1", "PROTEIN", 129, 133], ["Ang II", "PROTEIN", 134, 140], ["AT1 receptor", "PROTEIN", 141, 153], ["the angiotensinconverting enzyme", "TEST", 27, 59], ["ACE2", "TEST", 63, 67], ["angiotensin", "TEST", 69, 80], ["Ang", "TEST", 82, 85], ["Mas receptor axis", "TEST", 94, 111], ["the ACE1", "TEST", 125, 133], ["Ang II/AT1 receptor axis", "TREATMENT", 134, 158]]], ["With a homologous catalytic domain as for ACE1, ACE2 competes with ACE1 to convert Ang II to Ang-(1-7), which provides antivasoconstrictive, antiinflammatory, antihypertrophic, and antifibrotic effects on various vascular beds, including the pulmonary vasculature.", [["vascular beds", "ANATOMY", 213, 226], ["pulmonary vasculature", "ANATOMY", 242, 263], ["Ang II", "CHEMICAL", 83, 89], ["Ang-(1-7", "CHEMICAL", 93, 101], ["ACE1", "GENE_OR_GENE_PRODUCT", 42, 46], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["ACE1", "SIMPLE_CHEMICAL", 67, 71], ["Ang II", "GENE_OR_GENE_PRODUCT", 83, 89], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 93, 101], ["vascular beds", "MULTI-TISSUE_STRUCTURE", 213, 226], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 242, 263], ["homologous catalytic domain", "PROTEIN", 7, 34], ["ACE1", "PROTEIN", 42, 46], ["ACE2", "PROTEIN", 48, 52], ["ACE1", "PROTEIN", 67, 71], ["Ang II", "PROTEIN", 83, 89], ["a homologous catalytic domain", "TREATMENT", 5, 34], ["ACE1, ACE2 competes", "TREATMENT", 42, 61], ["ACE1", "TREATMENT", 67, 71], ["Ang", "TEST", 93, 96], ["antiinflammatory", "TREATMENT", 141, 157], ["antihypertrophic", "TREATMENT", 159, 175], ["antifibrotic effects", "TREATMENT", 181, 201], ["various vascular beds", "TREATMENT", 205, 226], ["antiinflammatory", "OBSERVATION_MODIFIER", 141, 157], ["antifibrotic", "OBSERVATION", 181, 193], ["vascular beds", "ANATOMY", 213, 226], ["pulmonary vasculature", "ANATOMY", 242, 263]]], ["4, 5 Thus, inhibiting the canonical RAS (ie, ACE1) and activating the counterbalancing ACE2/Ang-(1-7)/ Mas axis have complementary efficacies in cardiovascular diseases, including pulmonary hypertension (PH).", [["cardiovascular", "ANATOMY", 145, 159], ["pulmonary", "ANATOMY", 180, 189], ["Ang", "CHEMICAL", 92, 95], ["cardiovascular diseases", "DISEASE", 145, 168], ["pulmonary hypertension", "DISEASE", 180, 202], ["PH", "DISEASE", 204, 206], ["RAS", "GENE_OR_GENE_PRODUCT", 36, 39], ["ACE1", "GENE_OR_GENE_PRODUCT", 45, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 87, 91], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 92, 100], ["cardiovascular", "ANATOMICAL_SYSTEM", 145, 159], ["pulmonary", "ORGAN", 180, 189], ["canonical RAS", "PROTEIN", 26, 39], ["ACE1", "PROTEIN", 45, 49], ["ACE2", "PROTEIN", 87, 91], ["Ang", "PROTEIN", 92, 95], ["ACE1", "TEST", 45, 49], ["Ang", "TEST", 92, 95], ["Mas axis", "PROBLEM", 103, 111], ["cardiovascular diseases", "PROBLEM", 145, 168], ["pulmonary hypertension", "PROBLEM", 180, 202], ["efficacies", "OBSERVATION_MODIFIER", 131, 141], ["cardiovascular diseases", "OBSERVATION", 145, 168], ["pulmonary", "ANATOMY", 180, 189], ["hypertension", "OBSERVATION", 190, 202]]], ["[6] [7] [8] Posttranslational modifications (PTMs) play an essential role in regulating protein expression, activity, and subcellular distribution.", [["subcellular", "ANATOMY", 122, 133], ["PTMs", "PROTEIN", 45, 49], ["Posttranslational modifications (PTMs)", "TREATMENT", 12, 50], ["protein expression", "OBSERVATION", 88, 106], ["subcellular distribution", "OBSERVATION", 122, 146]]], ["As 2 major modes of PTMs, protein phosphorylation and ubiquitination are critical for cellular responses to physiological and pathophysiological stimuli.", [["cellular", "ANATOMY", 86, 94], ["cellular", "CELL", 86, 94], ["PTMs", "PROTEIN", 20, 24], ["protein phosphorylation", "TEST", 26, 49], ["pathophysiological stimuli", "TEST", 126, 152]]], ["9, 10 We have previously shown that AMP-activated protein kinase (AMPK) phosphorylates ACE2 Ser-680 (S680) in vascular endothelial cells (ECs) and thereby inhibits the proteasome-mediated ubiquitination of ACE2.", [["vascular endothelial cells", "ANATOMY", 110, 136], ["ECs", "ANATOMY", 138, 141], ["AMP", "CHEMICAL", 36, 39], ["AMP", "CHEMICAL", 36, 39], ["Ser", "CHEMICAL", 92, 95], ["AMP-activated protein kinase", "GENE_OR_GENE_PRODUCT", 36, 64], ["AMPK", "GENE_OR_GENE_PRODUCT", 66, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 87, 91], ["Ser-680", "AMINO_ACID", 92, 99], ["S680", "AMINO_ACID", 101, 105], ["vascular endothelial cells", "CELL", 110, 136], ["ECs", "CELL", 138, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 206, 210], ["AMP-activated protein kinase", "PROTEIN", 36, 64], ["AMPK", "PROTEIN", 66, 70], ["ACE2 Ser-680", "PROTEIN", 87, 99], ["S680", "PROTEIN", 101, 105], ["vascular endothelial cells", "CELL_TYPE", 110, 136], ["ECs", "CELL_TYPE", 138, 141], ["proteasome", "PROTEIN", 168, 178], ["ACE2", "PROTEIN", 206, 210], ["AMP", "TEST", 36, 39], ["activated protein kinase", "TEST", 40, 64], ["AMPK", "TEST", 66, 70], ["phosphorylates", "TEST", 72, 86], ["ACE2 Ser", "TEST", 87, 95], ["vascular endothelial cells", "TEST", 110, 136], ["the proteasome", "TREATMENT", 164, 178], ["vascular endothelial", "ANATOMY", 110, 130]]], ["8 Consequently, ACE2 stability is increased under conditions in which AMPK is activated (eg, metformin treatment).", [["metformin", "CHEMICAL", 93, 102], ["metformin", "CHEMICAL", 93, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 16, 20], ["AMPK", "GENE_OR_GENE_PRODUCT", 70, 74], ["metformin", "SIMPLE_CHEMICAL", 93, 102], ["ACE2", "PROTEIN", 16, 20], ["AMPK", "PROTEIN", 70, 74], ["metformin treatment", "TREATMENT", 93, 112], ["stability", "OBSERVATION_MODIFIER", 21, 30], ["increased", "OBSERVATION_MODIFIER", 34, 43]]], ["11, 12 Activation of the AMPK-ACE2 axis is beneficial to the pulmonary endothelium, as supported by the PH-resistant phenotype seen in a mouse line harboring the phosphomimetic form of ACE2 (ie, ACE2-S680D).", [["pulmonary endothelium", "ANATOMY", 61, 82], ["AMPK", "GENE_OR_GENE_PRODUCT", 25, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 30, 34], ["pulmonary endothelium", "TISSUE", 61, 82], ["mouse", "ORGANISM", 137, 142], ["ACE2", "GENE_OR_GENE_PRODUCT", 185, 189], ["ACE2", "GENE_OR_GENE_PRODUCT", 195, 199], ["AMPK", "PROTEIN", 25, 29], ["ACE2", "PROTEIN", 30, 34], ["phosphomimetic form", "PROTEIN", 162, 181], ["ACE2", "PROTEIN", 185, 189], ["ACE2", "PROTEIN", 195, 199], ["S680D", "PROTEIN", 200, 205], ["mouse", "SPECIES", 137, 142], ["mouse", "SPECIES", 137, 142], ["the AMPK", "TEST", 21, 29], ["the PH", "TEST", 100, 106], ["resistant phenotype", "PROBLEM", 107, 126], ["a mouse line", "TREATMENT", 135, 147], ["ACE2", "TEST", 185, 189], ["ACE2", "TEST", 195, 199], ["ACE2 axis", "ANATOMY", 30, 39], ["pulmonary endothelium", "ANATOMY", 61, 82], ["mouse line", "OBSERVATION", 137, 147]]], ["8 However, the molecular basis underlying ACE2 ubiquitination leading to its degradation and its correlation with the onset of PAH remains elusive.", [["PAH", "DISEASE", 127, 130], ["PAH", "CHEMICAL", 127, 130], ["ACE2", "GENE_OR_GENE_PRODUCT", 42, 46], ["PAH", "SIMPLE_CHEMICAL", 127, 130], ["ACE2", "PROTEIN", 42, 46], ["ACE2 ubiquitination", "PROBLEM", 42, 61], ["its degradation", "PROBLEM", 73, 88], ["PAH", "PROBLEM", 127, 130], ["ACE2 ubiquitination", "OBSERVATION", 42, 61], ["PAH", "OBSERVATION", 127, 130]]]], "5663b7326c779dd86680ebecc44927529d7ec686": [["Introduction(29.7%), expectoration (24.3%), and diarrhea (13.5%).", [["expectoration", "DISEASE", 21, 34], ["diarrhea", "DISEASE", 48, 56], ["expectoration", "TEST", 21, 34], ["diarrhea", "PROBLEM", 48, 56]]], ["The less common symptoms included pharyngalgia (2.7%), hemoptysis (2.7%) and weep tears (2.7%).", [["pharyngalgia", "DISEASE", 34, 46], ["hemoptysis", "DISEASE", 55, 65], ["weep tears", "DISEASE", 77, 87], ["The less common symptoms", "PROBLEM", 0, 24], ["pharyngalgia", "PROBLEM", 34, 46], ["hemoptysis", "PROBLEM", 55, 65], ["weep tears", "PROBLEM", 77, 87], ["less", "OBSERVATION_MODIFIER", 4, 8], ["common", "OBSERVATION_MODIFIER", 9, 15], ["hemoptysis", "OBSERVATION", 55, 65]]], ["Common complications included CVD (13.5%), followed by diabetes (5.4%) and hepatitis (5.4%).", [["CVD", "DISEASE", 30, 33], ["diabetes", "DISEASE", 55, 63], ["hepatitis", "DISEASE", 75, 84], ["Common complications", "PROBLEM", 0, 20], ["CVD", "PROBLEM", 30, 33], ["diabetes", "PROBLEM", 55, 63], ["hepatitis", "PROBLEM", 75, 84]]], ["Table 2 presented the laboratory testing results of these patients (PP group) on admission to our hospital.Blood cell counts, blood biochemicals and inflammatory biomarkers in patients with COVID-19Unfortunately, the results of the same patients at disease onset were not available since these patients were first admitted to mobile cabin hospital and then transferred to our hospital, we therefore randomly selected another 37 age-and sex-matched COVID-19 patients confirmed with non-severe disease (PA group), who had their blood test at disease onset on admission to our hospital, for comparison.", [["Blood cell", "ANATOMY", 107, 117], ["blood", "ANATOMY", 126, 131], ["blood", "ANATOMY", 526, 531], ["patients", "ORGANISM", 58, 66], ["Blood cell", "CELL", 107, 117], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["patients", "ORGANISM", 176, 184], ["patients", "ORGANISM", 237, 245], ["patients", "ORGANISM", 294, 302], ["patients", "ORGANISM", 457, 465], ["blood", "ORGANISM_SUBSTANCE", 526, 531], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 176, 184], ["patients", "SPECIES", 237, 245], ["patients", "SPECIES", 294, 302], ["patients", "SPECIES", 457, 465], ["the laboratory testing", "TEST", 18, 40], ["Blood cell counts", "TEST", 107, 124], ["blood biochemicals", "TEST", 126, 144], ["inflammatory biomarkers", "TEST", 149, 172], ["COVID", "TEST", 190, 195], ["non-severe disease", "PROBLEM", 481, 499], ["their blood test", "TEST", 520, 536], ["cell counts", "OBSERVATION", 113, 124], ["inflammatory", "OBSERVATION_MODIFIER", 149, 161]]], ["Compared with patients from the PA group, those from the PP group had significantly higher numbers of lymphocytes (1.", [["lymphocytes", "ANATOMY", 102, 113], ["patients", "ORGANISM", 14, 22], ["PA", "CANCER", 32, 34], ["lymphocytes", "CELL", 102, 113], ["lymphocytes", "CELL_TYPE", 102, 113], ["patients", "SPECIES", 14, 22], ["the PP group", "TEST", 53, 65], ["significantly higher numbers of lymphocytes", "PROBLEM", 70, 113], ["higher", "OBSERVATION_MODIFIER", 84, 90], ["numbers", "OBSERVATION_MODIFIER", 91, 98], ["lymphocytes", "ANATOMY", 102, 113]]], ["5 p<0.001), as compared to those from the PA group.", [["PA", "GENE_OR_GENE_PRODUCT", 42, 44]]], ["In together, these results demonstrated that PP patients, upon treatment in mobile cabin hospital and transferred to our hospital, had much improved laboratory findings than PA patients at disease onset, even though they had persistent SARS-CoV-2 shedding.Lymphocyte subsets in peripheral bloodIt has been reported that dysregulated immune response were correlated with the severity of COVID-19 8 All rights reserved.", [["Lymphocyte", "ANATOMY", 256, 266], ["peripheral blood", "ANATOMY", 278, 294], ["SARS", "DISEASE", 236, 240], ["PP", "ORGANISM", 45, 47], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 177, 185], ["CoV-2", "GENE_OR_GENE_PRODUCT", 241, 246], ["Lymphocyte", "CELL", 256, 266], ["peripheral blood", "ORGANISM_SUBSTANCE", 278, 294], ["Lymphocyte subsets", "CELL_TYPE", 256, 274], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 177, 185], ["treatment", "TREATMENT", 63, 72], ["persistent SARS", "PROBLEM", 225, 240], ["CoV", "TEST", 241, 244], ["Lymphocyte subsets", "TEST", 256, 274], ["peripheral blood", "TEST", 278, 294], ["COVID", "TEST", 386, 391], ["persistent", "OBSERVATION_MODIFIER", 225, 235], ["SARS", "OBSERVATION", 236, 240], ["peripheral", "ANATOMY_MODIFIER", 278, 288], ["blood", "ANATOMY", 289, 294], ["dysregulated", "OBSERVATION_MODIFIER", 320, 332], ["immune response", "OBSERVATION", 333, 348]]], ["No reuse allowed without permission.Lymphocyte subsets in peripheral blood(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Lymphocyte subsets in peripheral bloodThe copyright holder for this preprint this version posted March 30, 2020. .", [["Lymphocyte", "ANATOMY", 36, 46], ["peripheral blood", "ANATOMY", 58, 74], ["Lymphocyte", "ANATOMY", 209, 219], ["peripheral blood", "ANATOMY", 231, 247], ["Lymphocyte", "CELL", 36, 46], ["peripheral blood", "ORGANISM_SUBSTANCE", 58, 74], ["Lymphocyte", "CELL", 209, 219], ["peripheral blood", "ORGANISM_SUBSTANCE", 231, 247], ["Lymphocyte subsets", "CELL_TYPE", 36, 54], ["Lymphocyte subsets", "CELL_TYPE", 209, 227], ["Lymphocyte subsets in peripheral blood", "PROBLEM", 36, 74], ["Lymphocyte subsets", "TEST", 209, 227], ["peripheral blood", "TEST", 231, 247], ["The copyright holder", "TREATMENT", 247, 267], ["peripheral", "ANATOMY_MODIFIER", 58, 68], ["blood", "ANATOMY", 69, 74], ["med", "ANATOMY", 153, 156], ["peripheral", "ANATOMY_MODIFIER", 231, 241], ["blood", "ANATOMY", 242, 247]]], ["However, changes in adaptive immune cells in non-severe COVID-19 patients with persistent SARS-CoV-2 shedding has yet to be examined.", [["immune cells", "ANATOMY", 29, 41], ["COVID", "DISEASE", 56, 61], ["SARS", "DISEASE", 90, 94], ["immune cells", "CELL", 29, 41], ["patients", "ORGANISM", 65, 73], ["CoV-2", "GENE_OR_GENE_PRODUCT", 95, 100], ["adaptive immune cells", "CELL_TYPE", 20, 41], ["patients", "SPECIES", 65, 73], ["changes in adaptive immune cells", "PROBLEM", 9, 41], ["non-severe COVID", "TEST", 45, 61], ["persistent SARS", "PROBLEM", 79, 94], ["immune cells", "OBSERVATION", 29, 41], ["persistent", "OBSERVATION_MODIFIER", 79, 89], ["SARS", "OBSERVATION", 90, 94]]], ["For this purpose, peripheral blood samples from patients in the PA and PP group were collected, the absolute numbers and relative frequencies of each lymphocyte subpopulations were compared between these two groups.", [["peripheral blood samples", "ANATOMY", 18, 42], ["lymphocyte", "ANATOMY", 150, 160], ["peripheral blood samples", "ORGANISM_SUBSTANCE", 18, 42], ["patients", "ORGANISM", 48, 56], ["lymphocyte", "CELL", 150, 160], ["lymphocyte subpopulations", "CELL_TYPE", 150, 175], ["patients", "SPECIES", 48, 56], ["peripheral blood samples", "TEST", 18, 42], ["the PA and PP group", "TEST", 60, 79], ["the absolute numbers", "TEST", 96, 116], ["each lymphocyte subpopulations", "TREATMENT", 145, 175], ["lymphocyte subpopulations", "OBSERVATION", 150, 175]]], ["In addition, 54 age-and sex-matched healthy subjects were randomly selected as healthy control (the HC group).", [["subjects", "ORGANISM", 44, 52]]], ["As shown in Table 3 , we failed to find any differences between the PP group and the HC group, but patients from both groups had increased numbers of CD3 + T cells, CD4 + T cells, and NK cells compared to those from the PA group.", [["CD3 + T cells", "ANATOMY", 150, 163], ["CD4 + T cells", "ANATOMY", 165, 178], ["NK cells", "ANATOMY", 184, 192], ["HC", "CANCER", 85, 87], ["patients", "ORGANISM", 99, 107], ["CD3", "GENE_OR_GENE_PRODUCT", 150, 153], ["CD4", "GENE_OR_GENE_PRODUCT", 165, 168], ["NK cells", "CELL", 184, 192], ["PA", "CANCER", 220, 222], ["CD3", "PROTEIN", 150, 153], ["T cells", "CELL_TYPE", 156, 163], ["CD4", "PROTEIN", 165, 168], ["T cells", "CELL_TYPE", 171, 178], ["NK cells", "CELL_TYPE", 184, 192], ["patients", "SPECIES", 99, 107], ["the PP group", "TEST", 64, 76], ["CD3 + T cells", "PROBLEM", 150, 163], ["CD4 + T cells", "PROBLEM", 165, 178], ["NK cells", "PROBLEM", 184, 192], ["NK cells", "OBSERVATION", 184, 192]]], ["In addition, PA patients had significantly lower frequency of B cells compared with healthy subjects (Table 3 ).", [["B cells", "ANATOMY", 62, 69], ["PA", "GENE_OR_GENE_PRODUCT", 13, 15], ["patients", "ORGANISM", 16, 24], ["B cells", "CELL", 62, 69], ["B cells", "CELL_TYPE", 62, 69], ["patients", "SPECIES", 16, 24], ["B cells", "PROBLEM", 62, 69], ["B cells", "OBSERVATION", 62, 69]]], ["These results indicated that non-severe COVID-19 patients (PA group) have already dysregulated immune system at diasese onset, and those with persistent SARS-CoV-2 shedding could restore this abnormality to some level.Lymphocyte subsets in peripheral bloodUpon admission, PP patients received the same standard treatment in our hospital.", [["immune system", "ANATOMY", 95, 108], ["Lymphocyte", "ANATOMY", 218, 228], ["peripheral blood", "ANATOMY", 240, 256], ["SARS", "DISEASE", 153, 157], ["patients", "ORGANISM", 49, 57], ["PA", "CANCER", 59, 61], ["immune system", "ANATOMICAL_SYSTEM", 95, 108], ["CoV-2", "GENE_OR_GENE_PRODUCT", 158, 163], ["Lymphocyte", "CELL", 218, 228], ["peripheral blood", "ORGANISM_SUBSTANCE", 240, 256], ["patients", "ORGANISM", 275, 283], ["Lymphocyte subsets", "CELL_TYPE", 218, 236], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 275, 283], ["non-severe COVID", "TEST", 29, 45], ["already dysregulated immune system", "PROBLEM", 74, 108], ["persistent SARS", "PROBLEM", 142, 157], ["this abnormality", "PROBLEM", 187, 203], ["Lymphocyte subsets", "TEST", 218, 236], ["PP", "TEST", 272, 274], ["the same standard treatment", "TREATMENT", 293, 320], ["persistent", "OBSERVATION_MODIFIER", 142, 152], ["SARS", "OBSERVATION", 153, 157], ["peripheral", "ANATOMY_MODIFIER", 240, 250], ["blood", "ANATOMY", 251, 256]]], ["After at least 7 days, 18 of them that were tested negative for SARS-CoV-2 in two consecutive examinations were retrospectively allocated to the PPN group, and 19 of them who remained positive at the same time point were designated as PPP patients.", [["PPN", "CANCER", 145, 148], ["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 239, 247], ["SARS-CoV", "SPECIES", 64, 72], ["SARS", "PROBLEM", 64, 68], ["CoV", "TEST", 69, 72], ["two consecutive examinations", "TEST", 78, 106], ["positive", "OBSERVATION", 184, 192]]], ["Of note, the PPP group have more males than the PPN group (86.4% [16 of 19] vs 50% [9 of 18]; p=0.02; Table 1 ).", [["PPN", "CANCER", 48, 51], ["the PPP group", "TEST", 9, 22], ["vs", "TEST", 76, 78], ["p", "TEST", 94, 95]]], ["We did not find any differences in symptoms and laboratory findings for these two groups (supplementary Table 1 and 2).", [["any differences in symptoms", "PROBLEM", 16, 43], ["laboratory findings", "TEST", 48, 67]]], ["However, when lymphocyte subpopulations were examined, PPP patients were found to have significantly lower numbers of CD3 + T cells (p=0.001), CD4 + T cells (p=0.005), CD8 + T cells (p=0.003), and B cells (p=0.005), but higher proportion of NK cells (p=0.02) than PPN patients (Fig 1A and 1B) .", [["lymphocyte", "ANATOMY", 14, 24], ["CD3 + T cells", "ANATOMY", 118, 131], ["CD4 + T cells", "ANATOMY", 143, 156], ["CD8 + T cells", "ANATOMY", 168, 181], ["B cells", "ANATOMY", 197, 204], ["NK cells", "ANATOMY", 241, 249], ["lymphocyte", "CELL", 14, 24], ["patients", "ORGANISM", 59, 67], ["CD3", "GENE_OR_GENE_PRODUCT", 118, 121], ["CD4", "GENE_OR_GENE_PRODUCT", 143, 146], ["CD8", "GENE_OR_GENE_PRODUCT", 168, 171], ["B cells", "CELL", 197, 204], ["NK cells", "CELL", 241, 249], ["patients", "ORGANISM", 268, 276], ["lymphocyte subpopulations", "CELL_TYPE", 14, 39], ["CD3", "PROTEIN", 118, 121], ["T cells", "CELL_TYPE", 124, 131], ["CD4", "PROTEIN", 143, 146], ["T cells", "CELL_TYPE", 149, 156], ["CD8", "PROTEIN", 168, 171], ["T cells", "CELL_TYPE", 174, 181], ["B cells", "CELL_TYPE", 197, 204], ["NK cells", "CELL_TYPE", 241, 249], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 268, 276], ["lymphocyte subpopulations", "TEST", 14, 39], ["PPP", "TEST", 55, 58], ["significantly lower numbers of CD3 + T cells", "PROBLEM", 87, 131], ["CD4", "TEST", 143, 146], ["T cells", "TEST", 149, 156], ["CD8", "TEST", 168, 171], ["T cells", "TEST", 174, 181], ["p", "TEST", 183, 184], ["B cells", "TEST", 197, 204], ["p", "TEST", 206, 207], ["NK cells", "PROBLEM", 241, 249], ["p", "TEST", 251, 252], ["PPN", "TEST", 264, 267], ["Fig 1A", "TEST", 278, 284], ["NK cells", "OBSERVATION", 241, 249]]], ["Next, we determined the abnormalities for each parameters Lymphopenia was observed at illness onset in 72.8% of non-severe COVID-19 patients (the PA group) in our study, which is similar to those reported by Zhang et al [15] (75.4%), Mo et al [17] (73.5%), Wang et al [27] (70.3%), and Guan et al [2] (83.2%), suggesting the involvement of lymphocytes in the early phase of SARS-CoV-2 infection.", [["lymphocytes", "ANATOMY", 340, 351], ["Lymphopenia", "DISEASE", 58, 69], ["illness", "DISEASE", 86, 93], ["COVID", "DISEASE", 123, 128], ["SARS", "DISEASE", 374, 378], ["infection", "DISEASE", 385, 394], ["patients", "ORGANISM", 132, 140], ["lymphocytes", "CELL", 340, 351], ["SARS-CoV-2", "ORGANISM", 374, 384], ["lymphocytes", "CELL_TYPE", 340, 351], ["patients", "SPECIES", 132, 140], ["SARS-CoV-2", "SPECIES", 374, 384], ["the abnormalities", "PROBLEM", 20, 37], ["each parameters Lymphopenia", "PROBLEM", 42, 69], ["non-severe COVID", "TEST", 112, 128], ["our study", "TEST", 159, 168], ["Wang et al", "TEST", 257, 267], ["Guan et al", "TEST", 286, 296], ["the involvement of lymphocytes", "PROBLEM", 321, 351], ["SARS", "PROBLEM", 374, 378], ["CoV", "PROBLEM", 379, 382], ["2 infection", "PROBLEM", 383, 394], ["lymphocytes", "OBSERVATION", 340, 351], ["early", "OBSERVATION_MODIFIER", 359, 364], ["phase", "OBSERVATION_MODIFIER", 365, 370], ["SARS", "OBSERVATION", 374, 378], ["infection", "OBSERVATION", 385, 394]]], ["Furthermore, lymphocyte count was reported to be correlated with disease severity.", [["lymphocyte", "ANATOMY", 13, 23], ["lymphocyte", "CELL", 13, 23], ["lymphocyte count", "TEST", 13, 29], ["disease severity", "PROBLEM", 65, 81], ["lymphocyte count", "OBSERVATION", 13, 29], ["disease", "OBSERVATION", 65, 72]]], ["Significant higher numbers of lymphocytes were found in survivors versus non-survivors [4] , as well as critically ill versus severe [13, 14] , and severe versus non-severe cases [15, 16] .", [["lymphocytes", "ANATOMY", 30, 41], ["critically ill", "DISEASE", 104, 118], ["lymphocytes", "CELL", 30, 41], ["lymphocytes", "CELL_TYPE", 30, 41], ["Significant higher numbers of lymphocytes", "PROBLEM", 0, 41], ["critically ill", "PROBLEM", 104, 118], ["severe versus non-severe cases", "PROBLEM", 148, 178], ["higher", "OBSERVATION_MODIFIER", 12, 18], ["numbers", "OBSERVATION_MODIFIER", 19, 26], ["lymphocytes", "OBSERVATION", 30, 41], ["severe", "OBSERVATION_MODIFIER", 148, 154]]], ["We focused on non-severe patients with persistent viral presence, and found that the PP group had markedly higher lymphocyte count (1.5 [1.3-1.8] vs 0.9 [0.7-1.3]; p<0.001) than the PA group, and were comparable to healthy subjects.", [["lymphocyte", "ANATOMY", 114, 124], ["patients", "ORGANISM", 25, 33], ["lymphocyte", "CELL", 114, 124], ["PA", "GENE_OR_GENE_PRODUCT", 182, 184], ["patients", "SPECIES", 25, 33], ["persistent viral presence", "PROBLEM", 39, 64], ["the PP group", "TEST", 81, 93], ["markedly higher lymphocyte count", "PROBLEM", 98, 130], ["persistent", "OBSERVATION_MODIFIER", 39, 49], ["viral", "OBSERVATION", 50, 55], ["higher lymphocyte count", "OBSERVATION", 107, 130]]], ["This finding, together with alleviated symptoms and improvements of other laboratory findings, indicated that PP patients might be in the process of recovery, albeit their viral RNA were still tested positive.", [["patients", "ORGANISM", 113, 121], ["viral RNA", "RNA", 172, 181], ["patients", "SPECIES", 113, 121], ["alleviated symptoms", "PROBLEM", 28, 47], ["their viral RNA", "TEST", 166, 181]]], ["We therefore examined lymphocyte subsets and found that PPP patients had significantly lower numbers of CD3 + T cells (p=0.001), CD4 + T cells (p=0.005), CD8 + T cells (p=0.003), and B cells (p=0.005) than PPN patients (Fig 1A and 1B ).", [["lymphocyte", "ANATOMY", 22, 32], ["CD3 + T cells", "ANATOMY", 104, 117], ["CD4 + T cells", "ANATOMY", 129, 142], ["CD8 + T cells", "ANATOMY", 154, 167], ["B cells", "ANATOMY", 183, 190], ["lymphocyte", "CELL", 22, 32], ["patients", "ORGANISM", 60, 68], ["CD3", "GENE_OR_GENE_PRODUCT", 104, 107], ["CD4", "GENE_OR_GENE_PRODUCT", 129, 132], ["CD8", "GENE_OR_GENE_PRODUCT", 154, 157], ["B cells", "CELL", 183, 190], ["patients", "ORGANISM", 210, 218], ["lymphocyte subsets", "CELL_TYPE", 22, 40], ["CD3", "PROTEIN", 104, 107], ["T cells", "CELL_TYPE", 110, 117], ["CD4", "PROTEIN", 129, 132], ["T cells", "CELL_TYPE", 135, 142], ["CD8", "PROTEIN", 154, 157], ["T cells", "CELL_TYPE", 160, 167], ["B cells", "CELL_TYPE", 183, 190], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 210, 218], ["lymphocyte subsets", "TEST", 22, 40], ["PPP", "TEST", 56, 59], ["CD3 + T cells", "PROBLEM", 104, 117], ["CD4", "TEST", 129, 132], ["T cells", "TEST", 135, 142], ["CD8", "TEST", 154, 157], ["T cells", "TEST", 160, 167], ["p", "TEST", 169, 170], ["B cells", "TEST", 183, 190], ["PPN", "TEST", 206, 209], ["Fig 1A", "TEST", 220, 226], ["lymphocyte subsets", "OBSERVATION", 22, 40]]], ["When compared with healthy subjects, PPP patients again exhibited much less CD3 + T cells (p=0.044), CD4 + T cells (p=0.034), and B cells (p=0.02) (Fig 2C and 2D ).", [["CD3 + T cells", "ANATOMY", 76, 89], ["CD4 + T cells", "ANATOMY", 101, 114], ["B cells", "ANATOMY", 130, 137], ["patients", "ORGANISM", 41, 49], ["CD3", "GENE_OR_GENE_PRODUCT", 76, 79], ["CD4", "GENE_OR_GENE_PRODUCT", 101, 104], ["B cells", "CELL", 130, 137], ["CD3", "PROTEIN", 76, 79], ["T cells", "CELL_TYPE", 82, 89], ["CD4", "PROTEIN", 101, 104], ["T cells", "CELL_TYPE", 107, 114], ["B cells", "CELL_TYPE", 130, 137], ["patients", "SPECIES", 41, 49], ["PPP", "TEST", 37, 40], ["CD4", "TEST", 101, 104], ["T cells", "TEST", 107, 114], ["p", "TEST", 116, 117], ["B cells", "TEST", 130, 137], ["Fig", "TEST", 148, 151]]], ["Most strikingly, 10 PPN patients showed markedly increased CD3 + T cells (p=0.001), CD4 + T cells (p=0.002), CD8 + T cells (p=0.009), and B cells (p=0.008) after they turned negative for SARS-CoV-2.", [["CD3 + T cells", "ANATOMY", 59, 72], ["CD4 + T cells", "ANATOMY", 84, 97], ["CD8 + T cells", "ANATOMY", 109, 122], ["B cells", "ANATOMY", 138, 145], ["patients", "ORGANISM", 24, 32], ["CD3", "GENE_OR_GENE_PRODUCT", 59, 62], ["CD4", "GENE_OR_GENE_PRODUCT", 84, 87], ["CD8", "GENE_OR_GENE_PRODUCT", 109, 112], ["B cells", "CELL", 138, 145], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 187, 197], ["CD3", "PROTEIN", 59, 62], ["T cells", "CELL_TYPE", 65, 72], ["CD4", "PROTEIN", 84, 87], ["T cells", "CELL_TYPE", 90, 97], ["CD8", "PROTEIN", 109, 112], ["T cells", "CELL_TYPE", 115, 122], ["B cells", "CELL_TYPE", 138, 145], ["patients", "SPECIES", 24, 32], ["SARS-CoV", "SPECIES", 187, 195], ["markedly increased CD3 + T cells", "PROBLEM", 40, 72], ["CD4", "TEST", 84, 87], ["T cells", "TEST", 90, 97], ["CD8", "TEST", 109, 112], ["T cells", "TEST", 115, 122], ["p", "TEST", 124, 125], ["B cells", "TEST", 138, 145], ["SARS", "TEST", 187, 191], ["CoV", "TEST", 192, 195]]], ["Together, these results suggest that measurement of these lymphocyte subpopulations could be used to distinguish non-severe patients with persistent viral presence from healthy subjects and those turned negative, and thus have clinical relevance for discharge management.", [["lymphocyte", "ANATOMY", 58, 68], ["lymphocyte", "CELL", 58, 68], ["patients", "ORGANISM", 124, 132], ["lymphocyte subpopulations", "CELL_TYPE", 58, 83], ["patients", "SPECIES", 124, 132], ["these lymphocyte subpopulations", "TEST", 52, 83], ["persistent viral presence", "PROBLEM", 138, 163], ["healthy subjects", "PROBLEM", 169, 185], ["discharge management", "TREATMENT", 250, 270], ["persistent", "OBSERVATION_MODIFIER", 138, 148], ["viral", "OBSERVATION", 149, 154]]], ["The latter can induce the activation and differentiation of cognate B cells, and subsequently promote the production of virus-specific antibodies, including neutralizing antibodies [29] .", [["B cells", "ANATOMY", 68, 75], ["B cells", "CELL", 68, 75], ["cognate B cells", "CELL_TYPE", 60, 75], ["virus-specific antibodies", "PROTEIN", 120, 145], ["neutralizing antibodies", "PROTEIN", 157, 180], ["cognate B cells", "PROBLEM", 60, 75], ["the production of virus", "PROBLEM", 102, 125], ["specific antibodies", "TEST", 126, 145], ["neutralizing antibodies", "TEST", 157, 180]]], ["In turn, neutralizing antibodies are able to mediate antibody-dependent cell-mediated cytotoxicity to kill virus-infected cells, 12 All rights reserved.", [["cell", "ANATOMY", 72, 76], ["cells", "ANATOMY", 122, 127], ["cell", "CELL", 72, 76], ["cells", "CELL", 122, 127], ["neutralizing antibodies", "PROTEIN", 9, 32], ["infected cells", "CELL_TYPE", 113, 127], ["neutralizing antibodies", "TEST", 9, 32], ["antibody", "TEST", 53, 61], ["dependent cell", "PROBLEM", 62, 76], ["mediated cytotoxicity", "PROBLEM", 77, 98], ["kill virus", "PROBLEM", 102, 112], ["infected cells", "PROBLEM", 113, 127], ["infected cells", "OBSERVATION", 113, 127]]], ["No reuse allowed without permission.Lymphocyte subsets in peripheral blood(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Lymphocyte subsets in peripheral bloodThe copyright holder for this preprint this version posted March 30, 2020. . and to block the entrance of extracellular virus [30] .", [["Lymphocyte", "ANATOMY", 36, 46], ["peripheral blood", "ANATOMY", 58, 74], ["Lymphocyte", "ANATOMY", 209, 219], ["peripheral blood", "ANATOMY", 231, 247], ["extracellular", "ANATOMY", 353, 366], ["Lymphocyte", "CELL", 36, 46], ["peripheral blood", "ORGANISM_SUBSTANCE", 58, 74], ["Lymphocyte", "CELL", 209, 219], ["peripheral blood", "ORGANISM_SUBSTANCE", 231, 247], ["extracellular virus", "ORGANISM", 353, 372], ["Lymphocyte subsets", "CELL_TYPE", 36, 54], ["Lymphocyte subsets", "CELL_TYPE", 209, 227], ["Lymphocyte subsets in peripheral blood", "PROBLEM", 36, 74], ["Lymphocyte subsets", "TEST", 209, 227], ["peripheral blood", "TEST", 231, 247], ["The copyright holder", "TREATMENT", 247, 267], ["extracellular virus", "PROBLEM", 353, 372], ["peripheral", "ANATOMY_MODIFIER", 58, 68], ["blood", "ANATOMY", 69, 74], ["med", "ANATOMY", 153, 156], ["peripheral", "ANATOMY_MODIFIER", 231, 241], ["blood", "ANATOMY", 242, 247]]], ["Therefore, it's not surprising that changes in these cells could reflect the viral presence.", [["cells", "ANATOMY", 53, 58], ["cells", "CELL", 53, 58], ["changes in these cells", "PROBLEM", 36, 58], ["the viral presence", "PROBLEM", 73, 91], ["viral", "OBSERVATION", 77, 82]]], ["Accordingly, T cell subsets were reported to be profoundly affected in severe cases with SARS-CoV-2 infection [16] .", [["T cell", "ANATOMY", 13, 19], ["SARS-CoV-2 infection", "DISEASE", 89, 109], ["T cell", "CELL", 13, 19], ["SARS-CoV-2", "ORGANISM", 89, 99], ["T cell subsets", "CELL_TYPE", 13, 27], ["SARS-CoV-2", "SPECIES", 89, 99], ["SARS", "PROBLEM", 89, 93], ["CoV-2 infection", "PROBLEM", 94, 109], ["severe", "OBSERVATION_MODIFIER", 71, 77]]], ["However, we could not determine from our data and the current knowledge whether SARS-CoV-2 can directly infect these lymphocytes, or indirectly caused these alterations.", [["lymphocytes", "ANATOMY", 117, 128], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 80, 90], ["lymphocytes", "CELL", 117, 128], ["lymphocytes", "CELL_TYPE", 117, 128], ["SARS-CoV", "SPECIES", 80, 88], ["SARS", "PROBLEM", 80, 84], ["these alterations", "PROBLEM", 151, 168]]], ["We did not find any difference in NK cells between the PPP group and healthy subjects, in terms of both absolute numbers and relative frequency (Fig 2A and 2D) .", [["NK cells", "ANATOMY", 34, 42], ["NK cells", "CELL", 34, 42], ["NK cells", "CELL_TYPE", 34, 42], ["NK cells", "OBSERVATION", 34, 42]]], ["Instead, NK cells were even higher in the PPP group than in the PPN group (p=0.02, Fig 1A) .", [["NK cells", "ANATOMY", 9, 17], ["NK cells", "CELL", 9, 17], ["NK cells", "CELL_TYPE", 9, 17], ["NK cells", "TEST", 9, 17], ["NK cells", "OBSERVATION", 9, 17], ["higher", "OBSERVATION_MODIFIER", 28, 34]]], ["As an innate immune cells, NK cells is among the first cell types to combat virus infection [31] .", [["immune cells", "ANATOMY", 13, 25], ["NK cells", "ANATOMY", 27, 35], ["cell", "ANATOMY", 55, 59], ["infection", "DISEASE", 82, 91], ["immune cells", "CELL", 13, 25], ["NK cells", "CELL", 27, 35], ["cell", "CELL", 55, 59], ["innate immune cells", "CELL_TYPE", 6, 25], ["NK cells", "CELL_TYPE", 27, 35], ["NK cells", "PROBLEM", 27, 35], ["combat virus infection", "PROBLEM", 69, 91], ["immune cells", "OBSERVATION", 13, 25], ["NK cells", "OBSERVATION", 27, 35]]], ["However, PP patients in our study were likely to be in the late phase of SARS-CoV-2 infection, during which the role of NK cells remained to be defined.Lymphocyte subsets in peripheral bloodSeveral limitations to the present study warrant mention.", [["NK cells", "ANATOMY", 120, 128], ["Lymphocyte", "ANATOMY", 152, 162], ["peripheral blood", "ANATOMY", 174, 190], ["SARS", "DISEASE", 73, 77], ["infection", "DISEASE", 84, 93], ["patients", "ORGANISM", 12, 20], ["SARS-CoV-2", "ORGANISM", 73, 83], ["NK cells", "CELL", 120, 128], ["Lymphocyte", "CELL", 152, 162], ["peripheral blood", "ORGANISM_SUBSTANCE", 174, 190], ["NK cells", "CELL_TYPE", 120, 128], ["Lymphocyte subsets", "CELL_TYPE", 152, 170], ["patients", "SPECIES", 12, 20], ["SARS-CoV", "SPECIES", 73, 81], ["PP", "TEST", 9, 11], ["our study", "TEST", 24, 33], ["SARS", "PROBLEM", 73, 77], ["CoV", "PROBLEM", 78, 81], ["2 infection", "PROBLEM", 82, 93], ["NK cells", "PROBLEM", 120, 128], ["Lymphocyte subsets", "TEST", 152, 170], ["peripheral blood", "TEST", 174, 190], ["the present study", "TEST", 213, 230], ["likely to be", "UNCERTAINTY", 39, 51], ["late phase", "OBSERVATION_MODIFIER", 59, 69], ["SARS", "OBSERVATION", 73, 77], ["infection", "OBSERVATION", 84, 93], ["NK cells", "OBSERVATION", 120, 128], ["peripheral", "ANATOMY_MODIFIER", 174, 184], ["blood", "ANATOMY", 185, 190]]], ["First, this retrospective study was conducted in a single hospital, which may result in selection bias.", [["this retrospective study", "TEST", 7, 31]]], ["Our conclusion could be further strengthened by a multicenter, prospective study in a randomized setting.", [["prospective study", "TEST", 63, 80]]], ["Second, only 37 non-severe COVID-19 patients with persistent viral presence were included in this investigation, interpretation of our findings might be limited by the sample size.", [["COVID", "DISEASE", 27, 32], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["persistent viral presence", "PROBLEM", 50, 75], ["this investigation", "TEST", 93, 111], ["persistent", "OBSERVATION_MODIFIER", 50, 60], ["viral", "OBSERVATION", 61, 66], ["size", "OBSERVATION_MODIFIER", 175, 179]]], ["Third, these patients were transferred to our hospital, we do not have their laboratory results and lymphocyte measurements at disease onset, we therefore randomly selected ageand sex-matched PA patients for comparison.", [["lymphocyte", "ANATOMY", 100, 110], ["patients", "ORGANISM", 13, 21], ["lymphocyte", "CELL", 100, 110], ["PA", "ORGANISM", 192, 194], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 195, 203], ["lymphocyte measurements", "TEST", 100, 123]]], ["Fourth, quantitative viral RNA detection and isolation of live virus were not performed due to limited resources in our hospital, which prevent us from building connections between lymphocyte subpopulations and these parameters.Lymphocyte subsets in peripheral bloodDespite these limitations, the present study, to the best of our knowledge, is the first investigation to examine changes of lymphocyte subpopulations in non-severe COVID-19 patients with persistent viral presence.", [["lymphocyte", "ANATOMY", 181, 191], ["Lymphocyte", "ANATOMY", 228, 238], ["peripheral blood", "ANATOMY", 250, 266], ["lymphocyte", "ANATOMY", 391, 401], ["COVID", "DISEASE", 431, 436], ["lymphocyte", "CELL", 181, 191], ["Lymphocyte", "CELL", 228, 238], ["peripheral blood", "ORGANISM_SUBSTANCE", 250, 266], ["lymphocyte", "CELL", 391, 401], ["patients", "ORGANISM", 440, 448], ["lymphocyte subpopulations", "CELL_TYPE", 181, 206], ["Lymphocyte subsets", "CELL_TYPE", 228, 246], ["lymphocyte subpopulations", "CELL_TYPE", 391, 416], ["patients", "SPECIES", 440, 448], ["quantitative viral RNA detection", "TEST", 8, 40], ["live virus", "PROBLEM", 58, 68], ["lymphocyte subpopulations", "TREATMENT", 181, 206], ["these parameters", "TEST", 211, 227], ["Lymphocyte subsets", "TEST", 228, 246], ["peripheral blood", "TEST", 250, 266], ["the present study", "TEST", 293, 310], ["lymphocyte subpopulations", "PROBLEM", 391, 416], ["non-severe COVID", "TEST", 420, 436], ["persistent viral presence", "PROBLEM", 454, 479], ["viral RNA", "OBSERVATION", 21, 30], ["lymphocyte subpopulations", "OBSERVATION", 181, 206], ["peripheral", "ANATOMY_MODIFIER", 250, 260], ["blood", "ANATOMY", 261, 266], ["lymphocyte subpopulations", "OBSERVATION", 391, 416], ["persistent", "OBSERVATION_MODIFIER", 454, 464], ["viral", "OBSERVATION", 465, 470]]], ["We found that CD4 + T cells, CD8 + T cells, and B cells were markedly decreased in these patients.", [["CD4 + T cells", "ANATOMY", 14, 27], ["CD8 + T cells", "ANATOMY", 29, 42], ["B cells", "ANATOMY", 48, 55], ["CD4", "GENE_OR_GENE_PRODUCT", 14, 17], ["CD8", "GENE_OR_GENE_PRODUCT", 29, 32], ["B cells", "CELL", 48, 55], ["patients", "ORGANISM", 89, 97], ["CD4", "PROTEIN", 14, 17], ["T cells", "CELL_TYPE", 20, 27], ["CD8 + T cells", "CELL_TYPE", 29, 42], ["B cells", "CELL_TYPE", 48, 55], ["patients", "SPECIES", 89, 97], ["CD4", "TEST", 14, 17], ["T cells", "TEST", 20, 27], ["CD8", "TEST", 29, 32], ["T cells", "TEST", 35, 42], ["B cells", "PROBLEM", 48, 55], ["markedly", "OBSERVATION_MODIFIER", 61, 69], ["decreased", "OBSERVATION_MODIFIER", 70, 79]]], ["Our findings suggest that monitoring lymphocyte subpopulations could be clinical meaningful in discharge management for non-severe COVID-19 patients with persistent viral presence.Funding 13All rights reserved.", [["lymphocyte", "ANATOMY", 37, 47], ["COVID", "DISEASE", 131, 136], ["lymphocyte", "CELL", 37, 47], ["patients", "ORGANISM", 140, 148], ["lymphocyte subpopulations", "CELL_TYPE", 37, 62], ["patients", "SPECIES", 140, 148], ["monitoring lymphocyte subpopulations", "PROBLEM", 26, 62], ["non-severe COVID", "TEST", 120, 136], ["persistent viral presence", "PROBLEM", 154, 179], ["persistent", "OBSERVATION_MODIFIER", 154, 164], ["viral", "OBSERVATION", 165, 170]]], ["No reuse allowed without permission.Funding 13(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Funding 13The copyright holder for this preprint this version posted March 30, 2020. .", [["The copyright holder", "TREATMENT", 191, 211], ["med", "ANATOMY", 125, 128]]], ["P values were obtained from \u03c7\u00b2 tests , Fisher's exact tests, T tests or Mann-Whitney U tests, when appropriate.", [["P", "DNA", 0, 1], ["P values", "TEST", 0, 8], ["\u03c7\u00b2 tests", "TEST", 28, 36], ["Fisher's exact tests", "TEST", 39, 59], ["T tests", "TEST", 61, 68], ["Whitney U tests", "TEST", 77, 92]]], ["P < 0.05 was considered statistically significant (in bold).Funding 13Abbreviations: COVID-19, coronavirus disease 19; PA (positive on admission); PP (persistently positive); NLR: Neutrophil-to-lymphocyte ratio; PLTs, platelets; Hb, hemoglobin; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; SAA, serum amyloid A.20All rights reserved.", [["lymphocyte", "ANATOMY", 194, 204], ["PLTs", "ANATOMY", 212, 216], ["platelets", "ANATOMY", 218, 227], ["serum", "ANATOMY", 353, 358], ["coronavirus disease", "DISEASE", 95, 114], ["alanine", "CHEMICAL", 264, 271], ["aspartate", "CHEMICAL", 295, 304], ["alanine", "CHEMICAL", 264, 271], ["aspartate", "CHEMICAL", 295, 304], ["coronavirus", "ORGANISM", 95, 106], ["PA", "GENE_OR_GENE_PRODUCT", 119, 121], ["Neutrophil", "CELL", 180, 190], ["lymphocyte", "CELL", 194, 204], ["PLTs", "CELL", 212, 216], ["platelets", "CELL", 218, 227], ["Hb", "GENE_OR_GENE_PRODUCT", 229, 231], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 233, 243], ["ALB", "GENE_OR_GENE_PRODUCT", 245, 248], ["albumin", "GENE_OR_GENE_PRODUCT", 250, 257], ["ALT", "SIMPLE_CHEMICAL", 259, 262], ["alanine", "AMINO_ACID", 264, 271], ["aminotransferase", "SIMPLE_CHEMICAL", 272, 288], ["AST", "SIMPLE_CHEMICAL", 290, 293], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 295, 321], ["CRP", "GENE_OR_GENE_PRODUCT", 323, 326], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 328, 346], ["SAA", "GENE_OR_GENE_PRODUCT", 348, 351], ["serum", "ORGANISM_SUBSTANCE", 353, 358], ["NLR", "PROTEIN", 175, 178], ["Neutrophil-to-lymphocyte ratio", "PROTEIN", 180, 210], ["PLTs", "CELL_TYPE", 212, 216], ["platelets", "CELL_TYPE", 218, 227], ["Hb", "PROTEIN", 229, 231], ["hemoglobin", "PROTEIN", 233, 243], ["ALB", "PROTEIN", 245, 248], ["albumin", "PROTEIN", 250, 257], ["ALT", "PROTEIN", 259, 262], ["alanine aminotransferase", "PROTEIN", 264, 288], ["AST", "PROTEIN", 290, 293], ["aspartate aminotransferase", "PROTEIN", 295, 321], ["CRP", "PROTEIN", 323, 326], ["C-reactive protein", "PROTEIN", 328, 346], ["SAA", "PROTEIN", 348, 351], ["COVID", "TEST", 85, 90], ["coronavirus disease", "PROBLEM", 95, 114], ["PA", "TEST", 119, 121], ["PP", "TEST", 147, 149], ["NLR", "TEST", 175, 178], ["Neutrophil", "TEST", 180, 190], ["lymphocyte ratio", "TEST", 194, 210], ["PLTs", "TEST", 212, 216], ["platelets", "TEST", 218, 227], ["Hb", "TEST", 229, 231], ["hemoglobin", "TEST", 233, 243], ["ALB", "TEST", 245, 248], ["albumin", "TEST", 250, 257], ["ALT", "TEST", 259, 262], ["alanine aminotransferase", "TEST", 264, 288], ["AST", "TEST", 290, 293], ["aspartate aminotransferase", "TEST", 295, 321], ["CRP", "TEST", 323, 326], ["C", "TEST", 328, 329], ["reactive protein", "TEST", 330, 346], ["SAA", "TEST", 348, 351], ["serum amyloid", "TEST", 353, 366]]], ["No reuse allowed without permission.20(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.20The copyright holder for this preprint this version posted March 30, 2020. .21All rights reserved.", [["The copyright holder", "TREATMENT", 175, 195], ["med", "ANATOMY", 117, 120]]], ["No reuse allowed without permission.21(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.21The copyright holder for this preprint this version posted March 30, 2020. . blood of PP patients were tested positive again at least 7 days after they were admitted to our hospital (PPP), and PP patients were tested negative in 7 days after they were admitted to our hospital (PPN).", [["blood", "ANATOMY", 252, 257], ["blood", "ORGANISM_SUBSTANCE", 252, 257], ["patients", "ORGANISM", 264, 272], ["patients", "ORGANISM", 371, 379], ["patients", "SPECIES", 264, 272], ["patients", "SPECIES", 371, 379], ["The copyright holder", "TREATMENT", 175, 195], ["blood of PP patients", "TEST", 252, 272], ["PPP", "TEST", 358, 361], ["PP", "TEST", 368, 370], ["med", "ANATOMY", 117, 120]]], ["P < 0.05 was considered statistically significant (in bold). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 140, 143], ["license", "OBSERVATION", 150, 157], ["med", "ANATOMY", 276, 279], ["license", "OBSERVATION", 286, 293]]]], "PMC7369595": [["Non-energy impacts of teleworking are also summarized, as they are an important part of policymaking, though not part of the comprehensive review.Spatial and temporal study boundaries ::: IntroductionTo answer the title question (does teleworking save energy?) or more generally quantify the environmental impacts of humans, one must carefully define the study scope and boundaries (Tillman, Ekvall et al. 1994).", [["humans", "ORGANISM", 317, 323], ["humans", "SPECIES", 317, 323], ["humans", "SPECIES", 317, 323]]], ["While secondary and tertiary effects and beyond are known to occur, a balance using judgment and existing knowledge must be made to define the appropriate study scope that is comprehensive enough to answer the question, yet not so onerous as to prevent the question from being answered in a reasonable timeframe and cost.Spatial and temporal study boundaries ::: IntroductionOn the basis of the literature review that was performed in preparation of this paper, in addition to the authors\u2019 experience, this review\u2019s scope is limited to transportation, office buildings, residential building, and information and communications technology (ICT), as illustrated in Figure 1.", [["the appropriate study scope", "TEST", 139, 166], ["tertiary effects", "OBSERVATION", 20, 36]]], ["Some obvious omissions to this review include embodied energy/carbon of buildings, vehicles, transportation infrastructure and ICT equipment, and food and clothing.Spatial and temporal study boundaries ::: IntroductionWhile this paper is focused on energy, GHG emissions cannot be neglected, as they are arguably more indicative of environmental impact.", [["carbon", "CHEMICAL", 62, 68], ["ICT equipment", "TREATMENT", 127, 140]]], ["Emission factors, but local infrastructure, construction types, climate, and availability of transit all cause studies to be somewhat locally specific [47].Spatial and temporal study boundaries ::: IntroductionThe objective of this paper is to synthesize the existing knowledge on the energy/GHG emission impact of teleworking and then identify gaps in knowledge and research methods.", [["Emission factors", "PROBLEM", 0, 16]]], ["For each domain, the potential energy savings, rebound effects, and research methods are reviewed as per the literature.", [["rebound effects", "PROBLEM", 47, 62], ["research methods", "TEST", 68, 84]]], ["Following the core literature review section, the overall verdict of the studies is summarized to provide some meta-evidence towards the title question: does teleworking save energy?", [["the studies", "TEST", 69, 80]]], ["Finally, the paper provides a forward-looking overview of research method and some closing thoughts.Potential ::: Transportation and urban form ::: Literature reviewThe primary benefit to the teleworker and environment alike is the reduction in distance travelled (often by single-occupancy vehicles) [36], Pendyala, Goulias et al. 1991, [41], [61], van Lier, de Witte et al. 2014).", [["research method", "TREATMENT", 58, 73], ["reduction", "OBSERVATION_MODIFIER", 232, 241]]], ["In principle, teleworkers can reduce their travel to zero on teleworking days.", [["teleworkers", "ORGANISM", 14, 25]]], ["Flexible commuting times benefits teleworkers and overall traffic congestion alike, which in turn can reduce energy use and emissions of vehicles.Potential ::: Transportation and urban form ::: Literature reviewThe potential of teleworking for reducing transportation energy use and GHG emissions also depends on the form of transportation it is replacing (van Lier, de Witte et al. 2014).", [["overall traffic congestion", "PROBLEM", 50, 76], ["GHG emissions", "TREATMENT", 283, 296], ["congestion", "OBSERVATION", 66, 76]]], ["In regions with a high proportion of walking, cycling, and public transportation, the benefit of teleworking is significantly less than in sprawling cities where commuters primarily rely on personal automobiles and with bad congestion.", [["bad congestion", "DISEASE", 220, 234], ["bad congestion", "PROBLEM", 220, 234], ["high", "OBSERVATION_MODIFIER", 18, 22], ["congestion", "OBSERVATION", 224, 234]]], ["Tang, Mokhtarian et al. (2011) found that individuals with positive views towards public transit and cycling and negative views about driving were more likely to telework.", [["public transit", "TEST", 82, 96]]], ["Some papers focused on individuals, others increased the spatial scope to the household level, while others used city or nation boundaries as their analysis scope.", [["their analysis scope", "TEST", 142, 162]]], ["The benefit of teleworking ranges from negative (e.g., [117]to very significant (e.g., [46], with many papers reporting modest improvements (e.g., Shabanpour, Golshani et al. 2018).", [["teleworking ranges", "TEST", 15, 33], ["modest", "OBSERVATION_MODIFIER", 120, 126], ["improvements", "OBSERVATION", 127, 139]]], ["As shown in Table 4, only four of the reviewed papers predicted an increase in travel distance, energy use, and/or emissions.", [["increase", "OBSERVATION_MODIFIER", 67, 75]]]], "PMC7480842": [["IntroductionSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the RNA virus that causes coronavirus disease 2019 (COVID-19).", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 19, 57], ["coronavirus disease", "DISEASE", 102, 121], ["SARS-CoV-2", "ORGANISM", 61, 71], ["IntroductionSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 0, 71], ["Acute Respiratory Syndrome", "PROBLEM", 19, 45], ["Coronavirus 2", "PROBLEM", 46, 59], ["SARS-CoV", "TEST", 61, 69], ["the RNA virus", "PROBLEM", 76, 89], ["coronavirus disease", "PROBLEM", 102, 121], ["COVID", "TEST", 128, 133], ["Acute", "OBSERVATION_MODIFIER", 19, 24], ["Respiratory Syndrome", "OBSERVATION", 25, 45], ["coronavirus disease", "OBSERVATION", 102, 121]]], ["This virus is responsible for a spectrum of disease presentation, which ranges from asymptomatic infection to severe pneumonia, respiratory failure, and death [1].", [["respiratory", "ANATOMY", 128, 139], ["infection", "DISEASE", 97, 106], ["pneumonia", "DISEASE", 117, 126], ["respiratory failure", "DISEASE", 128, 147], ["death", "DISEASE", 153, 158], ["This virus", "PROBLEM", 0, 10], ["disease presentation", "PROBLEM", 44, 64], ["asymptomatic infection", "PROBLEM", 84, 106], ["severe pneumonia", "PROBLEM", 110, 126], ["respiratory failure", "PROBLEM", 128, 147], ["death", "PROBLEM", 153, 158], ["responsible for", "UNCERTAINTY", 14, 29], ["disease", "OBSERVATION", 44, 51], ["asymptomatic", "OBSERVATION_MODIFIER", 84, 96], ["infection", "OBSERVATION", 97, 106], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["pneumonia", "OBSERVATION", 117, 126], ["respiratory failure", "OBSERVATION", 128, 147]]], ["To date, SARS-CoV-2 has caused a significant degree of morbidity and mortality within the United States, with a large proportion of these cases concentrated in New York City [1].", [["SARS-CoV-2", "ORGANISM", 9, 19], ["SARS-CoV", "SPECIES", 9, 17], ["SARS", "TEST", 9, 13], ["morbidity", "PROBLEM", 55, 64], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["morbidity", "OBSERVATION", 55, 64]]], ["Given the novelty of this virus, there is limited data on treating these patients.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["this virus", "PROBLEM", 21, 31]]], ["As a result, management protocols vary and are rapidly evolving with emerging data and clinical experiences.IntroductionThe use of systemic corticosteroids in the management of COVID-19 infection is widely debated.", [["corticosteroids", "CHEMICAL", 140, 155], ["COVID-19", "CHEMICAL", 177, 185], ["infection", "DISEASE", 186, 195], ["corticosteroids", "CHEMICAL", 140, 155], ["COVID-19", "ORGANISM", 177, 185], ["management protocols", "TREATMENT", 13, 33], ["systemic corticosteroids", "TREATMENT", 131, 155], ["COVID", "TEST", 177, 182], ["infection", "PROBLEM", 186, 195], ["infection", "OBSERVATION", 186, 195]]], ["The use of corticosteroids with influenza pneumonia has previously been associated with a higher risk of death [2,3] and delayed viral clearance during Severe Acute Respiratory Syndrome-related coronavirus (SARS) and Middle East Respiratory Syndrome (MERS) outbreaks [4\u20136].", [["corticosteroids", "CHEMICAL", 11, 26], ["influenza pneumonia", "DISEASE", 32, 51], ["death", "DISEASE", 105, 110], ["Acute Respiratory Syndrome-related coronavirus", "DISEASE", 159, 205], ["SARS", "DISEASE", 207, 211], ["Middle East Respiratory Syndrome", "DISEASE", 217, 249], ["MERS", "DISEASE", 251, 255], ["corticosteroids", "CHEMICAL", 11, 26], ["Severe Acute Respiratory Syndrome-related coronavirus", "SPECIES", 152, 205], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 217, 256], ["corticosteroids", "TREATMENT", 11, 26], ["influenza pneumonia", "PROBLEM", 32, 51], ["death", "PROBLEM", 105, 110], ["delayed viral clearance", "PROBLEM", 121, 144], ["Severe Acute Respiratory Syndrome", "PROBLEM", 152, 185], ["coronavirus (SARS)", "PROBLEM", 194, 212], ["Middle East Respiratory Syndrome", "PROBLEM", 217, 249], ["pneumonia", "OBSERVATION", 42, 51], ["viral clearance", "OBSERVATION", 129, 144], ["Severe", "OBSERVATION_MODIFIER", 152, 158], ["Acute", "OBSERVATION_MODIFIER", 159, 164], ["Respiratory Syndrome", "OBSERVATION", 165, 185], ["coronavirus", "OBSERVATION_MODIFIER", 194, 205], ["Middle", "ANATOMY_MODIFIER", 217, 223], ["Respiratory Syndrome", "OBSERVATION", 229, 249]]], ["Alternatively, few studies supported the use of corticosteroids at a low-to-moderate dose in patients with coronavirus and Influenza A (H1N1) and SARS pneumonia [7,8].", [["corticosteroids", "CHEMICAL", 48, 63], ["coronavirus", "DISEASE", 107, 118], ["Influenza A", "DISEASE", 123, 134], ["SARS pneumonia", "DISEASE", 146, 160], ["corticosteroids", "CHEMICAL", 48, 63], ["corticosteroids", "SIMPLE_CHEMICAL", 48, 63], ["patients", "ORGANISM", 93, 101], ["coronavirus", "ORGANISM", 107, 118], ["Influenza A (H1N1)", "ORGANISM", 123, 141], ["patients", "SPECIES", 93, 101], ["coronavirus", "SPECIES", 107, 118], ["Influenza A (H1N1)", "SPECIES", 123, 141], ["corticosteroids", "TREATMENT", 48, 63], ["a low-to-moderate dose", "TREATMENT", 67, 89], ["coronavirus", "PROBLEM", 107, 118], ["Influenza A (H1N1)", "PROBLEM", 123, 141], ["SARS pneumonia", "PROBLEM", 146, 160], ["pneumonia", "OBSERVATION", 151, 160]]], ["On the other hand, the World Health Organization has recommended against routine use of systemic corticosteroids to patients with COVID-19 [9]; nevertheless, a consensus statement by the Chinese Thoracic Society recommends judicious use of corticosteroids in these patients [10].", [["corticosteroids", "CHEMICAL", 97, 112], ["COVID-19", "CHEMICAL", 130, 138], ["corticosteroids", "CHEMICAL", 240, 255], ["patients", "ORGANISM", 116, 124], ["corticosteroids", "SIMPLE_CHEMICAL", 240, 255], ["patients", "ORGANISM", 265, 273], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 265, 273], ["systemic corticosteroids", "TREATMENT", 88, 112], ["COVID", "TEST", 130, 135], ["corticosteroids", "TREATMENT", 240, 255], ["Thoracic", "ANATOMY", 195, 203]]], ["Recently, RECOVERY trial demonstrated the beneficial clinical effect of dexamethasone among patients with COVID-19 who required oxygen with and without invasive mechanical ventilation [11].IntroductionAlthough RECOVERY trial demonstrated a beneficial effect of dexamethasone on mortality, there are no other analogous studies that have reproduced similar results, and the current study is unique in terms of dose, duration, and type of corticosteroids used.", [["dexamethasone", "CHEMICAL", 72, 85], ["oxygen", "CHEMICAL", 128, 134], ["dexamethasone", "CHEMICAL", 261, 274], ["dexamethasone", "CHEMICAL", 72, 85], ["oxygen", "CHEMICAL", 128, 134], ["dexamethasone", "CHEMICAL", 261, 274], ["dexamethasone", "SIMPLE_CHEMICAL", 72, 85], ["patients", "ORGANISM", 92, 100], ["oxygen", "SIMPLE_CHEMICAL", 128, 134], ["dexamethasone", "SIMPLE_CHEMICAL", 261, 274], ["patients", "SPECIES", 92, 100], ["dexamethasone", "TREATMENT", 72, 85], ["COVID", "TREATMENT", 106, 111], ["oxygen", "TREATMENT", 128, 134], ["invasive mechanical ventilation", "TREATMENT", 152, 183], ["dexamethasone", "TREATMENT", 261, 274], ["other analogous studies", "TEST", 302, 325], ["the current study", "TEST", 368, 385], ["corticosteroids", "TREATMENT", 436, 451]]], ["We performed a retrospective cohort study on patients admitted to the general inpatient wards with a diagnosis of COVID-19 pneumonia complicated by acute hypoxemic respiratory failure.", [["respiratory", "ANATOMY", 164, 175], ["COVID", "DISEASE", 114, 119], ["pneumonia", "DISEASE", 123, 132], ["hypoxemic respiratory failure", "DISEASE", 154, 183], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["a retrospective cohort study", "TEST", 13, 41], ["COVID", "TEST", 114, 119], ["pneumonia", "PROBLEM", 123, 132], ["acute hypoxemic respiratory failure", "PROBLEM", 148, 183], ["pneumonia", "OBSERVATION", 123, 132], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["hypoxemic", "OBSERVATION_MODIFIER", 154, 163], ["respiratory failure", "OBSERVATION", 164, 183]]], ["The purpose of this study was to determine the clinical efficacy of corticosteroids on outcomes of intensive care unit (ICU) transfer, intubation, in-hospital death, discharge, and length of stay.", [["corticosteroids", "CHEMICAL", 68, 83], ["death", "DISEASE", 159, 164], ["corticosteroids", "CHEMICAL", 68, 83], ["corticosteroids", "SIMPLE_CHEMICAL", 68, 83], ["this study", "TEST", 15, 25], ["corticosteroids", "TREATMENT", 68, 83], ["intubation", "TREATMENT", 135, 145]]], ["We hypothesized that systemic corticosteroid use would be associated with a lower risk of a composite endpoint of ICU transfer, intubation, or death.Study population ::: MethodsThis is a retrospective cohort study of confirmed cases of COVID-19 pneumonia hospitalized at Metropolitan Hospital Center serving the East Harlem community in New York City.", [["death", "DISEASE", 143, 148], ["pneumonia", "DISEASE", 245, 254], ["systemic corticosteroid use", "TREATMENT", 21, 48], ["intubation", "TREATMENT", 128, 138], ["death", "PROBLEM", 143, 148], ["Methods", "TREATMENT", 170, 177], ["a retrospective cohort study", "TEST", 185, 213], ["COVID", "TEST", 236, 241], ["pneumonia", "PROBLEM", 245, 254], ["pneumonia", "OBSERVATION", 245, 254]]], ["All patients were diagnosed with COVID-19 pneumonia as per the World Health Organization\u2019s interim guidance document [12].", [["pneumonia", "DISEASE", 42, 51], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["COVID-19 pneumonia", "PROBLEM", 33, 51], ["pneumonia", "OBSERVATION", 42, 51]]], ["We collected information on consecutive patients admitted to the general wards in Metropolitan Hospital from March 15, 2020, to April 30, 2020, as per our inclusion and exclusion criteria.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48]]], ["The ethics committee of New York City Health and Hospital (STAR) and BRANY institution review board approved this study and permitted a waiver of informed consent from the study participant.", [["participant", "SPECIES", 178, 189], ["this study", "TEST", 109, 119]]], ["We accessed the hospital databases from May 1st to 10th, 2020.Study population ::: MethodsPatients were eligible for the study if they met the following inclusion criteria 1) Age \u2265 18 years old, 2) Confirmed cases of SARS-CoV-2 by PCR method, 3) Admitted in general wards, 4) PaO2/FiO2 (PF) ratio <300 if arterial blood gas was available or SpO2/Fio2 (SF) ratio <440, 5) Bilateral infiltrate on chest imaging validated by radiology staff.", [["arterial blood", "ANATOMY", 305, 319], ["chest", "ANATOMY", 395, 400], ["SARS", "DISEASE", 217, 221], ["arterial", "MULTI-TISSUE_STRUCTURE", 305, 313], ["blood", "ORGANISM_SUBSTANCE", 314, 319], ["SARS-CoV", "SPECIES", 217, 225], ["the study", "TEST", 117, 126], ["SARS", "PROBLEM", 217, 221], ["CoV", "TEST", 222, 225], ["PaO2/FiO2 (PF) ratio", "TEST", 276, 296], ["arterial blood gas", "TEST", 305, 323], ["SpO2", "TEST", 341, 345], ["Fio2 (SF) ratio", "TEST", 346, 361], ["Bilateral infiltrate", "PROBLEM", 371, 391], ["chest imaging", "TEST", 395, 408], ["Bilateral", "ANATOMY_MODIFIER", 371, 380], ["infiltrate", "OBSERVATION", 381, 391], ["chest", "ANATOMY", 395, 400]]], ["The exclusion criteria were 1) Patients with severe immunosuppression (HIV infection, long term use of immunosuppressive agents), 2) Pregnant woman or Lactating women, 3) Oral glucocorticoids were needed for other diseases, 4) Direct admission to intensive care unit (ICU), 5) if had any of primary composite outcome within first 24 hours of admission, 6) Patient who never required oxygen during the hospital course, 7) Patients who left against medical advice.Procedure ::: MethodsA team of resident physicians reviewed and collected demographic, laboratory, clinical, and outcomes data from electronic medical records between March 15 and April 30, 2020.", [["Oral", "ANATOMY", 171, 175], ["immunosuppression", "DISEASE", 52, 69], ["HIV infection", "DISEASE", 71, 84], ["glucocorticoids", "CHEMICAL", 176, 191], ["oxygen", "CHEMICAL", 383, 389], ["oxygen", "CHEMICAL", 383, 389], ["Patients", "ORGANISM", 31, 39], ["women", "ORGANISM", 161, 166], ["oxygen", "SIMPLE_CHEMICAL", 383, 389], ["Patients", "ORGANISM", 421, 429], ["Patients", "SPECIES", 31, 39], ["woman", "SPECIES", 142, 147], ["women", "SPECIES", 161, 166], ["Patient", "SPECIES", 356, 363], ["Patients", "SPECIES", 421, 429], ["HIV", "SPECIES", 71, 74], ["severe immunosuppression (HIV infection", "PROBLEM", 45, 84], ["immunosuppressive agents", "TREATMENT", 103, 127], ["Lactating women", "TREATMENT", 151, 166], ["Oral glucocorticoids", "TREATMENT", 171, 191], ["other diseases", "PROBLEM", 208, 222], ["oxygen", "TREATMENT", 383, 389], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["immunosuppression", "OBSERVATION", 52, 69]]], ["Patient confidentiality was protected by allocating a deidentified patient identification, and the electronic data was stored in a locked, password-protected computer.Procedure ::: MethodsNasopharyngeal swab samples were obtained from all patients at admission and tested using real-time reverse transcriptase-polymerase chain reaction assays at LabCorp laboratory to identify SARS-CoV-2 infected patients.", [["Nasopharyngeal swab samples", "ANATOMY", 188, 215], ["SARS-CoV-2 infected", "DISEASE", 377, 396], ["patient", "ORGANISM", 67, 74], ["Nasopharyngeal swab samples", "CANCER", 188, 215], ["patients", "ORGANISM", 239, 247], ["SARS-CoV-2", "ORGANISM", 377, 387], ["patients", "ORGANISM", 397, 405], ["reverse transcriptase", "PROTEIN", 288, 309], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 67, 74], ["patients", "SPECIES", 239, 247], ["patients", "SPECIES", 397, 405], ["SARS-CoV", "SPECIES", 377, 385], ["MethodsNasopharyngeal swab samples", "TEST", 181, 215], ["SARS", "TEST", 377, 381], ["CoV", "TEST", 382, 385]]], ["The decision to give corticosteroids was at the discretion of the treating physician.", [["corticosteroids", "CHEMICAL", 21, 36], ["corticosteroids", "CHEMICAL", 21, 36], ["corticosteroids", "TREATMENT", 21, 36]]], ["All corticosteroid dosages were converted to the equivalent dose of methylprednisolone [13,14].", [["methylprednisolone", "CHEMICAL", 68, 86], ["methylprednisolone", "CHEMICAL", 68, 86], ["methylprednisolone", "SIMPLE_CHEMICAL", 68, 86], ["All corticosteroid dosages", "TREATMENT", 0, 26], ["methylprednisolone", "TREATMENT", 68, 86]]], ["The calculation of the SF ratio and PF ratio has been elaborated in the S1 File.", [["The calculation of the SF ratio", "TEST", 0, 31], ["PF ratio", "TEST", 36, 44], ["S1", "ANATOMY", 72, 74]]], ["In the study, the index date was not taken as the date of admission.", [["the study", "TEST", 3, 12]]], ["In the non-corticosteroid cohort, the index date was taken as the date when the patient\u2019s SF ratio went below 440, or the PF ratio went below 300.", [["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["the patient\u2019s SF ratio", "TEST", 76, 98], ["the PF ratio", "TEST", 118, 130]]], ["For the corticosteroid cohort, the date when corticosteroid was started was taken as the index date.Outcomes ::: MethodsOur primary outcome was the composite outcome of intensive care unit (ICU) transfer, intubation, or death.", [["death", "DISEASE", 220, 225], ["corticosteroid", "SIMPLE_CHEMICAL", 45, 59], ["the corticosteroid cohort", "TREATMENT", 4, 29], ["corticosteroid", "TREATMENT", 45, 59], ["intubation", "TREATMENT", 205, 215], ["death", "PROBLEM", 220, 225]]], ["Secondary outcomes were discharge, intensive care unit transfer, intubation, death, composite of intubation or death, length of stay, and a daily trend of SF ratio since the index date.Statistical analysis ::: MethodsBaseline characteristics of both cohorts were expressed using descriptive statistics.", [["death", "DISEASE", 77, 82], ["death", "DISEASE", 111, 116], ["intubation", "TREATMENT", 65, 75], ["death", "PROBLEM", 77, 82], ["intubation", "TREATMENT", 97, 107], ["death", "PROBLEM", 111, 116]]], ["The continuous variables were exhibited as a mean \u00b1 standard deviation or a median with interquartile range (IQR) for normal and non-normal distribution, respectively.", [["normal", "OBSERVATION", 118, 124], ["non-normal", "OBSERVATION_MODIFIER", 129, 139], ["distribution", "OBSERVATION_MODIFIER", 140, 152]]], ["Categorical variables were extrapolated in frequency and proportions.", [["Categorical variables", "PROBLEM", 0, 21]]], ["The t-test and Mann-Whitney-Wilcoxon tests were applied for normal and non-normal distribution, respectively, to compare continuous variables between two cohorts.", [["The t-test", "TEST", 0, 10], ["Mann-Whitney-Wilcoxon tests", "TEST", 15, 42]]], ["Fisher\u2019s exact test or Pearson\u2019s chi2 tests were implemented to compare categorical variables.Statistical analysis ::: MethodsTime to event (composite primary outcome and secondary outcomes) was defined as the time from the index date of the study to the specified events.", [["chi2 tests", "TEST", 33, 43], ["the study", "TEST", 238, 247]]], ["We used the cox-proportional hazard model to determine univariable and multivariable hazard ratio (HR) and 95% confidence interval (CI) for the corticosteroid group compared with non-corticosteroid group on the development of composite primary outcome, ICU transfer, intubation, death, composite of intubation or death, and discharge.", [["non-corticosteroid", "CHEMICAL", 179, 197], ["death", "DISEASE", 279, 284], ["death", "DISEASE", 313, 318], ["the cox-proportional hazard model", "TREATMENT", 8, 41], ["HR", "TEST", 99, 101], ["CI", "TEST", 132, 134], ["the corticosteroid group", "TREATMENT", 140, 164], ["intubation", "TREATMENT", 267, 277], ["death", "PROBLEM", 279, 284], ["intubation", "TREATMENT", 299, 309], ["death", "PROBLEM", 313, 318]]], ["The multivariable cox-proportional model included SF ratio, age, gender, chronic lung disease, white blood cell count, platelet count, tocilizumab, and therapeutic dose of Enoxaparin (for the construction of multivariate model\u2013S2 File).", [["lung", "ANATOMY", 81, 85], ["white blood cell", "ANATOMY", 95, 111], ["platelet", "ANATOMY", 119, 127], ["chronic lung disease", "DISEASE", 73, 93], ["tocilizumab", "CHEMICAL", 135, 146], ["Enoxaparin", "CHEMICAL", 172, 182], ["Enoxaparin", "CHEMICAL", 172, 182], ["lung", "ORGAN", 81, 85], ["white blood cell", "CELL", 95, 111], ["platelet", "CELL", 119, 127], ["tocilizumab", "SIMPLE_CHEMICAL", 135, 146], ["Enoxaparin", "SIMPLE_CHEMICAL", 172, 182], ["SF ratio", "TEST", 50, 58], ["chronic lung disease", "PROBLEM", 73, 93], ["white blood cell count", "TEST", 95, 117], ["platelet count", "TEST", 119, 133], ["tocilizumab", "TREATMENT", 135, 146], ["Enoxaparin", "TREATMENT", 172, 182], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["lung", "ANATOMY", 81, 85], ["disease", "OBSERVATION", 86, 93]]], ["We applied the test for proportionality assumption based on the Schoenfeld Residuals.", [["the test", "TEST", 11, 19], ["proportionality assumption", "TREATMENT", 24, 50], ["the Schoenfeld Residuals", "TEST", 60, 84]]], ["For the primary outcome and other secondary outcomes, we constructed Kaplan-Meier curves and used the log-rank test to compare.", [["Meier curves", "TEST", 76, 88], ["the log-rank test", "TEST", 98, 115]]], ["Censoring was applied on the day of discharge.", [["Censoring", "TREATMENT", 0, 9]]], ["Linear regression was used to show the difference between the length of stay between two cohorts.", [["Linear regression", "PROBLEM", 0, 17], ["regression", "OBSERVATION", 7, 17], ["length", "OBSERVATION_MODIFIER", 62, 68]]], ["Mixed-effects linear regression with restricted maximum likelihood was used to perform a longitudinal analysis to assess the trend of SF ratio over time between two cohorts.", [["linear regression", "PROBLEM", 14, 31], ["a longitudinal analysis", "TEST", 87, 110], ["linear", "OBSERVATION_MODIFIER", 14, 20], ["regression", "OBSERVATION_MODIFIER", 21, 31], ["restricted", "OBSERVATION_MODIFIER", 37, 47], ["maximum", "OBSERVATION_MODIFIER", 48, 55]]], ["The fixed-effect constant was suppressed, and unstructured residual errors were generated.", [["unstructured residual errors", "PROBLEM", 46, 74], ["fixed", "OBSERVATION_MODIFIER", 4, 9], ["residual errors", "OBSERVATION", 59, 74]]], ["A likelihood ratio test vs. linear model chi-square test was used to assess the appropriateness of using a multilevel model.", [["A likelihood ratio test", "TEST", 0, 23], ["linear model chi-square test", "TEST", 28, 56], ["a multilevel model", "TREATMENT", 105, 123]]], ["Missing data were not imputed.", [["Missing data", "TEST", 0, 12]]], ["All tests were 2-sided, and a P-value less than 0.05 was considered statistically significant.", [["All tests", "TEST", 0, 9], ["a P-value", "TEST", 28, 37]]], ["All analyses were performed with STATA software, version 16.0 (StataCorp LLC).Study population ::: ResultWe screened 265 consecutive patients admitted to the Metropolitan Hospital, New York Medical College, from March 15 to April 30, 2020, and included 205 patients in the final analysis of the study.", [["patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 257, 265], ["All analyses", "TEST", 0, 12], ["STATA software", "TEST", 33, 47], ["version", "TEST", 49, 56], ["the study", "TEST", 291, 300], ["LLC", "ANATOMY", 73, 76]]], ["The mean age of the entire cohort was 57.61\u00b115.86 years, 153 (74.63%) patients were male, and 149 (73.04%) patients were of Hispanic ethnicity/race.", [["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 107, 115], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["The common comorbidities were hypertension (103, 50.24%), obesity (84, 42%), and diabetes (83, 40.49%) (Table 1).", [["hypertension", "DISEASE", 30, 42], ["obesity", "DISEASE", 58, 65], ["diabetes", "DISEASE", 81, 89], ["The common comorbidities", "PROBLEM", 0, 24], ["hypertension", "PROBLEM", 30, 42], ["obesity", "PROBLEM", 58, 65], ["diabetes", "PROBLEM", 81, 89], ["common", "OBSERVATION_MODIFIER", 4, 10], ["comorbidities", "OBSERVATION", 11, 24], ["hypertension", "OBSERVATION", 30, 42], ["obesity", "OBSERVATION", 58, 65]]], ["At the time of analysis, a total of 14 patients (out of 205) were still admitted to the hospital.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["analysis", "TEST", 15, 23]]], ["Of 205 patients, 60 (29.27%) patients received systemic corticosteroids, and 145 (70.73%) patients did not receive it.Corticosteroid cohort ::: ResultPatients in the corticosteroid cohort received systemic corticosteroids in the form of methylprednisolone (n = 29, 48.33%), prednisone (n = 10, 16.67%), hydrocortisone (n = 1, 1.67%), and dexamethasone (n = 20, 33.33%).", [["methylprednisolone", "CHEMICAL", 237, 255], ["prednisone", "CHEMICAL", 274, 284], ["hydrocortisone", "CHEMICAL", 303, 317], ["dexamethasone", "CHEMICAL", 338, 351], ["methylprednisolone", "CHEMICAL", 237, 255], ["prednisone", "CHEMICAL", 274, 284], ["hydrocortisone", "CHEMICAL", 303, 317], ["dexamethasone", "CHEMICAL", 338, 351], ["patients", "ORGANISM", 7, 15], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 90, 98], ["methylprednisolone", "SIMPLE_CHEMICAL", 237, 255], ["prednisone", "SIMPLE_CHEMICAL", 274, 284], ["hydrocortisone", "SIMPLE_CHEMICAL", 303, 317], ["dexamethasone", "SIMPLE_CHEMICAL", 338, 351], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 90, 98], ["systemic corticosteroids", "TREATMENT", 47, 71], ["systemic corticosteroids", "TREATMENT", 197, 221], ["methylprednisolone", "TREATMENT", 237, 255], ["prednisone (n", "TREATMENT", 274, 287], ["hydrocortisone (n", "TREATMENT", 303, 320], ["dexamethasone", "TREATMENT", 338, 351]]], ["Corticosteroid was commenced at a median of 2 days (IQR, 1\u20135) following admission, on a median or equivalent dose of 80 mg per day (IQR, 60\u2013107) of Methylprednisolone (equivalent to 12 (IQR, 9\u201316) mg of dexamethasone) for a median duration of 5 days (IQR, 4\u20137) (Table 1).Comparison of the cohort with and without corticosteroid ::: ResultTable 1 demonstrates the baseline characteristics and outcomes of the study population separated by corticosteroid treatment.", [["Methylprednisolone", "CHEMICAL", 148, 166], ["dexamethasone", "CHEMICAL", 203, 216], ["Methylprednisolone", "CHEMICAL", 148, 166], ["dexamethasone", "CHEMICAL", 203, 216], ["Corticosteroid", "SIMPLE_CHEMICAL", 0, 14], ["Methylprednisolone", "SIMPLE_CHEMICAL", 148, 166], ["dexamethasone", "SIMPLE_CHEMICAL", 203, 216], ["corticosteroid", "SIMPLE_CHEMICAL", 438, 452], ["Corticosteroid", "TREATMENT", 0, 14], ["Methylprednisolone", "TREATMENT", 148, 166], ["dexamethasone", "TREATMENT", 203, 216], ["the study population", "TEST", 404, 424], ["corticosteroid treatment", "TREATMENT", 438, 462], ["corticosteroid treatment", "OBSERVATION", 438, 462]]], ["Mean patient age was similar in both the cohorts (corticosteroids, 58.67\u00b113.35 years; non-corticosteroid, 57.18\u00b116.81 years, [P = 0.543]).", [["corticosteroids", "CHEMICAL", 50, 65], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["corticosteroids", "TREATMENT", 50, 65], ["non-corticosteroid", "TEST", 86, 104]]], ["The corticosteroid cohort had more male patients as compared with the non-corticosteroid cohort (NCC) (86.67% vs. 69.97%, P = 0.011).", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["P", "TEST", 122, 123]]], ["There was no difference in the distribution of Hispanics race/ethnicity between two cohorts (corticosteroid, 77.97% vs. non-corticosteroid, 71.03%; P = 0.48).", [["corticosteroid", "TEST", 93, 107], ["non-corticosteroid", "TEST", 120, 138], ["P", "TEST", 148, 149], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["distribution", "OBSERVATION_MODIFIER", 31, 43]]], ["Patients among the NCC were more obese than the corticosteroid cohort (46.81% vs. 30.51%, P = 0.033).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["more obese", "PROBLEM", 28, 38], ["the corticosteroid cohort", "TEST", 44, 69], ["P", "TEST", 90, 91]]], ["The prevalence of other comorbidities was similar across both cohorts.", [["other comorbidities", "PROBLEM", 18, 37]]], ["Patients in the corticosteroid cohort had a low median SpO2/FiO2 (SF ratio) of 190 (IQR, 92.5\u2013298.44) compared with the median SF ratio of 339.29 (IQR, 278.13\u2013419.05) in the non-corticosteroid cohort (P < 0.001).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["FiO2 (SF ratio", "TEST", 60, 74], ["the median SF ratio", "TEST", 116, 135], ["IQR", "TEST", 147, 150]]], ["More percentage of patients in the corticosteroid cohort received Tocilizumab and therapeutic dose of enoxaparin compared with the non-corticosteroid cohort (18.33% vs. 4.83%, P = 0.002; 66.67% vs. 24.83%, P = <0.001, respectively).", [["Tocilizumab", "CHEMICAL", 66, 77], ["enoxaparin", "CHEMICAL", 102, 112], ["Tocilizumab", "CHEMICAL", 66, 77], ["enoxaparin", "CHEMICAL", 102, 112], ["patients", "ORGANISM", 19, 27], ["Tocilizumab", "SIMPLE_CHEMICAL", 66, 77], ["enoxaparin", "SIMPLE_CHEMICAL", 102, 112], ["patients", "SPECIES", 19, 27], ["the corticosteroid cohort", "TREATMENT", 31, 56], ["Tocilizumab", "TREATMENT", 66, 77], ["enoxaparin", "TREATMENT", 102, 112], ["the non-corticosteroid cohort", "TEST", 127, 156], ["P", "TEST", 176, 177], ["P", "TEST", 206, 207]]], ["Among the laboratory parameters, median platelet counts (278.5 vs. 200, P = <0.001), and median AST (55 vs. 44, P = 0.048) were higher in corticosteroid cohort compared to non-corticosteroid cohort.", [["platelet", "ANATOMY", 40, 48], ["platelet", "CELL", 40, 48], ["AST", "PROTEIN", 96, 99], ["the laboratory parameters", "TEST", 6, 31], ["median platelet counts", "TEST", 33, 55], ["P", "TEST", 72, 73], ["median AST", "TEST", 89, 99], ["P", "TEST", 112, 113], ["corticosteroid cohort", "TREATMENT", 138, 159], ["non-corticosteroid cohort", "TREATMENT", 172, 197]]], ["Among inflammatory markers, a median D-Dimer (653.5 vs. 377, P = 0.004) and C-reactive protein (21 vs. 12.1, P = 0.005) were higher in corticosteroid cohort compared to NCC.Comparison of patients with and without composite primary outcome ::: ResultA comparison of demographic, clinical, and laboratory parameters of patients with and without the composite primary outcome is demonstrated in Table 2.", [["NCC", "ANATOMY", 169, 172], ["D-Dimer", "CHEMICAL", 37, 44], ["D-Dimer", "GENE_OR_GENE_PRODUCT", 37, 44], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 76, 94], ["patients", "ORGANISM", 187, 195], ["patients", "ORGANISM", 317, 325], ["inflammatory markers", "PROTEIN", 6, 26], ["C-reactive protein", "PROTEIN", 76, 94], ["patients", "SPECIES", 187, 195], ["patients", "SPECIES", 317, 325], ["inflammatory markers", "TEST", 6, 26], ["a median D-Dimer", "TEST", 28, 44], ["P", "TEST", 61, 62], ["C", "TEST", 76, 77], ["reactive protein", "TEST", 78, 94], ["P", "TEST", 109, 110], ["corticosteroid cohort", "TREATMENT", 135, 156], ["laboratory parameters", "TEST", 292, 313], ["inflammatory", "OBSERVATION_MODIFIER", 6, 18], ["reactive", "OBSERVATION_MODIFIER", 78, 86]]], ["Patients with the primary outcome were older (64.52\u00b115.46 vs. 53.78\u00b114.78; OR = 1.62 per 10 years of age; 95% CI, 1.30\u20132.01; P <0.001), more hypertensive (67.16% vs. 40.74%; OR = 2.98; 95% CI, 1.61\u20135.5; P = 0.001) and had more coronary artery disease (20.9% vs. 5.19%; OR = 4.83; 95% CI, 1.85\u201312.64; P = 0.001).", [["coronary artery", "ANATOMY", 227, 242], ["hypertensive", "DISEASE", 141, 153], ["coronary artery disease", "DISEASE", 227, 250], ["Patients", "ORGANISM", 0, 8], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 227, 242], ["Patients", "SPECIES", 0, 8], ["CI", "TEST", 110, 112], ["P", "TEST", 125, 126], ["more hypertensive", "PROBLEM", 136, 153], ["CI", "TEST", 189, 191], ["P", "TEST", 203, 204], ["more coronary artery disease", "PROBLEM", 222, 250], ["OR", "TEST", 269, 271], ["CI", "TEST", 284, 286], ["P", "TEST", 300, 301], ["coronary artery", "ANATOMY", 227, 242], ["disease", "OBSERVATION", 243, 250]]], ["Patients with the primary outcome were more hypoxemic as indicated by lower median SF ratio (240, IQR (104.44\u2013361.91) vs. 339.29, IQR (266.67\u2013419.05); OR = 0.96 per 10 unit increase; 95% CI, 0.93\u20130.98; P = 0.001), and more critically ill as indicated by more patient with \u22655 Sequential Organ Failure Assessment Score (SOFA) (25.37% vs. 11.11%; OR = 2.72, 95% CI, 1.26\u20135.87; P = 0.011).", [["hypoxemic", "DISEASE", 44, 53], ["critically ill", "DISEASE", 223, 237], ["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 259, 266], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 259, 266], ["hypoxemic", "PROBLEM", 44, 53], ["IQR", "TEST", 130, 133], ["CI", "TEST", 187, 189], ["P", "TEST", 202, 203], ["Sequential Organ Failure", "PROBLEM", 275, 299], ["Score", "TEST", 311, 316], ["SOFA", "TEST", 318, 322], ["OR", "TEST", 344, 346], ["CI", "TEST", 359, 361], ["P", "TEST", 374, 375], ["Organ", "ANATOMY", 286, 291], ["Failure", "OBSERVATION", 292, 299]]], ["Amon primary outcome group, more patients received a therapeutic dose of Enoxaparin (55.22% vs. 27.41%; OR = 3.27; 95% CI 1.7\u20136.03; P <0.001).", [["Enoxaparin", "CHEMICAL", 73, 83], ["Enoxaparin", "CHEMICAL", 73, 83], ["patients", "ORGANISM", 33, 41], ["Enoxaparin", "SIMPLE_CHEMICAL", 73, 83], ["patients", "SPECIES", 33, 41], ["Enoxaparin", "TREATMENT", 73, 83], ["CI", "TEST", 119, 121], ["P", "TEST", 132, 133]]], ["Patients with primary outcome had elevated median value of all inflammatory markers such as D-dimer (878.5, IQR (336\u20133372) vs. 389, IQR (238\u2013798); OR = 1.05 per 1000 unit increase; 95% CI, 1.001\u20131.10; P = 0.045), and C-reactive protein (21.53, IQR (12.95\u201329.78) vs. 11.2, IQR (6.69\u201322.14); OR = 1.06; 95% CI, 1.02\u20131.10; P = 0.003).Primary outcome (composite of ICU transfer, intubation or death) ::: ResultOut of 202 eligible patients, 13 (22.41%) patients developed primary outcome in the corticosteroid cohort compared with 54 (37.5%) patients in the non-corticosteroid cohort (P = 0.039).", [["death", "DISEASE", 389, 394], ["Patients", "ORGANISM", 0, 8], ["D-dimer", "GENE_OR_GENE_PRODUCT", 92, 99], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 217, 235], ["patients", "ORGANISM", 426, 434], ["patients", "ORGANISM", 448, 456], ["patients", "ORGANISM", 537, 545], ["inflammatory markers", "PROTEIN", 63, 83], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 426, 434], ["patients", "SPECIES", 448, 456], ["patients", "SPECIES", 537, 545], ["elevated median value", "PROBLEM", 34, 55], ["all inflammatory markers", "PROBLEM", 59, 83], ["D-dimer", "TEST", 92, 99], ["IQR", "TEST", 108, 111], ["IQR", "TEST", 132, 135], ["CI", "TEST", 185, 187], ["P", "TEST", 201, 202], ["C", "TEST", 217, 218], ["reactive protein", "TEST", 219, 235], ["IQR", "TEST", 244, 247], ["IQR", "TEST", 272, 275], ["OR", "TEST", 290, 292], ["CI", "TEST", 305, 307], ["P", "TEST", 320, 321], ["the corticosteroid cohort", "TREATMENT", 486, 511], ["inflammatory", "OBSERVATION_MODIFIER", 63, 75]]], ["In both unadjusted and adjusted analysis, patients who received corticosteroids were less likely to have had a primary outcome [(unadjusted hazard ratio, 0.45; 95% CI, 0.24 to 0.82; P\u20140.009), (Table 3, Fig 1, Panel A), (adjusted hazard ratio, 0.15; 95% CI, 0.07 to 0.33; P < 0.001) (Table 3)].", [["corticosteroids", "CHEMICAL", 64, 79], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["adjusted analysis", "TEST", 23, 40], ["corticosteroids", "TREATMENT", 64, 79], ["ratio", "TEST", 147, 152], ["CI", "TEST", 164, 166], ["P", "TEST", 182, 183], ["Fig", "TEST", 202, 205], ["hazard ratio", "TEST", 229, 241], ["CI", "TEST", 253, 255]]], ["Proportionality assumption was not violated (global test P = 0.153).Secondary outcomes ::: ResultIn the corticosteroid cohort, 12 (20.69%) patients were transferred to ICU as compared with 47 (32.64%) patients in the non-corticosteroid cohort (P = 0.09).", [["patients", "ORGANISM", 139, 147], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 201, 209], ["Proportionality assumption", "TEST", 0, 26], ["global test P", "TEST", 45, 58], ["the corticosteroid cohort", "TREATMENT", 100, 125]]], ["In the unadjusted and adjusted Cox-analysis, patients who received corticosteroid were less likely to require ICU transfer [(unadjusted hazard ratio, 0.49; 95% CI, 0.26 to 0.93; P\u2013 0.029), (adjusted hazard ratio, 0.16; 95% CI, 0.07 to 0.34; P < 0.001)] (Table 3, S1 Fig).", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["corticosteroid", "TREATMENT", 67, 81], ["ratio", "TEST", 143, 148], ["CI", "TEST", 160, 162], ["P\u2013", "TEST", 178, 180], ["hazard ratio", "TEST", 199, 211], ["CI", "TEST", 223, 225], ["P", "TEST", 241, 242]]], ["In the corticosteroid cohort, 11 (18.97%) patients were intubated compared with 36 (25.35%) patients in the non-corticosteroid cohort (P = 0.33).", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 92, 100], ["the corticosteroid cohort", "TEST", 3, 28], ["intubated", "TREATMENT", 56, 65]]], ["In the unadjusted and adjusted Cox-analysis, patients who received corticosteroid were less likely to require intubation [(unadjusted hazard ratio, 0.66; 95% CI, 0.33 to 1.29; P\u2013 0.221), (adjusted hazard ratio, 0.31; 95% CI, 0.14 to 0.70; P\u2013 0.005)] (Table 3, S2 Fig).", [["patients", "ORGANISM", 45, 53], ["corticosteroid", "SIMPLE_CHEMICAL", 67, 81], ["patients", "SPECIES", 45, 53], ["corticosteroid", "TREATMENT", 67, 81], ["intubation", "TREATMENT", 110, 120], ["ratio", "TEST", 141, 146], ["CI", "TEST", 158, 160], ["P\u2013", "TEST", 176, 178], ["hazard ratio", "TEST", 197, 209], ["CI", "TEST", 221, 223], ["P\u2013", "TEST", 239, 241]]], ["In the corticosteroid cohort, 8 (14.55%) patients died compared with 34 (25%) patients in the non-corticosteroid cohort (P = 0.09).", [["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 78, 86]]], ["In the unadjusted and adjusted Cox-analysis, patients who received corticosteroid were less likely to die [(unadjusted hazard ratio, 0.62; 95% CI, 0.29 to 1.35; P\u2013 0.228), (adjusted hazard ratio, 0.53; 95% CI, 0.22 to 1.31; P\u2013 0.172)]; however, it was statistically non-significant (Table 3, Fig 1, Panel B).", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["corticosteroid", "TREATMENT", 67, 81], ["ratio", "TEST", 126, 131], ["CI", "TEST", 143, 145], ["P\u2013", "TEST", 161, 163], ["hazard ratio", "TEST", 182, 194], ["CI", "TEST", 206, 208], ["P\u2013", "TEST", 224, 226], ["Fig", "TEST", 292, 295]]], ["In the corticosteroid cohort, 13 (22.41%) patients intubated or died compared with 46 (31.94%) patients in the non-corticosteroid cohort (P = 0.178).", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 95, 103], ["the corticosteroid cohort", "TEST", 3, 28]]], ["In the unadjusted and adjusted Cox-analysis, patients who received corticosteroid were less likely to have a composite of intubation or death events [(unadjusted hazard ratio, 0.60; 95% CI, 0.33 to 1.12; P\u2013 0.108), (adjusted hazard ratio, 0.31; 95% CI, 0.15 to 0.66; P\u2013 0.002)] (Table 3, Fig 1, Panel C).", [["death", "DISEASE", 136, 141], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["corticosteroid", "TREATMENT", 67, 81], ["death events", "PROBLEM", 136, 148], ["ratio", "TEST", 169, 174], ["CI", "TEST", 186, 188], ["P\u2013", "TEST", 204, 206], ["hazard ratio", "TEST", 225, 237], ["CI", "TEST", 249, 251], ["P\u2013", "TEST", 267, 269]]], ["In the corticosteroid cohort, 47 (85.45%) patients were discharged compared with 102 (75%) patients in non-corticosteroid cohort (P = 0.11).", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 91, 99], ["the corticosteroid cohort", "TEST", 3, 28]]], ["In the unadjusted and adjusted Cox-analysis, patients who had received corticosteroid had more likely to be discharged [(unadjusted hazard ratio, 1.17; 95% CI, 0.83 to 1.65; P\u2013 0.380), (adjusted hazard ratio, 3.65; 95% CI, 2.20 to 6.06; P < 0.001)] (Table 3, S3 Fig).", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["corticosteroid", "TREATMENT", 71, 85], ["CI", "TEST", 156, 158], ["P\u2013", "TEST", 174, 176], ["hazard ratio", "TEST", 195, 207], ["CI", "TEST", 219, 221], ["P", "TEST", 237, 238], ["Table", "TEST", 250, 255]]], ["Proportionality assumptions were not violated for any of the secondary outcomes tested by Cox-regression.", [["Proportionality assumptions", "TEST", 0, 27]]], ["The median length of stay was higher in the corticosteroid cohort (9 days, IQR (6\u201317)) compared to the non-corticosteroid cohort (7 days, IQR (5\u201313.5); P = 0.025) (Tables 1 and 3).", [["IQR", "TEST", 138, 141], ["P", "TEST", 152, 153], ["median", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17], ["higher", "OBSERVATION_MODIFIER", 30, 36]]], ["Using multivariable linear regression, length of stay was lower in corticosteroid cohort but statistically non-significant (coefficient -1.06; 95% CI, -4.26 to 2.14; P = 0.515).Daily trend of SpO2/FiO2 since the index date ::: ResultFig 2 demonstrates the comparison of a daily trend of SF ratio between patients with and without corticosteroids.", [["FiO2", "CHEMICAL", 197, 201], ["corticosteroids", "CHEMICAL", 330, 345], ["SF", "GENE_OR_GENE_PRODUCT", 287, 289], ["patients", "ORGANISM", 304, 312], ["patients", "SPECIES", 304, 312], ["multivariable linear regression", "PROBLEM", 6, 37], ["coefficient", "TEST", 124, 135], ["CI", "TEST", 147, 149], ["P", "TEST", 166, 167], ["SpO2", "TEST", 192, 196], ["FiO2", "TREATMENT", 197, 201], ["SF ratio", "TEST", 287, 295], ["corticosteroids", "TREATMENT", 330, 345], ["linear", "OBSERVATION_MODIFIER", 20, 26], ["regression", "OBSERVATION_MODIFIER", 27, 37], ["length", "OBSERVATION_MODIFIER", 39, 45]]], ["The graph depicts that the corticosteroid cohort had lower baseline SF ratios (b = -185.97, p<0.001), SF ratio was found to increase over time (b = 24.48, p = 0.025).", [["the corticosteroid cohort", "TEST", 23, 48], ["lower baseline SF ratios", "PROBLEM", 53, 77], ["SF ratio", "TEST", 102, 110], ["increase", "OBSERVATION_MODIFIER", 124, 132]]], ["Furthermore, significant interactions between treatment and time demonstrated that the non-corticosteroid cohort experienced a decrease in SF ratio over time compared to the corticosteroid cohort, who were found to experience an increase in SF ratio over time.", [["treatment", "TREATMENT", 46, 55], ["a decrease in SF ratio", "PROBLEM", 125, 147], ["an increase in SF ratio", "PROBLEM", 226, 249], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["decrease", "OBSERVATION_MODIFIER", 127, 135], ["increase", "OBSERVATION_MODIFIER", 229, 237], ["SF ratio", "OBSERVATION", 241, 249]]], ["The likelihood ratio test vs. linear model chi-square test indicated that the use of a multilevel model was appropriate for the data.Limitations ::: DiscussionThis study has several limitations, given the observational nature of the study.", [["The likelihood ratio test", "TEST", 0, 25], ["linear model chi-square test", "TEST", 30, 58], ["a multilevel model", "TREATMENT", 85, 103], ["the data", "TEST", 124, 132], ["This study", "TEST", 159, 169], ["the study", "TEST", 229, 238]]], ["It is a single-center study, and most of the patients were Hispanic that limits the generalizability of the study.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["center study", "TEST", 15, 27], ["the study", "TEST", 104, 113]]], ["However, this study could be taken as a role of corticosteroid in the predominantly Hispanic population.", [["corticosteroid", "SIMPLE_CHEMICAL", 48, 62], ["this study", "TEST", 9, 19], ["corticosteroid", "TREATMENT", 48, 62], ["corticosteroid", "OBSERVATION", 48, 62], ["predominantly", "OBSERVATION_MODIFIER", 70, 83]]], ["There were missing data for inflammatory markers and potential inaccuracies in the documentation of variables from the electronic health records; however, as mentioned above, two authors made sure the accuracy of the collected database.", [["inflammatory markers", "PROTEIN", 28, 48], ["inflammatory markers", "PROBLEM", 28, 48], ["the collected database", "TEST", 213, 235]]], ["Due to the retrospective nature of the study, it was not possible to collect data on side effects such as secondary superimposed infection and hyperglycemia.", [["infection", "DISEASE", 129, 138], ["hyperglycemia", "DISEASE", 143, 156], ["the study", "TEST", 35, 44], ["side effects", "PROBLEM", 85, 97], ["secondary superimposed infection", "PROBLEM", 106, 138], ["hyperglycemia", "PROBLEM", 143, 156], ["superimposed", "OBSERVATION_MODIFIER", 116, 128], ["infection", "OBSERVATION", 129, 138], ["hyperglycemia", "OBSERVATION", 143, 156]]], ["Authors believe that the physicians are familiar with the side effects of corticosteroid and ways to prevent and treat its complications as it is a long-known drug compared with newer medications on which we have very limited data.", [["corticosteroid", "SIMPLE_CHEMICAL", 74, 88], ["corticosteroid", "TREATMENT", 74, 88], ["its complications", "PROBLEM", 119, 136], ["a long-known drug", "PROBLEM", 146, 163], ["newer medications", "TREATMENT", 178, 195]]], ["Due to missing data for inflammatory markers, adjustment with those variables was not possible.", [["inflammatory markers", "PROTEIN", 24, 44], ["inflammatory markers", "PROBLEM", 24, 44]]], ["We did not have longitudinal data with follow-up.", [["longitudinal data", "TEST", 16, 33]]], ["A randomized clinical trial is the best approach to determine whether the benefit can be ascribed to any given therapeutic intervention as the trial design diminishes the two major hurdles of observational studies, namely unmeasured confounding and bias.", [["A randomized clinical trial", "TREATMENT", 0, 27], ["therapeutic intervention", "TREATMENT", 111, 135], ["observational studies", "TEST", 192, 213]]], ["A randomized clinical trial from China has been registered in which patients were randomly assigned to receive 1 mg/kg methylprednisolone (NCT04273321) or placebo.", [["methylprednisolone", "CHEMICAL", 119, 137], ["NCT04273321", "CHEMICAL", 139, 150], ["methylprednisolone", "CHEMICAL", 119, 137], ["NCT04273321", "CHEMICAL", 139, 150], ["patients", "ORGANISM", 68, 76], ["methylprednisolone", "SIMPLE_CHEMICAL", 119, 137], ["NCT04273321", "SIMPLE_CHEMICAL", 139, 150], ["patients", "SPECIES", 68, 76], ["methylprednisolone", "TREATMENT", 119, 137], ["placebo", "TREATMENT", 155, 162]]], ["The authors tried to minimize confounding by choosing the best possible model in multivariable regression in this retrospective cohort study.ConclusionsIn our analysis of hospitalized patients in the general ward with COVID-19 pneumonia complicated by acute hypoxic respiratory failure, early use of moderate dose systemic corticosteroid for the shorter duration was associated with a significantly lower rate of the primary outcomes of ICU transfer, intubation, or in-hospital death.", [["respiratory", "ANATOMY", 266, 277], ["pneumonia", "DISEASE", 227, 236], ["hypoxic respiratory failure", "DISEASE", 258, 285], ["death", "DISEASE", 478, 483], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192], ["this retrospective cohort study", "TEST", 109, 140], ["COVID", "TEST", 218, 223], ["pneumonia", "PROBLEM", 227, 236], ["acute hypoxic respiratory failure", "PROBLEM", 252, 285], ["moderate dose systemic corticosteroid", "TREATMENT", 300, 337], ["intubation", "TREATMENT", 451, 461], ["pneumonia", "OBSERVATION", 227, 236], ["acute", "OBSERVATION_MODIFIER", 252, 257], ["hypoxic", "OBSERVATION_MODIFIER", 258, 265], ["respiratory failure", "OBSERVATION", 266, 285], ["moderate", "OBSERVATION_MODIFIER", 300, 308]]], ["Given the observational design, the study should be interpreted with caution due to potential bias and residual confounders.", [["the study", "TEST", 32, 41], ["potential bias and residual confounders", "PROBLEM", 84, 123]]]], "af28adc6a41677cbd662c0efe1ea79aad512217c": [["INTRODUCTION COVID-19, a disease caused by the SARS-CoV-2 virus, was first reported in early December 2019 in Wuhan China.", [["COVID-19", "CELL", 13, 21], ["SARS-CoV-2 virus", "ORGANISM", 47, 63], ["CoV-2 virus", "SPECIES", 52, 63], ["SARS-CoV-2 virus", "SPECIES", 47, 63], ["a disease", "PROBLEM", 23, 32], ["the SARS-CoV-2 virus", "PROBLEM", 43, 63]]], ["1 The number of patients confirmed to have the disease rapidly increased and on 30 January 2020, and the disease was declared a public health emergency of international concern by the WHO.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["the disease", "PROBLEM", 43, 54], ["the disease", "PROBLEM", 101, 112], ["disease", "OBSERVATION", 47, 54], ["rapidly", "OBSERVATION_MODIFIER", 55, 62], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["disease", "OBSERVATION", 105, 112]]], ["As of 16 May 2020, a total of 4 396 392 confirmed cases and 300 441 deaths (6.8%) had been reported globally.", [["deaths", "DISEASE", 68, 74]]], ["2 In Africa, 75 498 cases and 2561 (3.4%) deaths had been reported by 16 May 2020.", [["deaths", "DISEASE", 42, 48]]], ["3 Africa faces many well-documented barriers to addressing pandemics, and COVID-19 has the potential to strain existing health infrastructure.", [["pandemics", "PROBLEM", 59, 68], ["COVID", "TREATMENT", 74, 79]]]], "8fe6466497dfb5ff2f1648153ef36f3d8b2ac262": [["As such, both the disease and the associated response measures heightened risk factors in already vulnerable populations, including families at risk for separation and children outside of parental care (Desai, 2020; Wang, Zhang, Zhao, Zhang, & Jiang, 2020) .", [["children", "ORGANISM", 168, 176], ["children", "SPECIES", 168, 176], ["the disease", "PROBLEM", 14, 25], ["disease", "OBSERVATION", 18, 25]]], ["Moreover, public and private service providers who served vulnerable children and families struggled to adapt programs and adequately meet the evolving needs of this population during the pandemic.", [["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77], ["this population", "PROBLEM", 161, 176]]], ["The present paper sought to 1) delineate the impact of the pandemic on vulnerable children and families and the organizations that served them and 2) provide data-informed recommendations for non-government organizations (NGOs) and public service providers to better support this population.", [["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90]]]], "PMC7213959": [["IntroductionRespiratory illness caused by a novel coronavirus was first noted in December of 2019 in Wuhan, Hubei Province, China (Zhu, et al. 2020).", [["IntroductionRespiratory illness", "DISEASE", 0, 31], ["coronavirus", "ORGANISM", 50, 61], ["IntroductionRespiratory illness", "PROBLEM", 0, 31], ["a novel coronavirus", "PROBLEM", 42, 61]]], ["The novel coronavirus is now referred to as severe and critical acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV).", [["acute respiratory syndrome coronavirus", "DISEASE", 64, 102], ["coronavirus", "ORGANISM", 10, 21], ["SARS-CoV", "SPECIES", 106, 114], ["ICTV", "SPECIES", 173, 177], ["The novel coronavirus", "PROBLEM", 0, 21], ["critical acute respiratory syndrome coronavirus", "PROBLEM", 55, 102], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["coronavirus", "OBSERVATION", 10, 21], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["respiratory syndrome", "OBSERVATION", 70, 90]]], ["The SARS-CoV-2 was transmitted through respiratory tract and could induce pneumonia (Chen, et al. 2020; Chu, et al. 2020).", [["respiratory tract", "ANATOMY", 39, 56], ["SARS", "DISEASE", 4, 8], ["pneumonia", "DISEASE", 74, 83], ["SARS-CoV-2", "ORGANISM", 4, 14], ["respiratory tract", "ORGANISM_SUBDIVISION", 39, 56], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["pneumonia", "PROBLEM", 74, 83], ["respiratory tract", "ANATOMY", 39, 56], ["pneumonia", "OBSERVATION", 74, 83]]], ["By 6 April, WHO has reported of 1, 210, 956 laboratory-confirmed cases of SARS-CoV-2 infection and 67,594 deaths worldwide (WHO, 2020).", [["SARS-CoV-2 infection", "DISEASE", 74, 94], ["deaths", "DISEASE", 106, 112], ["SARS-CoV-2", "ORGANISM", 74, 84], ["CoV-2", "SPECIES", 79, 84], ["SARS-CoV-2", "SPECIES", 74, 84], ["SARS", "PROBLEM", 74, 78], ["CoV", "PROBLEM", 79, 82], ["2 infection", "PROBLEM", 83, 94]]], ["The current outbreaks of coronavirus infection remind us that CoVs are still a severe and critical threats to global public health.IntroductionThere are no proven antiviral therapies or vaccines till now.", [["coronavirus infection", "DISEASE", 25, 46], ["coronavirus", "ORGANISM", 25, 36], ["CoVs", "SIMPLE_CHEMICAL", 62, 66], ["coronavirus", "SPECIES", 25, 36], ["coronavirus infection", "PROBLEM", 25, 46], ["antiviral therapies", "TREATMENT", 163, 182], ["vaccines", "TREATMENT", 186, 194], ["coronavirus infection", "OBSERVATION", 25, 46], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["no proven", "UNCERTAINTY", 153, 162], ["antiviral therapies", "OBSERVATION", 163, 182]]], ["Thus, the best way to deal with severe and critical infections of SARS-CoV-2 is to control the source of infection, early diagnosis, quarantine and supportive treatments.", [["infections", "DISEASE", 52, 62], ["SARS", "DISEASE", 66, 70], ["infection", "DISEASE", 105, 114], ["SARS-CoV-2", "ORGANISM", 66, 76], ["SARS-CoV", "SPECIES", 66, 74], ["severe and critical infections of SARS", "PROBLEM", 32, 70], ["CoV", "TEST", 71, 74], ["infection", "PROBLEM", 105, 114], ["quarantine", "TREATMENT", 133, 143], ["supportive treatments", "TREATMENT", 148, 169], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["critical", "OBSERVATION_MODIFIER", 43, 51], ["infections", "OBSERVATION", 52, 62], ["infection", "OBSERVATION", 105, 114]]], ["It is difficult for physicians to distinguish causative agents without a laboratory diagnosis due to the similar clinical presentations of different pathogens.", [["different pathogens", "PROBLEM", 139, 158], ["different", "OBSERVATION_MODIFIER", 139, 148], ["pathogens", "OBSERVATION", 149, 158]]], ["Therefore, the fast and accurate diagnosis of SARS-CoV-2 are particularly important for patients.", [["SARS", "DISEASE", 46, 50], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["SARS-CoV", "SPECIES", 46, 54], ["SARS", "PROBLEM", 46, 50]]], ["However, most studies only focused on SARS-CoV-2, while the co-infection with SARS-CoV-2 has been somewhat neglected.", [["co-infection", "DISEASE", 60, 72], ["SARS", "DISEASE", 78, 82], ["SARS-CoV-2", "ORGANISM", 38, 48], ["SARS-CoV-2", "ORGANISM", 78, 88], ["SARS-CoV", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 78, 86], ["most studies", "TEST", 9, 21], ["SARS", "TEST", 38, 42], ["CoV", "TEST", 43, 46], ["the co-infection", "PROBLEM", 56, 72], ["SARS", "PROBLEM", 78, 82], ["CoV", "TEST", 83, 86], ["co-infection", "OBSERVATION", 60, 72], ["somewhat", "OBSERVATION_MODIFIER", 98, 106], ["neglected", "OBSERVATION", 107, 116]]], ["Co-infection with certain pathogens may also hinder accurate disease diagnosis.", [["Co-infection", "DISEASE", 0, 12], ["Co-infection", "PROBLEM", 0, 12], ["certain pathogens", "PROBLEM", 18, 35]]], ["Wang et al. presented the latest status of the SARS-CoV-2 co-infection in China and added details on combined bacterial and fungal infections (Wang, et al. 2020).", [["SARS", "DISEASE", 47, 51], ["co-infection", "DISEASE", 58, 70], ["bacterial and fungal infections", "DISEASE", 110, 141], ["SARS-CoV-2", "ORGANISM", 47, 57], ["the SARS", "PROBLEM", 43, 51], ["CoV", "PROBLEM", 52, 55], ["2 co-infection", "PROBLEM", 56, 70], ["combined bacterial and fungal infections", "PROBLEM", 101, 141], ["fungal infections", "OBSERVATION", 124, 141]]], ["However, the types of co-infected pathogens and the proportion of co-infection in SARS-CoV-2-positive patients are unclear.", [["co-infection", "DISEASE", 66, 78], ["SARS", "DISEASE", 82, 86], ["SARS-CoV-2", "ORGANISM", 82, 92], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["SARS-CoV", "SPECIES", 82, 90], ["co-infected pathogens", "PROBLEM", 22, 43], ["co-infection", "PROBLEM", 66, 78], ["SARS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["co-infected", "OBSERVATION_MODIFIER", 22, 33], ["pathogens", "OBSERVATION", 34, 43], ["co-infection", "OBSERVATION", 66, 78]]], ["In this study, the clinical features of COVID-19 patients were analyzed, then 39 respiratory pathogens in their throat swab were detected by specific real-time RT-PCR.", [["throat swab", "ANATOMY", 112, 123], ["patients", "ORGANISM", 49, 57], ["throat", "ORGANISM", 112, 118], ["swab", "ORGANISM_SUBSTANCE", 119, 123], ["patients", "SPECIES", 49, 57], ["this study", "TEST", 3, 13], ["COVID", "TEST", 40, 45], ["39 respiratory pathogens", "PROBLEM", 78, 102], ["their throat swab", "TEST", 106, 123]]], ["This study will provide a reference for epidemic prevention and clinical treatment in Wuhan and other areas combating this epidemic.Clinical data and specimens collection ::: Materials and methodsFrom Jan 22 to Feb 2, 2020, 257 throat swab samples with initial positive real-time RT-PCR results were collected from local hospital in Jiangsu Province.", [["specimens", "ANATOMY", 150, 159], ["throat swab samples", "ANATOMY", 228, 247], ["throat swab samples", "CANCER", 228, 247], ["This study", "TEST", 0, 10], ["epidemic prevention", "TREATMENT", 40, 59], ["clinical treatment", "TREATMENT", 64, 82], ["Clinical data", "TEST", 132, 145], ["specimens collection", "TEST", 150, 170], ["throat swab samples", "TEST", 228, 247], ["RT-PCR", "TEST", 280, 286]]], ["The samples were taken immediately from each COVID-19 patient on admission.", [["samples", "ANATOMY", 4, 11], ["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["The samples", "TEST", 0, 11]]], ["All procedures conducted in this study involving human materials were approved by the Jiangsu Provincial Center for Disease Control Ethics Committee.Detection respiratory pathogens ::: Materials and methodsFirstly, SARS-CoV-2 was re-confirmed by real-time RT-PCR using the same protocol described previously (Chu, et al. 2020; Huang, et al. 2020).", [["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["SARS-CoV", "SPECIES", 215, 223], ["All procedures", "TREATMENT", 0, 14], ["this study", "TEST", 28, 38], ["methodsFirstly", "TEST", 199, 213]]], ["Other 39 respiratory pathogens including influenza A (FluA), influenza B (FluB), human respiratory syncytial virus (RSV), parainfluenza types 1, 2, 3 and 4 (PIV1, 2, 3, 4), human metapneumovirus (HMPV), coronaviruses 229E, OC43, NL63 and HKU1 (HCoV-229E, HCoV\u2212OC43, HCoV-NL63, HCoV-HKU1), human bocavirus adenovirus (HBoV), human adenovirus (HAdV), human rhinovirus (HRV), herpes simplex virus (HSV), cytomegalovirus (CMV), EB virus (EBV), Mycoplasma pneumonia (MP), Chlamydia pneumoniae (CP), Legionella pneumoniae(LP), Haemophilus influenzae (Hi), Moraxella catarrhalis (MC), Klebsiella pneumoniae (KP), Streptococcus pneumoniae (S.pneumoniae), Mycobacterium tuberculosis (TB), Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), Acinetobacter baumannii (A. baumannii), Pseudomonas aeruginosa (P. aeruginosa), pneumocystis carinii (PC), Bordetella pertussis and fungi (Aspergillus, Cryptococcus, Cryptococcus neoformans A, B, Mucor, Candida, Histoplasma capsulatum) were also detected using pathogen specific real-time RT-PCR as previously described (Zhu, et al. 2019).Statistical analysis ::: Materials and methodsKruskal-Wallis H-test was used to compare continuous variables among multiple groups, and Dunnett test was used for pair-wise comparison; categorical variables were expressed as number (%) and compared by Chi-square test or Fisher\u2019s exact test among multiple groups.", [["PC", "ANATOMY", 845, 847], ["influenza B", "DISEASE", 61, 72], ["respiratory syncytial virus", "DISEASE", 87, 114], ["parainfluenza", "DISEASE", 122, 135], ["human metapneumovirus", "DISEASE", 173, 194], ["herpes simplex virus (HSV), cytomegalovirus (CMV), EB virus", "DISEASE", 373, 432], ["Mycoplasma pneumonia", "DISEASE", 440, 460], ["Chlamydia pneumoniae", "DISEASE", 467, 487], ["Legionella pneumoniae", "DISEASE", 494, 515], ["Haemophilus influenzae", "DISEASE", 521, 543], ["Klebsiella pneumoniae", "DISEASE", 578, 599], ["Streptococcus pneumoniae", "DISEASE", 606, 630], ["Mycobacterium tuberculosis", "DISEASE", 647, 673], ["TB", "DISEASE", 675, 677], ["Staphylococcus aureus", "DISEASE", 708, 729], ["pneumocystis carinii", "DISEASE", 823, 843], ["Bordetella pertussis", "DISEASE", 850, 870], ["influenza A", "ORGANISM", 41, 52], ["FluA", "GENE_OR_GENE_PRODUCT", 54, 58], ["influenza B (FluB)", "ORGANISM", 61, 79], ["human respiratory syncytial virus", "ORGANISM", 81, 114], ["RSV", "ORGANISM", 116, 119], ["parainfluenza types 1", "ORGANISM", 122, 143], ["2", "GENE_OR_GENE_PRODUCT", 145, 146], ["3", "GENE_OR_GENE_PRODUCT", 148, 149], ["4", "GENE_OR_GENE_PRODUCT", 154, 155], ["PIV1", "GENE_OR_GENE_PRODUCT", 157, 161], ["2", "GENE_OR_GENE_PRODUCT", 163, 164], ["3", "GENE_OR_GENE_PRODUCT", 166, 167], ["human metapneumovirus", "ORGANISM", 173, 194], ["HMPV", "ORGANISM", 196, 200], ["coronaviruses 229E", "ORGANISM", 203, 221], ["OC43", "GENE_OR_GENE_PRODUCT", 223, 227], ["NL63", "GENE_OR_GENE_PRODUCT", 229, 233], ["HKU1", "GENE_OR_GENE_PRODUCT", 238, 242], ["HCoV-229E", "ORGANISM", 244, 253], ["HCoV\u2212OC43", "CELL", 255, 264], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 266, 275], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 277, 286], ["human bocavirus adenovirus", "ORGANISM", 289, 315], ["HBoV", "ORGANISM", 317, 321], ["human adenovirus (HAdV)", "ORGANISM", 324, 347], ["human rhinovirus (HRV),", "ORGANISM", 349, 372], ["herpes simplex virus", "ORGANISM", 373, 393], ["HSV", "ORGANISM", 395, 398], ["cytomegalovirus", "ORGANISM", 401, 416], ["CMV", "ORGANISM", 418, 421], ["EB virus", "ORGANISM", 424, 432], ["EBV", "ORGANISM", 434, 437], ["Mycoplasma pneumonia", "ORGANISM", 440, 460], ["MP", "GENE_OR_GENE_PRODUCT", 462, 464], ["Chlamydia pneumoniae", "ORGANISM", 467, 487], ["CP)", "ORGANISM", 489, 492], ["Legionella pneumoniae", "ORGANISM", 494, 515], ["LP)", "ORGANISM", 516, 519], ["Haemophilus influenzae", "ORGANISM", 521, 543], ["Hi)", "ORGANISM", 545, 548], ["Moraxella catarrhalis", "ORGANISM", 550, 571], ["MC)", "ORGANISM", 573, 576], ["Klebsiella pneumoniae", "ORGANISM", 578, 599], ["KP)", "ORGANISM", 601, 604], ["Streptococcus pneumoniae", "ORGANISM", 606, 630], ["S.pneumoniae", "ORGANISM", 632, 644], ["Mycobacterium tuberculosis (TB)", "ORGANISM", 647, 678], ["Escherichia coli", "ORGANISM", 680, 696], ["E. coli", "ORGANISM", 698, 705], ["Staphylococcus aureus", "ORGANISM", 708, 729], ["S. aureus)", "ORGANISM", 731, 741], ["Acinetobacter baumannii", "ORGANISM", 743, 766], ["A. baumannii", "ORGANISM", 768, 780], ["Pseudomonas aeruginosa", "ORGANISM", 783, 805], ["P. aeruginosa", "ORGANISM", 807, 820], ["pneumocystis carinii", "ORGANISM", 823, 843], ["PC", "CANCER", 845, 847], ["Bordetella pertussis", "ORGANISM", 850, 870], ["fungi", "ORGANISM", 875, 880], ["Aspergillus, Cryptococcus,", "ORGANISM", 882, 908], ["Cryptococcus neoformans A", "ORGANISM", 909, 934], ["B, Mucor, Candida, Histoplasma capsulatum", "ORGANISM", 936, 977], ["human", "SPECIES", 81, 86], ["respiratory syncytial virus", "SPECIES", 87, 114], ["RSV", "SPECIES", 116, 119], ["parainfluenza", "SPECIES", 122, 135], ["human", "SPECIES", 173, 178], ["metapneumovirus", "SPECIES", 179, 194], ["coronaviruses", "SPECIES", 203, 216], ["human", "SPECIES", 289, 294], ["bocavirus adenovirus", "SPECIES", 295, 315], ["human", "SPECIES", 324, 329], ["human", "SPECIES", 349, 354], ["rhinovirus", "SPECIES", 355, 365], ["herpes simplex virus", "SPECIES", 373, 393], ["EB virus", "SPECIES", 424, 432], ["Mycoplasma pneumonia", "SPECIES", 440, 460], ["Chlamydia pneumoniae", "SPECIES", 467, 487], ["Legionella pneumoniae", "SPECIES", 494, 515], ["Haemophilus influenzae", "SPECIES", 521, 543], ["Moraxella catarrhalis", "SPECIES", 550, 571], ["Klebsiella pneumoniae", "SPECIES", 578, 599], ["Streptococcus pneumoniae", "SPECIES", 606, 630], ["Mycobacterium tuberculosis", "SPECIES", 647, 673], ["Escherichia coli", "SPECIES", 680, 696], ["E. coli", "SPECIES", 698, 705], ["Staphylococcus aureus", "SPECIES", 708, 729], ["S. aureus", "SPECIES", 731, 740], ["Acinetobacter baumannii", "SPECIES", 743, 766], ["A. baumannii", "SPECIES", 768, 780], ["Pseudomonas aeruginosa", "SPECIES", 783, 805], ["P. aeruginosa", "SPECIES", 807, 820], ["pneumocystis carinii", "SPECIES", 823, 843], ["Bordetella pertussis", "SPECIES", 850, 870], ["Cryptococcus neoformans", "SPECIES", 909, 932], ["Histoplasma capsulatum", "SPECIES", 955, 977], ["human respiratory syncytial virus", "SPECIES", 81, 114], ["RSV", "SPECIES", 116, 119], ["human metapneumovirus", "SPECIES", 173, 194], ["HMPV", "SPECIES", 196, 200], ["human bocavirus adenovirus", "SPECIES", 289, 315], ["HBoV", "SPECIES", 317, 321], ["human adenovirus", "SPECIES", 324, 340], ["HAdV", "SPECIES", 342, 346], ["human rhinovirus", "SPECIES", 349, 365], ["HRV", "SPECIES", 367, 370], ["herpes simplex virus", "SPECIES", 373, 393], ["HSV", "SPECIES", 395, 398], ["CMV", "SPECIES", 418, 421], ["EB virus", "SPECIES", 424, 432], ["EBV", "SPECIES", 434, 437], ["Mycoplasma pneumonia", "SPECIES", 440, 460], ["Chlamydia pneumoniae", "SPECIES", 467, 487], ["Legionella pneumoniae", "SPECIES", 494, 515], ["Haemophilus influenzae", "SPECIES", 521, 543], ["Moraxella catarrhalis", "SPECIES", 550, 571], ["Klebsiella pneumoniae", "SPECIES", 578, 599], ["Streptococcus pneumoniae", "SPECIES", 606, 630], ["Mycobacterium tuberculosis", "SPECIES", 647, 673], ["Escherichia coli", "SPECIES", 680, 696], ["E. coli", "SPECIES", 698, 705], ["Staphylococcus aureus", "SPECIES", 708, 729], ["S. aureus", "SPECIES", 731, 740], ["Acinetobacter baumannii", "SPECIES", 743, 766], ["A. baumannii", "SPECIES", 768, 780], ["Pseudomonas aeruginosa", "SPECIES", 783, 805], ["P. aeruginosa", "SPECIES", 807, 820], ["pneumocystis carinii", "SPECIES", 823, 843], ["Bordetella pertussis", "SPECIES", 850, 870], ["Cryptococcus neoformans A", "SPECIES", 909, 934], ["Histoplasma capsulatum", "SPECIES", 955, 977], ["Other 39 respiratory pathogens", "PROBLEM", 0, 30], ["influenza", "PROBLEM", 41, 50], ["FluA", "TEST", 54, 58], ["influenza B (FluB)", "TEST", 61, 79], ["human respiratory syncytial virus", "TEST", 81, 114], ["RSV", "TEST", 116, 119], ["parainfluenza types", "TEST", 122, 141], ["PIV1", "TEST", 157, 161], ["human metapneumovirus", "TEST", 173, 194], ["HMPV", "TEST", 196, 200], ["coronaviruses", "TEST", 203, 216], ["OC43", "TEST", 223, 227], ["NL63", "TEST", 229, 233], ["HKU1", "TEST", 238, 242], ["HCoV", "TEST", 244, 248], ["HCoV", "TEST", 255, 259], ["OC43", "TEST", 260, 264], ["HCoV", "TEST", 266, 270], ["NL63", "TEST", 271, 275], ["HCoV", "TEST", 277, 281], ["HKU1", "TEST", 282, 286], ["human bocavirus adenovirus", "PROBLEM", 289, 315], ["HBoV", "TEST", 317, 321], ["human adenovirus (HAdV", "PROBLEM", 324, 346], ["human rhinovirus (HRV)", "PROBLEM", 349, 371], ["herpes simplex virus", "PROBLEM", 373, 393], ["HSV", "PROBLEM", 395, 398], ["cytomegalovirus (CMV)", "PROBLEM", 401, 422], ["EB virus (EBV)", "PROBLEM", 424, 438], ["Mycoplasma pneumonia (MP)", "PROBLEM", 440, 465], ["Chlamydia pneumoniae", "PROBLEM", 467, 487], ["CP", "PROBLEM", 489, 491], ["Legionella pneumoniae", "PROBLEM", 494, 515], ["LP", "TEST", 516, 518], ["Haemophilus influenzae", "PROBLEM", 521, 543], ["Moraxella catarrhalis", "PROBLEM", 550, 571], ["Klebsiella pneumoniae", "PROBLEM", 578, 599], ["Streptococcus pneumoniae (S.pneumoniae)", "PROBLEM", 606, 645], ["Mycobacterium tuberculosis (TB)", "PROBLEM", 647, 678], ["Escherichia coli (E. coli", "PROBLEM", 680, 705], ["Staphylococcus aureus (S. aureus", "PROBLEM", 708, 740], ["Acinetobacter baumannii", "PROBLEM", 743, 766], ["A. baumannii", "TEST", 768, 780], ["Pseudomonas aeruginosa (P. aeruginosa", "PROBLEM", 783, 820], ["pneumocystis carinii (PC)", "PROBLEM", 823, 848], ["Bordetella pertussis", "PROBLEM", 850, 870], ["fungi", "PROBLEM", 875, 880], ["Aspergillus", "PROBLEM", 882, 893], ["Cryptococcus", "PROBLEM", 895, 907], ["Cryptococcus neoformans A, B, Mucor, Candida, Histoplasma capsulatum", "TEST", 909, 977], ["Wallis H-test", "TEST", 1136, 1149], ["Dunnett test", "TEST", 1218, 1230], ["Chi-square test", "TEST", 1333, 1348], ["respiratory syncytial", "ANATOMY", 87, 108], ["metapneumovirus", "OBSERVATION", 179, 194], ["Mycoplasma pneumonia", "OBSERVATION", 440, 460], ["pneumoniae", "OBSERVATION", 477, 487], ["pneumoniae", "OBSERVATION", 505, 515], ["Moraxella catarrhalis", "OBSERVATION", 550, 571], ["Klebsiella pneumoniae", "OBSERVATION", 578, 599], ["Streptococcus pneumoniae", "OBSERVATION", 606, 630], ["Mycobacterium tuberculosis", "OBSERVATION", 647, 673], ["Escherichia coli", "OBSERVATION", 680, 696], ["Staphylococcus aureus", "OBSERVATION", 708, 729], ["Acinetobacter baumannii", "OBSERVATION", 743, 766], ["pneumocystis carinii", "OBSERVATION", 823, 843], ["Cryptococcus neoformans", "OBSERVATION", 909, 932]]], ["A value of P < 0.05 was considered to be significant.", [["A value", "TEST", 0, 7]]], ["SPSS 19.0 software and GraphPad 7.0 were used for statistical analysis.Characteristics of patients ::: ResultBaseline characteristics of all cases and different groups are described in Table 1.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["SPSS", "TEST", 0, 4], ["software", "TEST", 10, 18], ["GraphPad", "TEST", 23, 31], ["statistical analysis", "TEST", 50, 70]]], ["257 patients were diagnosed with the SARS-CoV-2 infection and their clinical severity was classified according to National Health Commission of the People's Republic of China revised criteria for diagnosis and treatment of novel coronavirus infection pneumonia (trial version fifth, revised version).", [["SARS-CoV-2 infection", "DISEASE", 37, 57], ["coronavirus infection", "DISEASE", 229, 250], ["pneumonia", "DISEASE", 251, 260], ["patients", "ORGANISM", 4, 12], ["SARS-CoV-2", "ORGANISM", 37, 47], ["coronavirus", "ORGANISM", 229, 240], ["patients", "SPECIES", 4, 12], ["SARS-CoV-2", "SPECIES", 37, 47], ["the SARS", "PROBLEM", 33, 41], ["CoV-2 infection", "PROBLEM", 42, 57], ["treatment", "TREATMENT", 210, 219], ["novel coronavirus infection pneumonia", "PROBLEM", 223, 260], ["infection", "OBSERVATION", 48, 57], ["coronavirus", "OBSERVATION_MODIFIER", 229, 240], ["infection", "OBSERVATION", 241, 250]]], ["These patients were categorized into four clinical types, of which 22 (8.5 %) were asymptomatic cases (A total of 19 patients showed symptoms after sampling), 78 (30.4 %) were mild cases, 140 (54.5 %) were moderate cases, and 17 (6.6 %) were severe/critical cases (including 14 severe cases and 3 critical cases).", [["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 117, 125], ["symptoms", "PROBLEM", 133, 141], ["sampling", "TEST", 148, 156], ["mild cases", "PROBLEM", 176, 186], ["severe/critical cases", "PROBLEM", 242, 263], ["14 severe cases", "PROBLEM", 275, 290], ["mild", "OBSERVATION_MODIFIER", 176, 180]]], ["There was no death of all the cases in our study, 3 cases of critical patients were admitted to intensive care unit (ICU).", [["death", "DISEASE", 13, 18], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["death", "PROBLEM", 13, 18], ["our study", "TEST", 39, 48], ["no", "UNCERTAINTY", 10, 12]]], ["The age of patients in moderate category was significantly lower than in mild category (P<0.01), whereas asymptomatic and severe/critical category did not significantly differ in age from the moderate category.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["severe/critical category", "PROBLEM", 122, 146], ["moderate", "OBSERVATION_MODIFIER", 23, 31], ["mild", "OBSERVATION_MODIFIER", 73, 77], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["moderate", "OBSERVATION_MODIFIER", 192, 200], ["category", "OBSERVATION", 201, 209]]], ["Totally, more men (53.7 %) than women were observed, but most of the patients were female (68.2 %) in asymptomatic category.", [["men", "ORGANISM", 14, 17], ["women", "ORGANISM", 32, 37], ["patients", "ORGANISM", 69, 77], ["men", "SPECIES", 14, 17], ["women", "SPECIES", 32, 37], ["patients", "SPECIES", 69, 77]]], ["Below 15 years of age, a total of 11 (4.3 %) were diagnosed with the SARS-CoV-2 infection and there were no case in severe/critical category.Co-infection of SARS-CoV-2 with respiratory pathogens ::: ResultA total of 243 (94.2 %) patients had viral, bacterial and fungal co-infections.", [["SARS-CoV-2 infection", "DISEASE", 69, 89], ["SARS", "DISEASE", 157, 161], ["respiratory pathogens", "DISEASE", 173, 194], ["viral, bacterial and fungal co-infections", "DISEASE", 242, 283], ["SARS-CoV-2", "ORGANISM", 157, 167], ["patients", "ORGANISM", 229, 237], ["CoV-2", "SPECIES", 162, 167], ["patients", "SPECIES", 229, 237], ["SARS-CoV-2", "SPECIES", 69, 79], ["SARS-CoV", "SPECIES", 157, 165], ["the SARS-CoV-2 infection", "PROBLEM", 65, 89], ["Co-infection of SARS", "PROBLEM", 141, 161], ["CoV", "TEST", 162, 165], ["respiratory pathogens", "PROBLEM", 173, 194], ["viral, bacterial and fungal co-infections", "PROBLEM", 242, 283], ["infection", "OBSERVATION", 80, 89], ["SARS", "OBSERVATION", 157, 161], ["fungal co-infections", "OBSERVATION", 263, 283]]], ["As shown in Fig. 1, 9 viruses, 11 bacteria and 4 fungi were detected.", [["11 bacteria and 4 fungi", "PROBLEM", 31, 54]]], ["81 patients (31.5 %) had viral co-infection, 236 (91.8 %) had bacterial co-infection, and 60 (23.3 %) had fungal co-infection (Table 2).", [["viral co-infection", "DISEASE", 25, 43], ["bacterial co-infection", "DISEASE", 62, 84], ["fungal co-infection", "DISEASE", 106, 125], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["viral co-infection", "PROBLEM", 25, 43], ["bacterial co-infection", "PROBLEM", 62, 84], ["fungal co-infection", "PROBLEM", 106, 125], ["co-infection", "OBSERVATION", 31, 43], ["bacterial", "OBSERVATION_MODIFIER", 62, 71], ["co-infection", "OBSERVATION", 72, 84], ["fungal", "OBSERVATION_MODIFIER", 106, 112], ["co-infection", "OBSERVATION", 113, 125]]], ["The co-infection pathogens were as follows: S.pneumoniae (153, 59.5 %), KP (143, 55.6 %), Hi (103, 40.1 %), Aspergillus (60, 23.3 %), EBV (52, 20.2 %), E. coli (24, 9.3 %), S. aureus (21, 8.2 %), HRV (12, 4.7 %), P.aeruginosa (12, 4.7 %), MC (11, 4.3 %), HAdV (10, 3.9 %), HSV (8, 3.1 %), A. baumannii (7, 2.8 %), CP (6, 2.5 %), Mucor (6, 2.5 %), influenza B (5, 1.9 %), MP (4, 1.6 %), Bordetella pertussis (3, 1.2 %), Candida (2, 0.8 %), CMV (3, 1.2 %), influenza A (2, 0.8 %), HBoV (1, 0.4 %), HMPV (1, 0.4 %) and Cryptococcus (1, 0.4 %).", [["co-infection", "DISEASE", 4, 16], ["S. aureus", "DISEASE", 173, 182], ["MC", "CHEMICAL", 239, 241], ["CP", "CHEMICAL", 314, 316], ["influenza B", "DISEASE", 347, 358], ["MP", "DISEASE", 371, 373], ["Bordetella pertussis", "DISEASE", 386, 406], ["influenza A", "DISEASE", 455, 466], ["HBoV", "DISEASE", 479, 483], ["EBV", "ORGANISM", 134, 137], ["E. coli", "ORGANISM", 152, 159], ["S. aureus", "ORGANISM", 173, 182], ["HAdV", "ORGANISM", 255, 259], ["HSV", "ORGANISM", 273, 276], ["A. baumannii", "ORGANISM", 289, 301], ["influenza B", "ORGANISM", 347, 358], ["MP", "GENE_OR_GENE_PRODUCT", 371, 373], ["Bordetella pertussis", "ORGANISM", 386, 406], ["CMV", "ORGANISM", 439, 442], ["influenza A", "ORGANISM", 455, 466], ["HBoV", "ORGANISM", 479, 483], ["HMPV", "ORGANISM", 496, 500], ["E. coli", "SPECIES", 152, 159], ["S. aureus", "SPECIES", 173, 182], ["A. baumannii", "SPECIES", 289, 301], ["influenza B", "SPECIES", 347, 358], ["Bordetella pertussis", "SPECIES", 386, 406], ["EBV", "SPECIES", 134, 137], ["E. coli", "SPECIES", 152, 159], ["S. aureus", "SPECIES", 173, 182], ["HRV", "SPECIES", 196, 199], ["HSV", "SPECIES", 273, 276], ["A. baumannii", "SPECIES", 289, 301], ["Bordetella pertussis", "SPECIES", 386, 406], ["CMV", "SPECIES", 439, 442], ["influenza A", "SPECIES", 455, 466], ["HBoV", "SPECIES", 479, 483], ["HMPV", "SPECIES", 496, 500], ["The co-infection pathogens", "PROBLEM", 0, 26], ["S.pneumoniae", "TEST", 44, 56], ["KP", "TEST", 72, 74], ["Hi", "TEST", 90, 92], ["Aspergillus", "TEST", 108, 119], ["EBV", "TEST", 134, 137], ["E. coli", "TEST", 152, 159], ["S. aureus", "TEST", 173, 182], ["HRV", "TEST", 196, 199], ["P.aeruginosa", "TEST", 213, 225], ["MC", "TEST", 239, 241], ["HAdV", "TEST", 255, 259], ["HSV", "TEST", 273, 276], ["A. baumannii", "TEST", 289, 301], ["CP", "TEST", 314, 316], ["Mucor", "TEST", 329, 334], ["influenza B", "TEST", 347, 358], ["MP", "TEST", 371, 373], ["Bordetella pertussis", "TEST", 386, 406], ["Candida", "TEST", 419, 426], ["CMV", "TEST", 439, 442], ["influenza A", "TEST", 455, 466], ["HBoV", "TEST", 479, 483], ["HMPV", "TEST", 496, 500], ["Cryptococcus", "TEST", 516, 528], ["co-infection", "OBSERVATION", 4, 16], ["coli", "ANATOMY", 155, 159], ["aureus", "OBSERVATION", 176, 182], ["baumannii", "OBSERVATION", 292, 301]]], ["The proportion of bacterial co-infection (75, 96.2 %) was highest, followed by bacterial-viral (26, 33.3 %), viral-fungal (11, 14.1 %) and viral-bacterial-fungal (11, 14.1 %) co-infections in mild category (P > 0.05; Table 2).", [["bacterial co-infection", "DISEASE", 18, 40], ["viral-fungal", "DISEASE", 109, 121], ["infections", "DISEASE", 178, 188], ["bacterial co-infection", "PROBLEM", 18, 40], ["bacterial-viral", "TEST", 79, 94], ["viral-fungal", "TEST", 109, 121], ["viral-bacterial-fungal", "PROBLEM", 139, 161], ["co-infections in mild category", "PROBLEM", 175, 205], ["P", "TEST", 207, 208], ["bacterial", "OBSERVATION_MODIFIER", 18, 27], ["co-infection", "OBSERVATION", 28, 40], ["mild", "OBSERVATION_MODIFIER", 192, 196]]], ["The rates of viral co-infection (6, 35.3 %), fungal co-infection (5, 29.5 %) and bacterial-fungal co-infection (5, 29.5 %) were the highest in severe/critical category (P > 0.05; Table 2).Co-infections varied with age and time of onset ::: ResultOf the 138 male patients, 128 (92.8 %) were co-infected, while 113 (95.0 %) females had co-infection.", [["viral co-infection", "DISEASE", 13, 31], ["fungal co-infection", "DISEASE", 45, 64], ["bacterial-fungal co-infection", "DISEASE", 81, 110], ["Co-infections", "DISEASE", 188, 201], ["co-infection", "DISEASE", 334, 346], ["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 262, 270], ["viral co-infection", "PROBLEM", 13, 31], ["fungal co-infection", "PROBLEM", 45, 64], ["bacterial-fungal co-infection", "PROBLEM", 81, 110], ["Co-infections", "PROBLEM", 188, 201], ["co-infected", "PROBLEM", 290, 301], ["co-infection", "PROBLEM", 334, 346], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["co-infection", "OBSERVATION", 19, 31], ["fungal", "OBSERVATION_MODIFIER", 45, 51], ["co-infection", "OBSERVATION", 52, 64], ["bacterial", "OBSERVATION_MODIFIER", 81, 90], ["fungal co-infection", "OBSERVATION", 91, 110], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["co-infection", "OBSERVATION", 334, 346]]], ["Below 15 years of age, there were 11 pathogens were found and HMPV only appeared in this group (Fig. 2A).", [["HMPV", "ORGANISM", 62, 66], ["HMPV", "SPECIES", 62, 66], ["11 pathogens", "PROBLEM", 34, 46], ["HMPV", "PROBLEM", 62, 66]]], ["The rates of KP, Aspergillus, E. coli, and HRV co-infection were the lowest.", [["Aspergillus, E. coli, and HRV co-infection", "DISEASE", 17, 59], ["E. coli", "ORGANISM", 30, 37], ["E. coli", "SPECIES", 30, 37], ["E. coli", "SPECIES", 30, 37], ["HRV", "SPECIES", 43, 46], ["The rates", "TEST", 0, 9], ["Aspergillus", "PROBLEM", 17, 28], ["E. coli", "PROBLEM", 30, 37], ["HRV co-infection", "PROBLEM", 43, 59], ["E. coli", "OBSERVATION", 30, 37]]], ["Between 15 and 44 years of age, 22 pathogens were discovered except for HMPV and Cryptococcus.", [["HMPV", "ORGANISM", 72, 76], ["HMPV", "SPECIES", 72, 76], ["22 pathogens", "PROBLEM", 32, 44], ["HMPV", "PROBLEM", 72, 76], ["Cryptococcus", "PROBLEM", 81, 93], ["Cryptococcus", "OBSERVATION", 81, 93]]], ["Among these, influenza A and HBoV were only found in this group (Fig. 2A).", [["influenza A and HBoV", "DISEASE", 13, 33], ["influenza A", "ORGANISM", 13, 24], ["HBoV", "ORGANISM", 29, 33], ["HBoV", "SPECIES", 29, 33], ["influenza A", "PROBLEM", 13, 24], ["HBoV", "PROBLEM", 29, 33]]], ["The rates of S.pneumoniae, KP, Hi, Aspergillus, EBV, E. coli, S. aureus, P.aeruginosa, HAdV, A. baumannii, Mucor, influenza B and MP co-infection were the highest.", [["influenza B and MP co-infection", "DISEASE", 114, 145], ["S.pneumoniae", "GENE_OR_GENE_PRODUCT", 13, 25], ["KP", "GENE_OR_GENE_PRODUCT", 27, 29], ["Hi, Aspergillus", "ORGANISM", 31, 46], ["EBV", "ORGANISM", 48, 51], ["E. coli", "ORGANISM", 53, 60], ["S. aureus", "ORGANISM", 62, 71], ["P.aeruginosa, HAdV", "ORGANISM", 73, 91], ["A. baumannii", "ORGANISM", 93, 105], ["Mucor, influenza B", "ORGANISM", 107, 125], ["MP", "GENE_OR_GENE_PRODUCT", 130, 132], ["E. coli", "SPECIES", 53, 60], ["S. aureus", "SPECIES", 62, 71], ["A. baumannii", "SPECIES", 93, 105], ["E. coli", "SPECIES", 53, 60], ["S. aureus", "SPECIES", 62, 71], ["A. baumannii", "SPECIES", 93, 105], ["The rates", "TEST", 0, 9], ["S.pneumoniae", "TEST", 13, 25], ["KP", "TEST", 27, 29], ["Hi", "PROBLEM", 31, 33], ["Aspergillus", "PROBLEM", 35, 46], ["EBV", "PROBLEM", 48, 51], ["E. coli", "PROBLEM", 53, 60], ["S. aureus", "PROBLEM", 62, 71], ["P.aeruginosa", "PROBLEM", 73, 85], ["HAdV", "PROBLEM", 87, 91], ["A. baumannii", "PROBLEM", 93, 105], ["Mucor", "PROBLEM", 107, 112], ["influenza B", "PROBLEM", 114, 125], ["MP co-infection", "PROBLEM", 130, 145], ["E. coli", "OBSERVATION", 53, 60], ["aureus", "OBSERVATION", 65, 71]]], ["Between 45 and 64 years of age, 19 pathogens were discovered and Cryptococcus only appeared in this group (Fig. 2A).", [["19 pathogens", "PROBLEM", 32, 44], ["Cryptococcus", "PROBLEM", 65, 77], ["Cryptococcus", "OBSERVATION", 65, 77]]], ["The rates of HRV, CP and MC co-infection were highest.", [["co-infection", "DISEASE", 28, 40], ["HRV", "PROBLEM", 13, 16], ["CP", "PROBLEM", 18, 20], ["MC co-infection", "PROBLEM", 25, 40], ["co-infection", "OBSERVATION", 28, 40]]], ["Above 65 years of age, there were 14 pathogens (Fig. 2A).", [["14 pathogens", "PROBLEM", 34, 46]]], ["The rates of EBV, S. aureus, P.aeruginosa and MC co-infection were the lowest.", [["co-infection", "DISEASE", 49, 61], ["EBV", "ORGANISM", 13, 16], ["S. aureus", "ORGANISM", 18, 27], ["P.aeruginosa", "CELL", 29, 41], ["S. aureus", "SPECIES", 18, 27], ["EBV", "SPECIES", 13, 16], ["S. aureus", "SPECIES", 18, 27], ["The rates", "TEST", 0, 9], ["EBV", "PROBLEM", 13, 16], ["S. aureus", "PROBLEM", 18, 27], ["P.aeruginosa", "PROBLEM", 29, 41], ["MC co-infection", "PROBLEM", 46, 61], ["EBV", "OBSERVATION", 13, 16], ["aureus", "OBSERVATION", 21, 27], ["co-infection", "OBSERVATION", 49, 61]]], ["However, the co-infection rates had no statistical significant difference among different age groups (P > 0.05).", [["the co-infection rates", "TEST", 9, 31], ["statistical significant difference", "PROBLEM", 39, 73], ["co-infection", "OBSERVATION", 13, 25], ["significant", "OBSERVATION_MODIFIER", 51, 62]]], ["The pathogen distribution was also analyzed along with disease course.", [["The pathogen distribution", "PROBLEM", 0, 25], ["pathogen", "OBSERVATION", 4, 12]]], ["The results showed that there were 19 pathogens in -4\u20130 days after onset, and CMV and HMPV co-infection only appeared in this group (Fig. 2B).", [["HMPV co-infection", "DISEASE", 86, 103], ["CMV", "ORGANISM", 78, 81], ["HMPV", "ORGANISM", 86, 90], ["CMV", "SPECIES", 78, 81], ["HMPV", "SPECIES", 86, 90], ["19 pathogens", "PROBLEM", 35, 47], ["CMV", "PROBLEM", 78, 81], ["HMPV co-infection", "PROBLEM", 86, 103], ["HMPV co-infection", "OBSERVATION", 86, 103]]], ["The rates of E. coli and HRV co-infection were the highest.", [["E. coli", "ORGANISM", 13, 20], ["HRV", "ORGANISM", 25, 28], ["E. coli", "SPECIES", 13, 20], ["E. coli", "SPECIES", 13, 20], ["HRV", "SPECIES", 25, 28], ["E. coli", "PROBLEM", 13, 20], ["HRV co-infection", "PROBLEM", 25, 41], ["E. coli", "OBSERVATION", 13, 20], ["co-infection", "OBSERVATION", 29, 41]]], ["HBoV and Candida only appeared in this group.", [["HBoV", "ORGANISM", 0, 4], ["HBoV", "SPECIES", 0, 4], ["HBoV", "PROBLEM", 0, 4], ["Candida", "PROBLEM", 9, 16], ["Candida", "OBSERVATION", 9, 16]]], ["The rates of S.pneumoniae, KP, Hi, Aspergillus, EBV, S. aureus, P.aeruginosa, MC, HAdV, HSV, A. baumannii and CP co-infection were the highest.", [["co-infection", "DISEASE", 113, 125], ["S.pneumoniae", "GENE_OR_GENE_PRODUCT", 13, 25], ["Hi, Aspergillus", "ORGANISM", 31, 46], ["EBV", "ORGANISM", 48, 51], ["S. aureus", "ORGANISM", 53, 62], ["P.aeruginosa", "GENE_OR_GENE_PRODUCT", 64, 76], ["MC", "GENE_OR_GENE_PRODUCT", 78, 80], ["HAdV", "ORGANISM", 82, 86], ["HSV", "ORGANISM", 88, 91], ["A. baumannii", "ORGANISM", 93, 105], ["CP co-infection", "ORGANISM", 110, 125], ["S. aureus", "SPECIES", 53, 62], ["A. baumannii", "SPECIES", 93, 105], ["EBV", "SPECIES", 48, 51], ["S. aureus", "SPECIES", 53, 62], ["HSV", "SPECIES", 88, 91], ["A. baumannii", "SPECIES", 93, 105], ["The rates", "TEST", 0, 9], ["S.pneumoniae", "TEST", 13, 25], ["KP", "TEST", 27, 29], ["Hi", "PROBLEM", 31, 33], ["Aspergillus", "PROBLEM", 35, 46], ["EBV", "PROBLEM", 48, 51], ["S. aureus", "PROBLEM", 53, 62], ["P.aeruginosa", "PROBLEM", 64, 76], ["MC", "PROBLEM", 78, 80], ["HAdV", "PROBLEM", 82, 86], ["HSV", "PROBLEM", 88, 91], ["A. baumannii", "PROBLEM", 93, 105], ["CP co-infection", "PROBLEM", 110, 125], ["aureus", "OBSERVATION", 56, 62], ["baumannii", "OBSERVATION", 96, 105], ["co-infection", "OBSERVATION", 113, 125]]], ["There were 18 pathogens in 5\u20138 days after onset, and Cryptococcus only appeared in this group (Fig. 2B).", [["18 pathogens", "PROBLEM", 11, 23], ["Cryptococcus", "PROBLEM", 53, 65], ["Cryptococcus", "OBSERVATION", 53, 65]]], ["The rates of Influenza B co-infection were highest.", [["Influenza B co-infection", "DISEASE", 13, 37], ["Influenza B", "ORGANISM", 13, 24], ["Influenza B", "SPECIES", 13, 24], ["Influenza B co-infection", "PROBLEM", 13, 37], ["Influenza", "OBSERVATION", 13, 22], ["co-infection", "OBSERVATION", 25, 37]]], ["Only 9 pathogens were found in 9\u201315 days after onset (Fig. 2B).", [["9 pathogens", "PROBLEM", 5, 16]]], ["No significant differences were found by days after onset (P>0.05).Co-infection pattern related to different clinical types ::: ResultThere were 10, 22, 20 and 13 pathogens were found in symptomatic, mild, moderate, and severe/critical cases, respectively (Fig. 3).", [["P", "TEST", 59, 60], ["Co-infection pattern", "PROBLEM", 67, 87], ["symptomatic, mild, moderate, and severe/critical cases", "PROBLEM", 187, 241], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["symptomatic", "OBSERVATION_MODIFIER", 187, 198], ["mild", "OBSERVATION_MODIFIER", 200, 204], ["moderate", "OBSERVATION_MODIFIER", 206, 214], ["severe", "OBSERVATION_MODIFIER", 220, 226]]], ["S.pneumoniae, KP, Hi, Aspergillus, EBV, E. coli, and S. aureus were simultaneously found in four clinical groups.", [["S.pneumoniae", "GENE_OR_GENE_PRODUCT", 0, 12], ["KP", "GENE_OR_GENE_PRODUCT", 14, 16], ["Hi, Aspergillus", "ORGANISM", 18, 33], ["EBV", "ORGANISM", 35, 38], ["E. coli", "ORGANISM", 40, 47], ["S. aureus", "ORGANISM", 53, 62], ["E. coli", "SPECIES", 40, 47], ["S. aureus", "SPECIES", 53, 62], ["E. coli", "SPECIES", 40, 47], ["S. aureus", "SPECIES", 53, 62], ["S.pneumoniae", "PROBLEM", 0, 12], ["KP", "PROBLEM", 14, 16], ["Hi", "PROBLEM", 18, 20], ["Aspergillus", "PROBLEM", 22, 33], ["EBV", "PROBLEM", 35, 38], ["E. coli", "PROBLEM", 40, 47], ["S. aureus", "PROBLEM", 53, 62], ["Hi", "ANATOMY", 18, 20], ["Aspergillus", "OBSERVATION", 22, 33], ["E. coli", "OBSERVATION", 40, 47], ["aureus", "OBSERVATION", 56, 62]]], ["S.pneumoniae, KP, Hi, Aspergillus, EBV were most frequently found.", [["EBV", "ORGANISM", 35, 38], ["S.pneumoniae", "PROBLEM", 0, 12], ["KP", "PROBLEM", 14, 16], ["Hi", "PROBLEM", 18, 20], ["Aspergillus", "PROBLEM", 22, 33], ["EBV", "PROBLEM", 35, 38], ["Hi", "ANATOMY", 18, 20], ["Aspergillus", "OBSERVATION", 22, 33]]], ["MC and A. baumannii were found in asymptomatic category, mild category and moderate category.", [["A. baumannii", "ORGANISM", 7, 19], ["A. baumannii", "SPECIES", 7, 19], ["A. baumannii", "SPECIES", 7, 19], ["A. baumannii", "PROBLEM", 7, 19], ["mild category", "PROBLEM", 57, 70], ["moderate category", "PROBLEM", 75, 92], ["baumannii", "OBSERVATION", 10, 19], ["mild", "OBSERVATION_MODIFIER", 57, 61], ["moderate", "OBSERVATION_MODIFIER", 75, 83]]], ["Although no statistical significance was found, the nucleic acid-positive rate of MC (3, 13.6 %) was the highest in mild category.", [["the nucleic acid-", "TEST", 48, 65], ["MC", "TEST", 82, 84], ["no", "UNCERTAINTY", 9, 11], ["mild", "OBSERVATION_MODIFIER", 116, 120], ["category", "OBSERVATION", 121, 129]]], ["HAdV, HRV, HSV and P.aeruginosa were found in mild category, moderate case, severe/critical category.", [["HAdV", "ORGANISM", 0, 4], ["HSV", "ORGANISM", 11, 14], ["P.aeruginosa", "GENE_OR_GENE_PRODUCT", 19, 31], ["HAdV", "SPECIES", 0, 4], ["HRV", "SPECIES", 6, 9], ["HSV", "SPECIES", 11, 14], ["HAdV", "PROBLEM", 0, 4], ["HRV", "PROBLEM", 6, 9], ["HSV", "PROBLEM", 11, 14], ["P.aeruginosa", "PROBLEM", 19, 31], ["mild category", "PROBLEM", 46, 59], ["severe/critical category", "PROBLEM", 76, 100], ["mild", "OBSERVATION_MODIFIER", 46, 50], ["moderate", "OBSERVATION_MODIFIER", 61, 69], ["severe", "OBSERVATION_MODIFIER", 76, 82]]], ["The positive rates of HRV (8, 10.3 %) were highest in mild category.", [["HRV", "TEST", 22, 25], ["mild category", "PROBLEM", 54, 67], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["rates", "OBSERVATION_MODIFIER", 13, 18], ["mild", "OBSERVATION_MODIFIER", 54, 58], ["category", "OBSERVATION", 59, 67]]], ["CMV was discovered in asymptomatic category and moderate category. influenza A, influenza B, CP, MP and Mucor were detected in mild case and moderate category.", [["influenza", "DISEASE", 67, 76], ["influenza B", "DISEASE", 80, 91], ["MP", "DISEASE", 97, 99], ["CMV", "ORGANISM", 0, 3], ["influenza A", "ORGANISM", 67, 78], ["influenza B", "ORGANISM", 80, 91], ["MP", "GENE_OR_GENE_PRODUCT", 97, 99], ["CMV", "SPECIES", 0, 3], ["CMV", "PROBLEM", 0, 3], ["moderate category", "PROBLEM", 48, 65], ["influenza", "PROBLEM", 67, 76], ["influenza B", "PROBLEM", 80, 91], ["CP", "PROBLEM", 93, 95], ["MP", "TEST", 97, 99], ["Mucor", "PROBLEM", 104, 109], ["moderate category", "PROBLEM", 141, 158], ["moderate", "OBSERVATION_MODIFIER", 48, 56], ["category", "OBSERVATION", 57, 65], ["mild", "OBSERVATION_MODIFIER", 127, 131], ["moderate", "OBSERVATION_MODIFIER", 141, 149]]], ["The positive rates of influenza A (1, 1.3 %), influenza B (2, 2.6 %), and MP (3, 3.9 %) were higher in mild category, whereas CP (4, 2.9 %) and Mucor (4, 2.9 %) were higher in moderate category.", [["influenza A", "DISEASE", 22, 33], ["influenza B", "DISEASE", 46, 57], ["MP", "DISEASE", 74, 76], ["CP", "DISEASE", 126, 128], ["influenza A", "ORGANISM", 22, 33], ["influenza B", "ORGANISM", 46, 57], ["influenza A", "SPECIES", 22, 33], ["influenza A", "TEST", 22, 33], ["influenza B", "TEST", 46, 57], ["MP", "TEST", 74, 76], ["mild category", "PROBLEM", 103, 116], ["CP", "TEST", 126, 128], ["Mucor", "TEST", 144, 149], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["rates", "OBSERVATION_MODIFIER", 13, 18], ["influenza", "OBSERVATION", 22, 31], ["mild", "OBSERVATION_MODIFIER", 103, 107], ["category", "OBSERVATION", 108, 116], ["moderate", "OBSERVATION_MODIFIER", 176, 184], ["category", "OBSERVATION", 185, 193]]], ["Bordetella pertussis and Candida were determined in moderate category, severe/critical category.DiscussionCo-infection may significantly inhibit the immune system of host, increase antibacterial therapy intolerance, and be harmful to the prognosis of the disease (Li and Zhou, 2013).", [["immune system", "ANATOMY", 149, 162], ["Bordetella pertussis", "DISEASE", 0, 20], ["Li", "CHEMICAL", 264, 266], ["Bordetella pertussis", "ORGANISM", 0, 20], ["Bordetella pertussis", "SPECIES", 0, 20], ["Bordetella pertussis", "SPECIES", 0, 20], ["Bordetella pertussis", "PROBLEM", 0, 20], ["Candida", "PROBLEM", 25, 32], ["severe/critical category", "PROBLEM", 71, 95], ["antibacterial therapy intolerance", "TREATMENT", 181, 214], ["moderate", "OBSERVATION_MODIFIER", 52, 60], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["antibacterial therapy", "OBSERVATION", 181, 202]]], ["In our study, 94.2 % of COVID-19 patients could be co-infected with one or more other pathogens, including 9 viruses, 11 bacteria and 4 fungi.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["our study", "TEST", 3, 12], ["COVID", "TEST", 24, 29], ["co-infected", "PROBLEM", 51, 62], ["more other pathogens", "PROBLEM", 75, 95], ["9 viruses", "PROBLEM", 107, 116], ["11 bacteria and 4 fungi", "PROBLEM", 118, 141], ["co-infected", "OBSERVATION", 51, 62]]], ["There was no death of all the cases.", [["death", "DISEASE", 13, 18], ["death", "PROBLEM", 13, 18], ["no", "UNCERTAINTY", 10, 12]]], ["Only 3 patients were admitted to the ICU.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15]]], ["The proportions of the co-infection had no statistical significant difference between ICU and non-ICU patients.", [["co-infection", "DISEASE", 23, 35], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["the co-infection", "PROBLEM", 19, 35], ["co-infection", "OBSERVATION", 23, 35], ["significant", "OBSERVATION_MODIFIER", 55, 66]]], ["The results suggested that there was no specific relationship between co-infection and ICU admission, as well as the occurrence of death.", [["co-infection", "DISEASE", 70, 82], ["death", "DISEASE", 131, 136], ["co-infection", "PROBLEM", 70, 82], ["death", "PROBLEM", 131, 136]]], ["The prognosis of patients with co-infection needs to be further studied.DiscussionBacterial co-infection in the setting of viral pneumonia is known as major cause of mortality (Guo, et al. 2019).", [["co-infection", "DISEASE", 31, 43], ["DiscussionBacterial co-infection", "DISEASE", 72, 104], ["viral pneumonia", "DISEASE", 123, 138], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["co-infection", "PROBLEM", 31, 43], ["DiscussionBacterial co-infection", "PROBLEM", 72, 104], ["viral pneumonia", "PROBLEM", 123, 138], ["co-infection", "OBSERVATION", 92, 104], ["viral", "OBSERVATION_MODIFIER", 123, 128], ["pneumonia", "OBSERVATION", 129, 138]]], ["Our results showed that bacterial co-infection were dominant in all COVID-19 patients.", [["bacterial co-infection", "DISEASE", 24, 46], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["bacterial co-infection", "PROBLEM", 24, 46], ["bacterial", "OBSERVATION_MODIFIER", 24, 33], ["co-infection", "OBSERVATION", 34, 46], ["dominant", "OBSERVATION_MODIFIER", 52, 60]]], ["S.pneumoniae, KP, and Hi were the most common bacterial co-infection in our study.", [["bacterial co-infection", "DISEASE", 46, 68], ["S.pneumoniae", "GENE_OR_GENE_PRODUCT", 0, 12], ["KP", "GENE_OR_GENE_PRODUCT", 14, 16], ["S.pneumoniae", "PROBLEM", 0, 12], ["KP", "PROBLEM", 14, 16], ["Hi", "PROBLEM", 22, 24], ["bacterial co-infection", "PROBLEM", 46, 68], ["our study", "TEST", 72, 81], ["most common", "OBSERVATION_MODIFIER", 34, 45], ["bacterial", "OBSERVATION_MODIFIER", 46, 55], ["co-infection", "OBSERVATION", 56, 68]]], ["Although some of them are co-colonization, they are conditional pathogen.", [["co-colonization", "PROBLEM", 26, 41], ["conditional pathogen", "PROBLEM", 52, 72]]], ["They might also pathogenic when the immune function of COVID-19 patients were decreased.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["COVID", "TEST", 55, 60]]], ["It suggested that pneumococcal conjugate and polysaccharide vaccines would offer an effective approach to preventing the most common co-infection during the COVID-19 pandemic.", [["co-infection", "DISEASE", 133, 145], ["pneumococcal conjugate", "SIMPLE_CHEMICAL", 18, 40], ["pneumococcal", "SPECIES", 18, 30], ["pneumococcal conjugate", "TREATMENT", 18, 40], ["polysaccharide vaccines", "TREATMENT", 45, 68], ["an effective approach", "TREATMENT", 81, 102], ["the most common co-infection", "PROBLEM", 117, 145], ["the COVID", "TEST", 153, 162], ["pandemic", "PROBLEM", 166, 174], ["pneumococcal conjugate", "OBSERVATION", 18, 40]]], ["In addition to bacteria, fungi was also a major factor of co-infection secondary to viral infections such as seen in influenza infection in which A. baumannii, Aspergillus, Candida and KP were discovered as common secondary infections (Gao, et al. 2013; Guo, et al. 2019).", [["co-infection", "DISEASE", 58, 70], ["viral infections", "DISEASE", 84, 100], ["influenza infection", "DISEASE", 117, 136], ["KP", "CHEMICAL", 185, 187], ["secondary infections", "DISEASE", 214, 234], ["A. baumannii", "ORGANISM", 146, 158], ["Aspergillus, Candida", "ORGANISM", 160, 180], ["A. baumannii", "SPECIES", 146, 158], ["A. baumannii", "SPECIES", 146, 158], ["bacteria", "PROBLEM", 15, 23], ["fungi", "PROBLEM", 25, 30], ["co-infection", "PROBLEM", 58, 70], ["viral infections", "PROBLEM", 84, 100], ["influenza infection", "PROBLEM", 117, 136], ["baumannii", "PROBLEM", 149, 158], ["Aspergillus", "PROBLEM", 160, 171], ["Candida", "PROBLEM", 173, 180], ["common secondary infections", "PROBLEM", 207, 234], ["bacteria", "OBSERVATION", 15, 23], ["co-infection", "OBSERVATION", 58, 70], ["viral", "OBSERVATION_MODIFIER", 84, 89], ["infections", "OBSERVATION", 90, 100], ["influenza", "OBSERVATION_MODIFIER", 117, 126], ["infection", "OBSERVATION", 127, 136]]], ["In this study, the highest rates of co-infection with bacteria and fungi were found among severe and critical category.", [["co-infection", "DISEASE", 36, 48], ["this study", "TEST", 3, 13], ["co-infection", "PROBLEM", 36, 48], ["bacteria", "PROBLEM", 54, 62], ["fungi", "PROBLEM", 67, 72], ["co-infection", "OBSERVATION", 36, 48]]], ["Some of pathogens are known antibiotic resistance which may make the treatment of COVID-19 patients more difficult.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["pathogens", "PROBLEM", 8, 17], ["antibiotic resistance", "TREATMENT", 28, 49], ["COVID", "TEST", 82, 87], ["pathogens", "OBSERVATION", 8, 17], ["antibiotic resistance", "OBSERVATION", 28, 49]]], ["Wang et al. studied 104 patients with SARS-CoV-2 infection and found that 3 (2.88 %) patients were co-infected with other coronavirus, 2 (1.94 %) were co-infected with influenza A (Wang, et al. 2020).", [["SARS-CoV-2 infection", "DISEASE", 38, 58], ["coronavirus", "DISEASE", 122, 133], ["influenza A", "DISEASE", 168, 179], ["patients", "ORGANISM", 24, 32], ["SARS-CoV-2", "ORGANISM", 38, 48], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 85, 93], ["SARS-CoV-2", "SPECIES", 38, 48], ["SARS", "PROBLEM", 38, 42], ["CoV-2 infection", "PROBLEM", 43, 58], ["co-infected", "PROBLEM", 99, 110], ["other coronavirus", "PROBLEM", 116, 133], ["influenza", "PROBLEM", 168, 177], ["infection", "OBSERVATION", 49, 58]]], ["In this study, we also found a few of influenza A, influenza B co-infections, but no coronavirus was detected.", [["influenza A", "DISEASE", 38, 49], ["influenza B co-infections", "DISEASE", 51, 76], ["influenza A", "ORGANISM", 38, 49], ["influenza B", "ORGANISM", 51, 62], ["coronavirus", "ORGANISM", 85, 96], ["this study", "TEST", 3, 13], ["influenza A", "PROBLEM", 38, 49], ["influenza B co-infections", "PROBLEM", 51, 76], ["coronavirus", "PROBLEM", 85, 96], ["influenza", "OBSERVATION", 38, 47], ["no", "UNCERTAINTY", 82, 84], ["coronavirus", "OBSERVATION", 85, 96]]], ["These results indicated that the co-infections with influenza A, influenza B or coronavirus were not common in COVID-19 patients, though the seasonal influenza is now prevalent.", [["co-infections", "DISEASE", 33, 46], ["influenza A", "DISEASE", 52, 63], ["influenza B", "DISEASE", 65, 76], ["coronavirus", "DISEASE", 80, 91], ["influenza", "DISEASE", 150, 159], ["influenza A", "ORGANISM", 52, 63], ["influenza B", "ORGANISM", 65, 76], ["coronavirus", "ORGANISM", 80, 91], ["patients", "ORGANISM", 120, 128], ["influenza B or coronavirus", "SPECIES", 65, 91], ["patients", "SPECIES", 120, 128], ["the co-infections", "PROBLEM", 29, 46], ["influenza A", "PROBLEM", 52, 63], ["influenza B", "PROBLEM", 65, 76], ["coronavirus", "PROBLEM", 80, 91], ["the seasonal influenza", "PROBLEM", 137, 159], ["co-infections", "OBSERVATION", 33, 46]]], ["However, influenza A, influenza B co-infections may increase the risks of COVID-19 patients.", [["influenza A", "DISEASE", 9, 20], ["influenza B co-infections", "DISEASE", 22, 47], ["influenza A", "ORGANISM", 9, 20], ["influenza B", "ORGANISM", 22, 33], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["influenza", "PROBLEM", 9, 18], ["influenza B co-infections", "PROBLEM", 22, 47], ["COVID", "TEST", 74, 79]]], ["Influenza vaccination is still recommended.", [["Influenza", "DISEASE", 0, 9], ["Influenza vaccination", "TREATMENT", 0, 21]]], ["It was notable that the positive rates of HAdV and HRV were higher than that of influenza viruses.", [["influenza viruses", "DISEASE", 80, 97], ["HAdV", "ORGANISM", 42, 46], ["influenza viruses", "ORGANISM", 80, 97], ["HAdV", "SPECIES", 42, 46], ["the positive rates of HAdV", "PROBLEM", 20, 46], ["HRV", "PROBLEM", 51, 54], ["influenza viruses", "PROBLEM", 80, 97], ["positive", "OBSERVATION_MODIFIER", 24, 32], ["influenza viruses", "OBSERVATION", 80, 97]]], ["HAdV and HRV are associated with lower mortality, but significant higher morbidity, causing a huge economic burden (Fendrick, et al. 2003).", [["HAdV", "ORGANISM", 0, 4], ["HAdV", "PROBLEM", 0, 4], ["HRV", "PROBLEM", 9, 12], ["lower mortality", "PROBLEM", 33, 48], ["significant higher morbidity", "PROBLEM", 54, 82], ["a huge economic burden", "PROBLEM", 92, 114], ["lower", "OBSERVATION_MODIFIER", 33, 38], ["mortality", "OBSERVATION", 39, 48], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["higher", "OBSERVATION_MODIFIER", 66, 72], ["morbidity", "OBSERVATION", 73, 82], ["huge", "OBSERVATION_MODIFIER", 94, 98], ["economic", "OBSERVATION_MODIFIER", 99, 107], ["burden", "OBSERVATION", 108, 114]]], ["EBV and HSV were the common pathogens carried by adults.", [["EBV", "ORGANISM", 0, 3], ["HSV", "ORGANISM", 8, 11], ["EBV", "SPECIES", 0, 3], ["HSV", "SPECIES", 8, 11], ["EBV", "PROBLEM", 0, 3], ["HSV", "PROBLEM", 8, 11], ["HSV", "OBSERVATION", 8, 11]]], ["The effects of their roles in the process of COVID-19 need to be explored.", [["COVID-19", "CHEMICAL", 45, 53], ["COVID-19", "GENE_OR_GENE_PRODUCT", 45, 53], ["COVID", "TREATMENT", 45, 50]]], ["CMV, HBoV, and HMPV were important pathogens of respiratory tract infection in children.", [["respiratory tract", "ANATOMY", 48, 65], ["respiratory tract infection", "DISEASE", 48, 75], ["CMV", "ORGANISM", 0, 3], ["HBoV", "ORGANISM", 5, 9], ["HMPV", "ORGANISM", 15, 19], ["respiratory tract", "ORGANISM_SUBDIVISION", 48, 65], ["children", "ORGANISM", 79, 87], ["children", "SPECIES", 79, 87], ["CMV", "SPECIES", 0, 3], ["HBoV", "SPECIES", 5, 9], ["HMPV", "SPECIES", 15, 19], ["CMV", "PROBLEM", 0, 3], ["HBoV", "PROBLEM", 5, 9], ["HMPV", "PROBLEM", 15, 19], ["respiratory tract infection", "PROBLEM", 48, 75], ["HBoV", "OBSERVATION", 5, 9], ["respiratory tract infection", "OBSERVATION", 48, 75]]], ["However, only a few of them were found co-infected with SARS-CoV-2.", [["SARS", "DISEASE", 56, 60], ["SARS-CoV-2", "ORGANISM", 56, 66], ["SARS-CoV", "SPECIES", 56, 64], ["co-infected", "OBSERVATION", 39, 50]]], ["The virus co-infection could cause both upper and lower respiratory tract infections, and demonstrate overlapped clinical presentations.", [["lower respiratory tract", "ANATOMY", 50, 73], ["co-infection", "DISEASE", 10, 22], ["respiratory tract infections", "DISEASE", 56, 84], ["upper", "ORGANISM_SUBDIVISION", 40, 45], ["lower", "ORGANISM_SUBDIVISION", 50, 55], ["respiratory tract", "ORGANISM_SUBDIVISION", 56, 73], ["The virus co-infection", "PROBLEM", 0, 22], ["both upper and lower respiratory tract infections", "PROBLEM", 35, 84], ["virus co-infection", "OBSERVATION", 4, 22], ["upper", "ANATOMY_MODIFIER", 40, 45], ["lower", "ANATOMY_MODIFIER", 50, 55], ["respiratory tract", "ANATOMY", 56, 73], ["infections", "OBSERVATION", 74, 84]]], ["Thus, other viruses should also be considered while diagnosing and treating SARS-CoV-2.DiscussionSimilar co-infection rate and pathogens in females was found when compared with males which mean both man and women are susceptible to other respiratory pathogens.", [["SARS", "DISEASE", 76, 80], ["respiratory pathogens", "DISEASE", 238, 259], ["SARS-CoV-2", "ORGANISM", 76, 86], ["man", "ORGANISM", 199, 202], ["women", "ORGANISM", 207, 212], ["man", "SPECIES", 199, 202], ["women", "SPECIES", 207, 212], ["SARS-CoV", "SPECIES", 76, 84], ["other viruses", "PROBLEM", 6, 19], ["SARS", "TEST", 76, 80], ["CoV", "TEST", 81, 84], ["DiscussionSimilar co-infection rate", "PROBLEM", 87, 122], ["pathogens", "PROBLEM", 127, 136], ["other respiratory pathogens", "PROBLEM", 232, 259], ["viruses", "OBSERVATION", 12, 19], ["respiratory", "ANATOMY", 238, 249], ["pathogens", "OBSERVATION", 250, 259]]], ["The species of co-infected pathogens were higher between patients of 15\u201364 years old than that of below 15 years and above 65 years of age.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["co-infected pathogens", "PROBLEM", 15, 36], ["co-infected", "OBSERVATION_MODIFIER", 15, 26], ["pathogens", "OBSERVATION_MODIFIER", 27, 36]]], ["We also found that the rates of influenza, HRV, and HAdV co-infection were higher among cases of 15\u201364 years old which was different from the previous studies in which the pathogens were found mainly affecting the young and aged people.", [["influenza, HRV, and HAdV co-infection", "DISEASE", 32, 69], ["HAdV", "ORGANISM", 52, 56], ["people", "ORGANISM", 229, 235], ["people", "SPECIES", 229, 235], ["HRV", "SPECIES", 43, 46], ["HAdV", "SPECIES", 52, 56], ["influenza", "PROBLEM", 32, 41], ["HRV", "PROBLEM", 43, 46], ["HAdV co-infection", "PROBLEM", 52, 69], ["the previous studies", "TEST", 138, 158], ["the pathogens", "PROBLEM", 168, 181], ["influenza", "OBSERVATION", 32, 41]]], ["It may be due to the decreased immunity after SARS-CoV-2 infection.", [["infection", "DISEASE", 57, 66], ["SARS-CoV-2", "ORGANISM", 46, 56], ["SARS-CoV", "SPECIES", 46, 54], ["the decreased immunity", "PROBLEM", 17, 39], ["SARS", "PROBLEM", 46, 50], ["CoV-2 infection", "PROBLEM", 51, 66], ["may be due to", "UNCERTAINTY", 3, 16], ["decreased", "OBSERVATION_MODIFIER", 21, 30], ["infection", "OBSERVATION", 57, 66]]], ["The highest Co-infection rate and the most pathogen species were detected in cases of 1\u20134 days after onset.", [["The highest Co-infection rate", "PROBLEM", 0, 29], ["the most pathogen species", "PROBLEM", 34, 59], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["Co-infection", "OBSERVATION", 12, 24]]], ["Along with the course of disease, both the rates and pathogen species of co-infection among COVID-19 patients were decreased significantly, which may due to the treatment the patients received.", [["co-infection", "DISEASE", 73, 85], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 175, 183], ["disease", "PROBLEM", 25, 32], ["co-infection", "PROBLEM", 73, 85], ["COVID", "TEST", 92, 97], ["disease", "OBSERVATION", 25, 32]]], ["We noticed that a high co-infection rate and pathogen species in patients of -4\u20130 days after onset, which indicated asymptomatic category also have high co-infection opportunity although the pathogen species was the lowest, and early treatment should be taken for them.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["a high co-infection rate", "PROBLEM", 16, 40], ["pathogen species", "PROBLEM", 45, 61], ["asymptomatic category", "PROBLEM", 116, 137], ["high co-infection opportunity", "PROBLEM", 148, 177], ["the pathogen species", "PROBLEM", 187, 207], ["early treatment", "TREATMENT", 228, 243], ["high", "OBSERVATION_MODIFIER", 18, 22], ["co-infection", "OBSERVATION", 23, 35], ["high", "OBSERVATION_MODIFIER", 148, 152], ["co-infection", "OBSERVATION", 153, 165]]], ["Pathogen species was also not high in severe/critical category, which may attribute to all of them have been taken medical intervention.ConclusionsIn this study, we tested for the presence of 24 types of respiratory pathogens in 257 COVID-19 patients.", [["respiratory pathogens", "DISEASE", 204, 225], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 242, 250], ["Pathogen species", "PROBLEM", 0, 16], ["medical intervention", "TREATMENT", 115, 135], ["this study", "TEST", 150, 160], ["respiratory pathogens", "PROBLEM", 204, 225], ["COVID", "TEST", 233, 238], ["respiratory pathogens", "OBSERVATION", 204, 225]]], ["At present, more and more patients of infectious diseases were characterized by an increased multi-pathogen co-infection, which has increased the difficulty in clinical diagnosis and treatment.", [["infectious diseases", "DISEASE", 38, 57], ["co-infection", "DISEASE", 108, 120], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["infectious diseases", "PROBLEM", 38, 57], ["an increased multi-pathogen co-infection", "PROBLEM", 80, 120], ["treatment", "TREATMENT", 183, 192], ["infectious", "OBSERVATION", 38, 48], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["multi-pathogen", "OBSERVATION_MODIFIER", 93, 107], ["co-infection", "OBSERVATION", 108, 120], ["increased", "OBSERVATION_MODIFIER", 132, 141]]], ["Therefore, while testing SARS-CoV-2, we needed simultaneously screen other respiratory pathogens which was very important to for the appropriate treatment and diagnosis.FundingThis study was funded by the National Major Science & Technology Projects for Infectious Disease Control and Prevention (2017ZX10103008, 2017ZX10302301), 10.13039/501100001809National Natural Science Foundation of China (81,871,666, 31,700,035), 10.13039/501100004608Natural Science Foundation of Jiangsu Province (BK20191489), the Key Research and Development Project of Jiangsu Province (BE2019761), Jiangsu Provincial Key Medical Discipline of Epidemiology (ZDXKA2016008), Jiangsu Provincial Medical Youth Talent (QNRC2016537) and \u201cSix One\u201d Project (LGY2017084).CRediT authorship contribution statement", [["respiratory pathogens", "DISEASE", 75, 96], ["Infectious Disease", "DISEASE", 254, 272], ["SARS-CoV-2", "ORGANISM", 25, 35], ["SARS-CoV", "SPECIES", 25, 33], ["testing SARS", "TEST", 17, 29], ["CoV", "TEST", 30, 33], ["simultaneously screen other respiratory pathogens", "PROBLEM", 47, 96], ["This study", "TEST", 176, 186], ["Infectious Disease Control", "TREATMENT", 254, 280]]]], "8c43b5c8a56828ee5687a2b572dc05333c2815a0": [["IntroductionThe 2014 International Symposium on HIV and Emerging Infectious Diseases (ISHEID) was held in Marseille, France, on May 21-23.", [["Infectious Diseases", "DISEASE", 65, 84], ["HIV", "SPECIES", 48, 51], ["HIV", "SPECIES", 48, 51]]], ["This meeting attracted more than 900 delegates from all over the world (75% outside France) and allowed interactive discussions around HIV, viral hepatitis, new influenza strains, MERS-CoV and Chikungunya infection.", [["viral hepatitis", "DISEASE", 140, 155], ["influenza", "DISEASE", 161, 170], ["Chikungunya infection", "DISEASE", 193, 214], ["HIV", "ORGANISM", 135, 138], ["MERS-CoV", "ORGANISM", 180, 188], ["Chikungunya", "ORGANISM", 193, 204], ["HIV", "SPECIES", 135, 138], ["HIV", "SPECIES", 135, 138], ["MERS-CoV", "SPECIES", 180, 188], ["HIV", "PROBLEM", 135, 138], ["viral hepatitis", "PROBLEM", 140, 155], ["new influenza strains", "PROBLEM", 157, 178], ["MERS", "PROBLEM", 180, 184], ["CoV", "PROBLEM", 185, 188], ["Chikungunya infection", "PROBLEM", 193, 214], ["viral hepatitis", "OBSERVATION", 140, 155], ["Chikungunya infection", "OBSERVATION", 193, 214]]], ["In this article we focus on some aspects of these discussions.Antiretroviral therapyFrom the point of view of HIV infection, the emphasis was very much on antiretroviral therapy with new compounds in development and results of recent Phase III trials as well as treatment issues in the young such as adolescents and less young in an aging epidemic in what has become a chronic disease.", [["HIV infection", "DISEASE", 110, 123], ["HIV", "ORGANISM", 110, 113], ["HIV", "SPECIES", 110, 113], ["adolescents", "SPECIES", 300, 311], ["HIV", "SPECIES", 110, 113], ["Antiretroviral therapyFrom", "TREATMENT", 62, 88], ["HIV infection", "PROBLEM", 110, 123], ["antiretroviral therapy", "TREATMENT", 155, 177], ["recent Phase III trials", "TREATMENT", 227, 250], ["treatment issues", "TREATMENT", 262, 278], ["a chronic disease", "PROBLEM", 367, 384], ["HIV", "OBSERVATION_MODIFIER", 110, 113], ["infection", "OBSERVATION", 114, 123], ["chronic", "OBSERVATION_MODIFIER", 369, 376], ["disease", "OBSERVATION", 377, 384]]], ["How to end the epidemic, the development of a prophylactic vaccine and HIV eradication took the front stage on several occasions during these three days.Antiretroviral therapyThe conference started by \"The Thirty Years of Discoveries of HIV\" and \"The Ten Big Mistakes We Did\".", [["HIV", "SPECIES", 71, 74], ["HIV", "SPECIES", 71, 74], ["HIV", "SPECIES", 237, 240], ["a prophylactic vaccine", "TREATMENT", 44, 66], ["HIV eradication", "TREATMENT", 71, 86], ["Antiretroviral therapy", "TREATMENT", 153, 175]]], ["Stefano Vella reminded us of the hopes in the early days of the epidemic of a prophylactic vaccine within the next 3 years.", [["a prophylactic vaccine", "TREATMENT", 76, 98]]], ["This prediction probably refers on Margaret Heckler declaration in 1984 [1] but what she said is that as we were able to grow HIV, this would help finding a vaccine one day.", [["HIV", "ORGANISM", 126, 129], ["HIV", "SPECIES", 126, 129], ["HIV", "PROBLEM", 126, 129]]], ["Vella also listed the short-life of the experiment in treatment interruptions and, to the contrary, the prolonged use of D4T, and the delay in using surrogate markers and understanding the ART-associated side-effects such as lipodystrophy.", [["lipodystrophy", "DISEASE", 225, 238], ["D4T", "SIMPLE_CHEMICAL", 121, 124], ["treatment interruptions", "TREATMENT", 54, 77], ["D4T", "TREATMENT", 121, 124], ["surrogate markers", "TEST", 149, 166], ["lipodystrophy", "PROBLEM", 225, 238], ["lipodystrophy", "OBSERVATION", 225, 238]]], ["We also took time to take into account the impact of ART as a preventative measure while the exact timing of ART initiation is still being assessed with in ongoing studies.", [["ART", "TREATMENT", 53, 56], ["a preventative measure", "TREATMENT", 60, 82], ["ART initiation", "TREATMENT", 109, 123], ["ongoing studies", "TEST", 156, 171]]], ["Stefano Vella concluded that the understanding of HIV pathogenesis and the development of new drugs paved the way for the dramatic progress of the 1990s in terms of morbidity and mortality with combination therapy.", [["HIV", "ORGANISM", 50, 53], ["HIV", "SPECIES", 50, 53], ["HIV", "SPECIES", 50, 53], ["HIV pathogenesis", "PROBLEM", 50, 66], ["new drugs", "TREATMENT", 90, 99], ["combination therapy", "TREATMENT", 194, 213], ["new", "OBSERVATION_MODIFIER", 90, 93], ["drugs", "OBSERVATION", 94, 99]]], ["Nearly 10 million of individuals are now on treatment worldwide and the appalling discrepancy in access between rich and developing countries is progressively being filled.", [["individuals", "ORGANISM", 21, 32], ["treatment", "TREATMENT", 44, 53]]], ["This process is also exemplified by the 2013 WHO Guidelines for the Treatment of Adults which have aligned themselves with those from other international committees.Antiretroviral therapyMark Wainberg [2] spoke about future challenges with a strong emphasis on finding a cure for HIV infection.", [["HIV infection", "DISEASE", 280, 293], ["HIV", "ORGANISM", 280, 283], ["Adults", "SPECIES", 81, 87], ["HIV", "SPECIES", 280, 283], ["Antiretroviral therapy", "TREATMENT", 165, 187], ["HIV infection", "PROBLEM", 280, 293], ["infection", "OBSERVATION", 284, 293]]], ["Current efforts to provide ARVs to the millions of people infected by HIV in developing countries may not be sustainable.", [["HIV", "DISEASE", 70, 73], ["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["HIV", "SPECIES", 70, 73], ["HIV", "SPECIES", 70, 73], ["ARVs", "TREATMENT", 27, 31], ["HIV", "PROBLEM", 70, 73]]], ["Professor Wainberg hypothesized that dolutegravir is a qualitatively superior drug than any of its predecessors and that drug resistance against dolutegravir may be impossible if this compound is used in first line therapy for reasons of efficient drug binding to the integrase enzyme and greatly reduced viral fitness if viruses do become minimally resistant.", [["dolutegravir", "CHEMICAL", 37, 49], ["dolutegravir", "CHEMICAL", 145, 157], ["dolutegravir", "CHEMICAL", 37, 49], ["dolutegravir", "CHEMICAL", 145, 157], ["dolutegravir", "SIMPLE_CHEMICAL", 37, 49], ["dolutegravir", "SIMPLE_CHEMICAL", 145, 157], ["integrase enzyme", "PROTEIN", 268, 284], ["dolutegravir", "TREATMENT", 37, 49], ["drug resistance", "TREATMENT", 121, 136], ["dolutegravir", "TREATMENT", 145, 157], ["first line therapy", "TREATMENT", 204, 222], ["efficient drug binding", "PROBLEM", 238, 260], ["the integrase enzyme", "TEST", 264, 284], ["greatly reduced viral fitness", "PROBLEM", 289, 318], ["viruses", "PROBLEM", 322, 329], ["minimally resistant", "PROBLEM", 340, 359]]], ["He stated that patients on dolutegravir may be unable to transmit HIV and that the use of this drug may therefore contribute to ending the HIV epidemic.Antiretroviral therapyThe sessions on the management of antiretroviral therapy reminded us that there is a robust pipeline of new compounds in development.", [["dolutegravir", "CHEMICAL", 27, 39], ["dolutegravir", "CHEMICAL", 27, 39], ["patients", "ORGANISM", 15, 23], ["dolutegravir", "SIMPLE_CHEMICAL", 27, 39], ["HIV", "ORGANISM", 66, 69], ["patients", "SPECIES", 15, 23], ["HIV", "SPECIES", 66, 69], ["HIV", "SPECIES", 139, 142], ["dolutegravir", "TREATMENT", 27, 39], ["HIV", "PROBLEM", 66, 69], ["this drug", "TREATMENT", 90, 99], ["the HIV epidemic", "PROBLEM", 135, 151], ["Antiretroviral therapy", "TREATMENT", 152, 174], ["the management", "TREATMENT", 190, 204], ["antiretroviral therapy", "TREATMENT", 208, 230], ["antiretroviral therapy", "OBSERVATION", 208, 230], ["new", "OBSERVATION_MODIFIER", 278, 281], ["compounds", "OBSERVATION_MODIFIER", 282, 291]]], ["Roy Gulick [3] discussed the need of new NRTIs with activity against resistant viral strains and less long-term toxicity.", [["NRTIs", "CHEMICAL", 41, 46], ["toxicity", "DISEASE", 112, 120], ["new NRTIs", "TREATMENT", 37, 46], ["resistant viral strains", "PROBLEM", 69, 92], ["less long-term toxicity", "PROBLEM", 97, 120]]], ["Tenofovir alafenamide fumarate known as TAF is under development and shows a viremia decrease of about 1 log over 10 days dosing and should display a safer toxicity profile in terms of kidney and bone than tenofovir.", [["kidney", "ANATOMY", 185, 191], ["bone", "ANATOMY", 196, 200], ["Tenofovir", "CHEMICAL", 0, 9], ["alafenamide fumarate", "CHEMICAL", 10, 30], ["viremia", "DISEASE", 77, 84], ["toxicity", "DISEASE", 156, 164], ["tenofovir", "CHEMICAL", 206, 215], ["Tenofovir alafenamide fumarate", "CHEMICAL", 0, 30], ["tenofovir", "CHEMICAL", 206, 215], ["Tenofovir alafenamide", "SIMPLE_CHEMICAL", 0, 21], ["fumarate", "SIMPLE_CHEMICAL", 22, 30], ["TAF", "GENE_OR_GENE_PRODUCT", 40, 43], ["kidney", "ORGAN", 185, 191], ["bone", "TISSUE", 196, 200], ["tenofovir", "SIMPLE_CHEMICAL", 206, 215], ["TAF", "PROTEIN", 40, 43], ["Tenofovir alafenamide fumarate", "TREATMENT", 0, 30], ["a viremia decrease", "PROBLEM", 75, 93], ["a safer toxicity profile", "PROBLEM", 148, 172], ["tenofovir", "TREATMENT", 206, 215], ["viremia", "OBSERVATION", 77, 84], ["kidney", "ANATOMY", 185, 191], ["bone", "ANATOMY", 196, 200]]], ["Doravirine, a potent new NNRTI which is metabolized by CYP3A4 and active in vitro against viral strains with K103N, Y181C, G190A, E101K, E138K or K103N/Y181C is in development.", [["Doravirine", "CHEMICAL", 0, 10], ["NNRTI", "CHEMICAL", 25, 30], ["Doravirine", "CHEMICAL", 0, 10], ["NNRTI", "CHEMICAL", 25, 30], ["Doravirine", "SIMPLE_CHEMICAL", 0, 10], ["NNRTI", "SIMPLE_CHEMICAL", 25, 30], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 55, 61], ["E138K", "GENE_OR_GENE_PRODUCT", 137, 142], ["Doravirine", "TREATMENT", 0, 10], ["a potent new NNRTI", "TREATMENT", 12, 30], ["viral strains", "PROBLEM", 90, 103], ["K103N", "TEST", 109, 114], ["Y181C", "TEST", 116, 121], ["E101K", "TEST", 130, 135], ["K", "TEST", 141, 142], ["K103N", "TEST", 146, 151], ["NNRTI", "OBSERVATION", 25, 30]]], ["The attachment inhibitor class has an interesting one daily compound active on both CCR5 and CCR2, cenicriviroc, which has also potential anti-inflammatory properties.", [["cenicriviroc", "CHEMICAL", 99, 111], ["CCR5", "GENE_OR_GENE_PRODUCT", 84, 88], ["CCR2", "GENE_OR_GENE_PRODUCT", 93, 97], ["cenicriviroc", "SIMPLE_CHEMICAL", 99, 111], ["CCR5", "PROTEIN", 84, 88], ["CCR2", "PROTEIN", 93, 97], ["cenicriviroc", "TREATMENT", 99, 111], ["anti-inflammatory properties", "TREATMENT", 138, 166], ["active", "OBSERVATION_MODIFIER", 69, 75], ["anti-inflammatory properties", "OBSERVATION", 138, 166]]], ["BMS-663068 is an attachment inhibitor with a new mechanism of action.", [["BMS-663068", "CHEMICAL", 0, 10], ["BMS-663068", "CHEMICAL", 0, 10], ["BMS-663068", "SIMPLE_CHEMICAL", 0, 10], ["BMS", "TEST", 0, 3], ["an attachment inhibitor", "TREATMENT", 14, 37]]], ["It binds to the envelope protein gp120 and is therefore different form the CCR5 class of drugs.", [["gp120", "GENE_OR_GENE_PRODUCT", 33, 38], ["CCR5", "GENE_OR_GENE_PRODUCT", 75, 79], ["envelope protein", "PROTEIN", 16, 32], ["gp120", "PROTEIN", 33, 38], ["CCR5", "PROTEIN", 75, 79]]], ["It is active against most HIV strains but not all, is potent and well tolerated.Antiretroviral therapyThe important results from The LATTE [3] study which showed that rilpivirne and GSK 1265744 (744) orally in maintenance therapy suppressed viremia are paving the way for the testing of injectable forms of this combination which might be deliverable on a monthly basis.", [["rilpivirne", "CHEMICAL", 167, 177], ["GSK 1265744", "CHEMICAL", 182, 193], ["viremia", "DISEASE", 241, 248], ["rilpivirne", "CHEMICAL", 167, 177], ["GSK 1265744", "CHEMICAL", 182, 193], ["rilpivirne", "SIMPLE_CHEMICAL", 167, 177], ["GSK 1265744", "SIMPLE_CHEMICAL", 182, 193], ["HIV", "SPECIES", 26, 29], ["most HIV strains", "PROBLEM", 21, 37], ["Antiretroviral therapy", "TREATMENT", 80, 102], ["The LATTE [3] study", "TEST", 129, 148], ["GSK", "TEST", 182, 185], ["maintenance therapy", "TREATMENT", 210, 229], ["viremia", "PROBLEM", 241, 248], ["the testing", "TEST", 272, 283], ["active", "OBSERVATION_MODIFIER", 6, 12]]], ["Its use as a pre-exposure prophylaxis agent will also be tested soon.", [["a pre-exposure prophylaxis agent", "TREATMENT", 11, 43]]], ["The exciting development of injectable long-acting ARV's was presented by Marta Boffito [4] .Antiretroviral therapyIn terms of first line therapy in 2014 Marc Nelson [5] presented the positive results from the recent trials of newly developed antiretroviral drugs such as those of phase III of elvitegravir and dolutegravir and stressed the favourable resistance profile of dolutegravir together reminding us of the mechanism of action at the tubular level of the booster cobicistat.", [["tubular", "ANATOMY", 443, 450], ["elvitegravir", "CHEMICAL", 294, 306], ["dolutegravir", "CHEMICAL", 311, 323], ["dolutegravir", "CHEMICAL", 374, 386], ["cobicistat", "CHEMICAL", 472, 482], ["elvitegravir", "CHEMICAL", 294, 306], ["dolutegravir", "CHEMICAL", 311, 323], ["dolutegravir", "CHEMICAL", 374, 386], ["elvitegravir", "SIMPLE_CHEMICAL", 294, 306], ["dolutegravir", "SIMPLE_CHEMICAL", 311, 323], ["dolutegravir", "SIMPLE_CHEMICAL", 374, 386], ["tubular", "MULTI-TISSUE_STRUCTURE", 443, 450], ["cobicistat", "SIMPLE_CHEMICAL", 472, 482], ["injectable long-acting ARV's", "TREATMENT", 28, 56], ["Antiretroviral therapy", "TREATMENT", 93, 115], ["first line therapy", "TREATMENT", 127, 145], ["antiretroviral drugs", "TREATMENT", 243, 263], ["elvitegravir", "TREATMENT", 294, 306], ["dolutegravir", "TREATMENT", 311, 323], ["dolutegravir", "TREATMENT", 374, 386], ["line therapy", "OBSERVATION", 133, 145], ["favourable resistance", "OBSERVATION_MODIFIER", 341, 362]]], ["Delays had occurred in detecting many ART-associated toxicities.", [["toxicities", "DISEASE", 53, 63], ["associated toxicities", "PROBLEM", 42, 63]]], ["Drug costs are at the forefront of the treatment agenda and generic formulations for many antiretrovirals are available or on the way which will have important impact on drug cost in the future.", [["Drug costs", "PROBLEM", 0, 10], ["the treatment agenda", "TREATMENT", 35, 55], ["generic formulations", "TREATMENT", 60, 80], ["many antiretrovirals", "TREATMENT", 85, 105], ["drug cost", "TREATMENT", 170, 179]]], ["A trial of first line therapy with lopinavir/ ritonavir (LPV/r) vs nevirapine and 2 NNRTIs in a developing country: W144 of a randomized trial by Nathan Clumeck [6] showed favourable outcome for the protein inhibitor-based regimen.Antiretroviral therapyIn the discussion on switch strategies Daniel Podzamer [7] reviewed the causes for switching ART within the context of imperfect ART with adherence problems, toxicity among others.", [["lopinavir/ ritonavir", "CHEMICAL", 35, 55], ["LPV", "CHEMICAL", 57, 60], ["nevirapine", "CHEMICAL", 67, 77], ["toxicity", "DISEASE", 411, 419], ["lopinavir", "CHEMICAL", 35, 44], ["ritonavir", "CHEMICAL", 46, 55], ["LPV", "CHEMICAL", 57, 60], ["nevirapine", "CHEMICAL", 67, 77], ["lopinavir", "SIMPLE_CHEMICAL", 35, 44], ["ritonavir", "SIMPLE_CHEMICAL", 46, 55], ["nevirapine", "SIMPLE_CHEMICAL", 67, 77], ["first line therapy", "TREATMENT", 11, 29], ["lopinavir", "TREATMENT", 35, 44], ["ritonavir (LPV/r)", "TREATMENT", 46, 63], ["nevirapine", "TREATMENT", 67, 77], ["2 NNRTIs", "TREATMENT", 82, 90], ["the protein inhibitor", "TREATMENT", 195, 216], ["based regimen", "TREATMENT", 217, 230], ["Antiretroviral therapyIn", "TREATMENT", 231, 255], ["switching ART", "TREATMENT", 336, 349], ["adherence problems", "PROBLEM", 391, 409]]], ["He reminded us that not all switch strategies have been tested.HIV as a chronic diseaseSome of the important issues that clinicians encounter nowadays with HIV as a chronic disease are characterized by processes which are associated with increased morbidity and morbidity and are not related to the traditional AIDS-defining events, such as cardio-vascular, renal, metabolic and bone diseases.", [["cardio-vascular", "ANATOMY", 341, 356], ["renal", "ANATOMY", 358, 363], ["bone", "ANATOMY", 379, 383], ["chronic disease", "DISEASE", 165, 180], ["AIDS", "DISEASE", 311, 315], ["cardio-vascular, renal, metabolic and bone diseases", "DISEASE", 341, 392], ["renal", "MULTI-TISSUE_STRUCTURE", 358, 363], ["bone", "TISSUE", 379, 383], ["HIV", "SPECIES", 63, 66], ["HIV", "SPECIES", 156, 159], ["HIV", "SPECIES", 63, 66], ["HIV", "SPECIES", 156, 159], ["all switch strategies", "TREATMENT", 24, 45], ["HIV", "PROBLEM", 63, 66], ["a chronic diseaseSome", "PROBLEM", 70, 91], ["HIV", "PROBLEM", 156, 159], ["a chronic disease", "PROBLEM", 163, 180], ["increased morbidity", "PROBLEM", 238, 257], ["morbidity", "PROBLEM", 262, 271], ["the traditional AIDS", "PROBLEM", 295, 315], ["cardio-vascular, renal, metabolic and bone diseases", "PROBLEM", 341, 392], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["chronic", "OBSERVATION_MODIFIER", 165, 172], ["disease", "OBSERVATION", 173, 180], ["increased", "OBSERVATION_MODIFIER", 238, 247], ["morbidity", "OBSERVATION", 248, 257], ["cardio-vascular", "ANATOMY", 341, 356], ["renal", "ANATOMY", 358, 363], ["metabolic", "OBSERVATION_MODIFIER", 365, 374], ["bone", "ANATOMY", 379, 383], ["diseases", "OBSERVATION", 384, 392]]], ["Chronic inflammation as discussed by Frank Miedema [8] is one of the critical factors in HIV pathogenesis and the most likely cause of non-AIDS end-organ disease encountered during chronic HIV infection such as atherosclerosis, cardiovascular disease, kidney failure and neuropathology.", [["organ", "ANATOMY", 148, 153], ["cardiovascular", "ANATOMY", 228, 242], ["kidney", "ANATOMY", 252, 258], ["inflammation", "DISEASE", 8, 20], ["end-organ disease", "DISEASE", 144, 161], ["HIV infection", "DISEASE", 189, 202], ["atherosclerosis", "DISEASE", 211, 226], ["cardiovascular disease", "DISEASE", 228, 250], ["kidney failure", "DISEASE", 252, 266], ["neuropathology", "DISEASE", 271, 285], ["HIV", "ORGANISM", 89, 92], ["organ", "ORGAN", 148, 153], ["cardiovascular", "ANATOMICAL_SYSTEM", 228, 242], ["kidney", "ORGAN", 252, 258], ["HIV", "SPECIES", 89, 92], ["HIV", "SPECIES", 189, 192], ["HIV", "SPECIES", 89, 92], ["HIV", "SPECIES", 189, 192], ["Chronic inflammation", "PROBLEM", 0, 20], ["HIV pathogenesis", "PROBLEM", 89, 105], ["non-AIDS end-organ disease", "PROBLEM", 135, 161], ["chronic HIV infection", "PROBLEM", 181, 202], ["atherosclerosis", "PROBLEM", 211, 226], ["cardiovascular disease", "PROBLEM", 228, 250], ["kidney failure", "PROBLEM", 252, 266], ["neuropathology", "PROBLEM", 271, 285], ["inflammation", "OBSERVATION", 8, 20], ["most likely", "UNCERTAINTY", 114, 125], ["non-AIDS", "OBSERVATION", 135, 143], ["organ", "ANATOMY", 148, 153], ["disease", "OBSERVATION", 154, 161], ["chronic", "OBSERVATION_MODIFIER", 181, 188], ["HIV", "OBSERVATION_MODIFIER", 189, 192], ["infection", "OBSERVATION", 193, 202], ["atherosclerosis", "OBSERVATION", 211, 226], ["cardiovascular", "ANATOMY", 228, 242], ["disease", "OBSERVATION", 243, 250], ["kidney", "ANATOMY", 252, 258], ["failure", "OBSERVATION", 259, 266]]], ["This process remains active even during combination ART.", [["active", "OBSERVATION", 21, 27]]], ["In Aging with HIV Paddy Mallon [9] reviewed the various markers of immune dysfunction and changes associated with ageing and HIV infection.", [["immune dysfunction", "DISEASE", 67, 85], ["HIV infection", "DISEASE", 125, 138], ["HIV", "ORGANISM", 125, 128], ["HIV", "SPECIES", 14, 17], ["HIV", "SPECIES", 125, 128], ["HIV", "SPECIES", 14, 17], ["HIV", "SPECIES", 125, 128], ["immune dysfunction", "PROBLEM", 67, 85], ["HIV infection", "PROBLEM", 125, 138], ["immune dysfunction", "OBSERVATION", 67, 85], ["infection", "OBSERVATION", 129, 138]]], ["The ageing process and HIV infection are associated with similar changes beside immune dysfunction such as bone changes and cardiovascular disease.", [["bone", "ANATOMY", 107, 111], ["cardiovascular", "ANATOMY", 124, 138], ["HIV infection", "DISEASE", 23, 36], ["immune dysfunction", "DISEASE", 80, 98], ["cardiovascular disease", "DISEASE", 124, 146], ["HIV", "ORGANISM", 23, 26], ["bone", "TISSUE", 107, 111], ["cardiovascular", "ANATOMICAL_SYSTEM", 124, 138], ["HIV", "SPECIES", 23, 26], ["HIV", "SPECIES", 23, 26], ["The ageing process", "PROBLEM", 0, 18], ["HIV infection", "PROBLEM", 23, 36], ["immune dysfunction", "PROBLEM", 80, 98], ["bone changes", "PROBLEM", 107, 119], ["cardiovascular disease", "PROBLEM", 124, 146], ["HIV", "OBSERVATION_MODIFIER", 23, 26], ["infection", "OBSERVATION", 27, 36], ["immune dysfunction", "OBSERVATION", 80, 98], ["bone", "ANATOMY", 107, 111], ["cardiovascular disease", "OBSERVATION", 124, 146]]], ["The rational conclusion regarding comorbidities in HIV-patients was to address them early and to have a long view regarding the choice of ART regimen taking into consideration all these factors according to Barry Peters [10] .", [["HIV", "ORGANISM", 51, 54], ["patients", "ORGANISM", 55, 63], ["HIV", "SPECIES", 51, 54], ["patients", "SPECIES", 55, 63], ["HIV", "SPECIES", 51, 54], ["comorbidities", "PROBLEM", 34, 47], ["ART regimen", "TREATMENT", 138, 149]]], ["The place of statins was reviewed by Kenneth Lichtenstein [11] .", [["statins", "CHEMICAL", 13, 20], ["statins", "CHEMICAL", 13, 20], ["statins", "TREATMENT", 13, 20]]], ["His conclusion was that in terms of risk of type 2 diabetes their benefit outweighed the risk.", [["diabetes", "DISEASE", 51, 59], ["type 2 diabetes", "PROBLEM", 44, 59]]], ["Lipids levels also are not the whole story and stressed the importance of lifestyle changes such as weight reduction and smoking cessation.HIV as a chronic diseaseOn the other side of the age spectrum we are dealing with a young population either infected vertically or horizontally due to improved treatments children born with HIV reach adulthood.", [["weight reduction", "DISEASE", 100, 116], ["smoking", "CHEMICAL", 121, 128], ["children", "ORGANISM", 310, 318], ["HIV", "SPECIES", 139, 142], ["children", "SPECIES", 310, 318], ["HIV", "SPECIES", 329, 332], ["HIV", "SPECIES", 139, 142], ["HIV", "SPECIES", 329, 332], ["Lipids levels", "TEST", 0, 13], ["lifestyle changes", "TREATMENT", 74, 91], ["weight reduction", "TREATMENT", 100, 116], ["smoking cessation", "TREATMENT", 121, 138], ["HIV", "PROBLEM", 139, 142], ["a chronic diseaseOn", "PROBLEM", 146, 165], ["HIV reach adulthood", "PROBLEM", 329, 348], ["chronic", "OBSERVATION_MODIFIER", 148, 155], ["diseaseOn", "OBSERVATION", 156, 165]]], ["Rana Chakraborthy [12] reiterated the importance of organizing the transitioning process of HIV Infected Youths into the Adult Healthcare system using multidisciplinary individualized approaches and the different needs regarding in particular stigma, mental health and high rates of teen pregnancy that these two populations have in terms of support.Ending the HIV pandemicLast but not least, how to stop the epidemic and achieve a cure?", [["HIV", "ORGANISM", 92, 95], ["HIV", "SPECIES", 361, 364], ["HIV", "SPECIES", 92, 95], ["HIV", "SPECIES", 361, 364], ["multidisciplinary individualized approaches", "TREATMENT", 151, 194]]], ["We need to track the current state of the epidemic, early diagnosis of the HIV infection, prevent the acquisition and the transmission of HIV.", [["HIV infection", "DISEASE", 75, 88], ["HIV", "DISEASE", 138, 141], ["HIV", "ORGANISM", 75, 78], ["HIV", "ORGANISM", 138, 141], ["HIV", "SPECIES", 75, 78], ["HIV", "SPECIES", 138, 141], ["HIV", "SPECIES", 75, 78], ["HIV", "SPECIES", 138, 141], ["the HIV infection", "PROBLEM", 71, 88], ["the acquisition", "TEST", 98, 113], ["HIV", "PROBLEM", 138, 141], ["infection", "OBSERVATION", 79, 88]]], ["Our preventative tools have grown in the past few years with the acknowledgment of the impact of ART as a tool for prevention.", [["grown", "OBSERVATION_MODIFIER", 28, 33]]], ["Myron Cohen discussed the different prevention strategies and interventions in the uninfected and infected individuals.", [["Myron Cohen", "TREATMENT", 0, 11], ["the different prevention strategies", "TREATMENT", 22, 57], ["interventions", "TREATMENT", 62, 75]]], ["Factors associated with amplified transmission include those associated with infectiousness such as blood and genital tract viral load, sexually transmitted diseases (STDs), viral clade and acute infection and susceptibility for the acquisition of the virus such as STDs among others.", [["blood", "ANATOMY", 100, 105], ["genital tract", "ANATOMY", 110, 123], ["sexually transmitted diseases", "DISEASE", 136, 165], ["STDs", "DISEASE", 167, 171], ["infection", "DISEASE", 196, 205], ["STDs", "DISEASE", 266, 270], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["genital tract", "ORGANISM_SUBDIVISION", 110, 123], ["infectiousness", "PROBLEM", 77, 91], ["blood and genital tract viral load", "PROBLEM", 100, 134], ["sexually transmitted diseases (STDs)", "PROBLEM", 136, 172], ["viral clade", "PROBLEM", 174, 185], ["acute infection", "PROBLEM", 190, 205], ["the virus", "PROBLEM", 248, 257], ["genital tract", "ANATOMY", 110, 123], ["acute", "OBSERVATION_MODIFIER", 190, 195], ["infection", "OBSERVATION", 196, 205]]], ["Joep Lange [15] reiterated the strong arguments in favor of early therapy and its individual and public health benefits in the implementation of TasP.", [["TasP", "SIMPLE_CHEMICAL", 145, 149], ["TasP", "PROTEIN", 145, 149], ["early therapy", "TREATMENT", 60, 73]]], ["Francois Dabis' recommendations for ending the epidemic within the next 20 years were to go to the communities, counsel and test, treat everybody, promote condom use and male circumcision and harm reduction.Ending the HIV pandemicIs there a possibility of a cure for HIV?", [["HIV", "DISEASE", 267, 270], ["HIV", "ORGANISM", 218, 221], ["HIV", "ORGANISM", 267, 270], ["HIV", "SPECIES", 218, 221], ["HIV", "SPECIES", 267, 270], ["HIV", "SPECIES", 218, 221], ["HIV", "SPECIES", 267, 270], ["harm reduction", "TREATMENT", 192, 206], ["HIV", "PROBLEM", 267, 270]]], ["In his update on reservoirs Lian Shan [16] showed the complexity of HIV-1 integration, in particular in memory precursor CD4 + T cells and the potential role of CTLs boosting in the elimination of infected cells.", [["memory precursor CD4 + T cells", "ANATOMY", 104, 134], ["cells", "ANATOMY", 206, 211], ["HIV-1", "ORGANISM", 68, 73], ["memory precursor CD4 + T cells", "CELL", 104, 134], ["CTLs", "CELL", 161, 165], ["cells", "CELL", 206, 211], ["memory precursor CD4 + T cells", "CELL_TYPE", 104, 134], ["CTLs", "CELL_TYPE", 161, 165], ["infected cells", "CELL_TYPE", 197, 211], ["HIV-1", "SPECIES", 68, 73], ["HIV", "PROBLEM", 68, 71], ["T cells", "PROBLEM", 127, 134], ["CTLs boosting", "TREATMENT", 161, 174], ["infected cells", "PROBLEM", 197, 211], ["infected cells", "OBSERVATION", 197, 211]]], ["The pharmacological approaches by Ole Schmeltz Sogaard [17] covered multiple immmunologcial interventions including neutralising antibodies beside therapeutic HIV vaccines, Anti-PD-L1 Ab, NK cells, peg INF-alpha and TLR agonists and others.", [["NK cells", "ANATOMY", 188, 196], ["HIV", "ORGANISM", 159, 162], ["Anti-PD-L1 Ab", "GENE_OR_GENE_PRODUCT", 173, 186], ["NK cells", "CELL", 188, 196], ["peg INF-alpha", "GENE_OR_GENE_PRODUCT", 198, 211], ["TLR agonists", "GENE_OR_GENE_PRODUCT", 216, 228], ["neutralising antibodies", "PROTEIN", 116, 139], ["Anti-PD-L1 Ab", "PROTEIN", 173, 186], ["NK cells", "CELL_TYPE", 188, 196], ["peg INF-alpha", "PROTEIN", 198, 211], ["TLR", "PROTEIN", 216, 219], ["HIV", "SPECIES", 159, 162], ["HIV", "SPECIES", 159, 162], ["multiple immmunologcial interventions", "TREATMENT", 68, 105], ["neutralising antibodies", "TREATMENT", 116, 139], ["therapeutic HIV vaccines", "TREATMENT", 147, 171], ["Anti-PD", "TEST", 173, 180], ["L1 Ab", "TREATMENT", 181, 186], ["NK cells", "TREATMENT", 188, 196], ["peg INF", "TREATMENT", 198, 205], ["alpha and TLR agonists", "TREATMENT", 206, 228], ["L1", "ANATOMY", 181, 183], ["NK cells", "OBSERVATION", 188, 196]]], ["Gene therapy and bone marrow transplantation were discussed by Joachim Hauber and Jan van Lutzen [18] .", [["bone marrow", "ANATOMY", 17, 28], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 17, 28], ["Gene therapy", "TREATMENT", 0, 12], ["bone marrow transplantation", "TREATMENT", 17, 44], ["bone", "ANATOMY", 17, 21]]], ["Gene therapy has had limitations because of the low number of transduced cells and genotoxicity.", [["cells", "ANATOMY", 73, 78], ["cells", "CELL", 73, 78], ["transduced cells", "CELL_LINE", 62, 78], ["Gene therapy", "TREATMENT", 0, 12], ["transduced cells", "PROBLEM", 62, 78], ["genotoxicity", "PROBLEM", 83, 95], ["transduced cells", "OBSERVATION", 62, 78]]], ["Zinc finger nucleases (ZFN) technology has the disadvantages of the possibility of off-target effect and chromosome instability.", [["chromosome", "ANATOMY", 105, 115], ["Zinc", "CHEMICAL", 0, 4], ["Zinc finger nucleases", "GENE_OR_GENE_PRODUCT", 0, 21], ["ZFN", "GENE_OR_GENE_PRODUCT", 23, 26], ["chromosome", "CELLULAR_COMPONENT", 105, 115], ["Zinc finger nucleases", "PROTEIN", 0, 21], ["ZFN", "PROTEIN", 23, 26], ["Zinc finger nucleases", "TREATMENT", 0, 21], ["chromosome instability", "PROBLEM", 105, 127], ["chromosome instability", "OBSERVATION", 105, 127]]], ["Joachim Hauber [19] presented the next generation LTR-specific Tre-recombinase which targets a majority of HIV-1 isolates.", [["LTR", "ANATOMY", 50, 53], ["LTR", "CELLULAR_COMPONENT", 50, 53], ["Tre-recombinase", "GENE_OR_GENE_PRODUCT", 63, 78], ["HIV-1", "ORGANISM", 107, 112], ["isolates", "ORGANISM", 113, 121], ["LTR", "DNA", 50, 53], ["Tre-recombinase", "PROTEIN", 63, 78], ["HIV-1", "SPECIES", 107, 112], ["HIV-1", "SPECIES", 107, 112]]], ["It attacks the reservoir directly and is presently expanding to other subtypes.", [["the reservoir", "TREATMENT", 11, 24], ["reservoir", "OBSERVATION_MODIFIER", 15, 24]]], ["Anne Gatignol [20] discussed the new therapeutic target in Gag RNA accessible to ribozyme and RNA interference molecules and in particular hepatitis delta-derived ribozyme to target HIV-1 RNA with long-term inhibitory activity suggesting that this type of molecules might be used in combination gene therapy or as drugs.Ending the HIV pandemicThe development of an HIV/ AIDS vaccine has been a long and difficult endeavor, which so far was met with many failures.", [["Gatignol", "CHEMICAL", 5, 13], ["HIV pandemic", "DISEASE", 331, 343], ["HIV/ AIDS", "DISEASE", 365, 374], ["Gatignol", "CHEMICAL", 5, 13], ["HIV-1", "ORGANISM", 182, 187], ["HIV", "ORGANISM", 365, 368], ["Gag RNA", "RNA", 59, 66], ["HIV-1 RNA", "RNA", 182, 191], ["HIV-1", "SPECIES", 182, 187], ["HIV", "SPECIES", 331, 334], ["HIV-1", "SPECIES", 182, 187], ["HIV pandemic", "SPECIES", 331, 343], ["HIV", "SPECIES", 365, 368], ["Gag RNA", "PROBLEM", 59, 66], ["ribozyme", "TREATMENT", 81, 89], ["RNA interference molecules", "PROBLEM", 94, 120], ["hepatitis delta-derived ribozyme", "TREATMENT", 139, 171], ["long-term inhibitory activity", "TREATMENT", 197, 226], ["gene therapy", "TREATMENT", 295, 307], ["an HIV/ AIDS vaccine", "TREATMENT", 362, 382], ["many failures", "PROBLEM", 449, 462], ["long-term", "OBSERVATION_MODIFIER", 197, 206], ["HIV pandemic", "OBSERVATION", 331, 343], ["HIV", "OBSERVATION", 365, 368], ["failures", "OBSERVATION", 454, 462]]], ["The hopes and challenges in HIV vaccine research were discussed at the 2014 ISHEID Conference.", [["HIV", "ORGANISM", 28, 31], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 28, 31], ["HIV vaccine", "TREATMENT", 28, 39]]], ["Vaccine challenges include the genetic diversity and mutability of HIV-1 that create a plethora of constantly changing antigens, the structural features of the viral envelope glycoprotein that disguise conserved receptorbinding sites from the immune system, and the presence of carbohydrate moieties that shield potential epitopes from antibodies.", [["immune system", "ANATOMY", 243, 256], ["carbohydrate", "CHEMICAL", 278, 290], ["HIV-1", "ORGANISM", 67, 72], ["antigens", "PROTEIN", 119, 127], ["viral envelope glycoprotein", "PROTEIN", 160, 187], ["receptorbinding sites", "DNA", 212, 233], ["carbohydrate moieties", "PROTEIN", 278, 299], ["epitopes", "PROTEIN", 322, 330], ["antibodies", "PROTEIN", 336, 346], ["HIV-1", "SPECIES", 67, 72], ["HIV-1", "SPECIES", 67, 72], ["Vaccine challenges", "TREATMENT", 0, 18], ["HIV", "PROBLEM", 67, 70], ["constantly changing antigens", "PROBLEM", 99, 127], ["the viral envelope glycoprotein", "PROBLEM", 156, 187], ["carbohydrate moieties", "PROBLEM", 278, 299], ["epitopes from antibodies", "PROBLEM", 322, 346]]], ["Indeed, HIV-1 gp120 contains a number of features that help the virus evade the host's humoral immunity, including variable loops, N-linked glycosylation, and conformational flexibility that disguise the conserved receptor-binding sites from the humoral immune system [2] .", [["N", "CHEMICAL", 131, 132], ["HIV-1", "ORGANISM", 8, 13], ["gp120", "ORGANISM", 14, 19], ["HIV-1 gp120", "PROTEIN", 8, 19], ["conserved receptor-binding sites", "PROTEIN", 204, 236], ["HIV-1", "SPECIES", 8, 13], ["HIV-1", "SPECIES", 8, 13], ["the virus", "PROBLEM", 60, 69], ["variable loops", "PROBLEM", 115, 129], ["N-linked glycosylation", "TREATMENT", 131, 153], ["conformational flexibility", "PROBLEM", 159, 185]]], ["The presence of carbohydrate moieties on gp120 shields potential epitopes from binding to antibodies, as shown by Czernekova et al. [21] .", [["carbohydrate", "CHEMICAL", 16, 28], ["gp120", "GENE_OR_GENE_PRODUCT", 41, 46], ["gp120", "PROTEIN", 41, 46], ["antibodies", "PROTEIN", 90, 100], ["carbohydrate moieties", "PROBLEM", 16, 37], ["gp120 shields", "TREATMENT", 41, 54], ["epitopes from binding to antibodies", "PROBLEM", 65, 100], ["carbohydrate moieties", "OBSERVATION", 16, 37]]], ["By partially removing N-glycans from gp120 they increased the reactivity of a panel of gp120-specific broadly neutralizing antibodies and sera from HIV-1-infected persons.Ending the HIV pandemicThe successful development of an HIV vaccine is one of the ten big challenges highlighted by Marc Wainberg [2] .", [["sera", "ANATOMY", 138, 142], ["HIV-1-infected", "DISEASE", 148, 162], ["HIV pandemic", "DISEASE", 182, 194], ["gp120", "GENE_OR_GENE_PRODUCT", 37, 42], ["gp120", "GENE_OR_GENE_PRODUCT", 87, 92], ["sera", "ORGANISM_SUBSTANCE", 138, 142], ["HIV-1", "ORGANISM", 148, 153], ["persons", "ORGANISM", 163, 170], ["HIV", "ORGANISM", 227, 230], ["N-glycans", "PROTEIN", 22, 31], ["gp120", "PROTEIN", 37, 42], ["gp120", "PROTEIN", 87, 92], ["neutralizing antibodies", "PROTEIN", 110, 133], ["HIV-1", "SPECIES", 148, 153], ["persons", "SPECIES", 163, 170], ["HIV", "SPECIES", 182, 185], ["HIV", "SPECIES", 227, 230], ["HIV-1", "SPECIES", 148, 153], ["HIV pandemic", "SPECIES", 182, 194], ["HIV", "SPECIES", 227, 230], ["N-glycans", "TREATMENT", 22, 31], ["gp120", "TEST", 87, 92], ["neutralizing antibodies", "TEST", 110, 133], ["sera", "TEST", 138, 142], ["HIV", "TEST", 148, 151], ["an HIV vaccine", "TREATMENT", 224, 238], ["HIV pandemic", "OBSERVATION", 182, 194], ["HIV", "OBSERVATION", 227, 230]]], ["He also pointed out that there is a very limited rate of success in the development of vaccines to all forms of sexually transmitted disease, with the obvious exception being Human Papilloma Virus [2] .", [["sexually transmitted disease", "DISEASE", 112, 140], ["Human Papilloma Virus", "DISEASE", 175, 196], ["Human Papilloma Virus", "ORGANISM", 175, 196], ["Human", "SPECIES", 175, 180], ["Human Papilloma Virus", "SPECIES", 175, 196], ["vaccines", "TREATMENT", 87, 95], ["sexually transmitted disease", "PROBLEM", 112, 140], ["Human Papilloma Virus", "PROBLEM", 175, 196], ["Papilloma", "OBSERVATION", 181, 190]]], ["As reviewed by Marc Girard [22] , the first efficacy trials for an HIV vaccine attempting to elicit protective antibodies against the viral envelope, VAX004 and VAX003, did not prevent HIV-1 infection or impact the level of viraemia in those infected.", [["VAX004", "CHEMICAL", 150, 156], ["VAX003", "CHEMICAL", 161, 167], ["HIV-1 infection", "DISEASE", 185, 200], ["viraemia", "DISEASE", 224, 232], ["HIV", "ORGANISM", 67, 70], ["VAX004", "SIMPLE_CHEMICAL", 150, 156], ["VAX003", "SIMPLE_CHEMICAL", 161, 167], ["HIV-1", "ORGANISM", 185, 190], ["protective antibodies", "PROTEIN", 100, 121], ["HIV", "SPECIES", 67, 70], ["HIV-1", "SPECIES", 185, 190], ["HIV", "SPECIES", 67, 70], ["HIV-1", "SPECIES", 185, 190], ["an HIV vaccine", "TREATMENT", 64, 78], ["protective antibodies", "TREATMENT", 100, 121], ["the viral envelope", "PROBLEM", 130, 148], ["VAX004", "TREATMENT", 150, 156], ["VAX003", "TREATMENT", 161, 167], ["HIV", "PROBLEM", 185, 188], ["1 infection", "PROBLEM", 189, 200], ["viraemia", "PROBLEM", 224, 232], ["infection", "OBSERVATION", 191, 200], ["viraemia", "OBSERVATION", 224, 232], ["infected", "OBSERVATION", 242, 250]]], ["The next set of antigens used in clinical efficacy studies were designed to test whether T cells could protect against HIV-1 infection.", [["T cells", "ANATOMY", 89, 96], ["HIV-1 infection", "DISEASE", 119, 134], ["T cells", "CELL", 89, 96], ["HIV-1", "ORGANISM", 119, 124], ["antigens", "PROTEIN", 16, 24], ["T cells", "CELL_TYPE", 89, 96], ["HIV-1", "SPECIES", 119, 124], ["HIV-1", "SPECIES", 119, 124], ["clinical efficacy studies", "TEST", 33, 58], ["T cells", "PROBLEM", 89, 96], ["HIV-1 infection", "PROBLEM", 119, 134], ["infection", "OBSERVATION", 125, 134]]], ["Neither the STEP trial (Ad5 gag/pol/nef ) nor HVTN 505 trial (DNA/rAd5 gag/ pol/nef/env prime/boost regimen) could protect against HIV-1 infection, or reduce early plasma HIV-1 levels.", [["plasma", "ANATOMY", 164, 170], ["HIV-1 infection", "DISEASE", 131, 146], ["Ad5", "ORGANISM", 24, 27], ["gag", "GENE_OR_GENE_PRODUCT", 28, 31], ["pol", "GENE_OR_GENE_PRODUCT", 32, 35], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["rAd5", "GENE_OR_GENE_PRODUCT", 66, 70], ["pol", "GENE_OR_GENE_PRODUCT", 76, 79], ["HIV-1", "ORGANISM", 131, 136], ["plasma", "ORGANISM_SUBSTANCE", 164, 170], ["HIV-1", "ORGANISM", 171, 176], ["pol", "DNA", 76, 79], ["nef", "DNA", 80, 83], ["HIV-1", "SPECIES", 131, 136], ["HIV-1", "SPECIES", 171, 176], ["HIV-1", "SPECIES", 131, 136], ["HIV-1", "SPECIES", 171, 176], ["the STEP trial", "TEST", 8, 22], ["Ad5 gag/pol/nef )", "TREATMENT", 24, 41], ["HVTN", "TEST", 46, 50], ["DNA/rAd5 gag/ pol/nef/env prime/boost regimen", "TREATMENT", 62, 107], ["HIV", "PROBLEM", 131, 134], ["1 infection", "PROBLEM", 135, 146], ["early plasma HIV", "TEST", 158, 174], ["infection", "OBSERVATION", 137, 146]]], ["The proof of concept that it is possible for a vaccine to elicit protective immunity that blocks infection came from the RV144 clinical trial in Thailand that yielded a 31% reduction in HIV-1 acquisition using a canarypox-gp120 prime-boost vaccination regimen [23] .", [["infection", "DISEASE", 97, 106], ["HIV-1", "ORGANISM", 186, 191], ["HIV-1", "SPECIES", 186, 191], ["HIV-1", "SPECIES", 186, 191], ["a vaccine", "TREATMENT", 45, 54], ["blocks infection", "PROBLEM", 90, 106], ["a 31% reduction", "TREATMENT", 167, 182], ["HIV", "TEST", 186, 189], ["a canarypox-gp120 prime", "TREATMENT", 210, 233], ["boost vaccination regimen", "TREATMENT", 234, 259]]], ["Moreover, as highlighted by Marc Girard, new surrogate markers of protection came from the RV144 trial, including the presence of V1-V2 targeted IgG.", [["V1-V2", "GENE_OR_GENE_PRODUCT", 130, 135], ["IgG", "GENE_OR_GENE_PRODUCT", 145, 148], ["V1", "PROTEIN", 130, 132], ["V2 targeted IgG", "PROTEIN", 133, 148]]], ["The V2 loop contains the binding site to the \u03b14\u03b27 receptor of CD4+ T cells involved in T cell migration to the GALT, and it is also part of several neutralization epitopes, including those recognized by broad neutralizing antibody (bNAb) VRC26.08 at the apex of the HIV-1 spike [24] .", [["T cells", "ANATOMY", 67, 74], ["T cell", "ANATOMY", 87, 93], ["\u03b14\u03b27 receptor", "GENE_OR_GENE_PRODUCT", 45, 58], ["CD4", "GENE_OR_GENE_PRODUCT", 62, 65], ["T cells", "CELL", 67, 74], ["T cell", "CELL", 87, 93], ["GALT", "GENE_OR_GENE_PRODUCT", 111, 115], ["bNAb) VRC26.08", "GENE_OR_GENE_PRODUCT", 232, 246], ["HIV-1", "ORGANISM", 266, 271], ["V2 loop", "PROTEIN", 4, 11], ["\u03b14\u03b27 receptor", "PROTEIN", 45, 58], ["CD4", "PROTEIN", 62, 65], ["T cells", "CELL_TYPE", 67, 74], ["neutralization epitopes", "PROTEIN", 148, 171], ["neutralizing antibody", "PROTEIN", 209, 230], ["NAb", "PROTEIN", 233, 236], ["VRC26.08", "PROTEIN", 238, 246], ["HIV-1", "SPECIES", 266, 271], ["HIV-1", "SPECIES", 266, 271], ["the binding site", "PROBLEM", 21, 37], ["T cells", "PROBLEM", 67, 74], ["T cell migration", "PROBLEM", 87, 103], ["several neutralization epitopes", "PROBLEM", 140, 171], ["broad neutralizing antibody", "TEST", 203, 230], ["the HIV", "TEST", 262, 269], ["V2 loop", "OBSERVATION", 4, 11], ["binding site", "OBSERVATION", 25, 37], ["CD4", "OBSERVATION", 62, 65], ["T cell migration", "OBSERVATION", 87, 103], ["GALT", "ANATOMY", 111, 115], ["several", "OBSERVATION_MODIFIER", 140, 147], ["neutralization", "OBSERVATION", 148, 162], ["apex", "ANATOMY_MODIFIER", 254, 258], ["HIV", "OBSERVATION", 266, 269]]], ["The RV144 trial also showed strong correlation between protection and IgG that target the C1 domain of gp120 and promote ADCC [25] .", [["IgG", "GENE_OR_GENE_PRODUCT", 70, 73], ["gp120", "GENE_OR_GENE_PRODUCT", 103, 108], ["IgG", "PROTEIN", 70, 73], ["C1 domain", "PROTEIN", 90, 99], ["gp120", "PROTEIN", 103, 108], ["The RV144 trial", "TEST", 0, 15], ["IgG", "TREATMENT", 70, 73]]], ["Several studies that addressed the question of correlates of protection from infection or from the disease were reported at the ISHEID Conference.", [["infection", "DISEASE", 77, 86], ["Several studies", "TEST", 0, 15], ["infection", "PROBLEM", 77, 86], ["the disease", "PROBLEM", 95, 106], ["infection", "OBSERVATION", 77, 86]]], ["The resistance to HIV-1 infection among exposed seronegative partners in HIV-discordant couples was associated with higher frequency of CD8 + T cells expressing CD107a/b and IFNascompared to unexposed subject [26] , suggesting a protective role of HIV-specific CTLs.", [["CD8 + T cells", "ANATOMY", 136, 149], ["CTLs", "ANATOMY", 261, 265], ["HIV-1 infection", "DISEASE", 18, 33], ["HIV-1", "ORGANISM", 18, 23], ["HIV", "ORGANISM", 73, 76], ["CD8", "GENE_OR_GENE_PRODUCT", 136, 139], ["CD107a", "GENE_OR_GENE_PRODUCT", 161, 167], ["b", "GENE_OR_GENE_PRODUCT", 168, 169], ["IFNascompared", "GENE_OR_GENE_PRODUCT", 174, 187], ["HIV", "ORGANISM", 248, 251], ["CTLs", "CELL", 261, 265], ["CD8", "PROTEIN", 136, 139], ["T cells", "CELL_TYPE", 142, 149], ["CD107a", "PROTEIN", 161, 167], ["CTLs", "CELL_TYPE", 261, 265], ["HIV-1", "SPECIES", 18, 23], ["HIV", "SPECIES", 73, 76], ["HIV-1", "SPECIES", 18, 23], ["HIV", "SPECIES", 73, 76], ["HIV", "SPECIES", 248, 251], ["HIV-1 infection", "PROBLEM", 18, 33], ["HIV", "PROBLEM", 73, 76], ["CD107a", "TEST", 161, 167]]], ["The protective role of CTLs was also suggested by the finding that HIV controllers exhibit high frequency of CD8 + T-cells displaying the phenotype CD38 neg HLA-DR + and exerting ex-vivo cytotoxic activity, the frequency of these cells being correlated with the capacity of CD8 + T cells to inhibit viral replication [27] .", [["CD8 + T-cells", "ANATOMY", 109, 122], ["cells", "ANATOMY", 230, 235], ["CD8 + T cells", "ANATOMY", 274, 287], ["CTLs", "CELL", 23, 27], ["HIV", "ORGANISM", 67, 70], ["CD8", "GENE_OR_GENE_PRODUCT", 109, 112], ["CD38", "GENE_OR_GENE_PRODUCT", 148, 152], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 157, 163], ["cells", "CELL", 230, 235], ["CD8", "GENE_OR_GENE_PRODUCT", 274, 277], ["CTLs", "CELL_TYPE", 23, 27], ["CD8 + T-cells", "CELL_TYPE", 109, 122], ["CD38", "PROTEIN", 148, 152], ["DR", "PROTEIN", 161, 163], ["CD8 + T cells", "CELL_TYPE", 274, 287], ["HIV", "SPECIES", 67, 70], ["HIV controllers", "PROBLEM", 67, 82], ["the phenotype CD38", "TEST", 134, 152], ["HLA", "TEST", 157, 160], ["exerting ex-vivo cytotoxic activity", "PROBLEM", 170, 205], ["these cells", "PROBLEM", 224, 235], ["CD8 + T cells", "TREATMENT", 274, 287], ["viral replication", "TREATMENT", 299, 316], ["cytotoxic activity", "OBSERVATION", 187, 205]]], ["A novel experimental approach was presented to analyze lymphocytes from post treatment controllers (PTC), in particular the presence of replication competent HIV, following transplantation of Rag2 -/c -/-(Rag-hu) mice with CD4 + T cells from the PTC and subsequent engraftment with human T cells [28] .Ending the HIV pandemicBroadly reactive neutralizing antibodies (bNAbs) have been found in select individuals living with HIV, demonstrating that humans are capable of making broadly neutralizing antibodies [29] .", [["lymphocytes", "ANATOMY", 55, 66], ["PTC", "ANATOMY", 100, 103], ["CD4 + T cells", "ANATOMY", 223, 236], ["PTC", "ANATOMY", 246, 249], ["T cells", "ANATOMY", 288, 295], ["HIV", "DISEASE", 424, 427], ["lymphocytes", "CELL", 55, 66], ["PTC", "CANCER", 100, 103], ["HIV", "ORGANISM", 158, 161], ["Rag2", "GENE_OR_GENE_PRODUCT", 192, 196], ["Rag", "GENE_OR_GENE_PRODUCT", 205, 208], ["CD4", "GENE_OR_GENE_PRODUCT", 223, 226], ["PTC", "CANCER", 246, 249], ["human", "ORGANISM", 282, 287], ["T cells", "CELL", 288, 295], ["HIV", "ORGANISM", 313, 316], ["neutralizing antibodies (bNAbs", "GENE_OR_GENE_PRODUCT", 342, 372], ["HIV", "ORGANISM", 424, 427], ["humans", "ORGANISM", 448, 454], ["lymphocytes", "CELL_TYPE", 55, 66], ["Rag2", "PROTEIN", 192, 196], ["Rag", "PROTEIN", 205, 208], ["CD4", "PROTEIN", 223, 226], ["T cells", "CELL_TYPE", 229, 236], ["human T cells", "CELL_TYPE", 282, 295], ["HIV pandemicBroadly reactive neutralizing antibodies", "PROTEIN", 313, 365], ["bNAbs", "PROTEIN", 367, 372], ["mice", "SPECIES", 213, 217], ["human", "SPECIES", 282, 287], ["HIV", "SPECIES", 313, 316], ["HIV", "SPECIES", 424, 427], ["humans", "SPECIES", 448, 454], ["HIV", "SPECIES", 158, 161], ["mice", "SPECIES", 213, 217], ["human", "SPECIES", 282, 287], ["HIV", "SPECIES", 313, 316], ["HIV", "SPECIES", 424, 427], ["humans", "SPECIES", 448, 454], ["A novel experimental approach", "TREATMENT", 0, 29], ["treatment controllers (PTC", "TREATMENT", 77, 103], ["Rag2", "TEST", 192, 196], ["CD4 + T cells", "PROBLEM", 223, 236], ["the PTC", "TEST", 242, 249], ["human T cells", "TEST", 282, 295], ["the HIV pandemicBroadly reactive neutralizing antibodies", "PROBLEM", 309, 365], ["HIV", "PROBLEM", 424, 427], ["replication", "OBSERVATION", 136, 147], ["HIV", "OBSERVATION", 158, 161], ["PTC", "ANATOMY", 246, 249], ["reactive", "OBSERVATION_MODIFIER", 333, 341], ["neutralizing antibodies", "OBSERVATION", 342, 365]]], ["They show potent cross-clade neutralizing activity against 70-90% of HIV-1 strains.", [["HIV-1", "ORGANISM", 69, 74], ["strains", "ORGANISM", 75, 82], ["HIV-1", "SPECIES", 69, 74], ["HIV-1", "SPECIES", 69, 74], ["HIV-1 strains", "PROBLEM", 69, 82], ["potent", "OBSERVATION_MODIFIER", 10, 16]]], ["They are remarkably protective against i.v. or mucosal HIV or SHIV infections in animal models, and they can suppress active infections in mice and macaques. bNAbs develop over a period of a few years (2.5 years average) in only 15-20% of HIV-1 infected persons, and they are the result of a long affinity maturation of B cells and extensive mutation of the B cell lineage that seem to be driven by long antigenic exposure [30] .", [["mucosal", "ANATOMY", 47, 54], ["B cells", "ANATOMY", 320, 327], ["B cell lineage", "ANATOMY", 358, 372], ["SHIV infections", "DISEASE", 62, 77], ["infections", "DISEASE", 125, 135], ["HIV-1 infected", "DISEASE", 239, 253], ["mucosal HIV", "ORGANISM", 47, 58], ["SHIV", "ORGANISM", 62, 66], ["mice", "ORGANISM", 139, 143], ["macaques", "ORGANISM", 148, 156], ["HIV-1", "ORGANISM", 239, 244], ["persons", "ORGANISM", 254, 261], ["B cells", "CELL", 320, 327], ["B cell lineage", "CELL", 358, 372], ["B cells", "CELL_TYPE", 320, 327], ["B cell lineage", "CELL_TYPE", 358, 372], ["HIV", "SPECIES", 55, 58], ["mice", "SPECIES", 139, 143], ["macaques", "SPECIES", 148, 156], ["HIV-1", "SPECIES", 239, 244], ["persons", "SPECIES", 254, 261], ["HIV", "SPECIES", 55, 58], ["SHIV", "SPECIES", 62, 66], ["mice", "SPECIES", 139, 143], ["HIV-1", "SPECIES", 239, 244], ["mucosal HIV", "PROBLEM", 47, 58], ["SHIV infections", "PROBLEM", 62, 77], ["active infections in mice and macaques", "PROBLEM", 118, 156], ["bNAbs", "PROBLEM", 158, 163], ["HIV", "PROBLEM", 239, 242], ["a long affinity maturation of B cells", "PROBLEM", 290, 327], ["extensive mutation", "PROBLEM", 332, 350], ["the B cell lineage", "TREATMENT", 354, 372], ["mucosal", "ANATOMY", 47, 54], ["HIV", "OBSERVATION", 55, 58], ["SHIV infections", "OBSERVATION", 62, 77], ["active", "OBSERVATION_MODIFIER", 118, 124], ["infections", "OBSERVATION", 125, 135], ["B cell lineage", "OBSERVATION", 358, 372]]], ["A vaccine should offer protection against the majority of HIV strains.", [["HIV", "ORGANISM", 58, 61], ["HIV", "SPECIES", 58, 61], ["HIV", "SPECIES", 58, 61], ["A vaccine", "TREATMENT", 0, 9], ["protection", "TREATMENT", 23, 33], ["HIV strains", "PROBLEM", 58, 69]]], ["Hence, a number of questions should be addressed: i) are we able to design a vaccine that induces rapid production of V1V2-specific protective Abs? ii) how to transfer the knowledge of cross-specific antigens into immunogens that will induce powerful protective response following vaccination? iii) do we know enough about B cell maturation and plasmocyte differentiation? iv) which immunogen to develop considering that broadly neutralizing Abs that were identified are hypermutated ? it may be needed to stimulate a succession of antibodies that recognize epitopes and neutralize them in a series of vaccination; v) how to induce the correct B cells and stimulate them to produce Abs with a high degree of affinity maturation ? vi) how to induce humoral memory that is mediated by long-lived antibody-secreting cells? vii) successful vaccines (smallpox, hepatitis A, YF) elicit broad integrated responses involving all effectors, including innate (TLRs), NK, Th1/Th2 responses.", [["B cell", "ANATOMY", 323, 329], ["plasmocyte", "ANATOMY", 345, 355], ["B cells", "ANATOMY", 644, 651], ["cells", "ANATOMY", 813, 818], ["NK", "ANATOMY", 957, 959], ["smallpox", "DISEASE", 846, 854], ["hepatitis A", "DISEASE", 856, 867], ["YF", "DISEASE", 869, 871], ["V1V2", "GENE_OR_GENE_PRODUCT", 118, 122], ["Abs", "GENE_OR_GENE_PRODUCT", 143, 146], ["B cell", "CELL", 323, 329], ["plasmocyte", "CELL", 345, 355], ["B cells", "CELL", 644, 651], ["antibody", "GENE_OR_GENE_PRODUCT", 794, 802], ["cells", "CELL", 813, 818], ["hepatitis A", "ORGANISM", 856, 867], ["YF", "ORGANISM", 869, 871], ["TLRs", "GENE_OR_GENE_PRODUCT", 950, 954], ["NK", "CELL", 957, 959], ["Th1", "GENE_OR_GENE_PRODUCT", 961, 964], ["Th2", "GENE_OR_GENE_PRODUCT", 965, 968], ["V1V2", "PROTEIN", 118, 122], ["protective Abs", "PROTEIN", 132, 146], ["cross-specific antigens", "PROTEIN", 185, 208], ["Abs", "PROTEIN", 442, 445], ["antibodies", "PROTEIN", 532, 542], ["epitopes", "PROTEIN", 558, 566], ["B cells", "CELL_TYPE", 644, 651], ["Abs", "PROTEIN", 682, 685], ["long-lived antibody-secreting cells", "CELL_TYPE", 783, 818], ["TLRs", "PROTEIN", 950, 954], ["V1V2", "SPECIES", 118, 122], ["YF", "SPECIES", 869, 871], ["a vaccine", "TREATMENT", 75, 84], ["rapid production of V1V2", "PROBLEM", 98, 122], ["cross-specific antigens into immunogens", "TREATMENT", 185, 224], ["B cell maturation", "PROBLEM", 323, 340], ["plasmocyte differentiation", "PROBLEM", 345, 371], ["iv) which immunogen", "TREATMENT", 373, 392], ["a succession of antibodies", "TREATMENT", 516, 542], ["affinity maturation", "PROBLEM", 708, 727], ["humoral memory", "PROBLEM", 748, 762], ["secreting cells", "PROBLEM", 803, 818], ["successful vaccines", "TREATMENT", 825, 844], ["secreting cells", "OBSERVATION", 803, 818], ["NK", "ANATOMY", 957, 959]]], ["Considering that innate immunity influences both the qualitative and quantitative features of adaptive immunity, we should identify the innate correlates of protection.Ending the HIV pandemicThe question still arises whether a vaccine that does not prevent infection but reduces HIV levels and preserves uninfected memory CD4 + T cells would benefit the recipient.", [["memory CD4 + T cells", "ANATOMY", 315, 335], ["HIV pandemic", "DISEASE", 179, 191], ["infection", "DISEASE", 257, 266], ["HIV", "ORGANISM", 279, 282], ["CD4", "GENE_OR_GENE_PRODUCT", 322, 325], ["uninfected memory CD4 + T cells", "CELL_TYPE", 304, 335], ["HIV", "SPECIES", 179, 182], ["HIV pandemic", "SPECIES", 179, 191], ["HIV", "SPECIES", 279, 282], ["a vaccine", "TREATMENT", 225, 234], ["infection", "PROBLEM", 257, 266], ["HIV levels", "PROBLEM", 279, 289], ["T cells", "PROBLEM", 328, 335], ["the recipient", "TREATMENT", 350, 363], ["HIV pandemic", "OBSERVATION", 179, 191], ["infection", "OBSERVATION", 257, 266]]], ["Several studies were presented at ISHEID conference reporting the development of new therapeutic vaccine candidates and their safety in preclinical and clinical trials.", [["Several studies", "TEST", 0, 15], ["new therapeutic vaccine candidates", "TREATMENT", 81, 115]]], ["A new technology was reported, conferring one-step in vivo production in targeted cells of an efficient and safe DNA-virus-like particle (VLP) expressing gagV3(BCE), and leading to the presentation of immunodominant HIV antigens [31] .", [["cells", "ANATOMY", 82, 87], ["cells", "CELL", 82, 87], ["DNA", "CELLULAR_COMPONENT", 113, 116], ["VLP", "ORGANISM", 138, 141], ["gagV3", "GENE_OR_GENE_PRODUCT", 154, 159], ["targeted cells", "CELL_TYPE", 73, 87], ["gagV3", "PROTEIN", 154, 159], ["BCE", "PROTEIN", 160, 163], ["immunodominant HIV antigens", "PROTEIN", 201, 228], ["HIV", "SPECIES", 216, 219], ["safe DNA-virus", "PROBLEM", 108, 122], ["immunodominant HIV antigens", "PROBLEM", 201, 228]]], ["In preclinical studies, GenePro, a lentiviral therapeutic vaccine that includes 7 out of 9 HIV genes, was able to induce in a single high dose a long-lasting and polyfunctional T-cell response in the nonhuman primate model [32] .", [["T-cell", "ANATOMY", 177, 183], ["GenePro", "CHEMICAL", 24, 31], ["GenePro", "SIMPLE_CHEMICAL", 24, 31], ["lentiviral", "ORGANISM", 35, 45], ["HIV", "ORGANISM", 91, 94], ["T-cell", "CELL", 177, 183], ["primate", "ORGANISM", 209, 216], ["HIV genes", "DNA", 91, 100], ["HIV", "SPECIES", 91, 94], ["GenePro", "TREATMENT", 24, 31], ["a lentiviral therapeutic vaccine", "TREATMENT", 33, 65], ["9 HIV genes", "PROBLEM", 89, 100]]], ["Another lentiviral-based therapeutic vaccine was presented, generating a strong, specific and long-lasting T-cell response in mice, and currently evaluated in HAART-treated patients in a phase I/II vaccine trial [33] .", [["T-cell", "ANATOMY", 107, 113], ["lentiviral", "ORGANISM", 8, 18], ["T-cell", "CELL", 107, 113], ["mice", "ORGANISM", 126, 130], ["patients", "ORGANISM", 173, 181], ["mice", "SPECIES", 126, 130], ["patients", "SPECIES", 173, 181], ["mice", "SPECIES", 126, 130], ["Another lentiviral", "TREATMENT", 0, 18], ["therapeutic vaccine", "TREATMENT", 25, 44], ["HAART", "TREATMENT", 159, 164], ["a phase I/II vaccine trial", "TREATMENT", 185, 211]]], ["A different approach consisted in the induction of neutralizing antibodies to HIV-1 matrix protein p17 that, through the interaction of its NH2-residing epitope AT20 with specific receptors, acts extracellularly as a viral toxin.", [["NH2", "CHEMICAL", 140, 143], ["HIV-1 matrix", "GENE_OR_GENE_PRODUCT", 78, 90], ["p17", "GENE_OR_GENE_PRODUCT", 99, 102], ["neutralizing antibodies", "PROTEIN", 51, 74], ["HIV-1 matrix protein p17", "PROTEIN", 78, 102], ["NH2", "PROTEIN", 140, 143], ["AT20", "PROTEIN", 161, 165], ["specific receptors", "PROTEIN", 171, 189], ["viral toxin", "PROTEIN", 217, 228], ["HIV-1", "SPECIES", 78, 83], ["HIV-1", "SPECIES", 78, 83], ["A different approach", "TREATMENT", 0, 20], ["neutralizing antibodies", "TREATMENT", 51, 74], ["HIV-1 matrix protein p17", "TREATMENT", 78, 102], ["its NH2", "TREATMENT", 136, 143], ["a viral toxin", "PROBLEM", 215, 228]]], ["A peptide-based immunogen, AT20-KLH, was used in a phase I trial and shown to generate p17-specific antibodies able to neutralize its binding to cell receptors in HAARTtreated patients, and still detected two years after the first injection [34] .Ending the HIV pandemicFinally, a novel approach to protect with antibodies against an infectious disease was recently developed: the vector-immunoprophylaxis (VIP) or Vector-mediated Ab gene transfer, which aims at eliciting passive immunization using an AAV vector that expresses the H and L chains of a monoclonal bNAb (such as VRC-01, VRC-07\u2026).", [["cell", "ANATOMY", 145, 149], ["infectious disease", "DISEASE", 334, 352], ["AT20", "SIMPLE_CHEMICAL", 27, 31], ["p17", "GENE_OR_GENE_PRODUCT", 87, 90], ["cell", "CELL", 145, 149], ["patients", "ORGANISM", 176, 184], ["HIV", "ORGANISM", 258, 261], ["Ab", "GENE_OR_GENE_PRODUCT", 431, 433], ["AAV", "ORGANISM", 503, 506], ["bNAb", "GENE_OR_GENE_PRODUCT", 564, 568], ["VRC-07\u2026", "CELL", 586, 593], ["AT20", "PROTEIN", 27, 31], ["KLH", "PROTEIN", 32, 35], ["p17", "PROTEIN", 87, 90], ["cell receptors", "PROTEIN", 145, 159], ["antibodies", "PROTEIN", 312, 322], ["H and L chains", "PROTEIN", 533, 547], ["monoclonal bNAb", "PROTEIN", 553, 568], ["patients", "SPECIES", 176, 184], ["HIV", "SPECIES", 258, 261], ["HIV", "SPECIES", 258, 261], ["AAV", "SPECIES", 503, 506], ["A peptide", "TEST", 0, 9], ["specific antibodies", "PROBLEM", 91, 110], ["a novel approach", "TREATMENT", 279, 295], ["antibodies", "TREATMENT", 312, 322], ["an infectious disease", "PROBLEM", 331, 352], ["the vector", "TREATMENT", 377, 387], ["immunoprophylaxis (VIP)", "TREATMENT", 388, 411], ["Vector-mediated Ab gene transfer", "TREATMENT", 415, 447], ["passive immunization", "TREATMENT", 473, 493], ["an AAV vector", "TREATMENT", 500, 513], ["a monoclonal bNAb", "PROBLEM", 551, 568], ["VRC", "TEST", 578, 581], ["VRC", "TEST", 586, 589], ["infectious", "OBSERVATION", 334, 344]]], ["This 'gene-therapy' approach has been successfully tested in animal models (BLT mice) conferring a full protection against mucosal HIV transmission [35] , suggesting that a sufficiently high circulating concentration of bNAb might substantially reduce the probability of sexual transmission of HIV between humans.Ending the HIV pandemicThe search for a HIV vaccine is a long story, starting in the early 90s by the first clinical trial performed in humans by Daniel Zagury [36] and a long road is still ahead.", [["mucosal", "ANATOMY", 123, 130], ["mucosal HIV transmission", "DISEASE", 123, 147], ["bNAb", "CHEMICAL", 220, 224], ["HIV pandemic", "DISEASE", 324, 336], ["BLT mice", "ORGANISM", 76, 84], ["mucosal HIV", "ORGANISM", 123, 134], ["bNAb", "SIMPLE_CHEMICAL", 220, 224], ["HIV", "ORGANISM", 294, 297], ["humans", "ORGANISM", 306, 312], ["HIV", "ORGANISM", 353, 356], ["humans", "ORGANISM", 449, 455], ["mice", "SPECIES", 80, 84], ["HIV", "SPECIES", 294, 297], ["humans", "SPECIES", 306, 312], ["HIV", "SPECIES", 324, 327], ["humans", "SPECIES", 449, 455], ["mice", "SPECIES", 80, 84], ["HIV", "SPECIES", 131, 134], ["HIV", "SPECIES", 294, 297], ["humans", "SPECIES", 306, 312], ["HIV pandemic", "SPECIES", 324, 336], ["HIV", "SPECIES", 353, 356], ["humans", "SPECIES", 449, 455], ["This 'gene-therapy' approach", "TREATMENT", 0, 28], ["a full protection", "TREATMENT", 97, 114], ["a sufficiently high circulating concentration of bNAb", "PROBLEM", 171, 224], ["HIV between humans", "PROBLEM", 294, 312], ["a HIV vaccine", "TREATMENT", 351, 364], ["HIV pandemic", "OBSERVATION", 324, 336]]], ["Promizing strategies are, however, in the pipeline [37] .Towards a HCV eradicationHepatitis C virus (HCV) is a major cause of chronic liver disease, with an estimated 170 million people infected worldwide [38] .", [["liver", "ANATOMY", 134, 139], ["Hepatitis C virus (HCV)", "DISEASE", 82, 105], ["chronic liver disease", "DISEASE", 126, 147], ["HCV eradication", "ORGANISM", 67, 82], ["Hepatitis C virus", "ORGANISM", 82, 99], ["HCV", "ORGANISM", 101, 104], ["liver", "ORGAN", 134, 139], ["people", "ORGANISM", 179, 185], ["Hepatitis C virus", "SPECIES", 82, 99], ["people", "SPECIES", 179, 185], ["HCV", "SPECIES", 67, 70], ["Hepatitis C virus", "SPECIES", 82, 99], ["HCV", "SPECIES", 101, 104], ["a HCV eradication", "TREATMENT", 65, 82], ["Hepatitis C virus (HCV", "PROBLEM", 82, 104], ["chronic liver disease", "PROBLEM", 126, 147], ["HCV", "OBSERVATION_MODIFIER", 67, 70], ["chronic", "OBSERVATION_MODIFIER", 126, 133], ["liver", "ANATOMY", 134, 139], ["disease", "OBSERVATION", 140, 147]]], ["HCV, identified in 1989, is an enveloped virus with a 9.6 kb single-stranded RNA genome, a member of the Flaviviridae family, genus Hepacivirus [39] .", [["HCV", "ORGANISM", 0, 3], ["9.6 kb single-stranded RNA genome", "DNA", 54, 87], ["HCV", "SPECIES", 0, 3], ["HCV", "PROBLEM", 0, 3], ["an enveloped virus", "PROBLEM", 28, 46], ["virus", "OBSERVATION", 41, 46]]], ["The development of new molecules called direct acting antivirals (DAA) leads to a complete change of the picture with the cure of the disease and a hope for an eradication.", [["new molecules", "PROBLEM", 19, 32], ["direct acting antivirals (DAA", "TREATMENT", 40, 69], ["the disease", "PROBLEM", 130, 141], ["an eradication", "TREATMENT", 157, 171], ["new", "OBSERVATION_MODIFIER", 19, 22], ["molecules", "OBSERVATION", 23, 32], ["disease", "OBSERVATION", 134, 141]]], ["Overall, the future is bright for patients chronically infected with HCV.", [["HCV", "DISEASE", 69, 72], ["patients", "ORGANISM", 34, 42], ["HCV", "ORGANISM", 69, 72], ["patients", "SPECIES", 34, 42], ["HCV", "SPECIES", 69, 72], ["HCV", "PROBLEM", 69, 72], ["infected", "OBSERVATION", 55, 63], ["HCV", "OBSERVATION", 69, 72]]], ["The challenge of the HCV disease is different for people regarding the location of their HCV infection.", [["HCV disease", "DISEASE", 21, 32], ["HCV infection", "DISEASE", 89, 102], ["HCV", "ORGANISM", 21, 24], ["people", "ORGANISM", 50, 56], ["HCV", "ORGANISM", 89, 92], ["people", "SPECIES", 50, 56], ["HCV", "SPECIES", 21, 24], ["HCV", "SPECIES", 89, 92], ["the HCV disease", "PROBLEM", 17, 32], ["their HCV infection", "PROBLEM", 83, 102], ["HCV", "OBSERVATION", 21, 24], ["HCV", "OBSERVATION_MODIFIER", 89, 92], ["infection", "OBSERVATION", 93, 102]]], ["A major challenge in the Western world will be to identify most or all patients with HCV associated liver disease that would benefit from therapy.", [["liver", "ANATOMY", 100, 105], ["liver disease", "DISEASE", 100, 113], ["patients", "ORGANISM", 71, 79], ["HCV", "ORGANISM", 85, 88], ["liver", "ORGAN", 100, 105], ["patients", "SPECIES", 71, 79], ["HCV", "SPECIES", 85, 88], ["A major challenge", "TREATMENT", 0, 17], ["HCV associated liver disease", "PROBLEM", 85, 113], ["therapy", "TREATMENT", 138, 145], ["liver", "ANATOMY", 100, 105], ["disease", "OBSERVATION", 106, 113]]], ["So far, only a minority of HCV-infected individuals is being diagnosed and of those, only a portion receives therapy.", [["HCV-infected", "DISEASE", 27, 39], ["HCV", "ORGANISM", 27, 30], ["individuals", "ORGANISM", 40, 51], ["HCV", "SPECIES", 27, 30], ["HCV", "PROBLEM", 27, 30], ["infected individuals", "PROBLEM", 31, 51], ["therapy", "TREATMENT", 109, 116], ["HCV", "OBSERVATION", 27, 30], ["infected", "OBSERVATION", 31, 39], ["therapy", "OBSERVATION", 109, 116]]], ["In the developing world, challenges will differ: making HCV therapies economically affordable in such areas of the world will become a major challenge.Towards a HCV eradicationThe HCV lifecycle begins with virion attachment to its specific receptor The HCV RNA genome serves as a template for viral replication and as a viral messenger RNA for viral production.", [["HCV", "ORGANISM", 56, 59], ["HCV", "ORGANISM", 180, 183], ["virion", "CELLULAR_COMPONENT", 206, 212], ["HCV RNA genome", "DNA", 253, 267], ["viral messenger RNA", "RNA", 320, 339], ["HCV", "SPECIES", 56, 59], ["HCV", "SPECIES", 161, 164], ["HCV", "SPECIES", 180, 183], ["HCV", "SPECIES", 253, 256], ["HCV therapies", "TREATMENT", 56, 69], ["a HCV eradication", "TREATMENT", 159, 176], ["The HCV lifecycle", "PROBLEM", 176, 193], ["virion attachment", "TREATMENT", 206, 223], ["The HCV RNA genome", "TREATMENT", 249, 267], ["a template", "TREATMENT", 278, 288], ["viral replication", "TREATMENT", 293, 310], ["a viral messenger RNA", "PROBLEM", 318, 339], ["viral production", "PROBLEM", 344, 360], ["HCV", "OBSERVATION", 161, 164], ["HCV", "OBSERVATION", 180, 183]]], ["It is translated into a polyprotein that is cleaved by proteases.", [["proteases", "PROTEIN", 55, 64], ["a polyprotein", "TREATMENT", 22, 35]]], ["Potentially, each step of the viral cycle is a target for drug development.", [["the viral cycle", "TREATMENT", 26, 41]]], ["The knowledge of the structures of HCV protease and HCV polymerase has allowed structurebased drug design to develop inhibitors to these enzymes [40, 41] .", [["HCV", "ORGANISM", 35, 38], ["HCV polymerase", "GENE_OR_GENE_PRODUCT", 52, 66], ["HCV protease", "PROTEIN", 35, 47], ["HCV polymerase", "PROTEIN", 52, 66], ["enzymes", "PROTEIN", 137, 144], ["HCV", "SPECIES", 35, 38], ["HCV", "SPECIES", 52, 55], ["HCV protease", "TREATMENT", 35, 47], ["HCV polymerase", "PROBLEM", 52, 66], ["these enzymes", "TEST", 131, 144], ["HCV", "OBSERVATION", 35, 38]]], ["Several findings suggest that HCV modulation of IFN induction and signaling attenuates the expression of IFN stimulated genes, allowing HCV to escape the antiviral actions of the host response.", [["HCV", "ORGANISM", 30, 33], ["IFN", "GENE_OR_GENE_PRODUCT", 48, 51], ["IFN", "GENE_OR_GENE_PRODUCT", 105, 108], ["HCV", "ORGANISM", 136, 139], ["IFN", "PROTEIN", 48, 51], ["IFN stimulated genes", "DNA", 105, 125], ["HCV", "SPECIES", 30, 33], ["HCV", "SPECIES", 136, 139], ["HCV modulation", "PROBLEM", 30, 44], ["IFN induction", "TREATMENT", 48, 61], ["IFN stimulated genes", "PROBLEM", 105, 125], ["HCV", "PROBLEM", 136, 139], ["the antiviral actions", "TREATMENT", 150, 171], ["HCV", "OBSERVATION", 30, 33]]], ["All the HCV enzymes -NS2-3 and NS3-4A proteases, NS3 helicase and NS5B RdRpare essential for HCV replication, and are potential drug discovery targets.", [["NS2-3", "GENE_OR_GENE_PRODUCT", 21, 26], ["NS3-4A", "GENE_OR_GENE_PRODUCT", 31, 37], ["NS3", "GENE_OR_GENE_PRODUCT", 49, 52], ["NS5B", "GENE_OR_GENE_PRODUCT", 66, 70], ["HCV", "ORGANISM", 93, 96], ["HCV enzymes", "PROTEIN", 8, 19], ["NS2-3 and NS3-4A proteases", "PROTEIN", 21, 47], ["NS3 helicase", "PROTEIN", 49, 61], ["NS5B RdRpare", "PROTEIN", 66, 78], ["HCV", "SPECIES", 8, 11], ["HCV", "SPECIES", 93, 96], ["All the HCV enzymes", "TEST", 0, 19], ["NS2", "TEST", 21, 24], ["NS3", "TEST", 31, 34], ["4A proteases", "TREATMENT", 35, 47], ["NS3 helicase", "TREATMENT", 49, 61], ["NS5B RdRpare", "TREATMENT", 66, 78], ["HCV replication", "TREATMENT", 93, 108]]], ["Therefore DAA with different viral targets, including NS3 protease inhibitors, nucleoside/nucleotide analogue and non-nucleoside inhibitors of the RNA-dependent RNA polymerase, and NS5A inhibitors are under development.Towards a HCV eradicationJ\u00fcgen Rockstroh described the progress made against HCV disease, with emphasis on drugs that combat HCV, which can now theoretically be considered to be curable since HCV does not integrate into cells.", [["cells", "ANATOMY", 439, 444], ["DAA", "CHEMICAL", 10, 13], ["nucleoside", "CHEMICAL", 79, 89], ["nucleotide", "CHEMICAL", 90, 100], ["HCV disease", "DISEASE", 296, 307], ["HCV", "DISEASE", 344, 347], ["nucleoside", "CHEMICAL", 79, 89], ["nucleotide", "CHEMICAL", 90, 100], ["DAA", "SIMPLE_CHEMICAL", 10, 13], ["nucleoside/nucleotide analogue", "SIMPLE_CHEMICAL", 79, 109], ["non-nucleoside inhibitors", "SIMPLE_CHEMICAL", 114, 139], ["NS5A", "GENE_OR_GENE_PRODUCT", 181, 185], ["HCV", "ORGANISM", 296, 299], ["HCV", "ORGANISM", 344, 347], ["HCV", "ORGANISM", 411, 414], ["cells", "CELL", 439, 444], ["RNA-dependent RNA polymerase", "PROTEIN", 147, 175], ["NS5A", "PROTEIN", 181, 185], ["HCV", "SPECIES", 229, 232], ["HCV", "SPECIES", 296, 299], ["HCV", "SPECIES", 344, 347], ["HCV", "SPECIES", 411, 414], ["DAA", "TREATMENT", 10, 13], ["different viral targets", "TREATMENT", 19, 42], ["NS3 protease inhibitors", "TREATMENT", 54, 77], ["nucleoside", "TREATMENT", 79, 89], ["nucleotide analogue", "TREATMENT", 90, 109], ["non-nucleoside inhibitors", "TREATMENT", 114, 139], ["the RNA-dependent RNA polymerase", "TREATMENT", 143, 175], ["NS5A inhibitors", "TREATMENT", 181, 196], ["a HCV eradication", "TREATMENT", 227, 244], ["HCV disease", "PROBLEM", 296, 307], ["drugs", "TREATMENT", 326, 331], ["HCV", "PROBLEM", 344, 347], ["HCV", "PROBLEM", 411, 414], ["viral targets", "OBSERVATION", 29, 42]]], ["However, Professor Rockstroh [42] highlighted that HCV therapy has not yet been employed to sufficient extent among individuals who are not enrolled in controlled clinical trials.", [["HCV", "ORGANISM", 51, 54], ["HCV", "SPECIES", 51, 54], ["HCV therapy", "TREATMENT", 51, 62]]], ["Clearly, it is possible that issues of non-adherence may compromise the success of anti-HCV drugs and that this, in turn, could lead to HCV drug resistance.", [["HCV", "ORGANISM", 136, 139], ["HCV", "SPECIES", 136, 139], ["anti-HCV drugs", "TREATMENT", 83, 97], ["HCV drug resistance", "PROBLEM", 136, 155]]], ["Further work is necessary on this topic.Towards a HCV eradicationA lecture on new anti HCV agents by Fabien Zoulim [43] made clear that pharmaceutical companies are still active in this area.", [["HCV", "SPECIES", 50, 53], ["HCV", "SPECIES", 87, 90], ["a HCV eradicationA lecture", "TREATMENT", 48, 74], ["new anti HCV agents", "TREATMENT", 78, 97], ["active", "OBSERVATION_MODIFIER", 171, 177]]], ["Professor Vicente Soriano [44] spoke about treatment of co-infected HCV/HIV patients and expressed hope that Sofosbuvir (SOF) would represent a huge improvement in our ability to treat HCV.", [["HCV/HIV", "DISEASE", 68, 75], ["Sofosbuvir", "CHEMICAL", 109, 119], ["HCV", "DISEASE", 185, 188], ["Sofosbuvir", "CHEMICAL", 109, 119], ["HCV", "ORGANISM", 68, 71], ["HIV", "ORGANISM", 72, 75], ["patients", "ORGANISM", 76, 84], ["Sofosbuvir", "SIMPLE_CHEMICAL", 109, 119], ["HCV", "ORGANISM", 185, 188], ["HIV", "SPECIES", 72, 75], ["patients", "SPECIES", 76, 84], ["HCV", "SPECIES", 68, 71], ["HIV", "SPECIES", 72, 75], ["HCV", "SPECIES", 185, 188], ["co-infected HCV", "PROBLEM", 56, 71], ["Sofosbuvir (SOF", "TREATMENT", 109, 124], ["HCV", "PROBLEM", 185, 188], ["huge", "OBSERVATION_MODIFIER", 144, 148], ["improvement", "OBSERVATION", 149, 160]]], ["Professor Marc Bourliere [45] spoke about new anti-HCV drugs would limit the use of the much more toxic Interferon/ (IFN)/Ribivirin(RBV) approach that has dominated the field for decades.Towards a HCV eradicationThere are key factors in deciding to treat a patient or to wait.", [["Ribivirin", "CHEMICAL", 122, 131], ["RBV", "CHEMICAL", 132, 135], ["Interferon", "GENE_OR_GENE_PRODUCT", 104, 114], ["IFN", "GENE_OR_GENE_PRODUCT", 117, 120], ["Ribivirin", "SIMPLE_CHEMICAL", 122, 131], ["RBV", "SIMPLE_CHEMICAL", 132, 135], ["patient", "ORGANISM", 257, 264], ["Interferon", "PROTEIN", 104, 114], ["IFN", "PROTEIN", 117, 120], ["patient", "SPECIES", 257, 264], ["HCV", "SPECIES", 197, 200], ["new anti-HCV drugs", "TREATMENT", 42, 60], ["toxic Interferon/ (IFN)", "TREATMENT", 98, 121], ["Ribivirin(RBV) approach", "TREATMENT", 122, 145], ["a HCV eradication", "TREATMENT", 195, 212], ["HCV", "OBSERVATION", 197, 200]]], ["Patients' factors include urgency to treat, likelihood of response, HCV genotype, treatment experience, IL28B genotype, degree of fibrosis and patient motivation.", [["fibrosis", "DISEASE", 130, 138], ["Patients", "ORGANISM", 0, 8], ["HCV", "ORGANISM", 68, 71], ["patient", "ORGANISM", 143, 150], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 143, 150], ["HCV", "SPECIES", 68, 71], ["Patients' factors", "PROBLEM", 0, 17], ["urgency", "PROBLEM", 26, 33], ["HCV genotype", "PROBLEM", 68, 80], ["IL28B genotype", "PROBLEM", 104, 118], ["fibrosis", "PROBLEM", 130, 138], ["fibrosis", "OBSERVATION", 130, 138]]], ["Treatment factors include efficacy of current options, safety of current options, duration of therapy, pill burden, dosing frequency, future options and their timelines, access and cost.Towards a HCV eradicationSimple as well as complex strategies are on development regarding the availability of the new DAA and the tolerance of IFN (Figure 1) .Towards a HCV eradicationIn genotype 1 patients, the combination of IFN + SOF has to be in balance with the IFN-free regimens based on Nucleoside Inhibitors (NI) + NS5A \u00b1 RBV or NI + Protease Inhibitor (PI) \u00b1 RBV.", [["IFN", "CHEMICAL", 414, 417], ["IFN", "CHEMICAL", 454, 457], ["Nucleoside", "CHEMICAL", 481, 491], ["RBV", "CHEMICAL", 517, 520], ["RBV", "CHEMICAL", 555, 558], ["Nucleoside", "CHEMICAL", 481, 491], ["RBV", "CHEMICAL", 517, 520], ["RBV", "CHEMICAL", 555, 558], ["patients", "ORGANISM", 385, 393], ["IFN", "GENE_OR_GENE_PRODUCT", 414, 417], ["Nucleoside Inhibitors", "SIMPLE_CHEMICAL", 481, 502], ["NI", "SIMPLE_CHEMICAL", 504, 506], ["RBV", "SIMPLE_CHEMICAL", 517, 520], ["NI + Protease Inhibitor", "SIMPLE_CHEMICAL", 524, 547], ["PI", "SIMPLE_CHEMICAL", 549, 551], ["RBV", "SIMPLE_CHEMICAL", 555, 558], ["IFN", "PROTEIN", 330, 333], ["IFN", "PROTEIN", 414, 417], ["IFN", "PROTEIN", 454, 457], ["NS5A", "PROTEIN", 510, 514], ["patients", "SPECIES", 385, 393], ["HCV", "SPECIES", 196, 199], ["HCV", "SPECIES", 356, 359], ["Treatment factors", "TREATMENT", 0, 17], ["current options", "TREATMENT", 38, 53], ["current options", "TREATMENT", 65, 80], ["therapy", "TREATMENT", 94, 101], ["pill burden", "TREATMENT", 103, 114], ["future options", "TREATMENT", 134, 148], ["a HCV eradicationSimple", "TREATMENT", 194, 217], ["the new DAA", "TREATMENT", 297, 308], ["a HCV eradication", "TREATMENT", 354, 371], ["IFN + SOF", "TREATMENT", 414, 423], ["the IFN-free regimens", "TREATMENT", 450, 471], ["Nucleoside Inhibitors", "TREATMENT", 481, 502], ["NS5A", "TREATMENT", 510, 514], ["RBV", "TREATMENT", 517, 520], ["NI + Protease Inhibitor", "TREATMENT", 524, 547], ["RBV", "TREATMENT", 555, 558], ["HCV", "OBSERVATION", 196, 199], ["HCV", "OBSERVATION", 356, 359]]], ["The combination of IFN + PI has also to be in balance with the IFN-free regimens such as PI + NS5A \u00b1 RBV or PI \u00b1 (Non Nucleoside Inhibitor) NNI + RBV or PI \u00b1 NNI + NS5A + RBV.Towards a HCV eradicationIn genotype 2 patients the combination of SOF + RBV for 12 weeks of treatment leads to a 93-95% SVR and will be the next standard-of-care.Towards a HCV eradicationIn genotype 3 patients the combination SOF + RBV for 24 weeks leads to a >90% SVR.", [["IFN", "CHEMICAL", 19, 22], ["IFN", "CHEMICAL", 63, 66], ["RBV", "CHEMICAL", 101, 104], ["NNI", "CHEMICAL", 140, 143], ["RBV", "CHEMICAL", 146, 149], ["RBV", "CHEMICAL", 171, 174], ["RBV", "CHEMICAL", 248, 251], ["RBV", "CHEMICAL", 408, 411], ["RBV", "CHEMICAL", 101, 104], ["NNI", "CHEMICAL", 140, 143], ["RBV", "CHEMICAL", 146, 149], ["NNI", "CHEMICAL", 158, 161], ["RBV", "CHEMICAL", 171, 174], ["RBV", "CHEMICAL", 248, 251], ["RBV", "CHEMICAL", 408, 411], ["IFN", "GENE_OR_GENE_PRODUCT", 19, 22], ["PI", "SIMPLE_CHEMICAL", 25, 27], ["PI + NS5A", "SIMPLE_CHEMICAL", 89, 98], ["RBV", "SIMPLE_CHEMICAL", 101, 104], ["PI \u00b1", "SIMPLE_CHEMICAL", 108, 112], ["Non Nucleoside Inhibitor", "SIMPLE_CHEMICAL", 114, 138], ["NNI", "SIMPLE_CHEMICAL", 140, 143], ["RBV", "SIMPLE_CHEMICAL", 146, 149], ["PI \u00b1 NNI", "SIMPLE_CHEMICAL", 153, 161], ["NS5A + RBV", "SIMPLE_CHEMICAL", 164, 174], ["HCV", "ORGANISM", 185, 188], ["patients", "ORGANISM", 214, 222], ["HCV", "ORGANISM", 348, 351], ["patients", "ORGANISM", 377, 385], ["IFN", "PROTEIN", 19, 22], ["IFN", "PROTEIN", 63, 66], ["NS5A", "PROTEIN", 94, 98], ["NS5A", "PROTEIN", 164, 168], ["patients", "SPECIES", 214, 222], ["patients", "SPECIES", 377, 385], ["HCV", "SPECIES", 185, 188], ["HCV", "SPECIES", 348, 351], ["IFN + PI", "TREATMENT", 19, 27], ["the IFN", "TREATMENT", 59, 66], ["free regimens", "TREATMENT", 67, 80], ["PI", "TREATMENT", 89, 91], ["NS5A", "TREATMENT", 94, 98], ["RBV", "TREATMENT", 101, 104], ["PI \u00b1", "TREATMENT", 108, 112], ["Nucleoside Inhibitor", "TREATMENT", 118, 138], ["NNI", "TREATMENT", 140, 143], ["RBV", "TREATMENT", 146, 149], ["PI", "TREATMENT", 153, 155], ["NS5A", "PROBLEM", 164, 168], ["RBV", "TREATMENT", 171, 174], ["a HCV eradicationIn genotype 2", "TREATMENT", 183, 213], ["SOF + RBV", "TREATMENT", 242, 251], ["treatment leads", "TREATMENT", 268, 283], ["a HCV eradicationIn genotype", "TREATMENT", 346, 374], ["RBV", "TREATMENT", 408, 411], ["NS5A", "OBSERVATION", 164, 168]]], ["Other DAA in combination are currently studied.Towards a HCV eradicationIn genotype 4 patients the combination of SOF + RBV leads to a 79% response in na\u00efve patients with 12 weeks of therapy and 100% with 14 weeks.", [["DAA", "CHEMICAL", 6, 9], ["RBV", "CHEMICAL", 120, 123], ["DAA", "CHEMICAL", 6, 9], ["RBV", "CHEMICAL", 120, 123], ["DAA", "SIMPLE_CHEMICAL", 6, 9], ["HCV", "ORGANISM", 57, 60], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 157, 165], ["HCV", "SPECIES", 57, 60], ["Other DAA", "TREATMENT", 0, 9], ["a HCV eradicationIn genotype 4", "TREATMENT", 55, 85], ["SOF + RBV leads", "TREATMENT", 114, 129], ["therapy", "TREATMENT", 183, 190], ["DAA", "OBSERVATION", 6, 9]]], ["The combination of the Abbvie drugs (ABT-450/r + ABT-267 \u00b1 RBV) leads to >90% SVR in both na\u00efve and experienced patients.Towards a HCV eradicationIn treatment experienced non-cirrhotic patients the combination of SOF + RBV for 24 weeks lead to 85% SVR.", [["ABT-450", "CHEMICAL", 37, 44], ["ABT-267 \u00b1 RBV", "CHEMICAL", 49, 62], ["non-cirrhotic", "DISEASE", 171, 184], ["RBV", "CHEMICAL", 219, 222], ["ABT-450", "CHEMICAL", 37, 44], ["ABT-267", "CHEMICAL", 49, 56], ["RBV", "CHEMICAL", 59, 62], ["RBV", "CHEMICAL", 219, 222], ["ABT-450", "SIMPLE_CHEMICAL", 37, 44], ["ABT-267", "SIMPLE_CHEMICAL", 49, 56], ["patients", "ORGANISM", 112, 120], ["HCV", "ORGANISM", 131, 134], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 185, 193], ["HCV", "SPECIES", 131, 134], ["the Abbvie drugs", "TREATMENT", 19, 35], ["ABT", "TEST", 37, 40], ["ABT", "TEST", 49, 52], ["RBV", "TREATMENT", 59, 62], ["SVR", "TEST", 78, 81], ["a HCV eradicationIn treatment", "TREATMENT", 129, 158], ["SOF + RBV", "TREATMENT", 213, 222], ["SVR", "TEST", 248, 251]]], ["In cirrhotic patients, the combination of IFN + RBV + SOF for 12 weeks leads to 83% SVR.Emerging infectious diseasesAccording to Harry Dalton [46] , hepatitis E must be considered as a common emerging disease in developed countries, where it is caused by genotype 3, mainly affects middle-ages/elderly males, and is zoonotic with a porcine primary host.", [["cirrhotic", "DISEASE", 3, 12], ["IFN", "CHEMICAL", 42, 45], ["RBV", "CHEMICAL", 48, 51], ["infectious diseasesAccording", "DISEASE", 97, 125], ["hepatitis E", "DISEASE", 149, 160], ["RBV", "CHEMICAL", 48, 51], ["patients", "ORGANISM", 13, 21], ["IFN", "GENE_OR_GENE_PRODUCT", 42, 45], ["hepatitis E", "ORGANISM", 149, 160], ["IFN", "PROTEIN", 42, 45], ["patients", "SPECIES", 13, 21], ["porcine", "SPECIES", 332, 339], ["IFN", "PROBLEM", 42, 45], ["RBV", "TREATMENT", 48, 51], ["SOF", "PROBLEM", 54, 57], ["SVR", "TEST", 84, 87], ["hepatitis E", "PROBLEM", 149, 160], ["a porcine primary host", "TREATMENT", 330, 352], ["cirrhotic", "OBSERVATION_MODIFIER", 3, 12], ["infectious", "OBSERVATION", 97, 107]]], ["However the route of transmission is not fully understood (no evident association with pigs in most of the cases).", [["pigs", "ORGANISM", 87, 91], ["pigs", "SPECIES", 87, 91]]], ["Blood transfusion must be considered accordingly to the high number of asymptomatic viraemic donors.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["donors", "ORGANISM", 93, 99], ["Blood transfusion", "TREATMENT", 0, 17], ["asymptomatic viraemic donors", "PROBLEM", 71, 99], ["viraemic donors", "OBSERVATION", 84, 99]]], ["It is now evident that HEV may cause persistent disease in immune-compromised solid organ transplant recipients, individuals with HIV and patients with haematological malignancy.", [["solid organ transplant", "ANATOMY", 78, 100], ["haematological malignancy", "ANATOMY", 152, 177], ["HIV", "DISEASE", 130, 133], ["haematological malignancy", "DISEASE", 152, 177], ["HEV", "ORGANISM", 23, 26], ["organ", "ORGAN", 84, 89], ["patients", "ORGANISM", 138, 146], ["haematological malignancy", "CANCER", 152, 177], ["HIV", "SPECIES", 130, 133], ["patients", "SPECIES", 138, 146], ["HEV", "SPECIES", 23, 26], ["HIV", "SPECIES", 130, 133], ["persistent disease", "PROBLEM", 37, 55], ["HIV", "PROBLEM", 130, 133], ["haematological malignancy", "PROBLEM", 152, 177], ["may cause", "UNCERTAINTY", 27, 36], ["persistent", "OBSERVATION_MODIFIER", 37, 47], ["disease", "OBSERVATION", 48, 55], ["compromised", "OBSERVATION_MODIFIER", 66, 77], ["solid organ", "OBSERVATION", 78, 89], ["transplant recipients", "OBSERVATION", 90, 111], ["malignancy", "OBSERVATION", 167, 177]]], ["Patients with chronic HEV infection have no symptoms, but some develop rapidly progressive liver cirrhosis.", [["liver", "ANATOMY", 91, 96], ["HEV infection", "DISEASE", 22, 35], ["liver cirrhosis", "DISEASE", 91, 106], ["Patients", "ORGANISM", 0, 8], ["liver", "ORGAN", 91, 96], ["Patients", "SPECIES", 0, 8], ["HEV", "SPECIES", 22, 25], ["chronic HEV infection", "PROBLEM", 14, 35], ["symptoms", "PROBLEM", 44, 52], ["rapidly progressive liver cirrhosis", "PROBLEM", 71, 106], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["HEV", "OBSERVATION_MODIFIER", 22, 25], ["infection", "OBSERVATION", 26, 35], ["rapidly", "OBSERVATION_MODIFIER", 71, 78], ["progressive", "OBSERVATION_MODIFIER", 79, 90], ["liver", "ANATOMY", 91, 96], ["cirrhosis", "OBSERVATION", 97, 106]]], ["HEV has important extra-hepatic manifestations, which deserve further investigation.", [["extra-hepatic", "ANATOMY", 18, 31], ["HEV", "ORGANISM", 0, 3], ["extra-hepatic", "ANATOMICAL_SYSTEM", 18, 31], ["HEV", "SPECIES", 0, 3], ["important extra-hepatic manifestations", "PROBLEM", 8, 46], ["further investigation", "TEST", 62, 83], ["extra-hepatic", "ANATOMY", 18, 31]]], ["For example, Dalton et al have shown that HEV is neuropathogenic, and can cause a wide range of neurological illness.Emerging infectious diseasesAs exposed by Bruno Lina [47] , humans are usually not infected by avian influenza A viruses from aquatic wild birds.", [["neurological", "ANATOMY", 96, 108], ["neurological illness", "DISEASE", 96, 116], ["infectious diseasesAs", "DISEASE", 126, 147], ["influenza A viruses", "DISEASE", 218, 237], ["HEV", "ORGANISM", 42, 45], ["Bruno Lina [47]", "ORGANISM", 159, 174], ["humans", "ORGANISM", 177, 183], ["avian influenza A viruses", "ORGANISM", 212, 237], ["birds", "ORGANISM", 256, 261], ["humans", "SPECIES", 177, 183], ["avian influenza A", "SPECIES", 212, 229], ["HEV", "SPECIES", 42, 45], ["humans", "SPECIES", 177, 183], ["neuropathogenic", "PROBLEM", 49, 64], ["neurological illness", "PROBLEM", 96, 116], ["Emerging infectious diseasesAs", "PROBLEM", 117, 147], ["HEV", "OBSERVATION", 42, 45], ["wide", "OBSERVATION_MODIFIER", 82, 86], ["infectious", "OBSERVATION", 126, 136]]], ["However, sporadic cases of avian influenza virus infection are observed every year, mostly in Asia.", [["avian influenza virus infection", "DISEASE", 27, 58], ["avian influenza virus", "ORGANISM", 27, 48], ["avian influenza virus", "SPECIES", 27, 48], ["avian influenza virus", "SPECIES", 27, 48], ["avian influenza virus infection", "PROBLEM", 27, 58], ["influenza virus", "OBSERVATION", 33, 48]]], ["By subsequent adaptation of these emerging viruses may result into human pandemic strains.Emerging infectious diseasesRecently, a novel influenza A virus of the H7N9 subtype has been isolated from severely diseased patients with pneumonia and acute respiratory distress syndrome and, apparently, from healthy poultry in March 2013 in Eastern China.", [["respiratory", "ANATOMY", 249, 260], ["infectious diseases", "DISEASE", 99, 118], ["pneumonia", "DISEASE", 229, 238], ["acute respiratory distress syndrome", "DISEASE", 243, 278], ["human", "ORGANISM", 67, 72], ["influenza A virus", "ORGANISM", 136, 153], ["H7N9 subtype", "ORGANISM", 161, 173], ["patients", "ORGANISM", 215, 223], ["human", "SPECIES", 67, 72], ["influenza A virus", "SPECIES", 136, 153], ["patients", "SPECIES", 215, 223], ["human", "SPECIES", 67, 72], ["influenza A virus", "SPECIES", 136, 153], ["H7N9", "SPECIES", 161, 165], ["these emerging viruses", "PROBLEM", 28, 50], ["human pandemic strains", "PROBLEM", 67, 89], ["Emerging infectious diseases", "PROBLEM", 90, 118], ["a novel influenza A virus", "PROBLEM", 128, 153], ["the H7N9 subtype", "PROBLEM", 157, 173], ["pneumonia", "PROBLEM", 229, 238], ["acute respiratory distress syndrome", "PROBLEM", 243, 278], ["viruses", "OBSERVATION", 43, 50], ["infectious", "OBSERVATION", 99, 109], ["severely", "OBSERVATION_MODIFIER", 197, 205], ["diseased", "OBSERVATION_MODIFIER", 206, 214], ["pneumonia", "OBSERVATION", 229, 238], ["acute", "OBSERVATION_MODIFIER", 243, 248], ["respiratory distress syndrome", "OBSERVATION", 249, 278]]], ["This virus is a result of a triple reassortment event that occurred in wild birds.", [["This virus", "PROBLEM", 0, 10], ["a triple reassortment event", "PROBLEM", 26, 53], ["triple reassortment", "OBSERVATION", 28, 47]]], ["Transmission to humans occurred in wet markets, mostly in large cities like Shanghai, in adults and elderly people, with a provisional fatality rate as high as 30% (122/413).", [["humans", "ORGANISM", 16, 22], ["people", "ORGANISM", 108, 114], ["humans", "SPECIES", 16, 22], ["people", "SPECIES", 108, 114], ["humans", "SPECIES", 16, 22], ["a provisional fatality rate", "TEST", 121, 148], ["large", "OBSERVATION_MODIFIER", 58, 63], ["cities", "OBSERVATION", 64, 70]]], ["No human to human transmission has been reported so far, which cannot be explained by the virological features of the H7N9 strains that harbours most of the known markers required to facilitate transmission in mammals.", [["human", "ORGANISM", 3, 8], ["human", "ORGANISM", 12, 17], ["H7N9 strains", "ORGANISM", 118, 130], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 12, 17], ["H7N9", "SPECIES", 118, 122], ["the H7N9 strains", "PROBLEM", 114, 130]]], ["WHO experts consider this virus as an imminent threat.Emerging infectious diseasesTen years after the SARS-CoV epidemic in Asia, a newly emerged Middle East lower respiratory tract syndrome (MERS-CoV) has been confirmed in 189 patients of which 82 had a fatal outcome.", [["infectious diseases", "DISEASE", 63, 82], ["SARS-CoV epidemic", "DISEASE", 102, 119], ["lower respiratory tract syndrome", "DISEASE", 157, 189], ["Middle East lower respiratory tract", "ORGANISM_SUBDIVISION", 145, 180], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235], ["SARS-CoV", "SPECIES", 102, 110], ["Middle East lower respiratory tract syndrome (MERS-CoV", "SPECIES", 145, 199], ["this virus", "PROBLEM", 21, 31], ["Emerging infectious diseases", "PROBLEM", 54, 82], ["the SARS", "PROBLEM", 98, 106], ["a newly emerged Middle East lower respiratory tract syndrome", "PROBLEM", 129, 189], ["infectious", "OBSERVATION", 63, 73], ["Middle", "ANATOMY_MODIFIER", 145, 151], ["lower", "ANATOMY_MODIFIER", 157, 162], ["respiratory tract", "ANATOMY", 163, 180]]], ["Bats harbor a high diversity of related viruses and are suspected to be the animal reservoir.", [["Bats", "CELL", 0, 4], ["related viruses", "PROBLEM", 32, 47], ["high diversity", "OBSERVATION_MODIFIER", 14, 28], ["viruses", "OBSERVATION", 40, 47], ["reservoir", "OBSERVATION_MODIFIER", 83, 92]]], ["Recent studies have revealed that dromedary camels are the most likely intermediate host.", [["dromedary camels", "ORGANISM", 34, 50], ["Recent studies", "TEST", 0, 14], ["dromedary camels", "PROBLEM", 34, 50], ["most likely", "UNCERTAINTY", 59, 70], ["intermediate host", "OBSERVATION", 71, 88]]], ["MERS-CoV has been circulating in dromedary camels for decades raising the question whether earlier human cases may have remained undetected.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 99, 104], ["MERS-CoV", "SPECIES", 0, 8], ["human", "SPECIES", 99, 104]]], ["Preliminary serological surveys in Saudi Arabia could not determine increased seroprevalence for MERS-CoV antibodies in the population.", [["MERS-CoV antibodies", "GENE_OR_GENE_PRODUCT", 97, 116], ["MERS-CoV antibodies", "PROTEIN", 97, 116], ["MERS-CoV", "SPECIES", 97, 105], ["MERS", "PROBLEM", 97, 101], ["CoV antibodies", "TEST", 102, 116]]], ["Invitro studies showed that MERS-CoV inhibited important cellular pathways in particular the INF response.", [["cellular", "ANATOMY", 57, 65], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 28, 36], ["cellular", "CELL", 57, 65], ["INF", "GENE_OR_GENE_PRODUCT", 93, 96], ["INF", "PROTEIN", 93, 96], ["MERS-CoV", "SPECIES", 28, 36], ["Invitro studies", "TEST", 0, 15], ["MERS", "PROBLEM", 28, 32], ["CoV", "PROBLEM", 33, 36]]], ["Confirmatory in-vivo experiments are still limited due to the lack of a suitable animal model, even non-human primates.", [["non-human", "ORGANISM", 100, 109], ["primates", "ORGANISM", 110, 118], ["Confirmatory in-vivo experiments", "TEST", 0, 32]]], ["A combination of pegylated IFN-alpha and RBV improved the clinical symptoms confirming previous in-vitro experiments.", [["pegylated IFN-alpha", "CHEMICAL", 17, 36], ["RBV", "CHEMICAL", 41, 44], ["RBV", "CHEMICAL", 41, 44], ["IFN-alpha", "GENE_OR_GENE_PRODUCT", 27, 36], ["RBV", "SIMPLE_CHEMICAL", 41, 44], ["pegylated IFN-alpha", "PROTEIN", 17, 36], ["pegylated IFN", "TREATMENT", 17, 30], ["alpha", "TREATMENT", 31, 36], ["RBV", "TREATMENT", 41, 44], ["the clinical symptoms", "PROBLEM", 54, 75], ["pegylated", "OBSERVATION_MODIFIER", 17, 26]]], ["The development of vaccines is ongoing and vaccination programs in dromedary camels might be the optimal choice to control the current outbreak and prevent future re-introductions into the human population.Emerging infectious diseasesIn 2006, during the major Chikungunya outbreak in La Reunion Island (Indian Ocean), many French military policemen were deployed.", [["infectious diseasesIn", "DISEASE", 215, 236], ["Chikungunya", "DISEASE", 260, 271], ["camels", "ORGANISM", 77, 83], ["human", "ORGANISM", 189, 194], ["human", "SPECIES", 189, 194], ["dromedary", "SPECIES", 67, 76], ["human", "SPECIES", 189, 194], ["vaccines", "TREATMENT", 19, 27], ["vaccination programs", "TREATMENT", 43, 63], ["infectious", "OBSERVATION_MODIFIER", 215, 225], ["Chikungunya", "OBSERVATION_MODIFIER", 260, 271]]], ["They also studied the clinical spectrum and treatment of the rheumatic complications of Chikungunya infection in patients from La Reunion island during the same period [50] .Emerging infectious diseasesIn 2006, all the military policemen deployed in Reunion Island during the chikungunya outbreak were enquired, 25% self-declared chikungunya infection (CHIK+) and 19% had positive serology.", [["Chikungunya infection", "DISEASE", 88, 109], ["infectious diseasesIn", "DISEASE", 183, 204], ["chikungunya", "DISEASE", 276, 287], ["chikungunya infection", "DISEASE", 330, 351], ["Chikungunya", "ORGANISM", 88, 99], ["patients", "ORGANISM", 113, 121], ["chikungunya", "ORGANISM", 330, 341], ["patients", "SPECIES", 113, 121], ["treatment", "TREATMENT", 44, 53], ["the rheumatic complications", "PROBLEM", 57, 84], ["Chikungunya infection", "PROBLEM", 88, 109], ["the chikungunya outbreak", "PROBLEM", 272, 296], ["chikungunya infection", "PROBLEM", 330, 351], ["CHIK", "TEST", 353, 357], ["positive serology", "PROBLEM", 372, 389], ["rheumatic", "OBSERVATION_MODIFIER", 61, 70], ["Chikungunya", "OBSERVATION_MODIFIER", 88, 99], ["infection", "OBSERVATION", 100, 109], ["infectious", "OBSERVATION_MODIFIER", 183, 193], ["chikungunya", "OBSERVATION_MODIFIER", 330, 341], ["infection", "OBSERVATION", 342, 351]]], ["In 2008, a self-questionnaire was sent to the same persons, 403 responded, 101 were CHIK+.", [["persons", "ORGANISM", 51, 58], ["persons", "SPECIES", 51, 58]]], ["The latter presented higher frequency of rheumatic disorders and significantly lower quality of life (QoL) than non-infected (CHIK-) responders, 30 months after the outbreak.", [["rheumatic disorders", "DISEASE", 41, 60], ["rheumatic disorders", "PROBLEM", 41, 60], ["higher frequency", "OBSERVATION_MODIFIER", 21, 37], ["rheumatic", "OBSERVATION_MODIFIER", 41, 50], ["disorders", "OBSERVATION", 51, 60]]], ["Six years later, the 646 participants to the 2006 enquiry were sent selfquestionnaires by postmail with informed consent to the present study and proposal of new biological testing.", [["participants", "ORGANISM", 25, 37], ["participants", "SPECIES", 25, 37], ["the present study", "TEST", 124, 141], ["new biological testing", "TEST", 158, 180]]], ["Only 609 could be reached, and 252 fulfilled the questionnaire: 81 CHIK + (32%) and 171 CHIK-.", [["CHIK", "TEST", 67, 71], ["CHIK", "TEST", 88, 92]]], ["CHIK + patients declared higher health care consumption between 2008 and 2012.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["CHIK", "PROBLEM", 0, 4]]], ["They complained of more frequent and intense joint pain (40% versus 22% at least once a week, 64% versus 38% moderate to intense pain), stiffness and swelling, more frequent fatigue, headache and depress mood (respectively 60% versus 32%, 42% vs29% and 21vs 6%, p < 0.001).", [["joint", "ANATOMY", 45, 50], ["pain", "DISEASE", 51, 55], ["pain", "DISEASE", 129, 133], ["stiffness", "DISEASE", 136, 145], ["swelling", "DISEASE", 150, 158], ["fatigue", "DISEASE", 174, 181], ["headache", "DISEASE", 183, 191], ["depress mood", "DISEASE", 196, 208], ["joint", "ORGANISM_SUBDIVISION", 45, 50], ["intense joint pain", "PROBLEM", 37, 55], ["moderate to intense pain)", "PROBLEM", 109, 134], ["stiffness", "PROBLEM", 136, 145], ["swelling", "PROBLEM", 150, 158], ["more frequent fatigue", "PROBLEM", 160, 181], ["headache", "PROBLEM", 183, 191], ["depress mood", "PROBLEM", 196, 208], ["intense", "OBSERVATION_MODIFIER", 37, 44], ["joint", "ANATOMY", 45, 50], ["pain", "OBSERVATION", 51, 55], ["swelling", "OBSERVATION", 150, 158]]], ["All dimensions of QoL were significantly impaired in CHIK + patients, reflecting social, physical and mental impact of the disease.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["the disease", "PROBLEM", 119, 130], ["dimensions", "OBSERVATION_MODIFIER", 4, 14], ["disease", "OBSERVATION", 123, 130]]], ["The large differences observed in rheumatic morbidity, fatigue, and QoL lead to the conclusion that CHIK infection has very long term impact on health, social life and QoL with a very low proportion of patients returning to their previous health status.Emerging infectious diseasesFollowing the acute febrile polyarthritis, miscellaneous long-lasting rheumatic musculoskeletal disorders (RMSKD) are reported, consistent with chronic inflammatory rheumatisms (CIR) notably rheumatoid arthritis (RA).", [["musculoskeletal", "ANATOMY", 361, 376], ["fatigue", "DISEASE", 55, 62], ["CHIK", "CHEMICAL", 100, 104], ["infection", "DISEASE", 105, 114], ["infectious diseases", "DISEASE", 262, 281], ["polyarthritis", "DISEASE", 309, 322], ["rheumatic musculoskeletal disorders", "DISEASE", 351, 386], ["RMSKD", "DISEASE", 388, 393], ["chronic inflammatory rheumatisms", "DISEASE", 425, 457], ["CIR", "DISEASE", 459, 462], ["rheumatoid arthritis", "DISEASE", 472, 492], ["RA", "DISEASE", 494, 496], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["The large differences", "PROBLEM", 0, 21], ["rheumatic morbidity", "PROBLEM", 34, 53], ["fatigue", "PROBLEM", 55, 62], ["CHIK infection", "PROBLEM", 100, 114], ["Emerging infectious diseases", "PROBLEM", 253, 281], ["the acute febrile polyarthritis", "PROBLEM", 291, 322], ["miscellaneous long-lasting rheumatic musculoskeletal disorders", "PROBLEM", 324, 386], ["chronic inflammatory rheumatisms", "PROBLEM", 425, 457], ["rheumatoid arthritis", "PROBLEM", 472, 492], ["large", "OBSERVATION_MODIFIER", 4, 9], ["differences", "OBSERVATION_MODIFIER", 10, 21], ["rheumatic", "OBSERVATION_MODIFIER", 34, 43], ["morbidity", "OBSERVATION", 44, 53], ["infectious", "OBSERVATION", 262, 272], ["acute", "OBSERVATION_MODIFIER", 295, 300], ["febrile", "OBSERVATION_MODIFIER", 301, 308], ["polyarthritis", "OBSERVATION", 309, 322], ["rheumatic", "OBSERVATION_MODIFIER", 351, 360], ["musculoskeletal", "ANATOMY", 361, 376], ["consistent with", "UNCERTAINTY", 409, 424], ["chronic", "OBSERVATION_MODIFIER", 425, 432], ["inflammatory", "OBSERVATION", 433, 445], ["rheumatoid", "OBSERVATION_MODIFIER", 472, 482], ["arthritis", "OBSERVATION", 483, 492], ["RA", "ANATOMY", 494, 496]]], ["The post CHIK-infection stage remains a challenge to treat, while the early use of disease-modifying antirheumatic drugs (DMARDs) is recommended in RA.", [["infection", "DISEASE", 14, 23], ["RA", "DISEASE", 148, 150], ["The post CHIK-infection stage", "PROBLEM", 0, 29], ["disease", "PROBLEM", 83, 90], ["antirheumatic drugs (DMARDs", "TREATMENT", 101, 128], ["antirheumatic drugs", "OBSERVATION", 101, 120], ["RA", "ANATOMY", 148, 150]]], ["After the 2005-2006 CHIK outbreak in Reunion Island, CHIK-related RSMKD were retrospectively categorized and the empirical use of DMARDs starting with methotrexate (MTX) to treat the CIR forms was analyzed.", [["CHIK", "CHEMICAL", 53, 57], ["RSMKD", "DISEASE", 66, 71], ["methotrexate", "CHEMICAL", 151, 163], ["MTX", "CHEMICAL", 165, 168], ["methotrexate", "CHEMICAL", 151, 163], ["MTX", "CHEMICAL", 165, 168], ["methotrexate", "SIMPLE_CHEMICAL", 151, 163], ["MTX", "SIMPLE_CHEMICAL", 165, 168], ["CHIK", "PROBLEM", 53, 57], ["DMARDs", "TREATMENT", 130, 136], ["methotrexate (MTX)", "TREATMENT", 151, 169]]], ["The medical files of patients referred to rheumatologists in Saint Denis between 12/2005-05/2012 for persisting rheumatic disorders (>4 months) after a proven CHIK infection were reviewed [50] .", [["rheumatic disorders", "DISEASE", 112, 131], ["infection", "DISEASE", 164, 173], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["persisting rheumatic disorders", "PROBLEM", 101, 131], ["a proven CHIK infection", "PROBLEM", 150, 173], ["rheumatic", "OBSERVATION", 112, 121]]], ["De novo post-CHIK RMSKD was distinguished from exacerbation of pre-existing disorders.", [["CHIK RMSKD", "PROTEIN", 13, 23], ["De novo post-CHIK RMSKD", "PROBLEM", 0, 23], ["pre-existing disorders", "PROBLEM", 63, 85]]], ["Among 159 patients included, 122 suffered from de novo RSMKD.", [["RSMKD", "DISEASE", 55, 60], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["de novo RSMKD", "PROBLEM", 47, 60]]], ["RA accounted for 40/ 92, spondylarthropathy for 33/94, and distal undifferentiated polyarthritis for 21/94.", [["RA", "DISEASE", 0, 2], ["spondylarthropathy", "DISEASE", 25, 43], ["polyarthritis", "DISEASE", 83, 96], ["spondylarthropathy", "CANCER", 25, 43], ["RA", "TEST", 0, 2], ["spondylarthropathy", "PROBLEM", 25, 43], ["distal undifferentiated polyarthritis", "PROBLEM", 59, 96], ["spondylarthropathy", "OBSERVATION", 25, 43], ["distal", "OBSERVATION_MODIFIER", 59, 65], ["undifferentiated", "OBSERVATION_MODIFIER", 66, 82], ["polyarthritis", "OBSERVATION", 83, 96]]], ["Seventy-two patients were treated with MTX, reaching efficacy in 54 cases, versus failure in 18 cases.", [["MTX", "CHEMICAL", 39, 42], ["MTX", "CHEMICAL", 39, 42], ["patients", "ORGANISM", 12, 20], ["MTX", "SIMPLE_CHEMICAL", 39, 42], ["patients", "SPECIES", 12, 20], ["MTX", "TREATMENT", 39, 42], ["failure in 18 cases", "PROBLEM", 82, 101]]], ["No severe side event was observed.", [["severe side event", "PROBLEM", 3, 20], ["severe", "OBSERVATION_MODIFIER", 3, 9]]], ["The group \"efficacy\" was significantly associated with the early introduction of MTX within the first year of CIR progression (p =0.034).ConclusionThis meeting was a strong reminder of the efforts made in different fields such as drug development with more potent and better tolerated compounds and also new types of delivery system which may lead to both preventative and therapeutic use.", [["MTX", "CHEMICAL", 81, 84], ["MTX", "CHEMICAL", 81, 84], ["MTX", "SIMPLE_CHEMICAL", 81, 84], ["MTX", "TREATMENT", 81, 84], ["CIR progression", "PROBLEM", 110, 125], ["delivery system", "TREATMENT", 317, 332]]], ["The effort to end the epidemic is now including multipronged interventions while the eradication paradigm remains well and alive with in-depth viroimmunological studies and new pharmacological and gene therapy interventions.", [["multipronged interventions", "TREATMENT", 48, 74], ["new pharmacological", "TREATMENT", 173, 192], ["gene therapy interventions", "TREATMENT", 197, 223]]], ["On the other hand, HCV infection is the first chronic viral disease that we are now able to cure but the same issues for \"test and treat\" as for HIV remain.", [["HCV infection", "DISEASE", 19, 32], ["HCV", "ORGANISM", 19, 22], ["HIV", "ORGANISM", 145, 148], ["HIV", "SPECIES", 145, 148], ["HCV", "SPECIES", 19, 22], ["HIV", "SPECIES", 145, 148], ["HCV infection", "PROBLEM", 19, 32], ["the first chronic viral disease", "PROBLEM", 36, 67], ["test", "TEST", 122, 126], ["HIV", "PROBLEM", 145, 148], ["HCV", "OBSERVATION_MODIFIER", 19, 22], ["infection", "OBSERVATION", 23, 32], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["viral disease", "OBSERVATION", 54, 67]]]], "0838c2059fdda4853ec31b2fbff7a572cf8a8ab7": [["I. INTRODUCTIONPowerful antibiotics and vaccines helped mitigate the threat from infectious diseases for several generations.", [["infectious diseases", "DISEASE", 81, 100], ["INTRODUCTIONPowerful antibiotics", "TREATMENT", 3, 35], ["vaccines", "TREATMENT", 40, 48], ["infectious diseases", "PROBLEM", 81, 100], ["infectious", "OBSERVATION", 81, 91]]], ["In 1900, most human deaths were associated with infectious diseases like tuberculosis and influenza.", [["deaths", "DISEASE", 20, 26], ["infectious diseases", "DISEASE", 48, 67], ["tuberculosis", "DISEASE", 73, 85], ["influenza", "DISEASE", 90, 99], ["human", "ORGANISM", 14, 19], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["infectious diseases", "PROBLEM", 48, 67], ["tuberculosis", "PROBLEM", 73, 85], ["influenza", "PROBLEM", 90, 99], ["infectious", "OBSERVATION", 48, 58], ["tuberculosis", "OBSERVATION", 73, 85], ["influenza", "OBSERVATION", 90, 99]]], ["As recently as 2000, the worldwide mortality associated with infectious diseases was 16.4 percent of deaths from all causes.", [["infectious diseases", "DISEASE", 61, 80], ["deaths", "DISEASE", 101, 107], ["infectious diseases", "PROBLEM", 61, 80]]], ["Unfortunately, this means there were still over 6 million deaths associated with infectious diseases [1] .", [["deaths", "DISEASE", 58, 64], ["infectious diseases", "DISEASE", 81, 100], ["infectious diseases", "PROBLEM", 81, 100]]], ["A recent review examined antimicrobial resistance and predicted that by 2050, the impact would include a reduction of the world's potential gross domestic product by 2% to 3.5% and cause an additional 10 million premature deaths a year [2] .", [["deaths", "DISEASE", 222, 228], ["gross domestic product", "TREATMENT", 140, 162]]], ["Although beyond the scope of this paper, it is worth noting that microorganisms have also been implicated as contributing to or causing many chronic diseases, including some forms of cancer, arthritis, and neurological disease [3] .I. INTRODUCTIONIt is tempting to approach the infectious disease challenge as doing battle with a pathogen enemy where brigades of combatant bacteria or viruses are held back or even defeated by increasingly sophisticated pharmaceutical weapons.", [["cancer", "ANATOMY", 183, 189], ["neurological", "ANATOMY", 206, 218], ["cancer", "DISEASE", 183, 189], ["arthritis", "DISEASE", 191, 200], ["neurological disease", "DISEASE", 206, 226], ["cancer", "CANCER", 183, 189], ["microorganisms", "PROBLEM", 65, 79], ["many chronic diseases", "PROBLEM", 136, 157], ["cancer", "PROBLEM", 183, 189], ["arthritis", "PROBLEM", 191, 200], ["neurological disease", "PROBLEM", 206, 226], ["the infectious disease challenge", "PROBLEM", 274, 306], ["a pathogen enemy", "PROBLEM", 328, 344], ["combatant bacteria", "PROBLEM", 363, 381], ["viruses", "PROBLEM", 385, 392], ["chronic", "OBSERVATION_MODIFIER", 141, 148], ["diseases", "OBSERVATION", 149, 157], ["cancer", "OBSERVATION", 183, 189], ["arthritis", "OBSERVATION", 191, 200], ["infectious", "OBSERVATION", 278, 288], ["viruses", "OBSERVATION", 385, 392], ["pharmaceutical weapons", "OBSERVATION", 454, 476]]], ["There is certainly a place for improved pharmaceuticals; however, a sustainable approach will need to be much more sophisticated.", [["a sustainable approach", "TREATMENT", 66, 88], ["improved", "OBSERVATION_MODIFIER", 31, 39], ["pharmaceuticals", "OBSERVATION", 40, 55]]], ["Microbes and their hosts form a complex and dynamic ecosystem, and a long-term strategy for infectious disease control must take into account the fact that diseases can result from changes in the microbe, the host, or the environment.", [["infectious disease", "DISEASE", 92, 110], ["a complex and dynamic ecosystem", "PROBLEM", 30, 61], ["a long-term strategy", "TREATMENT", 67, 87], ["infectious disease control", "TREATMENT", 92, 118], ["diseases", "PROBLEM", 156, 164], ["diseases", "OBSERVATION", 156, 164]]], ["This can include bacteria developing antibiotic resistance or acquiring metabolic traits that allow them to thrive in a new environmental niche, and viruses evolving to reduce the effectiveness of antivirals and vaccines.", [["bacteria", "PROBLEM", 17, 25], ["antibiotic resistance", "TREATMENT", 37, 58], ["acquiring metabolic traits", "PROBLEM", 62, 88], ["a new environmental niche", "PROBLEM", 118, 143], ["viruses", "PROBLEM", 149, 156], ["antivirals", "TREATMENT", 197, 207], ["vaccines", "TREATMENT", 212, 220], ["antibiotic resistance", "OBSERVATION", 37, 58]]], ["In addition to the evolution of existing pathogens, like the seasonal influenza virus, there are emerging pathogens that are often the result of changing or encroachment upon new ecosystems and the ''leap'' from a conventional host to a new host species.", [["influenza virus", "DISEASE", 70, 85], ["seasonal influenza virus", "ORGANISM", 61, 85], ["seasonal influenza virus", "SPECIES", 61, 85], ["seasonal influenza virus", "SPECIES", 61, 85], ["existing pathogens", "PROBLEM", 32, 50], ["the seasonal influenza virus", "PROBLEM", 57, 85], ["emerging pathogens", "PROBLEM", 97, 115], ["pathogens", "OBSERVATION", 41, 50], ["seasonal", "OBSERVATION_MODIFIER", 61, 69], ["influenza virus", "OBSERVATION", 70, 85], ["encroachment", "OBSERVATION", 157, 169], ["new", "OBSERVATION_MODIFIER", 175, 178]]], ["An example from recent headlines is the Middle East Respiratory Syndrome Coronavirus.", [["Respiratory Syndrome Coronavirus", "DISEASE", 52, 84], ["Middle East Respiratory Syndrome Coronavirus", "SPECIES", 40, 84], ["the Middle East Respiratory Syndrome Coronavirus", "PROBLEM", 36, 84], ["Middle", "ANATOMY_MODIFIER", 40, 46], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 52, 84]]], ["MERS-CoV appears to have reached humans by direct contact and potentially airborne transmission through animal hosts including camels [5] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["humans", "ORGANISM", 33, 39], ["camels", "ORGANISM", 127, 133], ["humans", "SPECIES", 33, 39], ["MERS-CoV", "SPECIES", 0, 8], ["humans", "SPECIES", 33, 39]]], ["The MERS-CoV is related to the coronavirus that caused severe acute respiratory syndrome (SARS).", [["coronavirus", "DISEASE", 31, 42], ["acute respiratory syndrome", "DISEASE", 62, 88], ["SARS", "DISEASE", 90, 94], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["coronavirus", "ORGANISM", 31, 42], ["coronavirus", "SPECIES", 31, 42], ["MERS-CoV", "SPECIES", 4, 12], ["The MERS-CoV", "PROBLEM", 0, 12], ["the coronavirus", "PROBLEM", 27, 42], ["severe acute respiratory syndrome", "PROBLEM", 55, 88], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory syndrome", "OBSERVATION", 68, 88]]], ["The SARS outbreak began in 2002 and likely spread to humans via bats [6] .", [["SARS", "DISEASE", 4, 8], ["humans", "ORGANISM", 53, 59], ["humans", "SPECIES", 53, 59], ["humans", "SPECIES", 53, 59], ["The SARS outbreak", "PROBLEM", 0, 17]]], ["Although the viruses are similar, this does not guarantee that utilization of the same medical and public health intervention techniques will be effective.", [["the viruses", "PROBLEM", 9, 20], ["public health intervention techniques", "TREATMENT", 99, 136], ["viruses", "OBSERVATION", 13, 20]]], ["There are many examples of emerging infectious disease outbreaks, including the on-going HIV/AIDS pandemic that has already caused 35 million deaths [7] .", [["infectious disease outbreaks", "DISEASE", 36, 64], ["HIV/AIDS pandemic", "DISEASE", 89, 106], ["deaths", "DISEASE", 142, 148], ["HIV", "SPECIES", 89, 92], ["emerging infectious disease outbreaks", "PROBLEM", 27, 64], ["infectious", "OBSERVATION", 36, 46]]], ["Each pathogen involved in an infectious disease outbreak provides an opportunity to identify what scientific data are needed to support effective interventions.I. INTRODUCTIONQuoted in the Global Health Security Agenda [8] , U.S. President Obama said in 2011 ''. . . we must come together to prevent, and detect, and fight every kind of biological dangerVwhether it's a pandemic like H1N1, or a terrorist threat, or a treatable disease.''", [["H1N1", "DISEASE", 384, 388], ["Each pathogen", "PROBLEM", 0, 13], ["an infectious disease outbreak", "PROBLEM", 26, 56], ["effective interventions", "TREATMENT", 136, 159], ["H1N1", "PROBLEM", 384, 388], ["a treatable disease", "PROBLEM", 416, 435], ["infectious", "OBSERVATION_MODIFIER", 29, 39], ["H1N1", "OBSERVATION", 384, 388]]], ["The Agenda complements and supports existing International Health Regulations of the World Health Organization [9], U.S. public health [10] , [11] , and biodefense objectives [12] - [14] .", [["biodefense objectives", "TEST", 153, 174]]], ["The framework for data requirements and response priorities used in this paper integrates across these initiatives and regulations.", [["response priorities", "TREATMENT", 40, 59]]], ["Specifically, in order to manage infectious diseases, capabilities are required for: preparedness, detection, characterization, response, and support for the return to normal, see Fig. 1 .", [["infectious diseases", "DISEASE", 33, 52], ["infectious diseases", "PROBLEM", 33, 52], ["normal", "OBSERVATION", 168, 174]]], ["These capabilities are relevant for addressing health interests from the global to the individual organism, e.g., human, animal, plant, or bacterium.", [["human", "ORGANISM", 114, 119], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 114, 119], ["bacterium", "PROBLEM", 139, 148]]], ["The global perspective is studied and implemented by public health, ecological, industrial, and other communities with the principal foci of public benefit, humanitarian needs, scaling, and statistical measures.", [["global", "OBSERVATION_MODIFIER", 4, 10]]], ["For an individual human, the perspectives are from medical, economic, relationship, and other personal priorities with the foci of individual health, quality of life, and gaining access to effective care.", [["human", "ORGANISM", 18, 23], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23]]], ["Integrating frameworks are needed to support optimization of technical, economic, medical, and ethical components of this complex system.", [["technical, economic, medical, and ethical components of this complex system", "PROBLEM", 61, 136]]], ["Infectious diseases are a major cause of death and economic impact worldwide.", [["Infectious diseases", "DISEASE", 0, 19], ["death", "DISEASE", 41, 46], ["death", "PROBLEM", 41, 46]]], ["A more robust, adaptable and scalable infrastructure would improve the capability to respond to epidemics.", [["A more robust, adaptable and scalable infrastructure", "PROBLEM", 0, 52], ["epidemics", "PROBLEM", 96, 105], ["robust", "OBSERVATION_MODIFIER", 7, 13]]], ["Because engineers contribute to the design and implementation of infrastructure, there are opportunities for innovative solutions to infectious disease response within existing systems that have utility, and therefore resources, before a public health emergency.", [["innovative solutions", "TREATMENT", 109, 129], ["infectious disease response", "PROBLEM", 133, 160]]], ["Examples of innovative leveraging of engineered infrastructure are provided throughout the paper.", [["engineered infrastructure", "OBSERVATION", 37, 62]]], ["The next section of this paper discusses opportunities for technology to improve on current approaches to infectious disease management and the following section discusses engineering challenges to accelerate the application of science to infectious disease planning and response at the global scale.", [["infectious disease", "DISEASE", 106, 124], ["infectious disease", "DISEASE", 239, 257], ["infectious disease management", "TREATMENT", 106, 135], ["infectious disease planning", "TREATMENT", 239, 266]]], ["I conclude with a brief discussion of the importance and opportunity for engineers to address the ethical issues needed to leverage traditional infrastructure for infectious disease response and help nurture a global culture of responsibility in both healthcare and technical applications.II. TECHNOLOGIES TO IMPROVE EXISTING APPROACHESLeveraging their significant investment in planning and response experience, I adopted from the U.S. pandemic influenza plan [10, p.", [["infectious disease", "DISEASE", 163, 181], ["II", "CHEMICAL", 289, 291], ["influenza", "DISEASE", 446, 455], ["the ethical issues", "PROBLEM", 94, 112], ["infectious disease response", "PROBLEM", 163, 190], ["a global culture", "TEST", 208, 224]]], ["G-58], infectious disease management goals to provide: public health policy-makers with data to guide response, and clinicians with scientific data to justify recommended treatments, vaccines, or other interventions.", [["G-58", "CHEMICAL", 0, 4], ["infectious disease", "DISEASE", 7, 25], ["G-58", "GENE_OR_GENE_PRODUCT", 0, 4], ["infectious disease management", "TREATMENT", 7, 36], ["treatments", "TREATMENT", 171, 181], ["vaccines", "TREATMENT", 183, 191], ["other interventions", "TREATMENT", 196, 215]]], ["I have integrated priorities from the influenza plan with a more pathogen-centric approach from the food industry [15] in Table 1 to provide descriptions of priority data to support infectious disease outbreak response. health have parallels shown in the inner and outer rings, respectively.", [["inner", "ANATOMY", 255, 260], ["outer rings", "ANATOMY", 265, 276], ["influenza", "DISEASE", 38, 47], ["infectious disease outbreak", "DISEASE", 182, 209], ["inner", "TISSUE", 255, 260], ["outer rings", "CELLULAR_COMPONENT", 265, 276], ["the influenza plan", "TREATMENT", 34, 52], ["infectious disease outbreak response", "PROBLEM", 182, 218], ["inner", "ANATOMY_MODIFIER", 255, 260], ["outer", "ANATOMY_MODIFIER", 265, 270], ["rings", "ANATOMY_MODIFIER", 271, 276]]], ["Because traditional diagnostics and treatments have long lead development, regulatory approval, and manufacturing lead times, it is challenging to provide timely and effective interventions at a public health scale for an outbreak caused by an emerging or novel pathogen.", [["traditional diagnostics", "TEST", 8, 31], ["treatments", "TREATMENT", 36, 46], ["regulatory approval", "TREATMENT", 75, 94], ["effective interventions", "TREATMENT", 166, 189], ["a public health scale", "TREATMENT", 193, 214], ["novel pathogen", "PROBLEM", 256, 270]]], ["Approaches to achieving robust, economically viable scaling include improved leveraging of existing infrastructure, establishment of an integrating framework like the Digital Immune System for optimization, and spiral development processes similar to homeostasis.Fitch: Engineering a Global Response to Infectious DiseasesThese data can be provided with currently available technologies.", [["Infectious Diseases", "DISEASE", 303, 322], ["spiral development processes", "PROBLEM", 211, 239]]], ["However, there are several recurring issues that inhibit global utilization.", [["several recurring issues", "PROBLEM", 19, 43], ["several", "OBSERVATION_MODIFIER", 19, 26], ["recurring", "OBSERVATION_MODIFIER", 27, 36], ["global", "OBSERVATION_MODIFIER", 57, 63]]], ["Limited availability is driven by many factors including cost, appropriate sharing of data and materials, and timely manufacture and distribution.Fitch: Engineering a Global Response to Infectious DiseasesOn a more basic level, one of the key factors in sustainable preparedness is infrastructure, and availability is a challenge here as well.", [["Infectious DiseasesOn", "DISEASE", 186, 207], ["Infectious", "OBSERVATION", 186, 196]]], ["Malnutrition due to starvation, unsafe water, and insufficient sanitation all impact infectious disease mortality.", [["Malnutrition", "DISEASE", 0, 12], ["infectious disease", "DISEASE", 85, 103], ["Malnutrition", "PROBLEM", 0, 12], ["starvation", "TREATMENT", 20, 30], ["infectious disease mortality", "PROBLEM", 85, 113], ["infectious", "OBSERVATION_MODIFIER", 85, 95]]], ["In 2004, over half of the deaths of children under five years old were associated with infectious diseases and the significant contributing factor for many of these deaths was under nutrition [16] .", [["deaths", "DISEASE", 26, 32], ["infectious diseases", "DISEASE", 87, 106], ["deaths", "DISEASE", 165, 171], ["children", "ORGANISM", 36, 44], ["children", "SPECIES", 36, 44], ["infectious diseases", "PROBLEM", 87, 106]]], ["Electrical and computer engineers are now providing valuable low-cost information linkages across systems so that weather satellite data can be utilized to help increase local crop yields and prepare water treatment and sanitation plants for adverse weather.", [["local crop yields", "TREATMENT", 170, 187], ["water treatment", "TREATMENT", 200, 215], ["sanitation plants", "TREATMENT", 220, 237], ["adverse weather", "PROBLEM", 242, 257]]], ["The computational algorithms and information networks can be applied worldwide for irrigation and weather prediction for storm and drought management [17] .Fitch: Engineering a Global Response to Infectious DiseasesRemote sensing has been utilized to indirectly detect Vibrio cholera [18] and predict a Rift Valley fever (RVF) outbreak [19] .", [["Infectious Diseases", "DISEASE", 196, 215], ["Rift Valley fever", "DISEASE", 303, 320], ["RVF", "DISEASE", 322, 325], ["Vibrio cholera", "ORGANISM", 269, 283], ["Rift Valley fever", "ORGANISM", 303, 320], ["Vibrio cholera", "SPECIES", 269, 283], ["Vibrio cholera", "SPECIES", 269, 283], ["Rift Valley fever (", "SPECIES", 303, 322], ["RVF", "SPECIES", 322, 325], ["irrigation", "TREATMENT", 83, 93], ["drought management", "TREATMENT", 131, 149], ["Vibrio cholera", "PROBLEM", 269, 283], ["a Rift Valley fever", "PROBLEM", 301, 320]]], ["In both of these examples, the disease and environmental biology were shown to correlate with changes that could be measured by air and space borne sensors.", [["the disease", "PROBLEM", 27, 38], ["disease", "OBSERVATION", 31, 38]]], ["For V. cholerae, sea-surface temperature and sea height were linked to the inland incursion of water with commensal plankton.", [["sea-surface", "ANATOMY", 17, 28], ["V. cholerae", "ORGANISM", 4, 15], ["sea", "ORGANISM_SUBDIVISION", 45, 48], ["V. cholerae", "SPECIES", 4, 15], ["V. cholerae", "SPECIES", 4, 15], ["V. cholerae", "PROBLEM", 4, 15]]], ["Satellite measurements of seasurface temperature, rainfall, and vegetation changes were used to predict the areas where outbreaks of RVF in humans and animals occurred in Africa.", [["RVF", "DISEASE", 133, 136], ["humans", "ORGANISM", 140, 146], ["humans", "SPECIES", 140, 146], ["RVF", "SPECIES", 133, 136], ["humans", "SPECIES", 140, 146], ["Satellite measurements", "TEST", 0, 22], ["seasurface temperature", "PROBLEM", 26, 48], ["vegetation changes", "PROBLEM", 64, 82], ["RVF", "PROBLEM", 133, 136], ["Africa", "PROBLEM", 171, 177], ["seasurface", "OBSERVATION_MODIFIER", 26, 36], ["temperature", "OBSERVATION_MODIFIER", 37, 48], ["rainfall", "OBSERVATION_MODIFIER", 50, 58], ["outbreaks", "OBSERVATION_MODIFIER", 120, 129], ["RVF", "OBSERVATION", 133, 136]]], ["The techniques and data used for RVF may be more broadly applicable to other vector-borne diseases.Fitch: Engineering a Global Response to Infectious DiseasesIn regions with limited infrastructure, it is often difficult or impossible to provide the refrigeration required to maintain the ''cold chain'' for life-saving vaccines and other medicines.", [["RVF", "DISEASE", 33, 36], ["Infectious Diseases", "DISEASE", 139, 158], ["RVF", "PROBLEM", 33, 36], ["borne diseases", "PROBLEM", 84, 98], ["the ''cold chain''", "TREATMENT", 284, 302], ["life-saving vaccines", "TREATMENT", 307, 327], ["other medicines", "TREATMENT", 332, 347], ["Infectious", "OBSERVATION", 139, 149]]], ["An inspirational consortium of industry, churches, and nonprofits in Zimbabwe, Africa, leveraged the reliable power requirements of cellphone towers to help address the refrigeration storage needs for many vaccines [20] .", [["cellphone towers", "TREATMENT", 132, 148], ["the refrigeration storage", "TREATMENT", 165, 190], ["many vaccines", "TREATMENT", 201, 214]]], ["The initiative has included innovative contributions by wireless providers, refrigerator manufacturers, and others in order to help provide immunizations against polio, measles, and diphtheria.Fitch: Engineering a Global Response to Infectious DiseasesAnother area in which technology is poised to impact infectious disease management is in gaining timely situational awareness of outbreaks.", [["polio", "DISEASE", 162, 167], ["measles", "DISEASE", 169, 176], ["diphtheria", "DISEASE", 182, 192], ["Infectious Diseases", "DISEASE", 233, 252], ["infectious disease", "DISEASE", 305, 323], ["measles", "ORGANISM", 169, 176], ["immunizations", "TREATMENT", 140, 153], ["polio", "PROBLEM", 162, 167], ["measles", "PROBLEM", 169, 176], ["diphtheria", "PROBLEM", 182, 192], ["infectious disease management", "TREATMENT", 305, 334], ["Infectious", "OBSERVATION", 233, 243], ["infectious", "OBSERVATION", 305, 315]]], ["Global and regional travel often make this a difficult task, and data collection and sharing for epidemiologists, care providers, patients, and the public is also limited by other factors such as privacy concerns for individual patients' medical data, governmental goals to protect tourism and other local-to-national interests, the lack of recognized standards for sharing protected data, and an accepted international norm for transfer of public and commercial material during and in response to an infectious disease.", [["infectious disease", "DISEASE", 501, 519], ["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 228, 236], ["an infectious disease", "PROBLEM", 498, 519], ["regional", "OBSERVATION_MODIFIER", 11, 19], ["infectious", "OBSERVATION", 501, 511]]], ["Improved network, encryption and access information technologies are also necessary to support managed care organizations and telemedicine applications.", [["telemedicine applications", "TREATMENT", 126, 151]]], ["A global system addressing these issues and capable of operating on time scales relevant to controlling an epidemic is needed.Fitch: Engineering a Global Response to Infectious DiseasesA comparison of five outbreak detection algorithms was conducted using a surveillance case study of the seasonal Ross River virus disease [21] .", [["Ross River virus disease", "DISEASE", 298, 322], ["Ross River virus", "ORGANISM", 298, 314], ["Ross River virus", "SPECIES", 298, 314], ["a surveillance case study", "TEST", 256, 281], ["the seasonal Ross River virus disease", "PROBLEM", 285, 322], ["Infectious", "OBSERVATION_MODIFIER", 166, 176], ["virus disease", "OBSERVATION", 309, 322]]], ["Challenges were identified for making quantitative comparisons of the algorithms as well as in evaluating the performance of each algorithm.", [["the algorithms", "TEST", 66, 80], ["each algorithm", "TEST", 125, 139]]], ["Using measured and simulated data, this approach showed promise for addressing shifts in health data that occur due to special events, worried well, and other population shifts that happen during significant events like pandemics.", [["this approach", "TEST", 35, 48], ["addressing shifts in health data", "PROBLEM", 68, 100], ["pandemics", "PROBLEM", 220, 229]]], ["Another study compared 101 animal and public health surveillance systems, finding challenges due to a limited number of common attributes, unclear surveillance objectives of the design, no common [23] .", [["Another study", "TEST", 0, 13]]], ["For example, the geographic location capability in many cell phones allows applications to push public health and animal disease outbreak information to users based on location.", [["cell", "ANATOMY", 56, 60], ["cell", "CELL", 56, 60]]], ["The U.S. Centers for Disease Control and Prevention (CDC) has the FluView application that provides geographic information on influenza-like illness activity [24] .", [["influenza-like illness", "DISEASE", 126, 148], ["Disease Control", "TREATMENT", 21, 36], ["the FluView application", "TREATMENT", 62, 85], ["influenza", "PROBLEM", 126, 135]]], ["Obviously, the pervasiveness of cell phones improves timely reporting from the field for both the public and the public health profession.", [["cell", "ANATOMY", 32, 36], ["cell", "CELL", 32, 36]]], ["Moving forward, addressing privacy issues will be critical so that geographic tracking of a phone's location could be used to help inform an individual of potential contact with infected persons or animals and support automated, anonymous, electronic integration of those data to accelerate the epidemiological detective work of identifying and surveying those same individuals for public health benefit.Fitch: Engineering a Global Response to Infectious DiseasesElectronic health information systems have made significant progress.", [["Infectious Diseases", "DISEASE", 444, 463], ["persons", "ORGANISM", 187, 194], ["persons", "SPECIES", 187, 194]]], ["However, even as recently as 2014, it was noted: ''Despite progress in establishing standards and services to support health information exchange and interoperability, practice patterns have not changed to the point that health care providers share patient health information electronically across organizational, vendor, and geographic boundaries.", [["patient", "ORGANISM", 249, 256], ["patient", "SPECIES", 249, 256]]], ["Continued development of quality management, human factors, and other standards to support usability and regulatory review are needed.Fitch: Engineering a Global Response to Infectious DiseasesAs the large-scale systems that require computer algorithms to scan and integrate data into summary reports continue to progress, significant benefit is being derived from systems with fairly simple technology.", [["human", "ORGANISM", 45, 50], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["quality management", "TREATMENT", 25, 43], ["computer algorithms", "TEST", 233, 252], ["scan", "TEST", 256, 260], ["quality management", "OBSERVATION", 25, 43], ["Infectious", "OBSERVATION", 174, 184]]], ["It has grown to over 30,000 subscribers in over 150 countries and has roles in outbreak detection including SARS in 2003 [28] .", [["SARS", "DISEASE", 108, 112], ["grown", "OBSERVATION_MODIFIER", 7, 12]]], ["A study in New York City showed that most physicians (82%) received Health Department communications, but less than half of those (37%) received the information through the HAN [31] .", [["A study", "TEST", 0, 7]]], ["An important trend is that 47% prefer e-mail distribution of communications and this preference trends with younger respondents.Fitch: Engineering a Global Response to Infectious DiseasesLooking to the future, achieving the benefits of distributed diagnostics and electronic reporting will depend on both technical and clinical integration.", [["Infectious DiseasesLooking", "DISEASE", 168, 194]]], ["This would improve individual care as well as reduce or eliminate separate data entry and reporting for public health surveillance.", [["public health surveillance", "TEST", 104, 130]]], ["In order to realize the benefits of personalized medicine with treatment customized to the individual, the costs, scalability, and compatibility across all data sources must be addressed.", [["personalized medicine", "TREATMENT", 36, 57], ["treatment", "TREATMENT", 63, 72]]], ["Personalized infectious disease medicine might include customization of antimicrobials to an individual patient to improve care and help reduce overuse and misuse of antibiotics.", [["infectious disease", "DISEASE", 13, 31], ["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["Personalized infectious disease medicine", "TREATMENT", 0, 40], ["antimicrobials", "TREATMENT", 72, 86], ["antibiotics", "TREATMENT", 166, 177]]], ["Similarly at the global health scale, timely identification of appropriate virus strains coupled with rapid manufacturing for seasonal influenza vaccination would reduce the disease burden of thousands.", [["influenza", "DISEASE", 135, 144], ["appropriate virus strains", "PROBLEM", 63, 88], ["rapid manufacturing", "TREATMENT", 102, 121], ["seasonal influenza vaccination", "TREATMENT", 126, 156], ["the disease burden of thousands", "PROBLEM", 170, 201]]], ["In personalized and global applications, the approaches will need to move from diagnostics, characterizations, and interventions aimed at a single specific disease causing pathogen to robust methods that can be adapted for safe and effective use in a timely manner for broad classes of disease.", [["interventions", "TREATMENT", 115, 128], ["a single specific disease", "PROBLEM", 138, 163], ["disease", "PROBLEM", 286, 293], ["disease", "OBSERVATION", 286, 293]]], ["Fully realizing these goals will require improved scientific understanding and new engineering and computational approaches.III. ENGINEERING TO ACCELERATE R&D AND IMPROVE CARE OF THE FUTUREThere are significant challenges in utilizing traditional engineering approaches in the life sciences.", [["traditional engineering approaches", "TREATMENT", 235, 269]]], ["Living organisms are complex by most machine standards.", [["Living organisms", "PROBLEM", 0, 16]]], ["Individual organisms are also typically influenced by peer organisms forming a community, by other living organisms that may be beneficial, neutral or detrimental, and by the environment.", [["Individual organisms", "PROBLEM", 0, 20]]], ["There are opportunities for engineers to develop improved measurement, analysis, and model systems to better characterize, predict and manage infectious diseases.", [["infectious diseases", "DISEASE", 142, 161], ["analysis", "TEST", 71, 79], ["model systems", "TEST", 85, 98], ["infectious diseases", "PROBLEM", 142, 161]]], ["Given the complexity of these interacting systems, there are significant challenges to the reductionist approaches familiar to design-based engineering.", [["these interacting systems", "PROBLEM", 24, 49], ["significant", "OBSERVATION_MODIFIER", 61, 72]]], ["Fortunately, as the history of vaccination demonstrates, a comprehensive knowledge of the biology is not always required in order to provide healthcare benefits.III. ENGINEERING TO ACCELERATE R&D AND IMPROVE CARE OF THE FUTUREWith the advent of deoxyribonucleic acid (DNA) sequencing and the efficient detection and laboratory replication of DNA through polymerase chain reaction (PCR) amplification, there are opportunities to organize scientific and medical data using DNA-based indices.", [["deoxyribonucleic acid", "CHEMICAL", 245, 266], ["deoxyribonucleic acid", "SIMPLE_CHEMICAL", 245, 266], ["DNA", "CELLULAR_COMPONENT", 268, 271], ["DNA", "CELLULAR_COMPONENT", 342, 345], ["DNA", "CELLULAR_COMPONENT", 471, 474], ["vaccination", "TREATMENT", 31, 42], ["deoxyribonucleic acid (DNA)", "TREATMENT", 245, 272], ["the efficient detection", "TEST", 288, 311], ["DNA through polymerase chain reaction", "PROBLEM", 342, 379], ["PCR", "TEST", 381, 384], ["medical data", "TEST", 452, 464]]], ["The field that has grown up around these technologies, genomics, is an excellent example of how engineering can enable profound advances in biological research.", [["grown", "OBSERVATION_MODIFIER", 19, 24]]], ["A significant contributor to the organizing principles and demonstrator of this DNAbased approach, Carl Woese, summarized in 2000 the impact as providing ''a new and powerful perspective, an image that unifies all life through its shared histories and common origin, at the same time emphasizing life's incredible diversity and the overwhelming importance of the microbial world,'' [32] .", [["this DNAbased approach", "TREATMENT", 75, 97], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["common origin", "OBSERVATION_MODIFIER", 252, 265]]], ["Here, I build on this insight as well as our previous assessment in 2000 of the engineering contributions and opportunities related to DNA sequence Fitch: Engineering a Global Response to Infectious Diseases data that describe an organism's genome, transcriptome and proteome [33] .", [["Infectious Diseases", "DISEASE", 188, 207], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["our previous assessment", "TEST", 41, 64], ["Infectious Diseases data", "PROBLEM", 188, 212], ["an organism's genome", "PROBLEM", 227, 247]]], ["As depicted in Fig. 2 , nucleic acid sequence provides a common framework to organize data related to infectious diseases.III. ENGINEERING TO ACCELERATE R&D AND IMPROVE CARE OF THE FUTUREToday's DNA sequencing instruments can produce terabases of data in a few days with per-base costs a million-fold lower than a decade ago.", [["nucleic acid", "CHEMICAL", 24, 36], ["infectious diseases", "DISEASE", 102, 121], ["DNA", "CELLULAR_COMPONENT", 195, 198], ["nucleic acid sequence", "TEST", 24, 45], ["infectious diseases", "PROBLEM", 102, 121], ["THE FUTUREToday's DNA sequencing instruments", "TREATMENT", 177, 221], ["infectious", "OBSERVATION", 102, 112]]], ["Recent studies have demonstrated the power of personalized approaches to major human diseases like cancer.", [["cancer", "ANATOMY", 99, 105], ["human diseases", "DISEASE", 79, 93], ["cancer", "DISEASE", 99, 105], ["human", "ORGANISM", 79, 84], ["cancer", "CANCER", 99, 105], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["Recent studies", "TEST", 0, 14], ["major human diseases like cancer", "PROBLEM", 73, 105], ["cancer", "OBSERVATION", 99, 105]]], ["It appears likely that the next few years will bring the personalized human genome and the miniaturized sequencing instrument, each for less than one thousand dollars.", [["human", "ORGANISM", 70, 75], ["personalized human genome", "DNA", 57, 82], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["appears likely", "UNCERTAINTY", 3, 17]]], ["Now is the time to innovate and apply the engineering approaches needed to utilize these and other data.III. ENGINEERING TO ACCELERATE R&D AND IMPROVE CARE OF THE FUTUREDNA sequencing and the associated bioinformatics tools for analysis provide a powerful methods-based approach to monitoring living systems.", [["the engineering approaches", "TREATMENT", 38, 64], ["these and other data", "TEST", 83, 103], ["analysis", "TEST", 228, 236], ["a powerful methods", "TREATMENT", 245, 263]]], ["DNA and ribonucleic acid (RNA) provide data that help characterize an individual's health status as well as the status of the surrounding environment.", [["ribonucleic acid", "CHEMICAL", 8, 24], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["ribonucleic acid", "GENE_OR_GENE_PRODUCT", 8, 24], ["ribonucleic acid", "RNA", 8, 24], ["DNA and ribonucleic acid (RNA)", "PROBLEM", 0, 30], ["ribonucleic acid", "OBSERVATION", 8, 24]]], ["Because sequencing converts biological information to digital data, computer networks, data management, integrity, scaling, analysis, privacy, and affordability are keys to expanding access.", [["digital data", "TEST", 54, 66], ["analysis", "TEST", 124, 132], ["privacy", "TREATMENT", 134, 141]]], ["Basing the system on DNA allows correlation techniques to identify patterns in the sequence dataVrecurring and deviate patterns.", [["DNA", "CELLULAR_COMPONENT", 21, 24], ["correlation techniques", "TEST", 32, 54], ["the sequence dataVrecurring", "TEST", 79, 106]]], ["These patterns can be indicative of healthy or pathologic host status as well as the absence or presence of pathogens in clinical and environmental samples.", [["samples", "ANATOMY", 148, 155], ["healthy or pathologic host status", "PROBLEM", 36, 69], ["pathogens", "PROBLEM", 108, 117], ["can be indicative of", "UNCERTAINTY", 15, 35]]], ["The growth of sequence databases with appropriate clinical and environmental metadata will improve the potential quality of the analyses and the impact on individual and public health.", [["sequence databases", "TEST", 14, 32]]], ["Growing databases will also need to address the scaling and privacy issues.", [["the scaling and privacy issues", "PROBLEM", 44, 74]]], ["One of the most powerful features of the digital immune system approach is the potential to detect a novel pathogen, i.e., one that is not already in the database.", [["a novel pathogen", "PROBLEM", 99, 115], ["pathogen", "OBSERVATION", 107, 115]]], ["The flexibility inherent in this methodbased approach is a huge strength and distinguishes it from many of the traditional methods which are not able to detect or characterize a new or emerging pathogen.III. ENGINEERING TO ACCELERATE R&D AND IMPROVE CARE OF THE FUTURESeasonal influenza provides an example of a system of method-based opportunities.", [["influenza", "DISEASE", 277, 286], ["this methodbased approach", "TREATMENT", 28, 53], ["a new or emerging pathogen", "PROBLEM", 176, 202], ["THE FUTURESeasonal influenza", "PROBLEM", 258, 286], ["flexibility", "OBSERVATION_MODIFIER", 4, 15], ["new", "OBSERVATION_MODIFIER", 178, 181], ["pathogen", "OBSERVATION", 194, 202]]], ["The influenza virus changes genetically as it uses an error-prone enzyme to replicate its genome, and mutates further as it migrates from host-tohost, across speciesVe.g., waterfowl to humans, and across ecosystems of the environment.", [["influenza virus", "DISEASE", 4, 19], ["influenza virus", "ORGANISM", 4, 19], ["humans", "ORGANISM", 185, 191], ["error-prone enzyme", "PROTEIN", 54, 72], ["influenza virus", "SPECIES", 4, 19], ["humans", "SPECIES", 185, 191], ["influenza virus", "SPECIES", 4, 19], ["humans", "SPECIES", 185, 191], ["The influenza virus changes", "PROBLEM", 0, 27], ["an error-prone enzyme", "TEST", 51, 72], ["influenza virus", "OBSERVATION", 4, 19]]], ["This mutation process gives rise to a different population of viruses in circulation each year, and poses a challenge to vaccine manufacturers, as one year's vaccine will typically have little value when confronted with the next year's viral strains.", [["This mutation process", "PROBLEM", 0, 21], ["a challenge to vaccine manufacturers", "TREATMENT", 106, 142], ["viral strains", "PROBLEM", 236, 249], ["viruses", "OBSERVATION", 62, 69]]], ["Each year's vaccine is constructed specifically to protect against the strains that are projected to be dominant in the upcoming flu season.", [["the strains", "PROBLEM", 67, 78], ["dominant", "OBSERVATION_MODIFIER", 104, 112]]], ["The current process uses egg-based techniques for manufacturing influenza vaccine and has been successfully utilized for decades as have the techniques for isolating and identifying emerging strains of the virus.", [["influenza", "DISEASE", 64, 73], ["egg-based techniques", "TREATMENT", 25, 45], ["manufacturing influenza vaccine", "TREATMENT", 50, 81], ["the techniques", "TREATMENT", 137, 151], ["the virus", "PROBLEM", 202, 211]]], ["Unfortunately, the combined pipeline is relatively slow and does not typically allow for vaccine manufacturing to be based on strains that have been detected at the start of the flu seasonVvaccine production must be started earlier, and so relies heavily on imperfect predictions as to which strains of influenza will dominate.III. ENGINEERING TO ACCELERATE R&D AND IMPROVE CARE OF THE FUTURERNA sequence data provide a method-based framework for managing influenza response at the global scale.", [["Vvaccine", "CHEMICAL", 188, 196], ["influenza", "DISEASE", 303, 312], ["influenza", "DISEASE", 456, 465], ["Vvaccine", "SIMPLE_CHEMICAL", 188, 196], ["vaccine manufacturing", "TREATMENT", 89, 110], ["strains", "PROBLEM", 126, 133], ["influenza", "PROBLEM", 303, 312], ["THE FUTURERNA sequence data", "TEST", 382, 409], ["a method", "TREATMENT", 418, 426], ["managing influenza response", "PROBLEM", 447, 474]]], ["In addition to the detection and identification of the virus, sequence data can be utilized to compare and predict the performance of egg and other manufacturing approaches.", [["egg", "ANATOMY", 134, 137], ["egg", "ORGANISM_SUBSTANCE", 134, 137], ["the detection", "TEST", 15, 28], ["the virus", "PROBLEM", 51, 60], ["sequence data", "TEST", 62, 75]]], ["As the sequence, clinical, animal, and environmental data are accumulated, there is also the potential to support computational safety and efficacy screening.", [["efficacy screening", "TEST", 139, 157]]], ["Shortening the current timeline from detection through vaccination would have significant positive health benefits.", [["vaccination", "TREATMENT", 55, 66]]], ["There are method-based approaches to vaccine manufacturing with significant potential to improve upon the egg-based approach.", [["vaccine manufacturing", "TREATMENT", 37, 58], ["significant", "OBSERVATION_MODIFIER", 64, 75]]], ["Even though the influenza virus has only eight genes and an ominous history of multimillion death pandemics, the scientific understanding is not yet sufficient to avoid the thousands of deaths annually from seasonal influenza nor to mitigate the potential from a pandemic strain. complex samples to be converted to nucleic acid sequence data that are easily represented in a digital computer.", [["samples", "ANATOMY", 288, 295], ["influenza virus", "DISEASE", 16, 31], ["death", "DISEASE", 92, 97], ["deaths", "DISEASE", 186, 192], ["influenza", "DISEASE", 216, 225], ["nucleic acid", "CHEMICAL", 315, 327], ["influenza virus", "ORGANISM", 16, 31], ["influenza virus", "SPECIES", 16, 31], ["the influenza virus", "PROBLEM", 12, 31], ["multimillion death pandemics", "PROBLEM", 79, 107], ["seasonal influenza", "PROBLEM", 207, 225], ["a pandemic strain", "PROBLEM", 261, 278], ["complex samples", "TEST", 280, 295], ["nucleic acid sequence data", "TEST", 315, 341], ["influenza virus", "OBSERVATION", 16, 31]]], ["These data can be used as a framework or index for health and disease related metadata supporting correlative studies across species and providing insight into infectious diseases.", [["infectious diseases", "DISEASE", 160, 179], ["correlative studies", "TEST", 98, 117]]], ["Because genetic material is traded among organisms and is often part of complex nonlinear networks within an organism and beyond, increased collection and interpretation of the associations across DNA sequence and metadata are needed.", [["DNA", "CELLULAR_COMPONENT", 197, 200], ["DNA sequence", "DNA", 197, 209], ["genetic material", "PROBLEM", 8, 24], ["complex nonlinear networks", "PROBLEM", 72, 98], ["increased collection", "PROBLEM", 130, 150], ["DNA sequence", "TEST", 197, 209], ["increased", "OBSERVATION_MODIFIER", 130, 139], ["collection", "OBSERVATION", 140, 150]]], ["A digital immune system for individuals and populations is envisioned that identifies causation and intervention options to support patient-specific and public health interventions.Fitch: Engineering a Global Response to Infectious DiseasesBiocontainment laboratories are needed to safely conduct the research needed to understand pathogens as well as analyze clinical samples.", [["Infectious Diseases", "DISEASE", 221, 240], ["patient", "ORGANISM", 132, 139], ["patient", "SPECIES", 132, 139], ["A digital immune system", "TEST", 0, 23], ["intervention options", "TREATMENT", 100, 120], ["public health interventions", "TREATMENT", 153, 180], ["Biocontainment laboratories", "TEST", 240, 267], ["pathogens", "PROBLEM", 331, 340]]], ["Characterization of existing pathogens increases understanding of current diseases and also helps to prepare for emerging diseases.", [["existing pathogens", "PROBLEM", 20, 38], ["current diseases", "PROBLEM", 66, 82], ["emerging diseases", "PROBLEM", 113, 130], ["pathogens", "OBSERVATION", 29, 38]]], ["Laboratories that work with infectious agents are categorized by biosafety level (BSL) ranging from a basic biomedical laboratory (BSL-1) to BSL-4 laboratories (Fig. 3 ) that can safely handle untreatable disease agents [35] .", [["infectious agents", "TREATMENT", 28, 45], ["BSL", "TEST", 131, 134], ["BSL", "TEST", 141, 144], ["untreatable disease agents", "PROBLEM", 193, 219]]], ["The engineering systems for automatically controlling airflow and other facility safety components are critical for supporting clinical and research laboratories.", [["automatically controlling airflow", "PROBLEM", 28, 61]]], ["Infectious disease research is benefiting from ''omic'' methods for characterizing proteins (proteomics), metabolites (metabolomics), messenger RNA (transcriptomics), etc. In order to safely produce genomic data more quickly, DNA sequencing instruments have been moved into our biocontainment laboratories.", [["Infectious disease", "DISEASE", 0, 18], ["DNA", "CELLULAR_COMPONENT", 226, 229], ["messenger RNA", "RNA", 134, 147], ["metabolites (metabolomics", "TEST", 106, 131], ["messenger RNA", "PROBLEM", 134, 147], ["genomic data", "PROBLEM", 199, 211], ["DNA sequencing instruments", "TREATMENT", 226, 252]]], ["These methods produce large volumes of data, requiring research and clinical labs to have access to traditional engineering disciplines in data management and analysis.Fitch: Engineering a Global Response to Infectious DiseasesData management is not the only challenge.", [["Infectious Diseases", "DISEASE", 208, 227], ["clinical labs", "TEST", 68, 81], ["traditional engineering disciplines", "TREATMENT", 100, 135], ["data management", "TREATMENT", 139, 154], ["analysis", "TEST", 159, 167], ["large", "OBSERVATION_MODIFIER", 22, 27], ["volumes", "OBSERVATION_MODIFIER", 28, 35]]], ["So far, our descriptions have implied a single host interacting with a single invading pathogenVthe war metaphor.", [["a single invading pathogen", "PROBLEM", 69, 95]]], ["For instance, the eradication of smallpox was accomplished through an aggressive worldwide campaign as was the animal and livestock disease rinderpest [36] .", [["smallpox", "DISEASE", 33, 41], ["livestock disease rinderpest", "DISEASE", 122, 150], ["smallpox", "TREATMENT", 33, 41], ["the animal and livestock disease rinderpest", "PROBLEM", 107, 150], ["aggressive", "OBSERVATION_MODIFIER", 70, 80], ["livestock disease", "OBSERVATION", 122, 139]]], ["It is that the war metaphor is an oversimplification with an often unrealizable aspiration for victory.", [["aspiration", "OBSERVATION", 80, 90]]], ["Consider that most hosts, including bacteria, have associated pathogens and symbiotic microbes.Fitch: Engineering a Global Response to Infectious DiseasesFor example, a tropical grass, fungus, and virus have been found to have a three-way symbiosis that confers heat tolerance [37] .", [["Infectious Diseases", "DISEASE", 135, 154], ["bacteria", "PROBLEM", 36, 44], ["associated pathogens and symbiotic microbes", "PROBLEM", 51, 94], ["a tropical grass, fungus", "PROBLEM", 167, 191], ["virus", "PROBLEM", 197, 202], ["symbiotic microbes", "OBSERVATION", 76, 94]]], ["When the virus is removed from the fungus, thermal tolerance is lost by the grass.", [["the virus", "PROBLEM", 5, 14], ["the fungus", "PROBLEM", 31, 41], ["virus", "OBSERVATION", 9, 14], ["fungus", "OBSERVATION", 35, 41]]], ["If the virus is reintroduced to the fungus, thermal tolerance is conferred to the grass.", [["the virus", "PROBLEM", 3, 12], ["virus", "OBSERVATION", 7, 12]]], ["Viruses can also integrate their genes into animal genomes as part of the animal's nuclear DNA affecting inherited traits [38] .", [["nuclear", "ANATOMY", 83, 90], ["nuclear DNA", "CELLULAR_COMPONENT", 83, 94], ["animal genomes", "DNA", 44, 58], ["animal's nuclear DNA", "DNA", 74, 94], ["Viruses", "PROBLEM", 0, 7]]], ["Virus infection is one of several naturally occurring changes in the nucleic acid of a genome.Fitch: Engineering a Global Response to Infectious DiseasesEven simple nucleic acid transfers among different biological entities often have difficult to predict results.", [["Virus infection", "DISEASE", 0, 15], ["nucleic acid", "CHEMICAL", 69, 81], ["Infectious Diseases", "DISEASE", 134, 153], ["nucleic acid", "CHEMICAL", 165, 177], ["Virus", "ORGANISM", 0, 5], ["Virus infection", "PROBLEM", 0, 15], ["Infectious Diseases", "PROBLEM", 134, 153], ["simple nucleic acid transfers", "PROBLEM", 158, 187], ["infection", "OBSERVATION", 6, 15], ["one of several naturally occurring", "OBSERVATION_MODIFIER", 19, 53], ["nucleic acid", "OBSERVATION", 69, 81]]], ["The complexity compounds as the number of entities increases and community behaviors emerge.Fitch: Engineering a Global Response to Infectious DiseasesFor each of the approximately one trillion human cells in our bodies, there are about ten microbes.", [["cells", "ANATOMY", 200, 205], ["Infectious Diseases", "DISEASE", 132, 151], ["human", "ORGANISM", 194, 199], ["cells", "CELL", 200, 205], ["human cells", "CELL_TYPE", 194, 205], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 194, 199], ["Infectious Diseases", "PROBLEM", 132, 151], ["complexity", "OBSERVATION_MODIFIER", 4, 14], ["compounds", "OBSERVATION_MODIFIER", 15, 24], ["increases", "OBSERVATION_MODIFIER", 51, 60], ["Infectious", "OBSERVATION", 132, 142]]], ["The microbes are distributed in different, highly specialized, communities in the gut, mouth, skin, etc. collectively referred to as the microbiota [39] , [40] .", [["communities", "ANATOMY", 63, 74], ["gut", "ANATOMY", 82, 85], ["mouth", "ANATOMY", 87, 92], ["skin", "ANATOMY", 94, 98], ["gut", "ORGANISM_SUBDIVISION", 82, 85], ["mouth", "ORGANISM_SUBDIVISION", 87, 92], ["skin", "ORGAN", 94, 98], ["microbes", "OBSERVATION", 4, 12], ["distributed", "OBSERVATION_MODIFIER", 17, 28], ["different", "OBSERVATION_MODIFIER", 32, 41], ["communities", "OBSERVATION_MODIFIER", 63, 74], ["gut", "ANATOMY", 82, 85], ["mouth", "ANATOMY", 87, 92], ["skin", "ANATOMY", 94, 98]]], ["Given a global population over 7 billion, there are approximately 10 23 cells/microbes associated with people on the planet.", [["cells", "ANATOMY", 72, 77], ["cells", "CELL", 72, 77], ["people", "ORGANISM", 103, 109], ["people", "SPECIES", 103, 109], ["global", "OBSERVATION_MODIFIER", 8, 14], ["population", "OBSERVATION_MODIFIER", 15, 25]]], ["Engineering, process, and other controls allow important infectious disease experiments to be conducted safely.", [["important infectious disease experiments", "PROBLEM", 47, 87]]], ["Representative Biosafety Level (BSL) labs are shown.", [["Representative Biosafety Level", "TEST", 0, 30], ["labs", "TEST", 37, 41]]], ["BSL-1 is for agents not known to cause disease in normal, healthy humans.", [["BSL-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["humans", "ORGANISM", 66, 72], ["humans", "SPECIES", 66, 72], ["humans", "SPECIES", 66, 72], ["agents", "TREATMENT", 13, 19], ["disease", "PROBLEM", 39, 46], ["normal", "OBSERVATION", 50, 56]]], ["BSL-2 is for moderate-risk agents that may cause disease of varying severity through ingestion or percutaneous or mucous membrane exposure.", [["percutaneous", "ANATOMY", 98, 110], ["mucous membrane", "ANATOMY", 114, 129], ["BSL-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 114, 129], ["moderate-risk agents", "PROBLEM", 13, 33], ["disease", "PROBLEM", 49, 56], ["varying severity through ingestion", "PROBLEM", 60, 94], ["percutaneous or mucous membrane exposure", "PROBLEM", 98, 138], ["may cause", "UNCERTAINTY", 39, 48], ["varying", "OBSERVATION_MODIFIER", 60, 67], ["severity", "OBSERVATION_MODIFIER", 68, 76], ["mucous membrane exposure", "OBSERVATION", 114, 138]]], ["BSL-3 is for agents with a known potential for aerosol transmission and that may cause serious and potentially lethal infections.", [["infections", "DISEASE", 118, 128], ["BSL-3", "GENE_OR_GENE_PRODUCT", 0, 5], ["agents", "TREATMENT", 13, 19], ["aerosol transmission", "TREATMENT", 47, 67], ["lethal infections", "PROBLEM", 111, 128], ["may cause", "UNCERTAINTY", 77, 86], ["lethal", "OBSERVATION_MODIFIER", 111, 117], ["infections", "OBSERVATION", 118, 128]]], ["BSL-4 is for agents that pose a high individual risk of life-threatening disease resulting from exposure to infectious aerosols, or for agents where the risk of aerosol transmission is unknown.", [["BSL-4", "CHEMICAL", 0, 5], ["BSL-4", "GENE_OR_GENE_PRODUCT", 0, 5], ["agents", "TREATMENT", 13, 19], ["life-threatening disease", "PROBLEM", 56, 80], ["infectious aerosols", "TREATMENT", 108, 127], ["agents", "TREATMENT", 136, 142], ["aerosol transmission", "PROBLEM", 161, 181], ["threatening", "OBSERVATION_MODIFIER", 61, 72], ["disease", "OBSERVATION", 73, 80]]], ["Agents appropriate for this level have no vaccine available, and infection resulting from exposure has no treatment other than supportive care.", [["infection", "DISEASE", 65, 74], ["Agents", "TREATMENT", 0, 6], ["vaccine", "TREATMENT", 42, 49], ["infection", "PROBLEM", 65, 74], ["treatment", "TREATMENT", 106, 115], ["supportive care", "TREATMENT", 127, 142], ["infection", "OBSERVATION", 65, 74]]], ["The global ecosystem is a highly interconnected network of hosts and environments each with its own associated microbiome.", [["global", "OBSERVATION_MODIFIER", 4, 10], ["ecosystem", "OBSERVATION", 11, 20]]], ["Nucleic acids, chemicals, and energy are shared within each environment as well as across the global network.", [["Nucleic acids", "CHEMICAL", 0, 13], ["Nucleic acids", "SIMPLE_CHEMICAL", 0, 13], ["Nucleic acids", "TEST", 0, 13], ["acids", "OBSERVATION_MODIFIER", 8, 13]]], ["New approaches are needed to visualize and understand the relationships among these environments to improve infectious disease management.Fitch: Engineering a Global Response to Infectious DiseasesFitch: Engineering a Global Response to Infectious Diseases been estimated that there are 10 27 cells of Prochlorococcus bacteria in the ocean [41] .", [["cells", "ANATOMY", 293, 298], ["Infectious Diseases", "DISEASE", 178, 197], ["Infectious Diseases", "DISEASE", 237, 256], ["cells", "CELL", 293, 298], ["Prochlorococcus bacteria", "CELL", 302, 326], ["infectious disease management", "TREATMENT", 108, 137], ["Prochlorococcus bacteria", "PROBLEM", 302, 326]]], ["Equally impressive, there are 10 30 viruses in the ocean causing roughly 10 23 viral infections every second [42] .", [["viral infections", "DISEASE", 79, 95], ["viral infections", "PROBLEM", 79, 95], ["impressive", "OBSERVATION_MODIFIER", 8, 18]]], ["As represented in Fig. 4 , whether, grass, animals, or humans, the microbes, the communities, and their host community are sharing chemicals, energy, and nucleic acids.Fitch: Engineering a Global Response to Infectious DiseasesIt is no surprise that clinical, animal, environmental, and other samples often have significant genetic complexity.", [["communities", "ANATOMY", 81, 92], ["nucleic acids", "CHEMICAL", 154, 167], ["Infectious Diseases", "DISEASE", 208, 227], ["humans", "ORGANISM", 55, 61], ["nucleic acids", "SIMPLE_CHEMICAL", 154, 167], ["humans", "SPECIES", 55, 61], ["humans", "SPECIES", 55, 61], ["nucleic acids", "TREATMENT", 154, 167], ["significant genetic complexity", "PROBLEM", 312, 342], ["Infectious", "OBSERVATION", 208, 218], ["no", "UNCERTAINTY", 233, 235]]], ["Information visualization tools like Krona (Fig. 5) , support analysis of complex metagenomic data [43] .", [["Information visualization tools", "TEST", 0, 31]]], ["These types of data can be used to support many applications including investigating food borne disease outbreaks [44] .", [["food borne disease", "DISEASE", 85, 103], ["many applications", "TREATMENT", 43, 60]]], ["Genomics helped explain the initiation of the Ebola outbreak in Sierra Leone in 2014 [45] .", [["Ebola", "DISEASE", 46, 51], ["Ebola", "ORGANISM", 46, 51]]], ["Genomes from 99 virus samples from 78 patients provided evidence that the index case and associated thirteen initial cases in Sierra Leone had attended the funeral of a traditional healer that had been seeing Ebola patients from nearby Guinea.", [["samples", "ANATOMY", 22, 29], ["Ebola", "DISEASE", 209, 214], ["patients", "ORGANISM", 38, 46], ["Ebola", "ORGANISM", 209, 214], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 215, 223], ["virus samples", "TEST", 16, 29]]], ["The sequence data also showed mutations in parts of the genome that might impact diagnostics, vaccines and therapies.", [["The sequence data", "TEST", 0, 17], ["mutations", "PROBLEM", 30, 39], ["vaccines", "TREATMENT", 94, 102], ["therapies", "TREATMENT", 107, 116]]], ["Even though the West Africa Ebola virus disease (EVD) epidemic is by far the largest to date, fortunately ''the clinical course of infection and the transmissibility of the virus are similar to those in previous EVD outbreaks'' [46] .", [["Ebola virus disease", "DISEASE", 28, 47], ["EVD", "DISEASE", 49, 52], ["infection", "DISEASE", 131, 140], ["West Africa Ebola virus", "ORGANISM", 16, 39], ["Ebola virus", "SPECIES", 28, 39], ["West Africa Ebola virus", "SPECIES", 16, 39], ["the West Africa Ebola virus disease", "PROBLEM", 12, 47], ["epidemic", "PROBLEM", 54, 62], ["infection", "PROBLEM", 131, 140], ["the virus", "PROBLEM", 169, 178], ["infection", "OBSERVATION", 131, 140], ["virus", "OBSERVATION", 173, 178]]], ["The goal is to be able to make these clinically relevant assessments from the virus genome prospectivelyVi.e., before the epidemic provides the observations.Fitch: Engineering a Global Response to Infectious DiseasesComputational algorithms and tools are available to find signatures of existing pathogens as well as recognize patterns that help identify previously unidentified pathogens.", [["Infectious Diseases", "DISEASE", 197, 216], ["Computational algorithms", "TEST", 216, 240], ["existing pathogens", "PROBLEM", 287, 305], ["previously unidentified pathogens", "PROBLEM", 355, 388]]], ["For instance, going beyond detecting disease outbreaks to being able to assess and predict disease risks is desired.", [["disease outbreaks", "PROBLEM", 37, 54], ["disease risks", "PROBLEM", 91, 104]]], ["These much more complicated models offer the potential to accelerate disease understanding and the development and safe utilization of medical interventions at both the individual and the global scales.", [["medical interventions", "TREATMENT", 135, 156]]], ["There are multiple initiatives underway that will lay the foundation and strengthen the underlying science.", [["multiple", "OBSERVATION_MODIFIER", 10, 18]]], ["The foundation will enable new engineering approaches that will achieve the greater goals for infectious disease management.Fitch: Engineering a Global Response to Infectious DiseasesUsing an approach that parallels the evolution of electrical circuit design and fabrication, the BioBricks approach is having increasing impact [47] .", [["Infectious Diseases", "DISEASE", 164, 183], ["new engineering approaches", "TREATMENT", 27, 53], ["infectious disease management", "TREATMENT", 94, 123], ["an approach", "TREATMENT", 189, 200], ["electrical circuit design", "TREATMENT", 233, 258], ["fabrication", "TREATMENT", 263, 274], ["the BioBricks approach", "TREATMENT", 276, 298], ["electrical circuit", "OBSERVATION", 233, 251]]], ["Just as early circuit designers benefited from standards for circuit fabrication, design, interfaces and modules, aspects of biology are amenable to these approaches.", [["circuit fabrication", "TREATMENT", 61, 80]]], ["Not only does the approach provide validation of reductionist concepts of each ''brick,'' but the innovative integration of parts also contributes to the characterization and future sharing of more complicated parts.", [["reductionist concepts", "TREATMENT", 49, 70], ["each ''brick", "TREATMENT", 74, 86], ["the characterization", "TEST", 150, 170]]], ["For instance, a rewritable digital memory system has been demonstrated that writes and rewrites nucleic acid bases in a chromosome [49] .", [["chromosome", "ANATOMY", 120, 130], ["nucleic acid", "CHEMICAL", 96, 108], ["chromosome", "CELLULAR_COMPONENT", 120, 130]]], ["Just as DNA sequencing brought a methods-based structure to pathogen detection, approaches like BioBricks bring structure to biological circuits.", [["DNA", "CELLULAR_COMPONENT", 8, 11], ["DNA sequencing", "TEST", 8, 22], ["pathogen detection", "TEST", 60, 78]]], ["The electronic circuit analogy continues with the opportunity for software to facilitate design and accelerate testing and evaluation.", [["accelerate testing", "TEST", 100, 118], ["evaluation", "TEST", 123, 133]]], ["Just as in our early example for influenza vaccine development, the components of the BioBricks approach are amenable to spiral engineering for both performance and cost.Fitch: Engineering a Global Response to Infectious DiseasesBuilding computer architectures and software that can implement ab initio test and evaluation calculations for infectious disease trials would require significant advances in algorithms, capabilities, and fundamental biochemical data.", [["influenza", "DISEASE", 33, 42], ["Infectious Diseases", "DISEASE", 210, 229], ["infectious disease", "DISEASE", 340, 358], ["influenza vaccine", "TREATMENT", 33, 50], ["the BioBricks approach", "TREATMENT", 82, 104], ["spiral engineering", "TREATMENT", 121, 139], ["ab initio test", "TEST", 293, 307], ["evaluation calculations", "TEST", 312, 335], ["infectious disease trials", "TREATMENT", 340, 365], ["algorithms", "TEST", 404, 414], ["capabilities", "TEST", 416, 428], ["fundamental biochemical data", "TEST", 434, 462]]], ["This is the domain of systems biology and the building blocks can include DNA, RNA, and peptides.Fitch: Engineering a Global Response to Infectious DiseasesProgress in systems biology is often paced by access to appropriately curated and calibrated dataVnot just the underlying nucleic acid content but the associated metadata that describe the host and the relevant associated microbial communities.", [["Infectious Diseases", "DISEASE", 137, 156], ["nucleic acid", "CHEMICAL", 278, 290], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["V", "GENE_OR_GENE_PRODUCT", 253, 254], ["the building blocks", "TREATMENT", 42, 61], ["DNA, RNA, and peptides", "PROBLEM", 74, 96], ["the underlying nucleic acid content", "PROBLEM", 263, 298], ["nucleic", "OBSERVATION", 278, 285], ["acid content", "OBSERVATION", 286, 298]]], ["This project is measuring multiple indicators of health over a nine month period and will include lifestyle coaching as part of the study [50] .", [["lifestyle coaching", "TREATMENT", 98, 116], ["the study", "TEST", 128, 137], ["multiple", "OBSERVATION_MODIFIER", 26, 34]]], ["If successful, the project already has plans to scale to a thousand and then 100 thousand participants.", [["participants", "SPECIES", 90, 102]]], ["There are similar concepts underway at organizations as diverse as Google X and Human Longevity.", [["Human", "ORGANISM", 80, 85], ["Human", "SPECIES", 80, 85]]], ["Even though these studies do not focus on infectious diseases, they are of significant value in helping to define the baselines for ''normal'' at different ages, genders, and many other variations that may affect health.IV. OPPORTUNITIESInfectious disease is a global issue that remains a significant cause of death and economic impact.", [["infectious diseases", "DISEASE", 42, 61], ["death", "DISEASE", 310, 315], ["these studies", "TEST", 12, 25], ["infectious diseases", "PROBLEM", 42, 61], ["OPPORTUNITIESInfectious disease", "PROBLEM", 224, 255], ["death", "PROBLEM", 310, 315], ["economic impact", "PROBLEM", 320, 335], ["disease", "OBSERVATION", 248, 255], ["global", "OBSERVATION_MODIFIER", 261, 267]]], ["Engineers and engineering have many opportunities to help mitigate these diseases ranging from using cell tower power to help deliver vaccines to providing new network analysis software to identify novel viruses in an outbreak.IV. OPPORTUNITIESThe joint evolution of engineering and life sciences brings expanded availability and opportunity to understand and design living systems.", [["cell", "ANATOMY", 101, 105], ["cell", "CELL", 101, 105], ["these diseases", "PROBLEM", 67, 81], ["cell tower power", "TREATMENT", 101, 117], ["deliver vaccines", "TREATMENT", 126, 142], ["novel viruses", "PROBLEM", 198, 211], ["joint", "ANATOMY", 248, 253]]], ["These are attributes that will be needed to address the medical and infrastructure needs for effective global infectious disease management.", [["infectious disease", "DISEASE", 110, 128], ["effective global infectious disease management", "TREATMENT", 93, 139], ["infectious", "OBSERVATION", 110, 120]]], ["Engineers have an opportunity to provide innovative application of existing infrastructure to infectious disease management and to help nurture a global culture of responsibility in both healthcare and technical applications. h", [["infectious disease", "DISEASE", 94, 112], ["innovative application", "TREATMENT", 41, 63], ["infectious disease management", "TREATMENT", 94, 123], ["a global culture", "TEST", 144, 160]]]], "PMC3846606": [["IntroductionVaricella zoster virus (VZV) is a neurotropic alphaherpesvirus and the etiological agent of varicella (chickenpox) and herpes zoster (shingles).", [["Varicella zoster", "DISEASE", 12, 28], ["neurotropic alphaherpesvirus", "DISEASE", 46, 74], ["varicella", "DISEASE", 104, 113], ["chickenpox", "DISEASE", 115, 125], ["herpes zoster", "DISEASE", 131, 144], ["shingles", "DISEASE", 146, 154], ["Varicella zoster virus", "ORGANISM", 12, 34], ["VZV", "ORGANISM", 36, 39], ["herpes zoster", "ORGANISM", 131, 144], ["Varicella zoster virus", "SPECIES", 12, 34], ["herpes zoster", "SPECIES", 131, 144], ["Varicella zoster virus", "SPECIES", 12, 34], ["VZV", "SPECIES", 36, 39], ["IntroductionVaricella zoster virus", "PROBLEM", 0, 34], ["VZV", "PROBLEM", 36, 39], ["a neurotropic alphaherpesvirus", "PROBLEM", 44, 74], ["varicella (chickenpox)", "PROBLEM", 104, 126], ["herpes zoster (shingles)", "PROBLEM", 131, 155], ["Varicella zoster virus", "OBSERVATION", 12, 34]]], ["VZV establishes latency within the sensory ganglia, and reactivation from latency can cause significant morbidity and occasionally mortality in older and immunocompromised individuals.", [["sensory ganglia", "ANATOMY", 35, 50], ["VZV", "ORGANISM", 0, 3], ["sensory ganglia", "MULTI-TISSUE_STRUCTURE", 35, 50], ["VZV", "SPECIES", 0, 3], ["VZV", "PROBLEM", 0, 3], ["significant morbidity", "PROBLEM", 92, 113], ["immunocompromised individuals", "PROBLEM", 154, 183], ["latency", "OBSERVATION_MODIFIER", 16, 23], ["sensory ganglia", "ANATOMY", 35, 50], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["morbidity", "OBSERVATION", 104, 113], ["immunocompromised", "OBSERVATION", 154, 171]]], ["Currently the FDA vaccine Zostavax\u00ae reduces the incidence of shingles by 51% and the burden of disease by approximately 61% [1,2].", [["Zostavax", "CHEMICAL", 26, 34], ["shingles", "DISEASE", 61, 69], ["the FDA vaccine Zostavax", "TREATMENT", 10, 34], ["shingles", "TREATMENT", 61, 69], ["disease", "PROBLEM", 95, 102]]], ["Thus, a significant portion of vaccine recipients still remains susceptible to VZV reactivation.", [["recipients", "ORGANISM", 39, 49], ["VZV", "ORGANISM", 79, 82], ["VZV", "SPECIES", 79, 82], ["vaccine recipients", "TREATMENT", 31, 49], ["VZV reactivation", "PROBLEM", 79, 95], ["significant", "OBSERVATION_MODIFIER", 8, 19], ["VZV reactivation", "OBSERVATION", 79, 95]]], ["To improve vaccine efficacy, we need to determine the function of the viral open reading frames (ORFs) that contribute to VZV pathogenesis and those that are important for the host immune response.IntroductionSimian varicella virus (SVV) is a homolog of VZV that causes varicella-like disease and establishes latency in sensory ganglia of rhesus macaques [3-5].", [["sensory ganglia", "ANATOMY", 320, 335], ["varicella virus", "DISEASE", 216, 231], ["varicella-like disease", "DISEASE", 270, 292], ["VZV", "ORGANISM", 122, 125], ["IntroductionSimian varicella virus", "ORGANISM", 197, 231], ["SVV", "ORGANISM", 233, 236], ["VZV", "ORGANISM", 254, 257], ["sensory ganglia", "ORGAN", 320, 335], ["rhesus", "ORGANISM", 339, 345], ["macaques", "ORGANISM", 346, 354], ["viral open reading frames", "DNA", 70, 95], ["ORFs", "DNA", 97, 101], ["IntroductionSimian varicella virus", "SPECIES", 197, 231], ["rhesus macaques", "SPECIES", 339, 354], ["VZV", "SPECIES", 122, 125], ["IntroductionSimian varicella virus", "SPECIES", 197, 231], ["SVV", "SPECIES", 233, 236], ["VZV", "SPECIES", 254, 257], ["rhesus macaques", "SPECIES", 339, 354], ["vaccine efficacy", "TREATMENT", 11, 27], ["the viral open reading frames", "PROBLEM", 66, 95], ["VZV pathogenesis", "PROBLEM", 122, 138], ["IntroductionSimian varicella virus", "PROBLEM", 197, 231], ["VZV", "PROBLEM", 254, 257], ["varicella-like disease", "PROBLEM", 270, 292], ["VZV", "OBSERVATION", 122, 125], ["varicella virus", "OBSERVATION", 216, 231], ["varicella", "OBSERVATION", 270, 279], ["latency", "OBSERVATION_MODIFIER", 309, 316], ["sensory ganglia", "ANATOMY", 320, 335]]], ["SVV shares significant DNA homology and genome colinearity with VZV [6-9].", [["SVV", "ORGANISM", 0, 3], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["VZV", "ORGANISM", 64, 67], ["SVV", "SPECIES", 0, 3], ["VZV", "SPECIES", 64, 67], ["SVV", "TEST", 0, 3], ["significant DNA homology", "PROBLEM", 11, 35], ["VZV", "TEST", 64, 67], ["genome colinearity", "OBSERVATION", 40, 58]]], ["VZV and SVV have the smallest genomes of the herpesvirus family.", [["VZV", "ORGANISM", 0, 3], ["SVV", "ORGANISM", 8, 11], ["herpesvirus", "ORGANISM", 45, 56], ["VZV", "SPECIES", 0, 3], ["SVV", "SPECIES", 8, 11], ["VZV", "PROBLEM", 0, 3], ["SVV", "TEST", 8, 11], ["SVV", "ANATOMY", 8, 11], ["smallest", "OBSERVATION_MODIFIER", 21, 29]]], ["VZV encodes at least 70 unique ORFs and SVV encodes 69 distinct ORFs [8,10].", [["VZV", "ORGANISM", 0, 3], ["ORFs", "DNA", 31, 35], ["SVV", "DNA", 40, 43], ["ORFs", "DNA", 64, 68], ["VZV", "SPECIES", 0, 3], ["VZV encodes", "PROBLEM", 0, 11], ["SVV encodes", "TEST", 40, 51], ["distinct ORFs", "TEST", 55, 68]]], ["Despite the smaller genome size and homology to herpes simplex virus (HSV), a number of VZV/SVV genes remain functionally uncharacterized.", [["herpes simplex virus", "DISEASE", 48, 68], ["herpes simplex virus", "ORGANISM", 48, 68], ["HSV", "ORGANISM", 70, 73], ["VZV", "ORGANISM", 88, 91], ["SVV", "ORGANISM", 92, 95], ["VZV/SVV genes", "DNA", 88, 101], ["herpes simplex virus", "SPECIES", 48, 68], ["herpes simplex virus", "SPECIES", 48, 68], ["HSV", "SPECIES", 70, 73], ["VZV", "SPECIES", 88, 91], ["SVV", "SPECIES", 92, 95], ["the smaller genome size", "PROBLEM", 8, 31], ["herpes simplex virus (HSV", "PROBLEM", 48, 73], ["VZV/SVV genes", "TEST", 88, 101], ["smaller", "OBSERVATION_MODIFIER", 12, 19], ["genome", "OBSERVATION_MODIFIER", 20, 26], ["size", "OBSERVATION_MODIFIER", 27, 31], ["herpes simplex virus", "OBSERVATION", 48, 68], ["VZV", "OBSERVATION", 88, 91], ["SVV genes", "OBSERVATION", 92, 101]]], ["Studies characterizing viral gene function utilizing in vitro tissue culture models do not always model the complex host-pathogen relationship that occurs in vivo.", [["tissue culture", "ANATOMY", 62, 76], ["Studies", "TEST", 0, 7], ["viral gene function", "PROBLEM", 23, 42], ["vitro tissue culture models", "TEST", 56, 83], ["viral gene function", "OBSERVATION", 23, 42]]], ["Recently, with the construction of an infectious SVV bacterial artificial chromosome (BAC), the production of mutations and deletions in specific SVV ORFs will allow the investigation of gene function during in vivo infection [11].", [["chromosome", "ANATOMY", 74, 84], ["BAC", "ANATOMY", 86, 89], ["infection", "DISEASE", 216, 225], ["chromosome", "CELLULAR_COMPONENT", 74, 84], ["BAC", "CELLULAR_COMPONENT", 86, 89], ["infectious SVV bacterial artificial chromosome", "DNA", 38, 84], ["BAC", "DNA", 86, 89], ["SVV ORFs", "DNA", 146, 154], ["SVV", "SPECIES", 146, 149], ["an infectious SVV bacterial artificial chromosome (BAC)", "PROBLEM", 35, 90], ["mutations", "PROBLEM", 110, 119], ["deletions in specific SVV ORFs", "PROBLEM", 124, 154], ["gene function", "PROBLEM", 187, 200], ["vivo infection", "PROBLEM", 211, 225], ["infectious", "OBSERVATION", 38, 48], ["artificial chromosome", "OBSERVATION", 63, 84]]], ["Previously, SVV BAC was shown to generate infectious virus with molecular properties and in vitro replication kinetics comparable to wild-type (WT) SVV [11].", [["SVV", "ORGANISM", 12, 15], ["wild-type (WT) SVV", "ORGANISM", 133, 151], ["SVV BAC", "DNA", 12, 19], ["SVV", "SPECIES", 12, 15], ["SVV BAC", "TEST", 12, 19], ["infectious virus", "PROBLEM", 42, 58], ["vitro replication kinetics", "TREATMENT", 92, 118], ["SVV", "TEST", 148, 151], ["infectious", "OBSERVATION", 42, 52]]], ["SVV BAC was also used to generate an ORF10 deletion virus, which demonstrated that SVV ORF10 is nonessential for replication in vitro[11].", [["SVV", "ORGANISM", 0, 3], ["ORF10", "GENE_OR_GENE_PRODUCT", 37, 42], ["SVV", "ORGANISM", 83, 86], ["ORF10", "GENE_OR_GENE_PRODUCT", 87, 92], ["SVV BAC", "DNA", 0, 7], ["SVV ORF10", "DNA", 83, 92], ["SVV", "SPECIES", 0, 3], ["SVV", "SPECIES", 83, 86], ["SVV BAC", "TEST", 0, 7], ["an ORF10 deletion virus", "PROBLEM", 34, 57], ["SVV", "TEST", 83, 86]]], ["In the current study we further investigate SVV BAC in vivo by monitoring replication kinetics, immune response and establishment of latency in rhesus macaques and show that SVV BAC is as pathogenic as WT SVV.Whole-genome analysis of SVV BAC ::: ResultsThe BAC derived SVV viral genome was comprehensively analyzed by comparative genomic hybridization (CGH) and directly compared to wild-type (WT) SVV.", [["SVV", "ORGANISM", 44, 47], ["rhesus", "ORGANISM", 144, 150], ["macaques", "ORGANISM", 151, 159], ["SVV", "ORGANISM", 174, 177], ["BAC", "ORGANISM", 178, 181], ["WT SVV", "ORGANISM", 202, 208], ["SVV", "ORGANISM", 234, 237], ["SVV", "ORGANISM", 269, 272], ["wild-type (WT) SVV", "ORGANISM", 383, 401], ["SVV BAC", "DNA", 44, 51], ["SVV BAC", "DNA", 174, 181], ["SVV BAC", "DNA", 234, 241], ["SVV viral genome", "DNA", 269, 285], ["rhesus macaques", "SPECIES", 144, 159], ["SVV", "SPECIES", 44, 47], ["rhesus macaques", "SPECIES", 144, 159], ["SVV", "SPECIES", 174, 177], ["SVV", "SPECIES", 205, 208], ["SVV", "SPECIES", 234, 237], ["the current study", "TEST", 3, 20], ["SVV BAC", "TREATMENT", 44, 51], ["latency in rhesus macaques", "PROBLEM", 133, 159], ["SVV BAC", "TEST", 174, 181], ["WT SVV", "TEST", 202, 208], ["The BAC derived SVV viral genome", "PROBLEM", 253, 285], ["SVV", "TEST", 398, 401], ["SVV BAC", "OBSERVATION", 234, 241], ["viral genome", "OBSERVATION", 273, 285]]], ["Using this technique, any differences in genomic sequence between SVV BAC and WT SVV results in variations in hybridization intensities to corresponding segments represented on the array, giving an altered hybridization ratio between SVV BAC and WT SVV (Figure 1A).", [["SVV BAC", "ORGANISM", 66, 73], ["WT SVV", "ORGANISM", 78, 84], ["SVV BAC", "DNA", 66, 73], ["SVV BAC", "DNA", 234, 241], ["this technique", "TREATMENT", 6, 20], ["genomic sequence", "TEST", 41, 57], ["SVV BAC", "TEST", 66, 73], ["WT SVV", "TEST", 78, 84], ["hybridization intensities", "TEST", 110, 135], ["an altered hybridization ratio", "PROBLEM", 195, 225], ["SVV BAC", "TEST", 234, 241], ["SVV BAC", "OBSERVATION", 234, 241]]], ["CGH analysis revealed that two areas displayed variations when compared to WT SVV, indicating differences in nucleotide sequence at these locations.", [["nucleotide", "CHEMICAL", 109, 119], ["nucleotide", "CHEMICAL", 109, 119], ["CGH analysis", "TEST", 0, 12], ["WT SVV", "TEST", 75, 81], ["differences in nucleotide sequence", "PROBLEM", 94, 128], ["two", "OBSERVATION_MODIFIER", 27, 30], ["areas", "OBSERVATION_MODIFIER", 31, 36], ["variations", "OBSERVATION_MODIFIER", 47, 57]]], ["These regions were amplified via PCR and directly sequenced resulting in the identification of two nucleotide substitutions that produced 1 missense mutation and 1 silent mutation within the coding region of the SVV BAC genome.", [["nucleotide", "CHEMICAL", 99, 109], ["nucleotide", "CHEMICAL", 99, 109], ["SVV BAC genome", "DNA", 212, 226], ["SVV", "SPECIES", 212, 215], ["PCR", "TEST", 33, 36], ["two nucleotide substitutions", "PROBLEM", 95, 123], ["1 missense mutation", "PROBLEM", 138, 157], ["1 silent mutation", "PROBLEM", 162, 179], ["nucleotide substitutions", "OBSERVATION", 99, 123], ["SVV", "ANATOMY", 212, 215], ["BAC genome", "OBSERVATION", 216, 226]]], ["Specifically, we identified a point mutation at nucleotide 41990 from G to A within ORF22, producing an amino acid change from valine to isoleucine (Figure 1B) and a transition of nucleotide 106546 from T to C producing a silent mutation within ORF62/71 (Figure 1C).", [["nucleotide", "CHEMICAL", 48, 58], ["amino acid", "CHEMICAL", 104, 114], ["valine", "CHEMICAL", 127, 133], ["isoleucine", "CHEMICAL", 137, 147], ["nucleotide 106546", "CHEMICAL", 180, 197], ["nucleotide", "CHEMICAL", 48, 58], ["amino acid", "CHEMICAL", 104, 114], ["valine", "CHEMICAL", 127, 133], ["isoleucine", "CHEMICAL", 137, 147], ["nucleotide", "CHEMICAL", 180, 190], ["ORF22", "GENE_OR_GENE_PRODUCT", 84, 89], ["amino acid", "AMINO_ACID", 104, 114], ["valine", "AMINO_ACID", 127, 133], ["isoleucine", "AMINO_ACID", 137, 147], ["T to C", "GENE_OR_GENE_PRODUCT", 203, 209], ["ORF22", "DNA", 84, 89], ["a point mutation", "PROBLEM", 28, 44], ["an amino acid change", "PROBLEM", 101, 121], ["valine to isoleucine", "TREATMENT", 127, 147], ["a transition of nucleotide", "TREATMENT", 164, 190], ["a silent mutation", "PROBLEM", 220, 237], ["amino acid", "OBSERVATION", 104, 114]]], ["The nucleotide change in ORF62/71 was also previously shown in the sequencing of an ORF61 deletion virus that was generated from the same parental SVV cosmid system [11-13].", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["ORF62/71", "GENE_OR_GENE_PRODUCT", 25, 33], ["ORF61", "GENE_OR_GENE_PRODUCT", 84, 89], ["ORF62/71", "DNA", 25, 33], ["The nucleotide change", "PROBLEM", 0, 21], ["an ORF61 deletion virus", "PROBLEM", 81, 104], ["change", "OBSERVATION_MODIFIER", 15, 21]]], ["SVV ORF22 is a putative tegument protein based on the function of herpes simplex virus type-1 (HSV-1) UL36 homolog.", [["tegument", "ANATOMY", 24, 32], ["herpes simplex", "DISEASE", 66, 80], ["SVV", "ORGANISM", 0, 3], ["ORF22", "GENE_OR_GENE_PRODUCT", 4, 9], ["herpes simplex virus type-1", "ORGANISM", 66, 93], ["HSV-1", "ORGANISM", 95, 100], ["UL36 homolog", "GENE_OR_GENE_PRODUCT", 102, 114], ["SVV ORF22", "PROTEIN", 0, 9], ["putative tegument protein", "PROTEIN", 15, 40], ["herpes simplex virus type-1 (HSV-1) UL36 homolog", "PROTEIN", 66, 114], ["herpes simplex virus type-1", "SPECIES", 66, 93], ["HSV-1", "SPECIES", 95, 100], ["SVV", "SPECIES", 0, 3], ["herpes simplex virus type-1", "SPECIES", 66, 93], ["HSV-1", "SPECIES", 95, 100], ["SVV", "TEST", 0, 3], ["a putative tegument protein", "TEST", 13, 40], ["herpes simplex virus type", "TEST", 66, 91], ["HSV", "TEST", 95, 98]]], ["The missense mutation in ORF22 did not render SVV BAC derived virus noninfectious or hamper replication kinetics and plaque size in vitro[11].Disease severity and viral load ::: ResultsRhesus macaques (RMs) were infected with SVV BAC or WT SVV at 4\u00d7105 PFU intrabronchially (n=4 per group, sex and age matched).", [["plaque", "ANATOMY", 117, 123], ["ORF22", "GENE_OR_GENE_PRODUCT", 25, 30], ["SVV BAC", "ORGANISM", 46, 53], ["plaque", "PATHOLOGICAL_FORMATION", 117, 123], ["ResultsRhesus macaques", "ORGANISM", 178, 200], ["SVV", "ORGANISM", 226, 229], ["ORF22", "DNA", 25, 30], ["ResultsRhesus macaques", "SPECIES", 178, 200], ["SVV", "SPECIES", 46, 49], ["SVV", "SPECIES", 226, 229], ["SVV", "SPECIES", 240, 243], ["The missense mutation", "PROBLEM", 0, 21], ["SVV BAC derived virus noninfectious", "PROBLEM", 46, 81], ["hamper replication kinetics", "PROBLEM", 85, 112], ["Disease severity", "PROBLEM", 142, 158], ["viral load", "TEST", 163, 173], ["SVV BAC", "TEST", 226, 233], ["WT SVV", "TEST", 237, 243], ["missense", "OBSERVATION", 4, 12], ["plaque", "OBSERVATION_MODIFIER", 117, 123], ["size", "OBSERVATION_MODIFIER", 124, 128], ["viral load", "OBSERVATION", 163, 173]]], ["We investigated the pathogenesis of BAC derived SVV in vivo by measuring disease progression, viral replication, immune response, and the establishment of latency compared to WT SVV.", [["SVV", "ORGANISM", 48, 51], ["SVV", "SPECIES", 178, 181], ["measuring disease progression", "PROBLEM", 63, 92], ["viral replication", "TREATMENT", 94, 111], ["latency", "PROBLEM", 155, 162], ["WT SVV", "TEST", 175, 181], ["viral replication", "OBSERVATION", 94, 111]]], ["We collected bronchoalveolar lavage (BAL) cells and blood (peripheral blood mononuclear cells, PBMC) at various days post-infection (dpi) and sensory ganglia were collected at necropsy (84\u201386 dpi).", [["bronchoalveolar lavage (BAL) cells", "ANATOMY", 13, 47], ["blood", "ANATOMY", 52, 57], ["peripheral blood mononuclear cells", "ANATOMY", 59, 93], ["PBMC", "ANATOMY", 95, 99], ["sensory ganglia", "ANATOMY", 142, 157], ["bronchoalveolar lavage (BAL) cells", "CELL", 13, 47], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["peripheral blood mononuclear cells", "CELL", 59, 93], ["PBMC", "CELL", 95, 99], ["sensory ganglia", "MULTI-TISSUE_STRUCTURE", 142, 157], ["bronchoalveolar lavage (BAL) cells", "CELL_TYPE", 13, 47], ["peripheral blood mononuclear cells", "CELL_TYPE", 59, 93], ["PBMC", "CELL_TYPE", 95, 99], ["bronchoalveolar lavage", "TEST", 13, 35], ["BAL) cells", "TEST", 37, 47], ["blood", "TEST", 52, 57], ["peripheral blood mononuclear cells", "TEST", 59, 93], ["PBMC", "TEST", 95, 99], ["dpi", "TEST", 133, 136], ["sensory ganglia", "PROBLEM", 142, 157], ["bronchoalveolar lavage", "OBSERVATION", 13, 35], ["sensory ganglia", "ANATOMY", 142, 157]]], ["All infected RMs displayed hallmarks of SVV infection including the development of rash, which lasted between 7 and 10 days.", [["SVV infection", "DISEASE", 40, 53], ["rash", "DISEASE", 83, 87], ["RMs", "ORGANISM", 13, 16], ["SVV", "ORGANISM", 40, 43], ["rash", "PATHOLOGICAL_FORMATION", 83, 87], ["SVV", "SPECIES", 40, 43], ["All infected RMs", "PROBLEM", 0, 16], ["SVV infection", "PROBLEM", 40, 53], ["rash", "PROBLEM", 83, 87], ["infected RMs", "OBSERVATION", 4, 16], ["hallmarks", "OBSERVATION_MODIFIER", 27, 36], ["SVV infection", "OBSERVATION", 40, 53], ["rash", "OBSERVATION", 83, 87]]], ["A representative RM infected with SVV BAC at 7 dpi is shown in Figure 2A and a representative RM infected with WT SVV at 7 dpi is shown in Figure 2B.", [["SVV", "ORGANISM", 34, 37], ["WT SVV", "ORGANISM", 111, 117], ["SVV BAC", "DNA", 34, 41], ["SVV", "SPECIES", 34, 37], ["SVV", "SPECIES", 114, 117], ["SVV BAC", "TREATMENT", 34, 41], ["WT SVV", "TREATMENT", 111, 117], ["infected", "OBSERVATION", 20, 28], ["SVV BAC", "OBSERVATION", 34, 41], ["infected", "OBSERVATION", 97, 105]]], ["A lesion area was biopsied at 10 dpi and viral loads were measured by quantitative real-time PCR (Figure 2C).", [["lesion area", "ANATOMY", 2, 13], ["lesion area", "CANCER", 2, 13], ["A lesion area", "PROBLEM", 0, 13], ["viral loads", "TEST", 41, 52], ["lesion", "OBSERVATION", 2, 8]]], ["By 10 dpi, we were able to detect viral DNA in all RMs except RMs 28553 and 28621 infected with WT SVV.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["WT SVV", "ORGANISM", 96, 102], ["viral DNA", "DNA", 34, 43], ["SVV", "SPECIES", 99, 102], ["viral DNA", "PROBLEM", 34, 43], ["RMs", "TEST", 62, 65], ["WT SVV", "TEST", 96, 102], ["viral DNA", "OBSERVATION", 34, 43]]], ["SVV viral loads were also measured by quantitative real-time PCR in BAL cells and whole blood samples.", [["BAL cells", "ANATOMY", 68, 77], ["whole blood samples", "ANATOMY", 82, 101], ["SVV", "ORGANISM", 0, 3], ["BAL cells", "CELL", 68, 77], ["blood samples", "ORGANISM_SUBSTANCE", 88, 101], ["BAL cells", "CELL_TYPE", 68, 77], ["SVV", "SPECIES", 0, 3], ["SVV viral loads", "TEST", 0, 15], ["BAL cells", "TEST", 68, 77], ["whole blood samples", "TEST", 82, 101], ["viral loads", "OBSERVATION", 4, 15], ["BAL cells", "OBSERVATION", 68, 77]]], ["BAL cell viral loads peaked at 3 dpi in both SVV BAC and WT SVV infected RMs then decreased to levels near or below our limit of detection by 63 dpi (Figure 2C).", [["BAL cell", "ANATOMY", 0, 8], ["BAL cell", "CELL", 0, 8], ["SVV", "ORGANISM", 45, 48], ["WT SVV", "ORGANISM", 57, 63], ["SVV", "SPECIES", 45, 48], ["SVV", "SPECIES", 60, 63], ["BAL cell viral loads", "TEST", 0, 20], ["SVV BAC", "TEST", 45, 52], ["WT SVV infected RMs", "PROBLEM", 57, 76], ["levels", "TEST", 95, 101], ["cell", "OBSERVATION", 4, 8], ["viral loads", "OBSERVATION", 9, 20], ["SVV BAC", "OBSERVATION", 45, 52], ["SVV", "OBSERVATION", 60, 63], ["infected RMs", "OBSERVATION", 64, 76]]], ["SVV viral loads in whole blood are significantly lower than in BAL cells, though we were able to detect SVV DNA in whole blood between 3 and 14 dpi in RMs infected with SVV BAC or WT SVV and then viral loads decreased to levels near or below our limit of detection (Figure 2D).", [["whole blood", "ANATOMY", 19, 30], ["BAL cells", "ANATOMY", 63, 72], ["whole blood", "ANATOMY", 115, 126], ["SVV", "ORGANISM", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["BAL cells", "CELL", 63, 72], ["SVV", "ORGANISM", 104, 107], ["DNA", "CELLULAR_COMPONENT", 108, 111], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["SVV", "ORGANISM", 169, 172], ["WT SVV", "ORGANISM", 180, 186], ["BAL cells", "CELL_TYPE", 63, 72], ["SVV DNA", "DNA", 104, 111], ["SVV", "SPECIES", 0, 3], ["SVV", "SPECIES", 104, 107], ["SVV", "SPECIES", 169, 172], ["SVV", "SPECIES", 183, 186], ["SVV viral loads", "TEST", 0, 15], ["whole blood", "TEST", 19, 30], ["BAL cells", "TEST", 63, 72], ["SVV DNA", "TEST", 104, 111], ["whole blood", "TEST", 115, 126], ["SVV BAC", "TEST", 169, 176], ["WT SVV", "TEST", 180, 186], ["viral loads", "TEST", 196, 207], ["viral loads", "OBSERVATION", 4, 15], ["BAL cells", "OBSERVATION", 63, 72], ["RMs", "OBSERVATION_MODIFIER", 151, 154], ["infected", "OBSERVATION", 155, 163], ["SVV BAC", "OBSERVATION", 169, 176]]], ["Therefore, the ability of SVV BAC to replicate in vivo was comparable to WT SVV.Cytokine and chemokine levels in BAL supernatant and plasma ::: ResultsWe measured the concentrations of multiple chemokines (Figure 3A), cytokines (Figure 3B), and growth factors (Figure 3C) in BAL fluid and plasma (data not shown) by multiplex technology.", [["BAL supernatant", "ANATOMY", 113, 128], ["plasma", "ANATOMY", 133, 139], ["BAL fluid", "ANATOMY", 275, 284], ["plasma", "ANATOMY", 289, 295], ["SVV", "ORGANISM", 26, 29], ["Cytokine", "GENE_OR_GENE_PRODUCT", 80, 88], ["BAL", "ORGANISM_SUBSTANCE", 113, 116], ["plasma", "ORGANISM_SUBSTANCE", 133, 139], ["Figure 3A", "GENE_OR_GENE_PRODUCT", 206, 215], ["Figure 3B", "GENE_OR_GENE_PRODUCT", 229, 238], ["BAL fluid", "ORGANISM_SUBSTANCE", 275, 284], ["plasma", "ORGANISM_SUBSTANCE", 289, 295], ["SVV BAC", "DNA", 26, 33], ["Cytokine", "PROTEIN", 80, 88], ["chemokine", "PROTEIN", 93, 102], ["chemokines", "PROTEIN", 194, 204], ["Figure 3A", "PROTEIN", 206, 215], ["cytokines", "PROTEIN", 218, 227], ["Figure 3B", "PROTEIN", 229, 238], ["growth factors", "PROTEIN", 245, 259], ["SVV", "SPECIES", 26, 29], ["SVV", "SPECIES", 76, 79], ["SVV BAC", "TREATMENT", 26, 33], ["SVV", "TEST", 76, 79], ["Cytokine and chemokine levels", "TEST", 80, 109], ["BAL supernatant", "TEST", 113, 128], ["multiple chemokines", "TEST", 185, 204], ["cytokines (Figure 3B", "PROBLEM", 218, 238], ["growth factors", "PROBLEM", 245, 259], ["Figure 3C", "TEST", 261, 270], ["BAL fluid", "TEST", 275, 284], ["plasma (data", "TEST", 289, 301]]], ["In BAL fluid infection with either SVV BAC or WT SVV induced production of several key chemokines, including MCP-1 (recruits monocytes, memory T cells, DCs [14]), MDC (recruits monocytes, monocyte-derived DCs, and NK cells [15]), MIF (inflammatory and atherogenic leukocyte recruitment [16]), MIG (recruits T cells [17]), MIP-1\u03b1 (recruits and activates polymorphonuclear leukocytes [18]), MIP-1\u03b2 (recruits NK cells and monocytes [18]), I-TAC (recruits T cells [19]), and eotaxin (recruits eosinophils [20]) (Figure 3).", [["BAL fluid", "ANATOMY", 3, 12], ["monocytes", "ANATOMY", 125, 134], ["memory T cells", "ANATOMY", 136, 150], ["DCs", "ANATOMY", 152, 155], ["MDC", "ANATOMY", 163, 166], ["monocytes", "ANATOMY", 177, 186], ["monocyte", "ANATOMY", 188, 196], ["DCs", "ANATOMY", 205, 208], ["NK cells", "ANATOMY", 214, 222], ["leukocyte", "ANATOMY", 264, 273], ["T cells", "ANATOMY", 307, 314], ["polymorphonuclear leukocytes", "ANATOMY", 353, 381], ["NK cells", "ANATOMY", 406, 414], ["monocytes", "ANATOMY", 419, 428], ["I-TAC", "ANATOMY", 436, 441], ["T cells", "ANATOMY", 452, 459], ["eosinophils", "ANATOMY", 489, 500], ["infection", "DISEASE", 13, 22], ["BAL fluid", "ORGANISM_SUBSTANCE", 3, 12], ["WT SVV", "ORGANISM", 46, 52], ["MCP-1", "GENE_OR_GENE_PRODUCT", 109, 114], ["monocytes", "CELL", 125, 134], ["memory T cells", "CELL", 136, 150], ["DCs", "CELL", 152, 155], ["MDC", "CELL", 163, 166], ["monocytes", "CELL", 177, 186], ["monocyte", "CELL", 188, 196], ["DCs", "CELL", 205, 208], ["NK cells", "CELL", 214, 222], ["MIF", "GENE_OR_GENE_PRODUCT", 230, 233], ["leukocyte", "CELL", 264, 273], ["MIG", "GENE_OR_GENE_PRODUCT", 293, 296], ["T cells", "CELL", 307, 314], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 322, 328], ["polymorphonuclear leukocytes", "CELL", 353, 381], ["MIP-1\u03b2", "GENE_OR_GENE_PRODUCT", 389, 395], ["NK cells", "CELL", 406, 414], ["monocytes", "CELL", 419, 428], ["I-TAC", "CELL", 436, 441], ["T cells", "CELL", 452, 459], ["eotaxin", "GENE_OR_GENE_PRODUCT", 471, 478], ["eosinophils", "CELL", 489, 500], ["chemokines", "PROTEIN", 87, 97], ["MCP-1", "PROTEIN", 109, 114], ["monocytes", "CELL_TYPE", 125, 134], ["memory T cells", "CELL_TYPE", 136, 150], ["DCs", "CELL_TYPE", 152, 155], ["MDC", "CELL_TYPE", 163, 166], ["monocytes", "CELL_TYPE", 177, 186], ["monocyte", "CELL_TYPE", 188, 196], ["DCs", "CELL_TYPE", 205, 208], ["NK cells", "CELL_TYPE", 214, 222], ["MIF", "PROTEIN", 230, 233], ["MIG", "PROTEIN", 293, 296], ["T cells", "CELL_TYPE", 307, 314], ["MIP-1\u03b1", "PROTEIN", 322, 328], ["polymorphonuclear leukocytes", "CELL_TYPE", 353, 381], ["MIP", "PROTEIN", 389, 392], ["\u03b2", "PROTEIN", 394, 395], ["NK cells", "CELL_TYPE", 406, 414], ["monocytes", "CELL_TYPE", 419, 428], ["I-TAC", "PROTEIN", 436, 441], ["T cells", "CELL_TYPE", 452, 459], ["eotaxin", "PROTEIN", 471, 478], ["eosinophils", "CELL_TYPE", 489, 500], ["SVV", "SPECIES", 35, 38], ["SVV", "SPECIES", 49, 52], ["BAL fluid infection", "PROBLEM", 3, 22], ["SVV BAC", "TEST", 35, 42], ["WT SVV", "PROBLEM", 46, 52], ["several key chemokines", "PROBLEM", 75, 97], ["MCP", "TEST", 109, 112], ["monocytes", "TEST", 125, 134], ["DCs", "TEST", 152, 155], ["monocytes", "TEST", 177, 186], ["monocyte", "TEST", 188, 196], ["DCs", "TEST", 205, 208], ["NK cells", "TEST", 214, 222], ["MIF", "TEST", 230, 233], ["atherogenic leukocyte recruitment", "TEST", 252, 285], ["MIG (recruits T cells", "TEST", 293, 314], ["MIP", "TEST", 322, 325], ["polymorphonuclear leukocytes", "TEST", 353, 381], ["MIP", "TEST", 389, 392], ["NK cells", "TEST", 406, 414], ["monocytes", "TEST", 419, 428], ["I-TAC", "TEST", 436, 441], ["T cells", "TEST", 452, 459], ["eotaxin", "TEST", 471, 478], ["eosinophils", "TEST", 489, 500], ["BAL", "ANATOMY", 3, 6], ["fluid infection", "OBSERVATION", 7, 22], ["SVV BAC", "OBSERVATION", 35, 42], ["monocytes", "ANATOMY", 125, 134], ["inflammatory", "OBSERVATION_MODIFIER", 235, 247], ["atherogenic", "OBSERVATION_MODIFIER", 252, 263], ["leukocyte", "OBSERVATION", 264, 273], ["NK cells", "OBSERVATION", 406, 414]]], ["Concentrations of these chemokines peaked at 7 dpi and returned to baseline by 14 dpi.Cytokine and chemokine levels in BAL supernatant and plasma ::: ResultsConcentrations of pro-inflammatory cytokines IFN\u03b3 (involved in anti-viral activities and differentiation of T helper 1 (Th1) subsets [21]), TNF\u03b1 (systemic inflammation [22]), IL-6 (pro- and anti-inflammatory responses [23]), IL-2 (T cell proliferation and homeostasis [24]) and IL-15 (proliferation of T cells and NK cells [25]) peaked at 7 dpi.", [["BAL supernatant", "ANATOMY", 119, 134], ["plasma", "ANATOMY", 139, 145], ["T cell", "ANATOMY", 388, 394], ["T cells", "ANATOMY", 459, 466], ["NK cells", "ANATOMY", 471, 479], ["Cytokine", "GENE_OR_GENE_PRODUCT", 86, 94], ["BAL", "ORGANISM_SUBSTANCE", 119, 122], ["plasma", "ORGANISM_SUBSTANCE", 139, 145], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 202, 206], ["T helper 1", "GENE_OR_GENE_PRODUCT", 265, 275], ["Th1", "GENE_OR_GENE_PRODUCT", 277, 280], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 297, 301], ["IL-6", "GENE_OR_GENE_PRODUCT", 332, 336], ["IL-2", "GENE_OR_GENE_PRODUCT", 382, 386], ["T cell", "CELL", 388, 394], ["IL-15", "GENE_OR_GENE_PRODUCT", 435, 440], ["T cells", "CELL", 459, 466], ["NK cells", "CELL", 471, 479], ["chemokines", "PROTEIN", 24, 34], ["Cytokine", "PROTEIN", 86, 94], ["chemokine", "PROTEIN", 99, 108], ["pro-inflammatory cytokines", "PROTEIN", 175, 201], ["IFN\u03b3", "PROTEIN", 202, 206], ["T helper 1 (Th1) subsets", "CELL_TYPE", 265, 289], ["TNF\u03b1", "PROTEIN", 297, 301], ["IL-15", "PROTEIN", 435, 440], ["T cells", "CELL_TYPE", 459, 466], ["NK cells", "CELL_TYPE", 471, 479], ["these chemokines", "TEST", 18, 34], ["Cytokine", "TEST", 86, 94], ["chemokine levels", "TEST", 99, 115], ["BAL supernatant", "TEST", 119, 134], ["plasma", "TEST", 139, 145], ["pro-inflammatory cytokines", "PROBLEM", 175, 201], ["anti-viral activities", "TREATMENT", 220, 241], ["T helper", "TEST", 265, 273], ["subsets", "TEST", 282, 289], ["TNF", "TEST", 297, 300], ["systemic inflammation", "PROBLEM", 303, 324], ["IL", "TEST", 332, 334], ["anti-inflammatory responses", "TEST", 347, 374], ["IL", "TEST", 382, 384], ["T cell proliferation", "TEST", 388, 408], ["homeostasis", "TEST", 413, 424], ["IL", "TEST", 435, 437], ["NK cells", "TEST", 471, 479]]], ["The concentrations of IL-1 receptor antagonist (RA), which prevents IL-1 from signaling through the IL-1R [26] and IL-10 (pleiotropic activities in inflammation and immune regulation [27]) peaked at 7 dpi.", [["inflammation", "DISEASE", 148, 160], ["IL-1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 22, 46], ["RA", "SIMPLE_CHEMICAL", 48, 50], ["IL-1", "GENE_OR_GENE_PRODUCT", 68, 72], ["IL-1R", "GENE_OR_GENE_PRODUCT", 100, 105], ["IL-10", "GENE_OR_GENE_PRODUCT", 115, 120], ["IL-1", "PROTEIN", 68, 72], ["The concentrations of IL-1 receptor antagonist (RA)", "TREATMENT", 0, 51], ["IL", "TEST", 115, 117], ["inflammation", "PROBLEM", 148, 160], ["immune regulation", "TEST", 165, 182]]], ["G-CSF, a pleiotropic cytokine, produced by endothelium, macrophages and other immune cells, which stimulates the survival, proliferation, differentiation, and function of neutrophils also peaked at 7 dpi [28].", [["endothelium", "ANATOMY", 43, 54], ["macrophages", "ANATOMY", 56, 67], ["immune cells", "ANATOMY", 78, 90], ["neutrophils", "ANATOMY", 171, 182], ["G-CSF", "GENE_OR_GENE_PRODUCT", 0, 5], ["endothelium", "TISSUE", 43, 54], ["macrophages", "CELL", 56, 67], ["immune cells", "CELL", 78, 90], ["neutrophils", "CELL", 171, 182], ["CSF", "PROTEIN", 2, 5], ["pleiotropic cytokine", "PROTEIN", 9, 29], ["macrophages", "CELL_TYPE", 56, 67], ["immune cells", "CELL_TYPE", 78, 90], ["neutrophils", "CELL_TYPE", 171, 182], ["G-CSF", "TEST", 0, 5], ["a pleiotropic cytokine", "PROBLEM", 7, 29], ["other immune cells", "PROBLEM", 72, 90], ["neutrophils", "TEST", 171, 182], ["CSF", "ANATOMY", 2, 5], ["endothelium", "ANATOMY", 43, 54], ["macrophages", "OBSERVATION", 56, 67], ["immune cells", "OBSERVATION", 78, 90]]], ["Levels of IL-12, important in the differentiation of na\u00efve T cells into CD4 Th1 cells [29], peaked at 10 dpi.", [["na\u00efve T cells", "ANATOMY", 53, 66], ["CD4 Th1 cells", "ANATOMY", 72, 85], ["IL-12", "GENE_OR_GENE_PRODUCT", 10, 15], ["na\u00efve T cells", "CELL", 53, 66], ["CD4 Th1 cells", "CELL", 72, 85], ["IL-12", "PROTEIN", 10, 15], ["na\u00efve T cells", "CELL_TYPE", 53, 66], ["CD4 Th1 cells", "CELL_TYPE", 72, 85], ["Levels", "TEST", 0, 6], ["IL", "TEST", 10, 12], ["Th1 cells", "TEST", 76, 85]]], ["Lastly, the concentration of IFN\u03b1, a type I interferon that is important in anti-viral immunity, peaked at 3 dpi.Cytokine and chemokine levels in BAL supernatant and plasma ::: ResultsGrowth factors EGF (stimulates cell growth, proliferation and differentiation [30]), and FGF-basic (multifunctional protein involved in angiogenesis and wound healing [31]) concentrations in BAL fluid peaked at 7 dpi.", [["BAL supernatant", "ANATOMY", 146, 161], ["plasma", "ANATOMY", 166, 172], ["cell", "ANATOMY", 215, 219], ["wound", "ANATOMY", 337, 342], ["BAL fluid", "ANATOMY", 375, 384], ["IFN\u03b1", "CHEMICAL", 29, 33], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 29, 33], ["type I interferon", "GENE_OR_GENE_PRODUCT", 37, 54], ["Cytokine", "GENE_OR_GENE_PRODUCT", 113, 121], ["BAL", "ORGANISM_SUBSTANCE", 146, 149], ["plasma", "ORGANISM_SUBSTANCE", 166, 172], ["EGF", "GENE_OR_GENE_PRODUCT", 199, 202], ["cell", "CELL", 215, 219], ["FGF", "GENE_OR_GENE_PRODUCT", 273, 276], ["wound", "PATHOLOGICAL_FORMATION", 337, 342], ["BAL fluid", "ORGANISM_SUBSTANCE", 375, 384], ["IFN\u03b1", "PROTEIN", 29, 33], ["type I interferon", "PROTEIN", 37, 54], ["Cytokine", "PROTEIN", 113, 121], ["chemokine", "PROTEIN", 126, 135], ["ResultsGrowth factors", "PROTEIN", 177, 198], ["EGF", "PROTEIN", 199, 202], ["FGF", "PROTEIN", 273, 276], ["multifunctional protein", "PROTEIN", 284, 307], ["a type I interferon", "TREATMENT", 35, 54], ["Cytokine", "TEST", 113, 121], ["chemokine levels", "TEST", 126, 142], ["BAL supernatant", "TEST", 146, 161], ["plasma", "TEST", 166, 172], ["ResultsGrowth factors EGF", "TEST", 177, 202], ["stimulates cell growth", "TEST", 204, 226], ["proliferation", "TEST", 228, 241], ["differentiation", "TEST", 246, 261], ["FGF", "TEST", 273, 276], ["wound healing", "PROBLEM", 337, 350], ["concentrations in BAL fluid", "TEST", 357, 384], ["wound", "ANATOMY", 337, 342], ["healing", "OBSERVATION_MODIFIER", 343, 350], ["BAL", "ANATOMY", 375, 378], ["fluid", "OBSERVATION", 379, 384]]], ["While levels of growth factors HGF (regulates cell growth, cell motility, and morphogenesis, and acts primarily upon epithelial and endothelial cells [32]) and VEGF (stimulates vasculogenesis and angiogenesis [33]) peaked at 10 dpi.Cytokine and chemokine levels in BAL supernatant and plasma ::: ResultsConcentrations of IL-1\u03b2, IL-4, IL-5, IL-8, IL-17, GM-CSF and RANTES (CCL5) and in BAL fluid were below our limit of detection (data not shown).", [["cell", "ANATOMY", 46, 50], ["cell", "ANATOMY", 59, 63], ["epithelial", "ANATOMY", 117, 127], ["endothelial cells", "ANATOMY", 132, 149], ["BAL supernatant", "ANATOMY", 265, 280], ["plasma", "ANATOMY", 285, 291], ["BAL fluid", "ANATOMY", 385, 394], ["HGF", "GENE_OR_GENE_PRODUCT", 31, 34], ["cell", "CELL", 46, 50], ["cell", "CELL", 59, 63], ["epithelial", "CELL", 117, 127], ["endothelial cells", "CELL", 132, 149], ["VEGF", "GENE_OR_GENE_PRODUCT", 160, 164], ["Cytokine", "GENE_OR_GENE_PRODUCT", 232, 240], ["BAL", "ORGANISM_SUBSTANCE", 265, 268], ["plasma", "ORGANISM_SUBSTANCE", 285, 291], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 321, 326], ["IL-4", "GENE_OR_GENE_PRODUCT", 328, 332], ["IL-5", "GENE_OR_GENE_PRODUCT", 334, 338], ["IL-8", "GENE_OR_GENE_PRODUCT", 340, 344], ["IL-17", "GENE_OR_GENE_PRODUCT", 346, 351], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 353, 359], ["RANTES", "GENE_OR_GENE_PRODUCT", 364, 370], ["CCL5", "GENE_OR_GENE_PRODUCT", 372, 376], ["BAL fluid", "ORGANISM_SUBSTANCE", 385, 394], ["growth factors", "PROTEIN", 16, 30], ["HGF", "PROTEIN", 31, 34], ["epithelial and endothelial cells", "CELL_TYPE", 117, 149], ["VEGF", "PROTEIN", 160, 164], ["Cytokine", "PROTEIN", 232, 240], ["chemokine", "PROTEIN", 245, 254], ["IL", "PROTEIN", 321, 323], ["IL-17", "PROTEIN", 346, 351], ["GM", "PROTEIN", 353, 355], ["CSF", "PROTEIN", 356, 359], ["RANTES", "PROTEIN", 364, 370], ["CCL5", "PROTEIN", 372, 376], ["growth factors HGF", "PROBLEM", 16, 34], ["cell growth", "TEST", 46, 57], ["cell motility", "TEST", 59, 72], ["morphogenesis", "TEST", 78, 91], ["epithelial and endothelial cells", "TEST", 117, 149], ["VEGF (stimulates vasculogenesis", "PROBLEM", 160, 191], ["angiogenesis", "TEST", 196, 208], ["Cytokine", "TEST", 232, 240], ["chemokine levels", "TEST", 245, 261], ["BAL supernatant", "TEST", 265, 280], ["plasma", "TEST", 285, 291], ["ResultsConcentrations", "TEST", 296, 317], ["IL", "TEST", 321, 323], ["IL", "TEST", 328, 330], ["IL", "TEST", 334, 336], ["IL", "TEST", 340, 342], ["IL", "TEST", 346, 348], ["GM-CSF and RANTES (CCL5)", "TEST", 353, 377], ["BAL fluid", "TEST", 385, 394], ["endothelial", "ANATOMY", 132, 143], ["CSF", "ANATOMY", 356, 359], ["BAL", "ANATOMY", 385, 388], ["fluid", "OBSERVATION", 389, 394]]], ["We did not detect any significant differences in concentrations of chemokines, cytokines or growth factors between RMs infected with SVV BAC or WT SVV.Cytokine and chemokine levels in BAL supernatant and plasma ::: ResultsWe also measured the concentration of the above chemokines, cytokines, and growth factors in plasma (data not shown).", [["BAL supernatant", "ANATOMY", 184, 199], ["plasma", "ANATOMY", 204, 210], ["plasma", "ANATOMY", 315, 321], ["RMs", "ORGANISM", 115, 118], ["SVV", "ORGANISM", 133, 136], ["WT SVV", "ORGANISM", 144, 150], ["Cytokine", "GENE_OR_GENE_PRODUCT", 151, 159], ["BAL", "ORGANISM_SUBSTANCE", 184, 187], ["plasma", "ORGANISM_SUBSTANCE", 204, 210], ["plasma", "ORGANISM_SUBSTANCE", 315, 321], ["chemokines", "PROTEIN", 67, 77], ["cytokines", "PROTEIN", 79, 88], ["growth factors", "PROTEIN", 92, 106], ["Cytokine", "PROTEIN", 151, 159], ["chemokine", "PROTEIN", 164, 173], ["chemokines", "PROTEIN", 270, 280], ["cytokines", "PROTEIN", 282, 291], ["growth factors", "PROTEIN", 297, 311], ["SVV", "SPECIES", 133, 136], ["SVV", "SPECIES", 147, 150], ["chemokines", "PROBLEM", 67, 77], ["cytokines", "PROBLEM", 79, 88], ["growth factors", "PROBLEM", 92, 106], ["SVV BAC", "TREATMENT", 133, 140], ["Cytokine and chemokine levels", "TEST", 151, 180], ["BAL supernatant", "TEST", 184, 199], ["the above chemokines", "TEST", 260, 280], ["cytokines", "TEST", 282, 291], ["plasma (data", "TEST", 315, 327]]], ["However, we were only able to detect changes in the levels of IFN\u03b3, which peaked at 7 dpi and returned to baseline by 10 dpi and no significant differences were detected between cohorts.B cell and antibody response to SVV BAC ::: ResultsWe compared the magnitude and kinetics of the B cell response as well as the generation of SVV-specific IgG antibody titers post-infection in RMs infected with SVV BAC or WT SVV.", [["B cell", "ANATOMY", 186, 192], ["B cell", "ANATOMY", 283, 289], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 62, 66], ["B cell", "CELL", 186, 192], ["B cell", "CELL", 283, 289], ["SVV", "ORGANISM", 328, 331], ["IgG", "GENE_OR_GENE_PRODUCT", 341, 344], ["RMs", "ORGANISM", 379, 382], ["SVV", "ORGANISM", 397, 400], ["WT SVV", "ORGANISM", 408, 414], ["IFN\u03b3", "PROTEIN", 62, 66], ["SVV BAC", "DNA", 218, 225], ["IgG antibody", "PROTEIN", 341, 353], ["SVV", "SPECIES", 218, 221], ["SVV", "SPECIES", 328, 331], ["SVV", "SPECIES", 397, 400], ["SVV", "SPECIES", 411, 414], ["changes in the levels of IFN\u03b3", "PROBLEM", 37, 66], ["significant differences", "PROBLEM", 132, 155], ["the B cell response", "TREATMENT", 279, 298], ["SVV", "TEST", 328, 331], ["specific IgG antibody titers", "TEST", 332, 360], ["SVV BAC", "TEST", 397, 404], ["no", "UNCERTAINTY", 129, 131], ["significant", "OBSERVATION_MODIFIER", 132, 143]]], ["The expansion of B cells is measured based on expression of Ki67, a nuclear protein involved in DNA replication [34] by flow cytometry.", [["B cells", "ANATOMY", 17, 24], ["nuclear", "ANATOMY", 68, 75], ["B cells", "CELL", 17, 24], ["Ki67", "GENE_OR_GENE_PRODUCT", 60, 64], ["nuclear", "CELLULAR_COMPONENT", 68, 75], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["B cells", "CELL_TYPE", 17, 24], ["Ki67", "PROTEIN", 60, 64], ["nuclear protein", "PROTEIN", 68, 83], ["B cells", "PROBLEM", 17, 24], ["Ki67", "TEST", 60, 64], ["a nuclear protein", "TEST", 66, 83], ["DNA replication", "TREATMENT", 96, 111], ["flow cytometry", "TEST", 120, 134], ["expansion", "OBSERVATION_MODIFIER", 4, 13], ["B cells", "OBSERVATION", 17, 24]]], ["SVV infection induces the proliferation of B cells indicated by an increase in the frequency of Ki67 positive cells on days 7 to 14 compared to day 0 in marginal zone (MZ)-like (CD27+IgD+) and memory (CD27+IgD\u2212) B cells, in BAL cells (Figure 4A) and PBMC (Figure 4B).", [["B cells", "ANATOMY", 43, 50], ["Ki67 positive cells", "ANATOMY", 96, 115], ["marginal zone (MZ)-like (CD27+IgD+)", "ANATOMY", 153, 188], ["memory (CD27+IgD\u2212) B cells", "ANATOMY", 193, 219], ["BAL cells", "ANATOMY", 224, 233], ["PBMC", "ANATOMY", 250, 254], ["SVV infection", "DISEASE", 0, 13], ["SVV", "ORGANISM", 0, 3], ["B cells", "CELL", 43, 50], ["Ki67", "GENE_OR_GENE_PRODUCT", 96, 100], ["marginal zone (MZ)", "CANCER", 153, 171], ["CD27", "GENE_OR_GENE_PRODUCT", 178, 182], ["IgD", "GENE_OR_GENE_PRODUCT", 183, 186], ["CD27", "GENE_OR_GENE_PRODUCT", 201, 205], ["BAL cells", "CELL", 224, 233], ["Figure 4A", "CELL", 235, 244], ["PBMC", "CELL", 250, 254], ["B cells", "CELL_TYPE", 43, 50], ["Ki67 positive cells", "CELL_TYPE", 96, 115], ["CD27", "PROTEIN", 178, 182], ["IgD", "PROTEIN", 183, 186], ["memory (CD27+IgD\u2212) B cells", "CELL_TYPE", 193, 219], ["BAL cells", "CELL_TYPE", 224, 233], ["PBMC", "CELL_TYPE", 250, 254], ["SVV", "SPECIES", 0, 3], ["SVV infection", "PROBLEM", 0, 13], ["B cells", "PROBLEM", 43, 50], ["an increase", "PROBLEM", 64, 75], ["Ki67 positive cells", "PROBLEM", 96, 115], ["MZ", "TEST", 168, 170], ["CD27", "TEST", 178, 182], ["IgD", "TEST", 183, 186], ["memory", "TEST", 193, 199], ["CD27", "TEST", 201, 205], ["B cells", "PROBLEM", 212, 219], ["BAL cells", "TEST", 224, 233], ["Figure 4A", "TEST", 235, 244], ["PBMC", "TEST", 250, 254], ["infection", "OBSERVATION", 4, 13], ["proliferation", "OBSERVATION_MODIFIER", 26, 39], ["B cells", "OBSERVATION", 43, 50], ["increase", "OBSERVATION_MODIFIER", 67, 75], ["BAL cells", "OBSERVATION", 224, 233]]], ["In BAL cells and PBMC we measured similar proliferation of both subsets of B cells and no statistical differences in RMs infected with either SVV BAC or WT SVV except for at 10 dpi in BAL cells of WT SVV infected RMs we detected higher proliferation of MZ-like B cells (p<0.05) compared to SVV BAC.", [["BAL cells", "ANATOMY", 3, 12], ["PBMC", "ANATOMY", 17, 21], ["B cells", "ANATOMY", 75, 82], ["BAL cells", "ANATOMY", 184, 193], ["MZ-like B cells", "ANATOMY", 253, 268], ["BAC", "ANATOMY", 294, 297], ["BAL cells", "CELL", 3, 12], ["PBMC", "CELL", 17, 21], ["B cells", "CELL", 75, 82], ["SVV BAC", "ORGANISM", 142, 149], ["WT SVV", "ORGANISM", 153, 159], ["BAL cells", "CELL", 184, 193], ["WT SVV", "ORGANISM", 197, 203], ["RMs", "ORGANISM", 213, 216], ["MZ-like B cells", "CELL", 253, 268], ["SVV", "ORGANISM", 290, 293], ["BAL cells", "CELL_TYPE", 3, 12], ["PBMC", "CELL_TYPE", 17, 21], ["B cells", "CELL_TYPE", 75, 82], ["SVV BAC", "DNA", 142, 149], ["BAL cells", "CELL_TYPE", 184, 193], ["B cells", "CELL_TYPE", 261, 268], ["SVV", "SPECIES", 142, 145], ["SVV", "SPECIES", 156, 159], ["SVV", "SPECIES", 200, 203], ["SVV", "SPECIES", 290, 293], ["BAL cells", "TEST", 3, 12], ["PBMC", "TEST", 17, 21], ["B cells", "PROBLEM", 75, 82], ["statistical differences in RMs infected", "PROBLEM", 90, 129], ["SVV BAC", "TEST", 142, 149], ["WT SVV", "TEST", 153, 159], ["BAL cells", "TEST", 184, 193], ["WT SVV infected RMs", "PROBLEM", 197, 216], ["MZ", "TEST", 253, 255], ["SVV BAC", "TEST", 290, 297], ["BAL cells", "OBSERVATION", 3, 12], ["PBMC", "ANATOMY", 17, 21], ["similar", "OBSERVATION_MODIFIER", 34, 41], ["proliferation", "OBSERVATION_MODIFIER", 42, 55], ["both subsets", "OBSERVATION_MODIFIER", 59, 71], ["B cells", "OBSERVATION", 75, 82], ["no", "UNCERTAINTY", 87, 89], ["RMs", "OBSERVATION_MODIFIER", 117, 120], ["infected", "OBSERVATION", 121, 129], ["SVV BAC", "OBSERVATION", 142, 149], ["BAL cells", "OBSERVATION", 184, 193], ["infected RMs", "OBSERVATION", 204, 216], ["higher", "OBSERVATION_MODIFIER", 229, 235], ["proliferation", "OBSERVATION_MODIFIER", 236, 249]]], ["We also measured SVV-specific IgG (Figure 4C) antibody endpoint titers in plasma using standard ELISA.", [["plasma", "ANATOMY", 74, 80], ["IgG", "GENE_OR_GENE_PRODUCT", 30, 33], ["plasma", "ORGANISM_SUBSTANCE", 74, 80], ["IgG", "PROTEIN", 30, 33], ["SVV", "TEST", 17, 20], ["specific IgG", "TEST", 21, 33], ["Figure", "TEST", 35, 41], ["antibody endpoint titers", "TEST", 46, 70], ["plasma", "TEST", 74, 80], ["standard ELISA", "TEST", 87, 101], ["SVV", "ANATOMY", 17, 20]]], ["The kinetics of IgG production were comparable during SVV BAC and WT SVV infection of RMs, the titers peaked around day 14 post-infection and remained stable until necropsy.T cell response to SVV BAC ::: ResultsNa\u00efve T cells following antigen encounter become activated, proliferate, and differentiate into central memory (CM, CD28+CD95+) and effector memory (EM, CD28\u2212CD95+) T cells.", [["T cell", "ANATOMY", 173, 179], ["T cells", "ANATOMY", 217, 224], ["central memory", "ANATOMY", 307, 321], ["CM", "ANATOMY", 323, 325], ["CD28+CD95+)", "ANATOMY", 327, 338], ["effector memory (EM", "ANATOMY", 343, 362], ["CD28\u2212CD95+) T cells", "ANATOMY", 364, 383], ["SVV infection", "DISEASE", 69, 82], ["infection", "DISEASE", 128, 137], ["IgG", "GENE_OR_GENE_PRODUCT", 16, 19], ["SVV", "ORGANISM", 54, 57], ["WT SVV", "ORGANISM", 66, 72], ["T cell", "CELL", 173, 179], ["SVV", "ORGANISM", 192, 195], ["ResultsNa\u00efve T cells", "CELL", 204, 224], ["CM", "CELL", 323, 325], ["CD28", "GENE_OR_GENE_PRODUCT", 327, 331], ["CD95", "GENE_OR_GENE_PRODUCT", 332, 336], ["EM", "CELL", 360, 362], ["CD28", "GENE_OR_GENE_PRODUCT", 364, 368], ["CD95", "GENE_OR_GENE_PRODUCT", 369, 373], ["IgG", "PROTEIN", 16, 19], ["SVV BAC", "DNA", 192, 199], ["T cells", "CELL_TYPE", 217, 224], ["CD28", "PROTEIN", 327, 331], ["CD95", "PROTEIN", 332, 336], ["effector memory (EM, CD28\u2212CD95+) T cells", "CELL_TYPE", 343, 383], ["SVV", "SPECIES", 54, 57], ["SVV", "SPECIES", 69, 72], ["SVV", "SPECIES", 192, 195], ["IgG production", "PROBLEM", 16, 30], ["SVV BAC", "TEST", 54, 61], ["WT SVV infection of RMs", "PROBLEM", 66, 89], ["the titers", "TEST", 91, 101], ["infection", "PROBLEM", 128, 137], ["necropsy", "PROBLEM", 164, 172], ["SVV BAC", "TEST", 192, 199], ["CD28", "TEST", 327, 331], ["CD95", "TEST", 332, 336], ["effector memory", "TEST", 343, 358], ["T cells", "PROBLEM", 376, 383], ["IgG production", "OBSERVATION", 16, 30], ["SVV infection", "OBSERVATION", 69, 82], ["infection", "OBSERVATION", 128, 137], ["stable", "OBSERVATION_MODIFIER", 151, 157], ["central", "ANATOMY_MODIFIER", 307, 314]]], ["We compared the kinetics and magnitude of the T cell response by measuring the frequency of Ki67 positive CM and EM T cells subsets in BAL cells (Figure 5A) and PBMC (Figure 5B) in SVV BAC or WT SVV infected RMs.", [["T cell", "ANATOMY", 46, 52], ["CM", "ANATOMY", 106, 108], ["EM T cells", "ANATOMY", 113, 123], ["BAL cells", "ANATOMY", 135, 144], ["PBMC", "ANATOMY", 161, 165], ["T cell", "CELL", 46, 52], ["Ki67", "GENE_OR_GENE_PRODUCT", 92, 96], ["CM", "CELL", 106, 108], ["EM T cells", "CELL", 113, 123], ["BAL cells", "CELL", 135, 144], ["Figure 5A", "CELL", 146, 155], ["PBMC", "CELL", 161, 165], ["SVV", "ORGANISM", 181, 184], ["Ki67 positive CM and EM T cells subsets", "CELL_TYPE", 92, 131], ["BAL cells", "CELL_TYPE", 135, 144], ["PBMC", "CELL_TYPE", 161, 165], ["SVV", "SPECIES", 181, 184], ["SVV", "SPECIES", 195, 198], ["the T cell response", "PROBLEM", 42, 61], ["Ki67 positive CM", "PROBLEM", 92, 108], ["EM T cells", "TEST", 113, 123], ["BAL cells", "TEST", 135, 144], ["Figure 5A", "TEST", 146, 155], ["PBMC", "TEST", 161, 165], ["Figure 5B", "TEST", 167, 176], ["SVV BAC", "TEST", 181, 188], ["WT SVV infected RMs", "PROBLEM", 192, 211], ["positive CM", "OBSERVATION_MODIFIER", 97, 108], ["BAL cells", "OBSERVATION", 135, 144], ["SVV", "OBSERVATION", 195, 198], ["infected RMs", "OBSERVATION", 199, 211]]], ["SVV BAC and WT SVV infection induced strong T cell proliferation in BAL cells as shown by an increase in Ki67 positive T cells from days 7 to 17 post-infection.", [["T cell", "ANATOMY", 44, 50], ["BAL cells", "ANATOMY", 68, 77], ["Ki67 positive T cells", "ANATOMY", 105, 126], ["SVV infection", "DISEASE", 15, 28], ["infection", "DISEASE", 150, 159], ["SVV", "ORGANISM", 0, 3], ["WT SVV", "ORGANISM", 12, 18], ["T cell", "CELL", 44, 50], ["BAL cells", "CELL", 68, 77], ["Ki67", "GENE_OR_GENE_PRODUCT", 105, 109], ["BAL cells", "CELL_TYPE", 68, 77], ["Ki67 positive T cells", "CELL_TYPE", 105, 126], ["SVV", "SPECIES", 0, 3], ["SVV", "SPECIES", 15, 18], ["SVV BAC", "TEST", 0, 7], ["WT SVV infection", "PROBLEM", 12, 28], ["strong T cell proliferation in BAL cells", "PROBLEM", 37, 77], ["an increase in Ki67 positive T cells", "PROBLEM", 90, 126], ["infection", "PROBLEM", 150, 159], ["SVV infection", "OBSERVATION", 15, 28], ["strong", "OBSERVATION_MODIFIER", 37, 43], ["T cell proliferation", "OBSERVATION", 44, 64], ["BAL cells", "OBSERVATION", 68, 77], ["increase", "OBSERVATION_MODIFIER", 93, 101], ["Ki67 positive T cells", "OBSERVATION", 105, 126], ["infection", "OBSERVATION", 150, 159]]], ["Within PBMC, T cell proliferation was detected in CD4 EM, CD8 CM and CD8 EM subsets but the magnitude was significantly reduced compared to the proliferation observed in BAL cells.", [["PBMC", "ANATOMY", 7, 11], ["T cell", "ANATOMY", 13, 19], ["CD4 EM", "ANATOMY", 50, 56], ["CD8 CM", "ANATOMY", 58, 64], ["CD8 EM", "ANATOMY", 69, 75], ["BAL cells", "ANATOMY", 170, 179], ["PBMC", "CELL", 7, 11], ["T cell", "CELL", 13, 19], ["CD4 EM", "GENE_OR_GENE_PRODUCT", 50, 56], ["CD8", "GENE_OR_GENE_PRODUCT", 58, 61], ["CD8", "GENE_OR_GENE_PRODUCT", 69, 72], ["BAL cells", "CELL", 170, 179], ["PBMC", "CELL_TYPE", 7, 11], ["CD4 EM, CD8 CM and CD8 EM subsets", "CELL_TYPE", 50, 83], ["BAL cells", "CELL_TYPE", 170, 179], ["T cell proliferation", "PROBLEM", 13, 33], ["cell proliferation", "OBSERVATION", 15, 33], ["CD8 CM", "OBSERVATION", 58, 64], ["significantly", "OBSERVATION_MODIFIER", 106, 119], ["reduced", "OBSERVATION_MODIFIER", 120, 127], ["BAL cells", "OBSERVATION", 170, 179]]], ["Similarly though, the magnitude and kinetics was comparable in RMs infected with SVV BAC and WT SVV.T cell response to SVV BAC ::: ResultsAdditionally, we determined the frequency of SVV-specific T cells within CD4 and CD8 T cell populations by measuring the combined number of IFN\u03b3-, TNF\u03b1- and, IFN\u03b3/TNF\u03b1-producing cells following stimulation with either SVV lysate or a SVV overlapping peptide pool covering ORFs 4, 31, 61 and 63 using intracellular cytokine staining (ICS).", [["T cell", "ANATOMY", 100, 106], ["T cells", "ANATOMY", 196, 203], ["CD4", "ANATOMY", 211, 214], ["CD8 T cell", "ANATOMY", 219, 229], ["cells", "ANATOMY", 316, 321], ["intracellular", "ANATOMY", 438, 451], ["SVV", "ORGANISM", 81, 84], ["WT SVV", "ORGANISM", 93, 99], ["T cell", "CELL", 100, 106], ["SVV", "ORGANISM", 183, 186], ["T cells", "CELL", 196, 203], ["CD4", "CELL", 211, 214], ["CD8", "GENE_OR_GENE_PRODUCT", 219, 222], ["IFN\u03b3-", "GENE_OR_GENE_PRODUCT", 278, 283], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 285, 289], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 296, 300], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 301, 305], ["cells", "CELL", 316, 321], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 438, 451], ["SVV BAC", "DNA", 119, 126], ["T cells", "CELL_TYPE", 196, 203], ["CD4 and CD8 T cell populations", "CELL_TYPE", 211, 241], ["IFN", "PROTEIN", 278, 281], ["TNF\u03b1", "PROTEIN", 285, 289], ["IFN\u03b3", "PROTEIN", 296, 300], ["TNF\u03b1", "PROTEIN", 301, 305], ["ORFs", "DNA", 410, 414], ["SVV", "SPECIES", 81, 84], ["SVV", "SPECIES", 96, 99], ["SVV", "SPECIES", 119, 122], ["SVV", "SPECIES", 356, 359], ["SVV BAC", "TEST", 81, 88], ["SVV BAC", "TEST", 119, 126], ["SVV", "TEST", 183, 186], ["CD4", "TEST", 211, 214], ["CD8 T cell populations", "PROBLEM", 219, 241], ["IFN", "TEST", 278, 281], ["TNF", "TEST", 285, 288], ["IFN\u03b3", "TEST", 296, 300], ["TNF", "TEST", 301, 304], ["SVV lysate", "TREATMENT", 356, 366], ["ORFs", "TEST", 410, 414], ["intracellular cytokine staining", "TEST", 438, 469], ["magnitude", "OBSERVATION_MODIFIER", 22, 31], ["SVV BAC", "OBSERVATION", 81, 88], ["SVV BAC", "OBSERVATION", 119, 126], ["CD8 T cell populations", "OBSERVATION", 219, 241], ["SVV lysate", "OBSERVATION", 356, 366], ["cytokine staining", "OBSERVATION", 452, 469]]], ["We stimulated both BAL cells (Figure 6A-D) and PBMC (Figure 6E,F) isolated from infected RMs at different dpi.", [["BAL cells", "ANATOMY", 19, 28], ["PBMC", "ANATOMY", 47, 51], ["BAL cells", "CELL", 19, 28], ["Figure 6A-D", "CELL", 30, 41], ["PBMC", "CELL", 47, 51], ["Figure 6E,F", "CELL", 53, 64], ["RMs", "ORGANISM", 89, 92], ["BAL cells", "CELL_TYPE", 19, 28], ["PBMC", "CELL_TYPE", 47, 51], ["BAL cells", "TEST", 19, 28], ["Figure 6A", "TEST", 30, 39], ["PBMC", "TEST", 47, 51], ["infected RMs", "PROBLEM", 80, 92], ["BAL cells", "OBSERVATION", 19, 28], ["infected RMs", "OBSERVATION", 80, 92]]], ["Within BAL cells of SVV BAC or WT SVV infected RMs, SVV-specific CD4 and CD8 T cells were detected 7 dpi, their frequency peaked between 14 and 21 dpi and declined to a memory set point.", [["BAL cells", "ANATOMY", 7, 16], ["BAC", "ANATOMY", 24, 27], ["CD4", "ANATOMY", 65, 68], ["CD8 T cells", "ANATOMY", 73, 84], ["BAL cells", "CELL", 7, 16], ["SVV", "ORGANISM", 20, 23], ["BAC", "CELL", 24, 27], ["WT SVV", "ORGANISM", 31, 37], ["infected RMs", "ORGANISM", 38, 50], ["SVV", "ORGANISM", 52, 55], ["CD4", "GENE_OR_GENE_PRODUCT", 65, 68], ["CD8", "GENE_OR_GENE_PRODUCT", 73, 76], ["BAL cells", "CELL_TYPE", 7, 16], ["CD4 and CD8 T cells", "CELL_TYPE", 65, 84], ["SVV", "SPECIES", 20, 23], ["SVV", "SPECIES", 34, 37], ["SVV", "SPECIES", 52, 55], ["BAL cells", "TEST", 7, 16], ["SVV BAC", "TEST", 20, 27], ["WT SVV infected RMs", "PROBLEM", 31, 50], ["SVV", "TEST", 52, 55], ["specific CD4", "TEST", 56, 68], ["CD8 T cells", "TEST", 73, 84], ["BAL cells", "OBSERVATION", 7, 16], ["SVV BAC", "OBSERVATION", 20, 27], ["infected RMs", "OBSERVATION", 38, 50]]], ["There were no statistically significant differences between animals infected with SVV BAC or WT SVV, and both cohorts did not produce a measurable CD4 or CD8 response in PBMCs following stimulation with overlapping viral peptide pools (data not shown).SVV viral load in sensory ganglia ::: ResultsSVV DNA viral loads in sensory ganglia were measured by quantitative PCR (Table 1).", [["PBMCs", "ANATOMY", 170, 175], ["sensory ganglia", "ANATOMY", 270, 285], ["sensory ganglia", "ANATOMY", 320, 335], ["SVV", "ORGANISM", 82, 85], ["WT SVV", "ORGANISM", 93, 99], ["CD4", "GENE_OR_GENE_PRODUCT", 147, 150], ["CD8", "GENE_OR_GENE_PRODUCT", 154, 157], ["PBMCs", "CELL", 170, 175], ["SVV", "ORGANISM", 252, 255], ["sensory ganglia", "MULTI-TISSUE_STRUCTURE", 270, 285], ["ResultsSVV", "ORGANISM", 290, 300], ["DNA", "CELLULAR_COMPONENT", 301, 304], ["sensory ganglia", "MULTI-TISSUE_STRUCTURE", 320, 335], ["CD4", "PROTEIN", 147, 150], ["CD8", "PROTEIN", 154, 157], ["PBMCs", "CELL_TYPE", 170, 175], ["SVV", "SPECIES", 82, 85], ["SVV", "SPECIES", 96, 99], ["SVV", "SPECIES", 252, 255], ["ResultsSVV", "SPECIES", 290, 300], ["SVV BAC", "TREATMENT", 82, 89], ["WT SVV", "PROBLEM", 93, 99], ["stimulation", "TREATMENT", 186, 197], ["overlapping viral peptide pools", "PROBLEM", 203, 234], ["SVV viral load", "TEST", 252, 266], ["DNA viral loads in sensory ganglia", "PROBLEM", 301, 335], ["quantitative PCR", "TEST", 353, 369], ["no", "UNCERTAINTY", 11, 13], ["statistically", "OBSERVATION_MODIFIER", 14, 27], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["viral load", "OBSERVATION", 256, 266], ["sensory ganglia", "ANATOMY", 270, 285], ["viral loads", "OBSERVATION", 305, 316], ["sensory ganglia", "ANATOMY", 320, 335]]], ["The viral loads reported in Table 1 reflect SVV genome copy numbers in a portion of the ganglia and are therefore not representative of the entire organ.", [["ganglia", "ANATOMY", 88, 95], ["organ", "ANATOMY", 147, 152], ["ganglia", "ORGAN", 88, 95], ["organ", "ORGAN", 147, 152], ["The viral loads", "TEST", 0, 15], ["viral loads", "OBSERVATION", 4, 15], ["SVV genome", "OBSERVATION", 44, 54], ["copy numbers", "OBSERVATION", 55, 67], ["portion", "ANATOMY_MODIFIER", 73, 80], ["ganglia", "ANATOMY", 88, 95]]], ["Four of the RMs went on to further studies therefore Table 1 shows the latent viral loads for two animals from each cohort.", [["further studies", "TEST", 27, 42], ["the latent viral loads", "PROBLEM", 67, 89], ["viral loads", "OBSERVATION", 78, 89]]], ["We detected SVV DNA within at least one sensory ganglia of each RM infected with SVV BAC and WT SVV indicating that the SVV BAC, like WT SVV is able to traffic to the sensory ganglia, the site of SVV latency.DiscussionCloning viral genomes as bacterial artificial chromosomes (BAC) is an efficient tool to manipulate the viral genome facilitating the study of viral genes in vitro and in vivo.", [["sensory ganglia", "ANATOMY", 40, 55], ["sensory ganglia", "ANATOMY", 167, 182], ["chromosomes", "ANATOMY", 264, 275], ["BAC", "ANATOMY", 277, 280], ["SVV", "ORGANISM", 12, 15], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["sensory ganglia", "ORGAN", 40, 55], ["SVV", "ORGANISM", 81, 84], ["WT SVV", "ORGANISM", 93, 99], ["SVV", "ORGANISM", 120, 123], ["WT SVV", "ORGANISM", 134, 140], ["sensory ganglia", "MULTI-TISSUE_STRUCTURE", 167, 182], ["SVV DNA", "DNA", 12, 19], ["SVV BAC", "DNA", 120, 127], ["Cloning viral genomes", "DNA", 218, 239], ["bacterial artificial chromosomes", "DNA", 243, 275], ["BAC", "DNA", 277, 280], ["viral genome", "DNA", 321, 333], ["viral genes", "DNA", 360, 371], ["SVV", "SPECIES", 12, 15], ["SVV", "SPECIES", 81, 84], ["SVV", "SPECIES", 120, 123], ["SVV DNA", "PROBLEM", 12, 19], ["SVV BAC", "TEST", 81, 88], ["WT SVV", "TEST", 93, 99], ["the SVV BAC", "TEST", 116, 127], ["WT SVV", "PROBLEM", 134, 140], ["Cloning viral genomes", "TREATMENT", 218, 239], ["bacterial artificial chromosomes (BAC", "PROBLEM", 243, 280], ["the study", "TEST", 347, 356], ["SVV DNA", "OBSERVATION", 12, 19], ["sensory ganglia", "ANATOMY", 40, 55], ["SVV BAC", "OBSERVATION", 81, 88], ["WT SVV", "OBSERVATION", 93, 99], ["SVV BAC", "OBSERVATION", 120, 127], ["WT SVV", "OBSERVATION", 134, 140], ["sensory ganglia", "ANATOMY", 167, 182], ["SVV latency", "OBSERVATION", 196, 207], ["viral genome", "OBSERVATION", 321, 333], ["viral genes", "OBSERVATION", 360, 371]]], ["BACs were constructed for the VZV parental Oka virus and the vaccine Oka virus [35-38].", [["BACs", "ANATOMY", 0, 4], ["BACs", "CELL", 0, 4], ["VZV parental Oka virus", "ORGANISM", 30, 52], ["Oka virus", "ORGANISM", 69, 78], ["Oka virus", "SPECIES", 43, 52], ["vaccine Oka virus", "SPECIES", 61, 78], ["VZV", "SPECIES", 30, 33], ["Oka virus", "SPECIES", 43, 52], ["Oka virus", "SPECIES", 69, 78], ["BACs", "TEST", 0, 4], ["the VZV parental Oka virus", "PROBLEM", 26, 52], ["the vaccine", "TREATMENT", 57, 68]]], ["All VZV ORFs have been deleted using BACs or cosmids and tested in cell culture providing valuable information on which VZV genes are essential for viral replication in vitro (reviewed in [39,40]).", [["cell culture", "ANATOMY", 67, 79], ["VZV", "ORGANISM", 4, 7], ["cell culture", "CELL", 67, 79], ["VZV", "ORGANISM", 120, 123], ["VZV ORFs", "DNA", 4, 12], ["BACs", "DNA", 37, 41], ["cosmids", "DNA", 45, 52], ["VZV genes", "DNA", 120, 129], ["VZV", "SPECIES", 4, 7], ["VZV", "SPECIES", 120, 123], ["All VZV ORFs", "PROBLEM", 0, 12], ["BACs or cosmids", "TREATMENT", 37, 52], ["cell culture", "TEST", 67, 79], ["viral replication", "TREATMENT", 148, 165]]], ["Subsequent in vivo analysis of VZV mutant viruses using the SCID-hu mouse model showed that VZV ORFs 1, 2, and 3 are dispensable for viral replication [38], whereas VZV ORF23, which was dispensable for replication in culture, was found to be required for replication in human skin xenografts [41].", [["skin xenografts", "ANATOMY", 276, 291], ["VZV mutant viruses", "ORGANISM", 31, 49], ["SCID-hu mouse", "ORGANISM", 60, 73], ["VZV", "ORGANISM", 92, 95], ["2", "GENE_OR_GENE_PRODUCT", 104, 105], ["3", "GENE_OR_GENE_PRODUCT", 111, 112], ["VZV", "ORGANISM", 165, 168], ["ORF23", "GENE_OR_GENE_PRODUCT", 169, 174], ["human", "ORGANISM", 270, 275], ["skin xenografts", "CANCER", 276, 291], ["VZV ORFs 1, 2, and 3", "DNA", 92, 112], ["VZV ORF23", "PROTEIN", 165, 174], ["mouse", "SPECIES", 68, 73], ["human", "SPECIES", 270, 275], ["VZV", "SPECIES", 31, 34], ["mouse", "SPECIES", 68, 73], ["VZV", "SPECIES", 92, 95], ["VZV", "SPECIES", 165, 168], ["human", "SPECIES", 270, 275], ["vivo analysis", "TEST", 14, 27], ["VZV mutant viruses", "PROBLEM", 31, 49], ["the SCID", "TEST", 56, 64], ["hu mouse model", "TEST", 65, 79], ["VZV ORFs", "TEST", 92, 100], ["viral replication", "PROBLEM", 133, 150], ["VZV ORF23", "TEST", 165, 174], ["culture", "TEST", 217, 224], ["replication in human skin xenografts", "TREATMENT", 255, 291], ["VZV ORFs", "OBSERVATION", 92, 100], ["skin", "ANATOMY", 276, 280]]], ["Similarly, VZV deleted for ORF7 replicated in MeWo cells but in vivo ORF7 was shown to be important for neuroinvasion [40,42].", [["MeWo cells", "ANATOMY", 46, 56], ["neuroinvasion", "DISEASE", 104, 117], ["VZV", "ORGANISM", 11, 14], ["ORF7", "GENE_OR_GENE_PRODUCT", 27, 31], ["MeWo cells", "CELL", 46, 56], ["ORF7", "GENE_OR_GENE_PRODUCT", 69, 73], ["ORF7", "PROTEIN", 27, 31], ["MeWo cells", "CELL_LINE", 46, 56], ["ORF7", "PROTEIN", 69, 73], ["VZV", "SPECIES", 11, 14], ["ORF7", "TREATMENT", 27, 31], ["MeWo cells", "TREATMENT", 46, 56], ["neuroinvasion", "PROBLEM", 104, 117], ["VZV", "OBSERVATION", 11, 14], ["MeWo cells", "OBSERVATION", 46, 56]]], ["Lastly, mutating the furin recognition site of VZV ORF31 (gB), an essential viral protein, did not affect VZV replication in vitro but attenuated viral replication in vivo[43].", [["furin", "GENE_OR_GENE_PRODUCT", 21, 26], ["VZV", "ORGANISM", 47, 50], ["ORF31", "GENE_OR_GENE_PRODUCT", 51, 56], ["gB", "GENE_OR_GENE_PRODUCT", 58, 60], ["VZV", "ORGANISM", 106, 109], ["furin recognition site", "PROTEIN", 21, 43], ["VZV ORF31", "PROTEIN", 47, 56], ["gB", "PROTEIN", 58, 60], ["essential viral protein", "PROTEIN", 66, 89], ["VZV", "SPECIES", 47, 50], ["VZV", "SPECIES", 106, 109], ["VZV ORF31", "TEST", 47, 56], ["an essential viral protein", "PROBLEM", 63, 89], ["VZV replication", "TREATMENT", 106, 121], ["viral protein", "OBSERVATION", 76, 89]]], ["Studying VZV mutant viruses in the SCID-hu mouse model has provided valuable insight into VZV biology, further evaluation of the role of different VZV ORFs in pathogenesis and the immune response in vivo is hampered by the fact that VZV is an obligate human pathogen.", [["VZV mutant viruses", "ORGANISM", 9, 27], ["SCID-hu mouse", "ORGANISM", 35, 48], ["VZV", "ORGANISM", 90, 93], ["VZV", "ORGANISM", 147, 150], ["VZV", "ORGANISM", 233, 236], ["human", "ORGANISM", 252, 257], ["VZV ORFs", "DNA", 147, 155], ["mouse", "SPECIES", 43, 48], ["human", "SPECIES", 252, 257], ["VZV", "SPECIES", 9, 12], ["mouse", "SPECIES", 43, 48], ["VZV", "SPECIES", 90, 93], ["VZV", "SPECIES", 147, 150], ["VZV", "SPECIES", 233, 236], ["human", "SPECIES", 252, 257], ["VZV mutant viruses", "PROBLEM", 9, 27], ["further evaluation", "TEST", 103, 121], ["different VZV ORFs", "PROBLEM", 137, 155], ["pathogenesis", "PROBLEM", 159, 171], ["VZV", "PROBLEM", 233, 236], ["an obligate human pathogen", "PROBLEM", 240, 266], ["viruses", "OBSERVATION", 20, 27], ["VZV", "OBSERVATION", 233, 236]]], ["SVV is a simian homolog of VZV that causes varicella and zoster in nonhuman primates [4-6].DiscussionRecently, the SVV genome was cloned as a BAC and SVV virus generated using the SVV BAC genetic system was found to be similar to WT SVV in vitro[11].", [["VZV", "DISEASE", 27, 30], ["varicella and zoster", "DISEASE", 43, 63], ["SVV", "ORGANISM", 0, 3], ["simian", "ORGANISM", 9, 15], ["VZV", "ORGANISM", 27, 30], ["zoster", "ORGANISM", 57, 63], ["nonhuman primates", "ORGANISM", 67, 84], ["SVV", "ORGANISM", 115, 118], ["BAC", "CELLULAR_COMPONENT", 142, 145], ["SVV virus", "ORGANISM", 150, 159], ["SVV", "ORGANISM", 180, 183], ["WT SVV", "ORGANISM", 230, 236], ["SVV genome", "DNA", 115, 125], ["SVV", "SPECIES", 0, 3], ["VZV", "SPECIES", 27, 30], ["SVV virus", "SPECIES", 150, 159], ["SVV", "SPECIES", 180, 183], ["SVV", "TEST", 0, 3], ["VZV", "PROBLEM", 27, 30], ["varicella", "PROBLEM", 43, 52], ["zoster", "PROBLEM", 57, 63], ["the SVV genome", "PROBLEM", 111, 125], ["a BAC and SVV virus", "PROBLEM", 140, 159], ["VZV", "OBSERVATION", 27, 30], ["varicella", "OBSERVATION_MODIFIER", 43, 52], ["zoster", "OBSERVATION", 57, 63], ["SVV genome", "OBSERVATION", 115, 125]]], ["Mutagenesis of SVV ORF10 showed that SVV ORF10 is nonessential for replication in vitro[11].", [["SVV", "ORGANISM", 15, 18], ["ORF10", "GENE_OR_GENE_PRODUCT", 19, 24], ["SVV", "ORGANISM", 37, 40], ["ORF10", "GENE_OR_GENE_PRODUCT", 41, 46], ["SVV ORF10", "DNA", 15, 24], ["SVV ORF10", "DNA", 37, 46], ["SVV", "SPECIES", 15, 18], ["SVV", "SPECIES", 37, 40], ["Mutagenesis of SVV ORF10", "TEST", 0, 24], ["SVV ORF10", "TREATMENT", 37, 46], ["SVV", "ANATOMY", 15, 18]]], ["Additionally, generation of a SVV ORF 63/70 mutant demonstrated impaired growth in Vero cells [44].", [["Vero cells", "ANATOMY", 83, 93], ["SVV", "ORGANISM", 30, 33], ["63/70", "GENE_OR_GENE_PRODUCT", 38, 43], ["Vero cells", "CELL", 83, 93], ["SVV ORF 63/70 mutant", "PROTEIN", 30, 50], ["Vero cells", "CELL_LINE", 83, 93], ["a SVV ORF", "TEST", 28, 37], ["impaired growth in Vero cells", "PROBLEM", 64, 93], ["impaired", "OBSERVATION_MODIFIER", 64, 72], ["growth", "OBSERVATION_MODIFIER", 73, 79], ["Vero cells", "OBSERVATION", 83, 93]]], ["In the present study we further the analysis of SVV BAC by infecting rhesus macaques and investigating the pathogenesis of SVV BAC compared to WT SVV in vivo.", [["SVV", "ORGANISM", 48, 51], ["BAC", "ORGANISM", 52, 55], ["rhesus", "ORGANISM", 69, 75], ["macaques", "ORGANISM", 76, 84], ["SVV", "ORGANISM", 123, 126], ["WT SVV", "ORGANISM", 143, 149], ["SVV BAC", "DNA", 48, 55], ["rhesus macaques", "SPECIES", 69, 84], ["SVV", "SPECIES", 48, 51], ["rhesus macaques", "SPECIES", 69, 84], ["SVV", "SPECIES", 123, 126], ["SVV", "SPECIES", 146, 149], ["the analysis", "TEST", 32, 44], ["SVV BAC", "TREATMENT", 48, 55], ["infecting rhesus macaques", "TREATMENT", 59, 84], ["SVV BAC", "PROBLEM", 123, 130], ["WT SVV", "TEST", 143, 149], ["SVV BAC", "OBSERVATION", 48, 55], ["SVV BAC", "OBSERVATION", 123, 130]]], ["The combination of the rhesus macaque animal model and the SVV BAC will provide a robust tool to examine viral ORFs important for pathogenesis and help to target VZV ORFs that will improve vaccine efficacy.DiscussionTo compare the genome of the SVV BAC to WT SVV we utilized comparative genomic hybridization.", [["rhesus", "ORGANISM", 23, 29], ["macaque", "ORGANISM", 30, 37], ["SVV", "ORGANISM", 59, 62], ["VZV", "ORGANISM", 162, 165], ["SVV", "ORGANISM", 245, 248], ["SVV BAC", "DNA", 59, 66], ["viral ORFs", "DNA", 105, 115], ["VZV ORFs", "DNA", 162, 170], ["SVV BAC", "DNA", 245, 252], ["rhesus macaque", "SPECIES", 23, 37], ["rhesus macaque", "SPECIES", 23, 37], ["SVV", "SPECIES", 59, 62], ["VZV", "SPECIES", 162, 165], ["SVV", "SPECIES", 245, 248], ["SVV", "SPECIES", 259, 262], ["the rhesus macaque animal model", "TREATMENT", 19, 50], ["the SVV BAC", "TREATMENT", 55, 66], ["viral ORFs", "PROBLEM", 105, 115], ["pathogenesis", "PROBLEM", 130, 142], ["VZV ORFs", "PROBLEM", 162, 170], ["comparative genomic hybridization", "TREATMENT", 275, 308]]], ["CGH analysis was employed as a cost-effective and accurate strategy to analyze genomic DNA from multiple viruses.", [["DNA", "CELLULAR_COMPONENT", 87, 90], ["genomic DNA", "DNA", 79, 90], ["CGH analysis", "TEST", 0, 12], ["genomic DNA", "PROBLEM", 79, 90], ["multiple viruses", "PROBLEM", 96, 112], ["multiple", "OBSERVATION_MODIFIER", 96, 104], ["viruses", "OBSERVATION", 105, 112]]], ["This technique is sensitive enough to detect single base changes in addition to insertions, deletion or rearrangements in the genome [45-47].", [["single base changes", "PROBLEM", 45, 64], ["deletion", "PROBLEM", 92, 100]]], ["We sequenced two sites in the SVV BAC genome that displayed variations in hybridization when compared to WT SVV.", [["SVV BAC genome", "DNA", 30, 44], ["SVV", "SPECIES", 30, 33], ["SVV", "SPECIES", 108, 111], ["variations in hybridization", "PROBLEM", 60, 87], ["WT SVV", "TEST", 105, 111], ["SVV", "ANATOMY", 30, 33], ["BAC genome", "OBSERVATION", 34, 44], ["variations", "OBSERVATION_MODIFIER", 60, 70]]], ["In ORF22 a point mutation at nucleotide 41990 was found producing an amino acid change from valine to isoleucine.", [["nucleotide 41990", "CHEMICAL", 29, 45], ["amino acid", "CHEMICAL", 69, 79], ["valine", "CHEMICAL", 92, 98], ["isoleucine", "CHEMICAL", 102, 112], ["nucleotide", "CHEMICAL", 29, 39], ["amino acid", "CHEMICAL", 69, 79], ["valine", "CHEMICAL", 92, 98], ["isoleucine", "CHEMICAL", 102, 112], ["ORF22", "GENE_OR_GENE_PRODUCT", 3, 8], ["amino acid", "AMINO_ACID", 69, 79], ["valine", "AMINO_ACID", 92, 98], ["isoleucine", "AMINO_ACID", 102, 112], ["ORF22", "DNA", 3, 8], ["a point mutation", "PROBLEM", 9, 25], ["an amino acid change", "TREATMENT", 66, 86], ["valine to isoleucine", "TREATMENT", 92, 112], ["amino acid", "OBSERVATION", 69, 79]]], ["SVV and VZV ORF22 are putative tegument proteins based on homology to HSV-1 UL36 [48].", [["tegument", "ANATOMY", 31, 39], ["SVV", "ORGANISM", 0, 3], ["VZV", "ORGANISM", 8, 11], ["ORF22", "GENE_OR_GENE_PRODUCT", 12, 17], ["HSV-1", "ORGANISM", 70, 75], ["SVV", "PROTEIN", 0, 3], ["VZV ORF22", "PROTEIN", 8, 17], ["tegument proteins", "PROTEIN", 31, 48], ["SVV", "SPECIES", 0, 3], ["VZV", "SPECIES", 8, 11], ["HSV-1", "SPECIES", 70, 75], ["SVV", "TEST", 0, 3], ["VZV", "PROBLEM", 8, 11], ["putative tegument proteins", "PROBLEM", 22, 48], ["HSV", "TEST", 70, 73]]], ["UL36 is a HSV-1 late gene and the HSV-1 virion contains 100\u2013150 copies of UL36 [49,50].", [["UL36", "GENE_OR_GENE_PRODUCT", 0, 4], ["HSV-1", "ORGANISM", 10, 15], ["HSV-1", "ORGANISM", 34, 39], ["virion", "ORGANISM", 40, 46], ["UL36", "GENE_OR_GENE_PRODUCT", 74, 78], ["UL36", "DNA", 0, 4], ["HSV-1 late gene", "DNA", 10, 25], ["HSV-1", "SPECIES", 34, 39], ["HSV-1", "SPECIES", 10, 15], ["HSV-1", "SPECIES", 34, 39], ["a HSV", "TEST", 8, 13], ["the HSV", "TEST", 30, 37], ["UL36", "TEST", 74, 78]]], ["UL36 is essential to HSV-1 replication and the phenotype of a null mutant virus showed accumulation of capsids containing cytosolic DNA that did not mature into enveloped virions [51-53].", [["cytosolic", "ANATOMY", 122, 131], ["virions", "ANATOMY", 171, 178], ["UL36", "GENE_OR_GENE_PRODUCT", 0, 4], ["HSV-1", "ORGANISM", 21, 26], ["cytosolic", "CELLULAR_COMPONENT", 122, 131], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["UL36", "PROTEIN", 0, 4], ["cytosolic DNA", "DNA", 122, 135], ["HSV-1", "SPECIES", 21, 26], ["HSV-1", "SPECIES", 21, 26], ["HSV", "TEST", 21, 24], ["a null mutant virus", "PROBLEM", 60, 79], ["accumulation of capsids containing cytosolic DNA", "PROBLEM", 87, 135], ["HSV", "OBSERVATION", 21, 24], ["cytosolic DNA", "OBSERVATION", 122, 135]]], ["Though, the evidence suggests that the amino acid change in SVV BAC does not constitute a significant change in the protein.", [["amino acid", "CHEMICAL", 39, 49], ["amino acid", "CHEMICAL", 39, 49], ["amino acid", "AMINO_ACID", 39, 49], ["SVV BAC", "DNA", 60, 67], ["SVV", "SPECIES", 60, 63], ["the amino acid change", "PROBLEM", 35, 56], ["SVV BAC", "TEST", 60, 67], ["a significant change in the protein", "PROBLEM", 88, 123], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["change", "OBSERVATION", 102, 108]]], ["In vitro SVV BAC displays similar plaque size and replication kinetics in Vero cell monolayers as compared to WT SVV [11].", [["plaque", "ANATOMY", 34, 40], ["Vero cell monolayers", "ANATOMY", 74, 94], ["SVV", "ORGANISM", 9, 12], ["plaque", "PATHOLOGICAL_FORMATION", 34, 40], ["Vero cell monolayers", "CELL", 74, 94], ["SVV BAC", "DNA", 9, 16], ["Vero cell monolayers", "CELL_LINE", 74, 94], ["SVV", "SPECIES", 9, 12], ["vitro SVV BAC", "TEST", 3, 16], ["similar plaque size", "PROBLEM", 26, 45], ["replication kinetics", "PROBLEM", 50, 70], ["Vero cell monolayers", "TREATMENT", 74, 94], ["WT SVV", "TEST", 110, 116], ["SVV BAC", "OBSERVATION", 9, 16], ["similar", "OBSERVATION_MODIFIER", 26, 33], ["plaque", "OBSERVATION", 34, 40], ["size", "OBSERVATION_MODIFIER", 41, 45], ["replication", "OBSERVATION_MODIFIER", 50, 61], ["kinetics", "OBSERVATION_MODIFIER", 62, 70], ["Vero cell monolayers", "OBSERVATION", 74, 94]]], ["Our data in vivo shows that SVV BAC displays similar replication kinetics, immune response and establishment of latency compared to WT SVV.", [["SVV BAC", "ORGANISM", 28, 35], ["WT SVV", "ORGANISM", 132, 138], ["SVV BAC", "DNA", 28, 35], ["SVV", "SPECIES", 28, 31], ["SVV", "SPECIES", 135, 138], ["Our data", "TEST", 0, 8], ["SVV BAC", "TEST", 28, 35], ["similar replication kinetics", "PROBLEM", 45, 73], ["latency", "PROBLEM", 112, 119], ["WT SVV", "TEST", 132, 138], ["replication kinetics", "OBSERVATION", 53, 73]]], ["Potentially the position of the amino acid change or that the change is a nonpolar side chain to a nonpolar side change allows for WT behavior.DiscussionThe replication kinetics of SVV BAC in the bronchoalveolar lavage cells (the site of virus inoculation) and in the peripheral blood was statistically similar to WT SVV.", [["bronchoalveolar lavage cells", "ANATOMY", 196, 224], ["peripheral blood", "ANATOMY", 268, 284], ["amino acid", "CHEMICAL", 32, 42], ["amino acid", "CHEMICAL", 32, 42], ["amino acid", "AMINO_ACID", 32, 42], ["SVV", "ORGANISM", 181, 184], ["bronchoalveolar lavage cells", "CELL", 196, 224], ["peripheral blood", "ORGANISM_SUBSTANCE", 268, 284], ["SVV BAC", "DNA", 181, 188], ["bronchoalveolar lavage cells", "CELL_TYPE", 196, 224], ["SVV", "SPECIES", 181, 184], ["the amino acid change", "TREATMENT", 28, 49], ["a nonpolar side chain", "TREATMENT", 72, 93], ["a nonpolar side change", "TREATMENT", 97, 119], ["SVV BAC", "TREATMENT", 181, 188], ["the bronchoalveolar lavage cells", "TREATMENT", 192, 224], ["virus inoculation", "TREATMENT", 238, 255], ["the peripheral blood", "TEST", 264, 284], ["WT SVV", "TEST", 314, 320], ["SVV BAC", "OBSERVATION", 181, 188], ["bronchoalveolar lavage cells", "OBSERVATION", 196, 224], ["peripheral", "ANATOMY_MODIFIER", 268, 278], ["blood", "ANATOMY", 279, 284]]], ["Related, the spread of varicella rash was also similar between cohorts and lasted between 7 and 10 days post-infection.", [["varicella rash", "DISEASE", 23, 37], ["varicella rash", "PROBLEM", 23, 37], ["spread", "OBSERVATION_MODIFIER", 13, 19], ["varicella rash", "OBSERVATION", 23, 37]]], ["In Figure 2A and B we show pictures of two RMs infected with SVV BAC or WT SVV, which showed representative rash and also illustrates the variation in rash spread we see in our animals.", [["rash", "DISEASE", 108, 112], ["rash", "DISEASE", 151, 155], ["B", "CELL", 17, 18], ["SVV", "ORGANISM", 61, 64], ["WT SVV", "ORGANISM", 72, 78], ["rash", "PATHOLOGICAL_FORMATION", 108, 112], ["SVV", "SPECIES", 61, 64], ["SVV", "SPECIES", 75, 78], ["two RMs", "PROBLEM", 39, 46], ["SVV BAC", "PROBLEM", 61, 68], ["WT SVV", "PROBLEM", 72, 78], ["representative rash", "PROBLEM", 93, 112], ["the variation", "PROBLEM", 134, 147], ["rash spread", "PROBLEM", 151, 162], ["RMs", "OBSERVATION_MODIFIER", 43, 46], ["infected", "OBSERVATION", 47, 55], ["SVV BAC", "OBSERVATION", 61, 68], ["rash", "OBSERVATION", 108, 112]]], ["In two animals infected with WT SVV, we did not detect viral DNA in the skin lesions but due to the nature of the skin punch biopsies as well as the timing of the rash, which varies between animals usually between 7 to 10 days post-infection, we may not have obtained a lesion spot with detectable viral DNA.DiscussionWe also followed the immune response to SVV BAC during acute infection and found SVV BAC to elicit a parallel immune response in vivo.", [["skin lesions", "ANATOMY", 72, 84], ["skin punch biopsies", "ANATOMY", 114, 133], ["lesion spot", "ANATOMY", 270, 281], ["rash", "DISEASE", 163, 167], ["acute infection", "DISEASE", 373, 388], ["WT SVV", "ORGANISM", 29, 35], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["skin lesions", "PATHOLOGICAL_FORMATION", 72, 84], ["skin punch biopsies", "MULTI-TISSUE_STRUCTURE", 114, 133], ["DNA", "CELLULAR_COMPONENT", 304, 307], ["SVV", "ORGANISM", 358, 361], ["SVV", "ORGANISM", 399, 402], ["viral DNA", "DNA", 55, 64], ["viral DNA", "DNA", 298, 307], ["SVV BAC", "DNA", 358, 365], ["SVV BAC", "DNA", 399, 406], ["SVV", "SPECIES", 32, 35], ["SVV", "SPECIES", 358, 361], ["SVV", "SPECIES", 399, 402], ["WT SVV", "TEST", 29, 35], ["viral DNA", "PROBLEM", 55, 64], ["the skin lesions", "PROBLEM", 68, 84], ["the skin punch biopsies", "TEST", 110, 133], ["the rash", "PROBLEM", 159, 167], ["a lesion spot", "PROBLEM", 268, 281], ["detectable viral DNA", "PROBLEM", 287, 307], ["SVV BAC", "TEST", 358, 365], ["acute infection", "PROBLEM", 373, 388], ["SVV BAC", "TREATMENT", 399, 406], ["infected", "OBSERVATION", 15, 23], ["viral DNA", "OBSERVATION", 55, 64], ["skin", "ANATOMY", 72, 76], ["lesions", "OBSERVATION", 77, 84], ["skin", "ANATOMY", 114, 118], ["punch", "OBSERVATION", 119, 124], ["rash", "OBSERVATION", 163, 167], ["lesion", "OBSERVATION", 270, 276], ["viral DNA", "OBSERVATION", 298, 307], ["acute", "OBSERVATION_MODIFIER", 373, 378], ["infection", "OBSERVATION", 379, 388]]], ["We analyzed the proliferation kinetics of antigen experienced B cells, the production of SVV-specific IgG antibodies as well as the proliferation kinetics of memory T cells and the IFN\u03b3/TNF\u03b1 response of SVV-specific CD4 and CD8 T cells, and each parameter was analogous.", [["B cells", "ANATOMY", 62, 69], ["memory T cells", "ANATOMY", 158, 172], ["CD4", "ANATOMY", 216, 219], ["CD8 T cells", "ANATOMY", 224, 235], ["B cells", "CELL", 62, 69], ["SVV", "ORGANISM", 89, 92], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 102, 116], ["memory T cells", "CELL", 158, 172], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 181, 185], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 186, 190], ["SVV", "ORGANISM", 203, 206], ["CD4", "CELL", 216, 219], ["CD8", "GENE_OR_GENE_PRODUCT", 224, 227], ["B cells", "CELL_TYPE", 62, 69], ["SVV", "PROTEIN", 89, 92], ["IgG antibodies", "PROTEIN", 102, 116], ["memory T cells", "CELL_TYPE", 158, 172], ["IFN\u03b3", "PROTEIN", 181, 185], ["TNF\u03b1", "PROTEIN", 186, 190], ["CD4 and CD8 T cells", "CELL_TYPE", 216, 235], ["SVV", "SPECIES", 89, 92], ["SVV", "SPECIES", 203, 206], ["the proliferation kinetics", "TEST", 12, 38], ["B cells", "PROBLEM", 62, 69], ["SVV", "TEST", 89, 92], ["specific IgG antibodies", "PROBLEM", 93, 116], ["the IFN\u03b3/TNF", "TEST", 177, 189], ["SVV", "TEST", 203, 206], ["CD8 T cells", "PROBLEM", 224, 235], ["proliferation kinetics", "OBSERVATION", 16, 38]]], ["We did measure a statistical difference in MZ-like B cells at 10 dpi in the BAL where RMs infected with WT SVV displayed a higher peak percentage of Ki67 positive cells.", [["MZ-like B cells", "ANATOMY", 43, 58], ["BAL", "ANATOMY", 76, 79], ["Ki67 positive cells", "ANATOMY", 149, 168], ["MZ", "CHEMICAL", 43, 45], ["MZ-like B cells", "CELL", 43, 58], ["WT SVV", "ORGANISM", 104, 110], ["Ki67", "GENE_OR_GENE_PRODUCT", 149, 153], ["cells", "CELL", 163, 168], ["MZ", "CELL_TYPE", 43, 45], ["B cells", "CELL_TYPE", 51, 58], ["Ki67 positive cells", "CELL_TYPE", 149, 168], ["a statistical difference in MZ-like B cells", "PROBLEM", 15, 58], ["the BAL", "TEST", 72, 79], ["RMs infected", "PROBLEM", 86, 98], ["WT SVV", "TEST", 104, 110], ["Ki67 positive cells", "PROBLEM", 149, 168], ["BAL", "ANATOMY", 76, 79], ["RMs", "OBSERVATION_MODIFIER", 86, 89], ["infected", "OBSERVATION", 90, 98], ["Ki67 positive cells", "OBSERVATION", 149, 168]]], ["However, this difference did not translate to a higher antibody titer in the WT SVV infected RMs.", [["SVV infected", "DISEASE", 80, 92], ["WT SVV", "ORGANISM", 77, 83], ["SVV", "SPECIES", 80, 83], ["a higher antibody titer", "PROBLEM", 46, 69], ["SVV", "ANATOMY", 80, 83], ["infected RMs", "OBSERVATION", 84, 96]]], ["This difference could be due to the small sample size (n=4) and the outbred nature of rhesus macaques.DiscussionInfection with SVV BAC also resulted in a comparable upregulation of chemokines, cytokines, and growth factors during the early stages of acute infection in the lungs compared to RMs infected with WT SVV.", [["sample", "ANATOMY", 42, 48], ["lungs", "ANATOMY", 273, 278], ["infection", "DISEASE", 256, 265], ["rhesus", "ORGANISM", 86, 92], ["macaques", "ORGANISM", 93, 101], ["lungs", "ORGAN", 273, 278], ["WT SVV", "ORGANISM", 309, 315], ["chemokines", "PROTEIN", 181, 191], ["cytokines", "PROTEIN", 193, 202], ["growth factors", "PROTEIN", 208, 222], ["rhesus macaques", "SPECIES", 86, 101], ["rhesus macaques", "SPECIES", 86, 101], ["SVV", "SPECIES", 127, 130], ["SVV", "SPECIES", 312, 315], ["the small sample size", "PROBLEM", 32, 53], ["SVV BAC", "TEST", 127, 134], ["cytokines", "PROBLEM", 193, 202], ["growth factors", "PROBLEM", 208, 222], ["acute infection in the lungs", "PROBLEM", 250, 278], ["WT SVV", "TEST", 309, 315], ["could be due to", "UNCERTAINTY", 16, 31], ["small", "OBSERVATION_MODIFIER", 36, 41], ["sample", "OBSERVATION_MODIFIER", 42, 48], ["size", "OBSERVATION_MODIFIER", 49, 53], ["rhesus macaques", "OBSERVATION", 86, 101], ["chemokines", "OBSERVATION", 181, 191], ["acute", "OBSERVATION_MODIFIER", 250, 255], ["infection", "OBSERVATION", 256, 265], ["lungs", "ANATOMY", 273, 278]]], ["Peak levels of IFN\u03b1, an important antiviral cytokine, occurred at 3 dpi, which corresponds to peak viral loads in the lungs also at 3 dpi.", [["lungs", "ANATOMY", 118, 123], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 15, 19], ["lungs", "ORGAN", 118, 123], ["IFN\u03b1", "PROTEIN", 15, 19], ["antiviral cytokine", "PROTEIN", 34, 52], ["Peak levels", "TEST", 0, 11], ["IFN\u03b1", "TEST", 15, 19], ["an important antiviral cytokine", "PROBLEM", 21, 52], ["peak viral loads in the lungs", "PROBLEM", 94, 123], ["antiviral cytokine", "OBSERVATION", 34, 52], ["peak viral loads", "OBSERVATION", 94, 110], ["lungs", "ANATOMY", 118, 123]]], ["Type I interferons are early immune effectors and are important cytokines during initial infection to limit viral replication and spread, including herpesviruses [54-56].", [["infection", "DISEASE", 89, 98], ["Type I interferons", "GENE_OR_GENE_PRODUCT", 0, 18], ["Type I interferons", "PROTEIN", 0, 18], ["cytokines", "PROTEIN", 64, 73], ["Type I interferons", "PROBLEM", 0, 18], ["early immune effectors", "PROBLEM", 23, 45], ["important cytokines", "PROBLEM", 54, 73], ["initial infection", "PROBLEM", 81, 98], ["viral replication", "PROBLEM", 108, 125], ["herpesviruses", "PROBLEM", 148, 161], ["interferons", "OBSERVATION", 7, 18], ["immune effectors", "OBSERVATION", 29, 45]]], ["The concentrations of several T cell-recruiting chemokines (MCP-1, MIG, I-TAC) peaked 7 days prior to the observed peak in proliferating T cells in BAL samples.", [["T cell", "ANATOMY", 30, 36], ["T cells", "ANATOMY", 137, 144], ["BAL samples", "ANATOMY", 148, 159], ["T cell", "CELL", 30, 36], ["MCP-1", "GENE_OR_GENE_PRODUCT", 60, 65], ["MIG", "GENE_OR_GENE_PRODUCT", 67, 70], ["I-TAC", "GENE_OR_GENE_PRODUCT", 72, 77], ["T cells", "CELL", 137, 144], ["BAL samples", "TISSUE", 148, 159], ["chemokines", "PROTEIN", 48, 58], ["MCP", "PROTEIN", 60, 63], ["MIG", "PROTEIN", 67, 70], ["I", "PROTEIN", 72, 73], ["TAC", "PROTEIN", 74, 77], ["proliferating T cells", "CELL_TYPE", 123, 144], ["several T cell", "TREATMENT", 22, 36], ["MCP", "TEST", 60, 63], ["MIG, I-TAC", "TREATMENT", 67, 77], ["BAL samples", "TEST", 148, 159], ["concentrations", "OBSERVATION_MODIFIER", 4, 18]]], ["We also detected increased concentrations of TNF\u03b1 (3 dpi) and IFN\u03b3 (7 dpi), which is indicative of Th1 immune responses and correlates with an increase in CD4 CM in BAL samples.", [["CD4 CM", "ANATOMY", 155, 161], ["BAL samples", "ANATOMY", 165, 176], ["TNF\u03b1 (3 dpi", "GENE_OR_GENE_PRODUCT", 45, 56], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 62, 66], ["CD4 CM", "GENE_OR_GENE_PRODUCT", 155, 161], ["BAL samples", "CANCER", 165, 176], ["TNF\u03b1", "PROTEIN", 45, 49], ["IFN\u03b3", "PROTEIN", 62, 66], ["CD4", "PROTEIN", 155, 158], ["increased concentrations of TNF", "PROBLEM", 17, 48], ["IFN\u03b3", "TEST", 62, 66], ["Th1 immune responses", "PROBLEM", 99, 119], ["an increase in CD4 CM", "PROBLEM", 140, 161], ["BAL samples", "TEST", 165, 176], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["concentrations", "OBSERVATION_MODIFIER", 27, 41], ["indicative of", "UNCERTAINTY", 85, 98], ["Th1 immune", "OBSERVATION", 99, 109], ["increase", "OBSERVATION_MODIFIER", 143, 151], ["CD4 CM", "OBSERVATION", 155, 161]]], ["Peak concentrations of IL-2 were detected 7 days prior (7 dpi) to the peak proliferation of CD4 and CD8 T cells (14 dpi).", [["CD4", "ANATOMY", 92, 95], ["CD8 T cells", "ANATOMY", 100, 111], ["IL-2", "GENE_OR_GENE_PRODUCT", 23, 27], ["CD4", "GENE_OR_GENE_PRODUCT", 92, 95], ["CD8 T", "GENE_OR_GENE_PRODUCT", 100, 105], ["IL", "PROTEIN", 23, 25], ["CD4 and CD8 T cells", "CELL_TYPE", 92, 111], ["Peak concentrations", "TEST", 0, 19], ["IL", "TEST", 23, 25], ["the peak proliferation", "TEST", 66, 88], ["CD4", "TEST", 92, 95], ["CD8 T cells", "TEST", 100, 111]]], ["Levels of IL-12, which play a role in enhancing cytotoxic function of CD8 T cells, peaked 4 days before peak proliferation of CD8 T cells in BAL samples.", [["CD8 T cells", "ANATOMY", 70, 81], ["CD8 T cells", "ANATOMY", 126, 137], ["BAL samples", "ANATOMY", 141, 152], ["IL-12", "GENE_OR_GENE_PRODUCT", 10, 15], ["CD8 T cells", "CELL", 70, 81], ["CD8 T cells", "CELL", 126, 137], ["BAL samples", "CANCER", 141, 152], ["IL-12", "PROTEIN", 10, 15], ["CD8 T cells", "CELL_TYPE", 70, 81], ["CD8 T cells", "CELL_TYPE", 126, 137], ["Levels of IL", "TEST", 0, 12], ["CD8 T cells", "PROBLEM", 70, 81], ["peak proliferation", "TEST", 104, 122], ["CD8 T cells", "PROBLEM", 126, 137], ["BAL samples", "TEST", 141, 152], ["CD8 T cells", "OBSERVATION", 126, 137]]], ["Interestingly, we also detected an increase in growth factors in the BAL fluid, which peaked from 7 to 10 days post-infection.", [["BAL fluid", "ANATOMY", 69, 78], ["BAL fluid", "ORGANISM_SUBSTANCE", 69, 78], ["growth factors", "PROTEIN", 47, 61], ["an increase in growth factors", "PROBLEM", 32, 61], ["the BAL fluid", "PROBLEM", 65, 78], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["growth", "OBSERVATION_MODIFIER", 47, 53], ["factors", "OBSERVATION_MODIFIER", 54, 61], ["BAL", "ANATOMY", 69, 72], ["fluid", "OBSERVATION", 73, 78], ["7 to 10 days", "OBSERVATION_MODIFIER", 98, 110]]], ["Many of these growth factors are involved in wound healing and might represent a response to tissue injury induced by SVV replication within the lungs (site of inoculation).DiscussionLastly we found that both SVV BAC and WT SVV established latency within the sensory ganglia.", [["wound", "ANATOMY", 45, 50], ["tissue", "ANATOMY", 93, 99], ["lungs", "ANATOMY", 145, 150], ["site", "ANATOMY", 152, 156], ["sensory ganglia", "ANATOMY", 259, 274], ["tissue injury", "DISEASE", 93, 106], ["wound", "PATHOLOGICAL_FORMATION", 45, 50], ["tissue", "TISSUE", 93, 99], ["SVV", "ORGANISM", 118, 121], ["lungs", "ORGAN", 145, 150], ["SVV", "ORGANISM", 209, 212], ["sensory ganglia", "MULTI-TISSUE_STRUCTURE", 259, 274], ["growth factors", "PROTEIN", 14, 28], ["SVV BAC", "DNA", 209, 216], ["SVV", "SPECIES", 118, 121], ["SVV", "SPECIES", 209, 212], ["these growth factors", "PROBLEM", 8, 28], ["wound healing", "PROBLEM", 45, 58], ["tissue injury", "PROBLEM", 93, 106], ["inoculation", "PROBLEM", 160, 171], ["SVV BAC", "TEST", 209, 216], ["WT SVV", "TEST", 221, 227], ["growth", "OBSERVATION_MODIFIER", 14, 20], ["wound", "ANATOMY", 45, 50], ["healing", "OBSERVATION", 51, 58], ["might represent", "UNCERTAINTY", 63, 78], ["injury", "OBSERVATION", 100, 106], ["SVV replication", "OBSERVATION", 118, 133], ["lungs", "ANATOMY", 145, 150], ["inoculation", "OBSERVATION", 160, 171], ["SVV BAC", "OBSERVATION", 209, 216], ["WT SVV", "OBSERVATION", 221, 227], ["latency", "OBSERVATION_MODIFIER", 240, 247], ["sensory ganglia", "ANATOMY", 259, 274]]], ["Viral DNA was detected in at least one ganglion from each RM measured by quantitative PCR.", [["ganglion", "ANATOMY", 39, 47], ["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["ganglion", "TISSUE", 39, 47], ["Viral DNA", "PROBLEM", 0, 9], ["quantitative PCR", "TEST", 73, 89], ["DNA", "OBSERVATION", 6, 9]]], ["In summary, SVV BAC is as pathogenic in vivo as WT SVV.", [["SVV", "ORGANISM", 12, 15], ["SVV BAC", "DNA", 12, 19], ["SVV", "SPECIES", 12, 15], ["SVV BAC", "TEST", 12, 19], ["pathogenic", "PROBLEM", 26, 36], ["WT SVV", "TEST", 48, 54], ["SVV BAC", "OBSERVATION", 12, 19]]], ["Future studies will utilize the SVV BAC genetic system to generate knockout viruses to help characterize the role of SVV genes in acute infection, the establishment and maintenance of latency, and reactivation in vivo, a critical step in the understanding of viral factors that impact VZV pathogenesis and the immune response to VZV.Cells and viruses ::: Materials and methodsBacterial artificial chromosome (BAC)-derived SVV was generated from self-excisable pSVV-BAC resulting in complete excision of plasmid sequences from the virus genome [11].", [["Cells", "ANATOMY", 333, 338], ["BAC", "ANATOMY", 409, 412], ["acute infection", "DISEASE", 130, 145], ["SVV", "ORGANISM", 117, 120], ["VZV", "ORGANISM", 285, 288], ["VZV", "ORGANISM", 329, 332], ["Cells", "CELL", 333, 338], ["BAC", "CELLULAR_COMPONENT", 409, 412], ["SVV", "ORGANISM", 422, 425], ["pSVV-BAC", "CELL", 460, 468], ["SVV genes", "DNA", 117, 126], ["viral factors", "PROTEIN", 259, 272], ["self-excisable pSVV-BAC", "DNA", 445, 468], ["plasmid sequences", "DNA", 503, 520], ["SVV", "SPECIES", 117, 120], ["VZV", "SPECIES", 285, 288], ["VZV", "SPECIES", 329, 332], ["SVV", "SPECIES", 422, 425], ["Future studies", "TEST", 0, 14], ["the SVV BAC genetic system", "TREATMENT", 28, 54], ["knockout viruses", "PROBLEM", 67, 83], ["SVV genes", "PROBLEM", 117, 126], ["acute infection", "PROBLEM", 130, 145], ["latency", "PROBLEM", 184, 191], ["viral factors", "PROBLEM", 259, 272], ["VZV pathogenesis", "PROBLEM", 285, 301], ["VZV", "PROBLEM", 329, 332], ["methodsBacterial artificial chromosome (BAC)", "PROBLEM", 369, 413], ["SVV", "TEST", 422, 425], ["BAC", "PROBLEM", 465, 468], ["complete excision of plasmid sequences", "TREATMENT", 482, 520], ["the virus genome", "PROBLEM", 526, 542], ["SVV genes", "OBSERVATION", 117, 126], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["infection", "OBSERVATION", 136, 145], ["viruses", "OBSERVATION", 343, 350], ["artificial chromosome", "OBSERVATION", 386, 407]]], ["Wild-type (WT) simian varicella virus (SVV, Cercopithecine herpesvirus 9) and SVV BAC were propagated as previously described, briefly Vero cells maintained in Eagle\u2019s minimal essential medium (EMEM) supplemented with 5% newborn bovine serum, penicillin and streptomycin, WT SVV and SVV BAC infected Veros were harvested by scraping and frozen in Vero media supplemented with 10% dimethyl sulfoxide (DMSO) [11].", [["Vero cells", "ANATOMY", 135, 145], ["serum", "ANATOMY", 236, 241], ["Veros", "ANATOMY", 300, 305], ["simian varicella virus", "DISEASE", 15, 37], ["penicillin", "CHEMICAL", 243, 253], ["streptomycin", "CHEMICAL", 258, 270], ["dimethyl sulfoxide", "CHEMICAL", 380, 398], ["DMSO", "CHEMICAL", 400, 404], ["penicillin", "CHEMICAL", 243, 253], ["streptomycin", "CHEMICAL", 258, 270], ["dimethyl sulfoxide", "CHEMICAL", 380, 398], ["DMSO", "CHEMICAL", 400, 404], ["Wild-type (WT) simian varicella virus", "ORGANISM", 0, 37], ["SVV", "ORGANISM", 39, 42], ["Cercopithecine herpesvirus 9", "ORGANISM", 44, 72], ["SVV BAC", "ORGANISM", 78, 85], ["Vero cells", "CELL", 135, 145], ["bovine", "ORGANISM", 229, 235], ["serum", "ORGANISM_SUBSTANCE", 236, 241], ["penicillin", "SIMPLE_CHEMICAL", 243, 253], ["streptomycin", "SIMPLE_CHEMICAL", 258, 270], ["WT SVV", "ORGANISM", 272, 278], ["SVV", "ORGANISM", 283, 286], ["Veros", "CELL", 300, 305], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 380, 398], ["DMSO", "SIMPLE_CHEMICAL", 400, 404], ["Vero cells", "CELL_LINE", 135, 145], ["simian varicella virus", "SPECIES", 15, 37], ["Cercopithecine herpesvirus", "SPECIES", 44, 70], ["bovine", "SPECIES", 229, 235], ["simian varicella virus", "SPECIES", 15, 37], ["SVV", "SPECIES", 39, 42], ["Cercopithecine herpesvirus 9", "SPECIES", 44, 72], ["SVV", "SPECIES", 78, 81], ["bovine", "SPECIES", 229, 235], ["SVV", "SPECIES", 275, 278], ["SVV", "SPECIES", 283, 286], ["simian varicella virus", "PROBLEM", 15, 37], ["SVV", "TEST", 39, 42], ["Cercopithecine herpesvirus", "TREATMENT", 44, 70], ["SVV BAC", "TEST", 78, 85], ["5% newborn bovine serum", "TREATMENT", 218, 241], ["penicillin", "TREATMENT", 243, 253], ["streptomycin", "TREATMENT", 258, 270], ["WT", "TEST", 272, 274], ["SVV", "TEST", 275, 278], ["SVV BAC infected Veros", "TREATMENT", 283, 305], ["frozen in Vero media", "TREATMENT", 337, 357], ["10% dimethyl sulfoxide (DMSO)", "TREATMENT", 376, 405]]], ["Virus stocks were titered by plaque assay on primary rhesus fibroblasts maintained in Dulbecco\u2019s modified Eagle\u2019s Medium (DMEM) supplemented with 10% fetal bovine serum and penicillin, streptomycin and L-glutamine.", [["plaque", "ANATOMY", 29, 35], ["fibroblasts", "ANATOMY", 60, 71], ["fetal bovine serum", "ANATOMY", 150, 168], ["penicillin", "CHEMICAL", 173, 183], ["streptomycin", "CHEMICAL", 185, 197], ["L-glutamine", "CHEMICAL", 202, 213], ["penicillin", "CHEMICAL", 173, 183], ["streptomycin", "CHEMICAL", 185, 197], ["L-glutamine", "CHEMICAL", 202, 213], ["Virus", "ORGANISM", 0, 5], ["rhesus", "ORGANISM", 53, 59], ["fibroblasts", "CELL", 60, 71], ["bovine", "ORGANISM", 156, 162], ["serum", "ORGANISM_SUBSTANCE", 163, 168], ["penicillin", "SIMPLE_CHEMICAL", 173, 183], ["streptomycin", "SIMPLE_CHEMICAL", 185, 197], ["L-glutamine", "SIMPLE_CHEMICAL", 202, 213], ["primary rhesus fibroblasts", "CELL_TYPE", 45, 71], ["bovine", "SPECIES", 156, 162], ["bovine", "SPECIES", 156, 162], ["Virus stocks", "TREATMENT", 0, 12], ["primary rhesus fibroblasts", "TREATMENT", 45, 71], ["Dulbecco\u2019s modified Eagle\u2019s Medium (DMEM)", "TREATMENT", 86, 127], ["10% fetal bovine serum", "TREATMENT", 146, 168], ["penicillin", "TREATMENT", 173, 183], ["streptomycin", "TREATMENT", 185, 197], ["L-glutamine", "TREATMENT", 202, 213]]], ["WT SVV cell lysate was obtained by scraping infected primary rhesus fibroblasts at the height of CPE followed by centrifugation and sonication using 7 pulses of 70\u201380 Watts (Sonicator 3000, Misonix Inc., Farmingdale NY) and frozen at \u221280\u00b0C.Animals and sample collection ::: Materials and methodsAll rhesus macaques were housed at the Oregon National Primate Research Center and were handled in accordance with good animal practices as defined by the Office of Laboratory Animal Welfare.", [["cell lysate", "ANATOMY", 7, 18], ["fibroblasts", "ANATOMY", 68, 79], ["sample", "ANATOMY", 252, 258], ["SVV cell", "CELL", 3, 11], ["rhesus", "ORGANISM", 61, 67], ["fibroblasts", "CELL", 68, 79], ["rhesus", "ORGANISM", 299, 305], ["macaques", "ORGANISM", 306, 314], ["primary rhesus fibroblasts", "CELL_TYPE", 53, 79], ["rhesus macaques", "SPECIES", 299, 314], ["SVV", "SPECIES", 3, 6], ["rhesus macaques", "SPECIES", 299, 314], ["WT SVV cell lysate", "TEST", 0, 18], ["scraping infected primary rhesus fibroblasts", "PROBLEM", 35, 79], ["CPE", "PROBLEM", 97, 100], ["Misonix", "TREATMENT", 190, 197], ["SVV cell lysate", "OBSERVATION", 3, 18], ["infected", "OBSERVATION_MODIFIER", 44, 52], ["primary rhesus fibroblasts", "OBSERVATION", 53, 79]]], ["Rhesus macaques (RM, Macaca mulatta) were SVV seronegative prior to infection measured by ELISA.", [["infection", "DISEASE", 68, 77], ["Rhesus macaques", "ORGANISM", 0, 15], ["Macaca mulatta", "ORGANISM", 21, 35], ["SVV", "ORGANISM", 42, 45], ["Rhesus macaques", "SPECIES", 0, 15], ["Macaca mulatta", "SPECIES", 21, 35], ["Rhesus macaques", "SPECIES", 0, 15], ["Macaca mulatta", "SPECIES", 21, 35], ["SVV", "SPECIES", 42, 45], ["Rhesus macaques (RM, Macaca mulatta)", "TREATMENT", 0, 36], ["SVV seronegative", "PROBLEM", 42, 58], ["infection", "PROBLEM", 68, 77], ["ELISA", "TEST", 90, 95]]], ["RMs (n=4 per group) were infected intrabronchially with 4\u00d7105 PFU WT SVV or SVV BAC infected Veros.", [["SVV", "ORGANISM", 76, 79], ["Veros", "CELL", 93, 98], ["SVV", "SPECIES", 69, 72], ["SVV", "SPECIES", 76, 79], ["SVV", "TEST", 69, 72], ["SVV BAC infected Veros", "PROBLEM", 76, 98], ["infected", "OBSERVATION", 25, 33], ["infected Veros", "OBSERVATION", 84, 98]]], ["Peripheral blood mononuclear cells (PBMC) and bronchoalveolar lavage (BAL) cells were collected from rhesus macaques as previously described [5].", [["Peripheral blood mononuclear cells", "ANATOMY", 0, 34], ["PBMC", "ANATOMY", 36, 40], ["bronchoalveolar lavage (BAL) cells", "ANATOMY", 46, 80], ["Peripheral blood mononuclear cells", "CELL", 0, 34], ["PBMC", "CELL", 36, 40], ["bronchoalveolar lavage (BAL) cells", "CELL", 46, 80], ["macaques", "ORGANISM", 108, 116], ["Peripheral blood mononuclear cells", "CELL_TYPE", 0, 34], ["PBMC", "CELL_TYPE", 36, 40], ["bronchoalveolar lavage (BAL) cells", "CELL_TYPE", 46, 80], ["rhesus macaques", "SPECIES", 101, 116], ["rhesus macaques", "SPECIES", 101, 116], ["Peripheral blood mononuclear cells", "TEST", 0, 34], ["PBMC", "TEST", 36, 40], ["bronchoalveolar lavage (BAL) cells", "TEST", 46, 80], ["blood", "ANATOMY", 11, 16], ["mononuclear cells", "OBSERVATION", 17, 34], ["bronchoalveolar lavage", "OBSERVATION", 46, 68]]], ["Animals were euthanized at 84 to 86 days post-infection.", [["Animals", "ORGANISM", 0, 7]]], ["Sensory ganglia: trigeminal ganglia (TG), cervical, thoracic and lumbar-sacral dorsal root ganglia (DRG-C, DRG-T, and DRG-L/S respectively) were divided, flash frozen and stored at \u221280\u00b0C until analysis.Comparative genome analysis of SVV BAC and SVV WT DNA ::: Materials and methodsA microarray hybridization-based method was used to compare SVV\u0394ORF61 genomic DNA (test) to WT SVV (reference) DNA provided by NimbleGen Systems, Inc. (CGS 385K Mutation Mapping array Phase 1, Madison WI).", [["Sensory ganglia", "ANATOMY", 0, 15], ["trigeminal ganglia", "ANATOMY", 17, 35], ["TG", "ANATOMY", 37, 39], ["cervical", "ANATOMY", 42, 50], ["thoracic", "ANATOMY", 52, 60], ["lumbar-sacral dorsal root ganglia", "ANATOMY", 65, 98], ["DRG-C", "ANATOMY", 100, 105], ["DRG", "ANATOMY", 107, 110], ["CGS", "CHEMICAL", 433, 436], ["Sensory ganglia", "TISSUE", 0, 15], ["trigeminal ganglia", "MULTI-TISSUE_STRUCTURE", 17, 35], ["TG", "MULTI-TISSUE_STRUCTURE", 37, 39], ["cervical", "ORGAN", 42, 50], ["thoracic", "MULTI-TISSUE_STRUCTURE", 52, 60], ["root ganglia", "TISSUE", 86, 98], ["DRG-C", "CELL", 100, 105], ["DRG-T", "CELL", 107, 112], ["DRG-L/S", "CELL", 118, 125], ["SVV", "ORGANISM", 233, 236], ["DNA", "CELLULAR_COMPONENT", 252, 255], ["DNA", "CELLULAR_COMPONENT", 359, 362], ["DNA", "CELLULAR_COMPONENT", 392, 395], ["SVV BAC", "DNA", 233, 240], ["SVV WT DNA", "DNA", 245, 255], ["SVV\u0394ORF61 genomic DNA", "DNA", 341, 362], ["WT SVV (reference) DNA", "DNA", 373, 395], ["SVV", "SPECIES", 233, 236], ["SVV", "SPECIES", 245, 248], ["trigeminal ganglia (TG), cervical, thoracic and lumbar-sacral dorsal root ganglia", "PROBLEM", 17, 98], ["DRG", "TEST", 100, 103], ["DRG", "TEST", 107, 110], ["DRG", "TEST", 118, 121], ["flash frozen", "TEST", 154, 166], ["analysis", "TEST", 193, 201], ["Comparative genome analysis", "TEST", 202, 229], ["SVV BAC", "TEST", 233, 240], ["methodsA microarray hybridization", "TEST", 274, 307], ["CGS", "TEST", 433, 436], ["Mutation Mapping array Phase", "TEST", 442, 470], ["ganglia", "ANATOMY", 8, 15], ["trigeminal ganglia", "ANATOMY", 17, 35], ["cervical", "ANATOMY", 42, 50], ["thoracic", "ANATOMY", 52, 60], ["lumbar", "ANATOMY", 65, 71], ["sacral", "ANATOMY_MODIFIER", 72, 78], ["dorsal", "ANATOMY_MODIFIER", 79, 85], ["root ganglia", "ANATOMY", 86, 98], ["DRG", "OBSERVATION", 100, 103], ["SVV BAC", "OBSERVATION", 233, 240]]], ["Design of the microarray used published sequence data for the Delta herpesvirus strain of SVV (NC_002686, [8]).", [["Delta herpesvirus", "ORGANISM", 62, 79], ["SVV", "ORGANISM", 90, 93], ["Delta herpesvirus", "SPECIES", 62, 79], ["SVV", "SPECIES", 90, 93], ["the microarray", "TEST", 10, 24], ["published sequence data", "TEST", 30, 53], ["the Delta herpesvirus strain of SVV", "PROBLEM", 58, 93], ["SVV", "ANATOMY", 90, 93]]], ["The oligonucleotides were 29\u201339 bp in length and tiled throughout the genome every 7\u20138 bases on both forward and reverse strands.", [["7\u20138 bases", "DNA", 83, 92], ["forward and reverse strands", "DNA", 101, 128], ["The oligonucleotides", "TEST", 0, 20], ["bp", "TEST", 32, 34], ["length", "TEST", 38, 44], ["reverse strands", "OBSERVATION", 113, 128]]], ["Viral DNA was isolated from nucleocapsids purified from SVV-infected Vero cells as previously described [7].", [["nucleocapsids", "ANATOMY", 28, 41], ["Vero cells", "ANATOMY", 69, 79], ["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["nucleocapsids", "ORGANISM_SUBSTANCE", 28, 41], ["SVV", "ORGANISM", 56, 59], ["Vero cells", "CELL", 69, 79], ["Viral DNA", "DNA", 0, 9], ["SVV-infected Vero cells", "CELL_LINE", 56, 79], ["Viral DNA", "PROBLEM", 0, 9], ["nucleocapsids", "PROBLEM", 28, 41], ["SVV", "TEST", 56, 59], ["infected Vero cells", "PROBLEM", 60, 79], ["infected", "OBSERVATION_MODIFIER", 60, 68], ["Vero cells", "OBSERVATION", 69, 79]]], ["Hybridization data was analyzed using SignalMap software (NimbleGen Systems, Inc., Madison WI).", [["Hybridization data", "TEST", 0, 18]]], ["The identified mismatches were directly sequenced from PCR products obtained from amplifying the surrounding sequence.", [["PCR products", "DNA", 55, 67], ["The identified mismatches", "PROBLEM", 0, 25], ["PCR products", "TEST", 55, 67], ["mismatches", "OBSERVATION", 15, 25]]], ["The primers employed for Figure 1 include: (B) primer 1, 5\u2032-CCATATGTACCAACGGGAACA-3\u2032 and primer 2, 5\u2032-AAGCATGCATTTTCGATTGGA-3\u2032; (C) primer 1, 5\u2032-GCCTGGAGCCCAGATATTCGA-3\u2032 and primer 2, 5\u2032-ACGGTGTGCGTGGATGCATCA-3\u2032.DNA extraction and quantitative real-time PCR (qPCR) ::: Materials and methodsDNA was extracted from heparinized whole blood (WB), BAL cells, and portions of frozen ganglia using ArchivePure DNA Cell/Tissue Kit (5 PRIME, Gaithersburg MD) according to the manufacturer\u2019s protocol.", [["whole blood", "ANATOMY", 325, 336], ["WB", "ANATOMY", 338, 340], ["BAL cells", "ANATOMY", 343, 352], ["ganglia", "ANATOMY", 377, 384], ["Cell", "ANATOMY", 407, 411], ["Tissue", "ANATOMY", 412, 418], ["blood", "ORGANISM_SUBSTANCE", 331, 336], ["WB", "CELL", 338, 340], ["BAL cells", "CELL", 343, 352], ["ganglia", "ORGAN", 377, 384], ["primer 2", "DNA", 89, 97], ["primer 2", "DNA", 174, 182], ["3\u2032.DNA", "DNA", 209, 215], ["BAL cells", "CELL_TYPE", 343, 352], ["The primers", "TREATMENT", 0, 11], ["CCATATGTACCAACGGGAACA", "TEST", 60, 81], ["primer", "TEST", 89, 95], ["AAGCATGCATTTTCGATTGGA", "TEST", 102, 123], ["primer", "TEST", 132, 138], ["GCCTGGAGCCCAGATATTCGA", "TEST", 145, 166], ["primer", "TEST", 174, 180], ["ACGGTGTGCGTGGATGCATCA", "TEST", 187, 208], ["heparinized whole blood (WB", "TEST", 313, 340], ["BAL cells", "TEST", 343, 352], ["frozen ganglia", "PROBLEM", 370, 384], ["BAL cells", "OBSERVATION", 343, 352], ["frozen ganglia", "ANATOMY", 370, 384]]], ["SVV DNA viral loads in WB, BAL cells and sensory ganglia were measured by qPCR using Maxima Probe/ROX qPCR Master Mix (2X) (Fermentas, Glen Burnie MD) and primers/Taqman probe specific for SVV ORF21.", [["WB", "ANATOMY", 23, 25], ["BAL cells", "ANATOMY", 27, 36], ["sensory ganglia", "ANATOMY", 41, 56], ["SVV", "ORGANISM", 0, 3], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["WB", "CELL", 23, 25], ["BAL cells", "CELL", 27, 36], ["sensory ganglia", "MULTI-TISSUE_STRUCTURE", 41, 56], ["SVV", "ORGANISM", 189, 192], ["ORF21", "GENE_OR_GENE_PRODUCT", 193, 198], ["BAL cells", "CELL_TYPE", 27, 36], ["Taqman probe", "DNA", 163, 175], ["SVV ORF21", "DNA", 189, 198], ["SVV", "SPECIES", 0, 3], ["SVV", "SPECIES", 189, 192], ["SVV DNA viral loads", "TEST", 0, 19], ["WB", "TEST", 23, 25], ["BAL cells", "TEST", 27, 36], ["sensory ganglia", "PROBLEM", 41, 56], ["Maxima Probe/ROX qPCR Master Mix", "TREATMENT", 85, 117], ["SVV ORF21", "TREATMENT", 189, 198], ["viral loads", "OBSERVATION", 8, 19], ["BAL cells", "OBSERVATION", 27, 36], ["sensory ganglia", "ANATOMY", 41, 56]]], ["Following an initial 10 minute 95\u00b0C step, 40 cycles of 15 sec at 95\u00b0C and 1 minute at 60\u00b0C were completed using StepOnePlus (Life Technologies, Carlsbad CA).", [["StepOnePlus (Life Technologies", "TREATMENT", 112, 142], ["Carlsbad CA", "PROBLEM", 144, 155]]], ["SVV BAC DNA was used as quantification standards [11].Cytokine analysis ::: Materials and methodsPlasma and BAL supernatant samples (stored at \u221280\u00b0C) were thawed and analyzed using Cytokine Monkey Magnetic 28-plex panel as per the manufacturer\u2019s instructions (Life Technologies).", [["BAL supernatant samples", "ANATOMY", 108, 131], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["Plasma", "ORGANISM_SUBSTANCE", 97, 103], ["BAL", "ORGANISM_SUBSTANCE", 108, 111], ["SVV BAC DNA", "DNA", 0, 11], ["Cytokine", "PROTEIN", 54, 62], ["Cytokine", "PROTEIN", 181, 189], ["SVV", "SPECIES", 0, 3], ["SVV BAC DNA", "TEST", 0, 11], ["Cytokine analysis", "TEST", 54, 71], ["methodsPlasma", "TEST", 90, 103], ["BAL supernatant samples", "TEST", 108, 131], ["Cytokine Monkey Magnetic", "TEST", 181, 205]]], ["IFN\u03b1 levels were measured using Cynomolgus/Rhesus IFN\u03b1 Serum ELISA Kit according to the manufacturer\u2019s instructions (PBL Interferon Source, Piscataway NJ).", [["Serum", "ANATOMY", 55, 60], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Rhesus", "ORGANISM", 43, 49], ["Serum", "ORGANISM_SUBSTANCE", 55, 60], ["IFN\u03b1", "PROTEIN", 0, 4], ["IFN", "PROTEIN", 50, 53], ["IFN\u03b1 levels", "TEST", 0, 11], ["Cynomolgus/Rhesus IFN", "TREATMENT", 32, 53], ["Serum ELISA", "TEST", 55, 66]]], ["Samples were run in duplicate.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["Values below the limit of detection were designated as ND, or not detected.Enzyme-linked immunosorbent assay (ELISA) ::: Materials and methodsELISA plates were coated with SVV lysate overnight at 4\u00b0C, blocked with 5% milk in wash buffer (0.05% Tween in PBS) for 1 h at room-temperature (RT), washed three times with wash buffer, and incubated with heat-inactivated (55\u00b0C, 30 min) plasma samples in 3-fold dilutions in duplicate for 1 h.", [["milk", "ANATOMY", 217, 221], ["plasma samples", "ANATOMY", 380, 394], ["Tween", "CHEMICAL", 244, 249], ["milk", "ORGANISM_SUBSTANCE", 217, 221], ["plasma samples", "ORGANISM_SUBSTANCE", 380, 394], ["SVV", "SPECIES", 172, 175], ["Values", "TEST", 0, 6], ["Enzyme", "TEST", 75, 81], ["immunosorbent assay", "TEST", 89, 108], ["methodsELISA plates", "TREATMENT", 135, 154], ["SVV lysate", "TREATMENT", 172, 182], ["5% milk in wash buffer", "TREATMENT", 214, 236], ["wash buffer", "TREATMENT", 316, 327], ["heat", "TREATMENT", 348, 352], ["plasma samples", "TEST", 380, 394], ["3-fold dilutions", "TREATMENT", 398, 414]]], ["After washing three times with wash buffer, horseradish peroxidase (HRP)-conjugated anti-rhesus IgG (Nordic Immunology, Netherlands) was added for 1 h, followed by addition of chromagen o-phenylenediamine\u20222HCl (OPD) (Sigma, St Louis MO) substrate for 20 minutes to allow detection and quantitation of bound antibody molecules.", [["chromagen o-phenylenediamine\u20222HCl", "CHEMICAL", 176, 209], ["chromagen o-phenylenediamine\u20222HCl", "CHEMICAL", 176, 209], ["OPD", "CHEMICAL", 211, 214], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 44, 66], ["HRP", "SIMPLE_CHEMICAL", 68, 71], ["anti-rhesus IgG", "SIMPLE_CHEMICAL", 84, 99], ["chromagen o-phenylenediamine\u20222HCl", "SIMPLE_CHEMICAL", 176, 209], ["OPD", "SIMPLE_CHEMICAL", 211, 214], ["St Louis MO", "SIMPLE_CHEMICAL", 224, 235], ["horseradish peroxidase", "PROTEIN", 44, 66], ["HRP", "PROTEIN", 68, 71], ["anti-rhesus IgG", "PROTEIN", 84, 99], ["antibody molecules", "PROTEIN", 307, 325], ["horseradish", "SPECIES", 44, 55], ["wash buffer", "TREATMENT", 31, 42], ["horseradish peroxidase", "TREATMENT", 44, 66], ["conjugated anti-rhesus IgG", "TREATMENT", 73, 99], ["chromagen o-phenylenediamine", "TREATMENT", 176, 204], ["bound antibody molecules", "PROBLEM", 301, 325]]], ["The reaction was stopped with the addition of 1 M HCl.", [["HCl", "CHEMICAL", 50, 53], ["The reaction", "PROBLEM", 0, 12], ["1 M HCl", "TREATMENT", 46, 53]]], ["The optical density was measured at 490 nm using an ELISA plate reader (SpectraMax 190, Molecular Devices, Sunnyvale CA).", [["an ELISA plate reader", "TREATMENT", 49, 70], ["SpectraMax", "TREATMENT", 72, 82], ["Molecular Devices", "TREATMENT", 88, 105], ["Sunnyvale CA)", "TREATMENT", 107, 120], ["optical", "OBSERVATION_MODIFIER", 4, 11], ["density", "OBSERVATION", 12, 19]]], ["Endpoint IgG titers were calculated using log-log transformation of the linear portion of the curve with 0.1 optical density (OD) units as the cut-off.", [["IgG", "PROTEIN", 9, 12], ["Endpoint IgG titers", "TEST", 0, 19], ["0.1 optical density (OD) units", "TREATMENT", 105, 135]]], ["Titers were standardized using a positive control sample included with each assay.Measurement of T cell and B cell frequency and proliferation ::: Materials and methodsBAL cells and PBMC were surface stained with antibodies against 1) CD4 (eBioscience, San Diego CA), CD8\u03b2 (Beckman Coulter), CD28, and CD95 (BioLegend, San Diego CA) to delineate the naive (CD28+CD95\u2212), central memory (CD28+CD95+), and effector memory (CD28\u2212CD95+) T cell subsets; 2) CD20 (Beckman Coulter, Brea CA), IgD (Southern Biotech, Birmingham AL), and CD27 (BioLegend) to delineate na\u00efve (CD20+IgD+CD27\u2212), marginal zone-like (MZ-like) (CD20+IgD+CD27+), and memory (CD20+IgD\u2212CD27+) B cell subsets.", [["T cell", "ANATOMY", 97, 103], ["B cell", "ANATOMY", 108, 114], ["methodsBAL cells", "ANATOMY", 161, 177], ["PBMC", "ANATOMY", 182, 186], ["surface", "ANATOMY", 192, 199], ["central memory", "ANATOMY", 370, 384], ["CD28+CD95+)", "ANATOMY", 386, 397], ["effector memory (CD28\u2212CD95+) T cell", "ANATOMY", 403, 438], ["CD20+IgD+CD27\u2212", "ANATOMY", 564, 578], ["marginal zone-like (MZ-like) (CD20+IgD+CD27+)", "ANATOMY", 581, 626], ["memory (CD20+IgD\u2212CD27+) B cell", "ANATOMY", 632, 662], ["T cell", "CELL", 97, 103], ["B cell", "CELL", 108, 114], ["methodsBAL cells", "CELL", 161, 177], ["PBMC", "CELL", 182, 186], ["CD4", "GENE_OR_GENE_PRODUCT", 235, 238], ["San Diego CA", "GENE_OR_GENE_PRODUCT", 253, 265], ["CD8\u03b2", "GENE_OR_GENE_PRODUCT", 268, 272], ["Beckman Coulter", "GENE_OR_GENE_PRODUCT", 274, 289], ["CD28", "GENE_OR_GENE_PRODUCT", 292, 296], ["CD95", "GENE_OR_GENE_PRODUCT", 302, 306], ["BioLegend", "GENE_OR_GENE_PRODUCT", 308, 317], ["San Diego CA", "GENE_OR_GENE_PRODUCT", 319, 331], ["CD28", "GENE_OR_GENE_PRODUCT", 357, 361], ["CD95", "GENE_OR_GENE_PRODUCT", 362, 366], ["CD28", "GENE_OR_GENE_PRODUCT", 386, 390], ["CD95", "GENE_OR_GENE_PRODUCT", 391, 395], ["CD28", "GENE_OR_GENE_PRODUCT", 420, 424], ["CD95", "GENE_OR_GENE_PRODUCT", 425, 429], ["CD20", "GENE_OR_GENE_PRODUCT", 451, 455], ["Brea CA", "GENE_OR_GENE_PRODUCT", 474, 481], ["IgD", "GENE_OR_GENE_PRODUCT", 484, 487], ["CD27", "GENE_OR_GENE_PRODUCT", 527, 531], ["BioLegend", "GENE_OR_GENE_PRODUCT", 533, 542], ["CD20", "GENE_OR_GENE_PRODUCT", 564, 568], ["IgD", "GENE_OR_GENE_PRODUCT", 569, 572], ["CD27", "GENE_OR_GENE_PRODUCT", 573, 577], ["CD20", "GENE_OR_GENE_PRODUCT", 611, 615], ["IgD", "GENE_OR_GENE_PRODUCT", 616, 619], ["CD27", "GENE_OR_GENE_PRODUCT", 620, 624], ["CD20", "GENE_OR_GENE_PRODUCT", 640, 644], ["IgD", "GENE_OR_GENE_PRODUCT", 645, 648], ["CD27", "GENE_OR_GENE_PRODUCT", 649, 653], ["methodsBAL cells", "CELL_LINE", 161, 177], ["PBMC", "CELL_TYPE", 182, 186], ["antibodies", "PROTEIN", 213, 223], ["CD4", "PROTEIN", 235, 238], ["eBioscience", "PROTEIN", 240, 251], ["San Diego CA", "PROTEIN", 253, 265], ["CD8\u03b2", "PROTEIN", 268, 272], ["Beckman Coulter", "PROTEIN", 274, 289], ["CD28", "PROTEIN", 292, 296], ["CD95", "PROTEIN", 302, 306], ["BioLegend", "PROTEIN", 308, 317], ["San Diego CA", "PROTEIN", 319, 331], ["CD28", "PROTEIN", 357, 361], ["CD95", "PROTEIN", 362, 366], ["CD28", "PROTEIN", 386, 390], ["CD95", "PROTEIN", 391, 395], ["effector memory (CD28\u2212CD95+) T cell subsets", "CELL_TYPE", 403, 446], ["CD20", "PROTEIN", 451, 455], ["Beckman Coulter", "PROTEIN", 457, 472], ["Brea CA", "PROTEIN", 474, 481], ["IgD", "PROTEIN", 484, 487], ["Southern Biotech", "PROTEIN", 489, 505], ["CD27", "PROTEIN", 527, 531], ["BioLegend", "PROTEIN", 533, 542], ["CD20", "PROTEIN", 564, 568], ["IgD", "PROTEIN", 569, 572], ["CD27", "PROTEIN", 573, 577], ["CD20", "PROTEIN", 611, 615], ["IgD", "PROTEIN", 616, 619], ["CD27", "PROTEIN", 620, 624], ["CD20", "PROTEIN", 640, 644], ["IgD", "PROTEIN", 645, 648], ["CD27", "PROTEIN", 649, 653], ["B cell subsets", "CELL_TYPE", 656, 670], ["a positive control sample", "TREATMENT", 31, 56], ["each assay", "TEST", 71, 81], ["Measurement of T cell", "TEST", 82, 103], ["methodsBAL cells", "TEST", 161, 177], ["PBMC", "TEST", 182, 186], ["antibodies", "TEST", 213, 223], ["CD4", "TEST", 235, 238], ["eBioscience", "TEST", 240, 251], ["San Diego CA", "TEST", 253, 265], ["CD8", "TEST", 268, 271], ["Beckman Coulter", "TEST", 274, 289], ["CD28", "TEST", 292, 296], ["CD95", "TEST", 302, 306], ["CD28", "TEST", 357, 361], ["CD28", "TEST", 386, 390], ["CD95", "TEST", 391, 395], ["CD95", "TEST", 425, 429], ["T cell subsets", "PROBLEM", 432, 446], ["na\u00efve", "TEST", 557, 562], ["CD20", "TEST", 564, 568], ["IgD", "TEST", 569, 572], ["marginal zone", "TEST", 581, 594], ["MZ", "TEST", 601, 603], ["CD20", "TEST", 611, 615], ["IgD", "TEST", 616, 619], ["CD27", "TEST", 620, 624], ["memory", "TEST", 632, 638], ["CD20", "TEST", 640, 644], ["IgD", "TEST", 645, 648], ["CD27", "TEST", 649, 653], ["T cell", "OBSERVATION", 97, 103], ["B cell", "OBSERVATION", 108, 114], ["central", "ANATOMY_MODIFIER", 370, 377], ["marginal", "ANATOMY_MODIFIER", 581, 589], ["zone", "ANATOMY_MODIFIER", 590, 594], ["cell subsets", "OBSERVATION", 658, 670]]], ["Cells were fixed and permeabilized according to manufacturer recommendations (BioLegend) before the addition of Ki67-specific antibody (BD Biosciences, San Jose, CA).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Ki67", "GENE_OR_GENE_PRODUCT", 112, 116], ["Ki67", "PROTEIN", 112, 116], ["specific antibody", "PROTEIN", 117, 134], ["BD Biosciences", "PROTEIN", 136, 150], ["CA", "PROTEIN", 162, 164], ["Cells", "TEST", 0, 5], ["Ki67", "TEST", 112, 116]]], ["The samples were analyzed using the LSRII instrument (Beckton, Dickinson and Company, San Jose CA) and FlowJo software (TreeStar, Ashland OR).Intracellular cytokine staining ::: Materials and methodsBAL cells and PBMC were stimulated with SVV lysate (1 \u03bcg) or SVV overlapping peptide pool containing open reading frames (ORFs) 4, 31, 61 and 63 for 1 h followed by addition of Brefeldin A (Sigma, St Louis MO) to block cytokine export for 14 h.", [["samples", "ANATOMY", 4, 11], ["Intracellular", "ANATOMY", 142, 155], ["methodsBAL cells", "ANATOMY", 192, 208], ["PBMC", "ANATOMY", 213, 217], ["Brefeldin A", "CHEMICAL", 376, 387], ["Brefeldin A", "CHEMICAL", 376, 387], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 142, 155], ["methodsBAL cells", "CELL", 192, 208], ["PBMC", "CELL", 213, 217], ["Brefeldin A", "SIMPLE_CHEMICAL", 376, 387], ["Sigma", "SIMPLE_CHEMICAL", 389, 394], ["St Louis MO", "ORGANISM", 396, 407], ["cytokine", "PROTEIN", 156, 164], ["methodsBAL cells", "CELL_LINE", 192, 208], ["PBMC", "CELL_TYPE", 213, 217], ["open reading frames", "DNA", 300, 319], ["ORFs", "DNA", 321, 325], ["cytokine", "PROTEIN", 418, 426], ["SVV", "SPECIES", 239, 242], ["The samples", "TEST", 0, 11], ["Intracellular cytokine staining", "TEST", 142, 173], ["methodsBAL cells", "TREATMENT", 192, 208], ["PBMC", "TREATMENT", 213, 217], ["SVV lysate", "TREATMENT", 239, 249], ["SVV overlapping peptide pool", "TREATMENT", 260, 288], ["ORFs", "TEST", 321, 325], ["Brefeldin A (Sigma, St Louis MO", "TREATMENT", 376, 407], ["block cytokine export", "TREATMENT", 412, 433], ["cytokine staining", "OBSERVATION", 156, 173], ["methodsBAL cells", "OBSERVATION", 192, 208]]], ["After stimulation cells were surface stained with antibodies against CD4, and CD8\u03b2, as described above.", [["cells", "ANATOMY", 18, 23], ["surface", "ANATOMY", 29, 36], ["cells", "CELL", 18, 23], ["CD4", "GENE_OR_GENE_PRODUCT", 69, 72], ["CD8\u03b2", "GENE_OR_GENE_PRODUCT", 78, 82], ["antibodies", "PROTEIN", 50, 60], ["CD4", "PROTEIN", 69, 72], ["CD8\u03b2", "PROTEIN", 78, 82], ["stimulation cells", "TREATMENT", 6, 23], ["antibodies", "TEST", 50, 60], ["CD4", "TEST", 69, 72], ["CD8\u03b2", "TEST", 78, 82]]], ["Samples were fixed, permeabilized (BioLegend) and dual-stained using antibodies against IFN\u03b3 (eBioscience) and TNF\u03b1 (eBioscience).", [["Samples", "ANATOMY", 0, 7], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 88, 92], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 111, 115], ["BioLegend", "PROTEIN", 35, 44], ["antibodies", "PROTEIN", 69, 79], ["IFN\u03b3", "PROTEIN", 88, 92], ["eBioscience", "PROTEIN", 94, 105], ["TNF\u03b1", "PROTEIN", 111, 115], ["eBioscience", "PROTEIN", 117, 128], ["Samples", "TEST", 0, 7], ["antibodies", "TEST", 69, 79], ["IFN", "TEST", 88, 91], ["eBioscience", "TEST", 94, 105], ["TNF", "TEST", 111, 114]]], ["Samples were analyzed using the LSRII instrument and FlowJo software.Statistical analysis ::: Materials and methodsStatistical analysis and graphing was conducted with GraphPad Prism software (GraphPad Software Inc., La Jolla CA).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["the LSRII instrument", "TREATMENT", 28, 48], ["Statistical analysis", "TEST", 115, 135], ["graphing", "TEST", 140, 148], ["Prism software", "TEST", 177, 191], ["La Jolla CA", "PROBLEM", 217, 228]]], ["Significance values for Figures 2, 3, 4, 5, and 6 utilized repeated measures of ANOVA with the Bonferroni post-test to explore differences between groups (SVV BAC and WT SVV) at each time-point.Competing interestsThe authors declared that they have no competing interests.Authors\u2019 contributionsStudy design: IM and CM; data collection: CM, JD, KH, FE, NA; data interpretation and manuscript preparation: IM and CM.", [["CM", "DISEASE", 315, 317], ["CM", "DISEASE", 336, 338], ["CM", "DISEASE", 411, 413], ["Significance values", "TEST", 0, 19], ["Figures", "TEST", 24, 31], ["SVV BAC", "TEST", 155, 162], ["SVV", "TEST", 170, 173]]], ["WG provided SVV BAC and WT SVV.", [["SVV BAC", "DNA", 12, 19], ["WG", "TEST", 0, 2], ["SVV BAC", "TEST", 12, 19], ["WT SVV", "TEST", 24, 30], ["SVV BAC", "OBSERVATION", 12, 19]]]]}